
Division of Extramural Activities Annual Report 2014



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health


Molecular Analysis for Therapy Choice (NCI-MATCH): A Novel Clinical Trial

Recently, the ability to assess hundreds to thousands of genomic variants in a single next-generation sequencing assay, together with gene sequencing data from The Cancer Genome Atlas (TCGA) and the development of treatment protocols that target cancer-specific molecular abnormalities, has contributed significantly to realizing the promise of precision medicine in oncology. Although various drugs have received Food and Drug Administration (FDA) approval for the treatment of specific mutations in certain cancers, it is less clear whether the same drug will be efficacious in tumors of different histologic type bearing the same mutation.

The goal of NCI-MATCH is to provide clinical evidence that a drug targeting a particular molecular profile may also be effective in the treatment of more than one tumor type. NCI-MATCH is a unique master protocol of phase II clinical trials, each of which targets a particular molecular profile for eligibility, rather than the histology of a particular tumor (e.g., lung, breast, colon or prostate cancer). As a master protocol, these phase II trials, or arms, are planned to be completed at different times, and new "arms" can be added when evidence suggests that a given drug or investigational agent or combination of agents has efficacy against tumors with a particular molecular profile. Initial stages of NCI-MATCH will include 10 arms. Each arm will enroll adults 18 years of age or older with advanced solid tumors or lymphomas that are no longer responsive to standard treatment and have begun to grow. All patients will have a tumor biopsy taken at trial entry. Biopsy specimens will be sent to one of four genetic testing CLIA-certified laboratories where they will be analyzed using next-generation sequencing for more than 4,000 variants (mutations, amplifications, rearrangements, and translocations) from 143 cancer genes.

NCI-MATCH is the most rigorous and complex trial to be performed in the NCI's National Clinical Trial Network (NCTN). The trial is coordinated by the ECOG-ACRIN Cancer Research Group in concert with the three other adult NCTN groups (Alliance for Clinical Trials in Oncology, NRG Oncology Group, and SWOG) and the NCI Community Oncology Research Program (NCORP). The combined networks currently consist of approximately 2,400 clinical sites; therefore, patients may not need to travel far from their home to participate in the trial. Scientific expertise from NCI-Designated Cancer Centers and the NCTN groups will be employed to ascertain that treatments in NCI-MATCH and the gene variants used for eligibility meet inclusion criteria. Either single drugs (FDA approved or investigational) or combinations with a defined safe dose are eligible, provided that they have been shown to shrink tumors that have the particular molecular abnormality. For a given genomic variant to be "actionable" for NCI-MATCH, it must either be the subject of a companion diagnostic test, been shown to be associated with tumor shrinkage in patients whose tumors carry the abnormality, or have high-level preclinical evidence (model systems) that the variant can predict for drug efficacy.

NCI-MATCH is part of a portfolio of precision medicine clinical trials launched with NCI support that includes ALCHEMIST (a trial for patients with lung cancer removed by surgery) and Lung-MAP (a trial using targeted treatment in patients with squamous lung cancer that has progressed after standard treatment). In these trials, additional correlative information is being sought, including data from broader sequencing studies that may help refine which patients are most likely to benefit from targeted treatment.



References Cited:

Conley BA and Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol. 2014;41(3):297-9.


Kim ES, Herbst RS, Wistuba H, Lee JJ, Bumenschein GR Jr, Tsao A, et al. The BATTLE trial: Personalizing therapy for lung cancer. *Cancer Discov.* 2011;1:44-53.

Mody RJ, Wu Y-M, Lonigro RJ, Cao X, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. *JAMA*. 2015;314(9):913-25.

Hyman DM, Puzanov I, Subbiah V, Faris JE, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726-36.

Kandoth C, McLellan MD, Vandin F, Ye K, Niu G, Lu Ch, et al. Mutational landscape and significance across 12 major cancer types. *Nature*. 2013; 502: 333-9

Division of Extramural Activities Annual Report 2014



Images and narrative are the courtesy of Dr. Barbara Conley, Associate Director of the Cancer Diagnosis Program (CDP) in the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI). The Precision Medicine: NCI-MATCH Clinical Trial illustration is modified from the "NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial" graphic (www.cancer.gov/ nci-match). The Promise of Precision Oncology illustration is the courtesy of Dr. James Doroshow, Director, DCTD, NCI and Deputy Director, NCI.

NCI DEA 2014 Annual Report

Contents

Introduction
Overview of the Division of Extramural Activities
Special Activities in the Office of the Director, DEA
Program Coordination: A Resource for New Funding Initiatives
Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt
of Applications
Peer Review — The Next Step
NCI Grant and RFA Funding
Supporting Peer Review Consultants
DEA's Role in Advisory Activities
Committee Management Activities
Portfolio Tracking and Analysis
Information Resources Management
Organizational Structure of the Division of Extramural Activities

Figures

-	
Figure 1.	Receipt and Referral of NCI Grant Applications, FY2010-2014
Figure 2.	DEA Review Workload, FY2010 – 2014 10
Figure 3.	Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed, FY2010 – 201412
Figure 4.	Program Project (P01), SPORE, and Other Multi-Project Research Applications Reviewed, FY2010 – FY201413
Figure 5.	Technology Initiatives Applications Reviewed, FY2010 - 2014
Figure 6.	NCI Grant and RFA Funding Percentages by Concept Area, FY201317
Figure 7.	NCI Grant and RFA Funding Percentages by Concept Area, FY2014
Figure 8.	BSA-Approved RFA Concept Set-Asides by Division/Office/Center (DOC)18
Figure 9.	FY2014 Success Rates for Applications in High Incidence Cancers
Figure 10.	FY2014 Success Rates for Applications in Selected Special Interest Categories
Tables	
Table 1a.	Requests for Applications (RFAs) Published by the NCI in FY2014, Sorted by Date of Publication
Table 1b.	Requests for Applications (RFAs) Published by the NCI in FY2014, Sorted by Division, Office, and Center
Table 2.	NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2014, Sorted by Date of Publication
Table 3a.	Program Announcements (PAs) Published by the NCI in FY2014, Sorted by Date of Publication
Table 3b.	Program Announcements (PAs) Published by the NCI in FY2014, Sorted by Division, Office, and Center
Table 4.	NCI Participation in Trans-NIH Program Announcements (PAs/PARs) in FY2014, Sorted by Date of Publication
Table 5.	Applications Received for Referral by the NCI/DEA in FY2014, Sorted by Mechanism
Table 6.	Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA in FY2014, Sorted by Mechanism

Table 7.	Applications Reviewed by NCI Initial Review Group (IRG) Subcommittees and Special Emphasis Panels (SEPs) in FY201457			
Table 8.	Summary of Investigator-Initiated Program Project (P01) Applications Reviewed in FY2014			
Table 9.	Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCI Program Division, in FY2014			
Table 10.	Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY201458			
Table 11.	Program Announcements (PAs) Reviewed by the NCI/DEA in FY2014 60			
Table 12.	Requests for Proposals (RFPs) Reviewed by the NCI/DEA in FY201463			
Table 13.	Summary of NCI Grant Awards by Mechanism in FY2014			
Table 14.	Average Total Cost and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2010 – FY2014			
Table 15.	NCI Organ and Related Site-Specific Dollars for FY2010 – FY2014 – Annual Percent Change			
Table 16.	NCI Special Interest Category (SIC) Dollars for FY2010 – FY2014 – Annual Percent Change			
Table 17.	NCI Funding of Foreign Research Grants in FY201497			
Table 18.	Foreign Components of U.S. Domestic Research Grants in FY2014100			
Appendixes	3			
Appendix A	A: Activities of the National Cancer Advisory Board (NCAB)			

Appendix A:	Activities of the National Cancer Advisory Board (NCAB)	. 102
Appendix B:	Activities of the Board of Scientific Advisors (BSA)	. 103
Appendix C:	List of Chartered Committees	104
	NCI Initial Review Group Consultants	
Appendix E:	NCI Grant Mechanisms and Descriptions	170
	Glossary of Acronyms	
	Cancer Information Sources on the Internet	

Introduction



The Division of Extramural Activities (DEA) is the organizational component of the National Cancer Institute (NCI) responsible for coordinating the scientific review of extramural research before funding and for conducting systematic surveillance of

that research after funding. The Division solicits advice from individuals and/or committees of experts on the technical and scientific merit of grants, cooperative agreements, and contracts. The peer review process is critically important to science in that it allows good ideas to surface and be evaluated based on their merit and promise. The peer review system is the keystone for ensuring that the best science is supported.

DEA coordinates the activities of: (1) the National Cancer Advisory Board (NCAB), which consists of members appointed by the President, conducts the second-level review of grants and cooperative agreements and advises the Director, NCI, on policy for the conduct of the National Cancer Program; (2) the Board of Scientific Advisors (BSA), which is composed of distinguished scientists from outside the NCI and representatives from the advocacy community who advise the NCI leadership on the progress and future direction of the NCI extramural program, evaluates NCI extramural programs, and reviews NCI-initiated research concepts; and (3) extramural training opportunities for NCI Program and Review staff.


As a Division, we evaluate the content of all extramural research funded by the NCI and annually track the NCI research portfolio of more than 8,000 research and training awards by using consistent budget-linked scientific information to provide a basis for budget projections; maintain extensive records of this research and provide specialized

analyses of the costs, goals, and accomplishments of the research; and serve as an NCI resource to others for reporting and dissemination of the NCI's research portfolio. DEA monitors budgetary limitations for grant applications; participates in establishing policies to expedite funding; and initiates and implements changes to applications, guidelines, and award processes. The Division also coordinates the review and response to appeals from applicants regarding the peer review process or the subsequent disposition and management of grants, cooperative agreements, and contracts; and responds to and coordinates requests from the NIH Office of Extramural Research's Agency Extramural Research Integrity Officer (RIO) for information and assistance regarding scientists (or institutions) supported by NCI research funds who were the subject of allegations, inquiries, and/or investigations of possible research misconduct.

The intent of this annual report is to provide insight and useful information about the research funding process and the role of DEA in support of NCI's mission. A comprehensive look at each of the major areas of responsibility within the Division is provided. The data presented cover Fiscal Year (FY) 2014 (1 October 2013 - 30 September 2014) and provide data comparison with previous years.

To implement a biomedical research program of the highest quality, the NCI draws on the national pool of scientists actively engaged in research for assistance in selecting the best research and training projects. We sincerely want to thank the more than 2,400 researchers, clinicians, and advocates who gave unselfishly of their time in FY2014 and have contributed to the continuing success of NCI's peer review and advisory activities.

> Paulette S. Gray, Ph.D. Director Division of Extramural Activities



Division of Extramural Activities

The paramount goal of the National Cancer Institute (NCI) is to develop the knowledge base that will ultimately lessen the impact of cancer. Among the most important contributors to this base are the outstanding extramurally funded scientists supported by the NCI through grants, contracts, and cooperative agreements. The DEA was established within the NCI to provide the Institute and the scientific community with expert scientific review of the merits of extramural research. An important part of DEA's mission is to manage and coordinate the second level of grant review by the National Cancer Advisory Board (NCAB); concept review of all new and reissued Requests for Applications (RFAs) and Research and Development (R&D) Requests for Proposals (RFPs) by the Board of Scientific Advisors (BSA), and activities of the Frederick National Laboratory Advisory Committee (FNLAC), which reviews the state of research at the Frederick National Laboratory of Cancer Research (FNLCR).

The Committee Management Office (CMO) provides oversight of all NCI-chartered advisory boards and committees, working groups, task forces, and chartered review groups. The CMO also serves as an NIH service center for the National Institutes of Health (NIH), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the NIH Council of Councils (CoC). The CMO provides policy guidance and assistance to ensure that the NCI and client HHS/NIH Institutes, Centers, and Offices operate within the appropriate Federal Advisory Committee Act (FACA), the Government in Sunshine Act, and various other policies, procedures, and guidelines.

The DEA also provides effective and timely coordination of program initiatives from the initial concept stage through publication of RFAs, Program Announcements (PAs), RFPs, Notices, and, finally, the peer review of grant and cooperative agreement applications and contract proposals. The Office of Referral, Review, and Program Coordination (ORRPC), which consists of four review branches and a program coordination and referral branch, provides: (1) coordination of the development and issuance of NCI program initiatives; (2) execution of grant receipt and referral; and (3) management of NCI peer review activities. Review

activities include the organization and management of peer review for all applications and proposals received in response to RFAs, PAs, PAs with Special Receipt (PARs), complex, multi-component grant and cooperative agreement initiatives, and R&D RFPs. The program coordination responsibilities of the DEA, in cooperation with NCI extramural program Divisions, Offices, and Centers, extend to the development of all new extramural program guidelines and funding opportunity announcements (FOAs).

Another program coordination activity is the development and maintenance of referral guidelines for assignment of grant applications to the NCI. These guidelines, included in the *Referral Guidelines for Funding Components of PHS*, are critical to the development of program initiatives across the NIH, as well as the prompt referral of unsolicited grant applications to the NCI. These guidelines differ from the NCI Internal Referral Guidelines, which are vital to the prompt referral of grant applications to the appropriate NCI program areas.

The Research Analysis and Evaluation Branch (RAEB) works closely with the NCI Office of Budget and Finance (OBF) to provide budget-linked portfolio data for NCI grants, cooperative agreements, and contracts. In doing so, the Institute has the capability of responding expeditiously to congressional and other inquiries. RAEB has historical budget-linked portfolio data that go back to the 1930s.

The DEA conducts continual evaluation of program initiatives and coordinates policies and procedures to ensure that all aspects are as clear and accessible as possible to NCI staff, advisory groups, and applicants. To facilitate this evaluation, the DEA Office of Extramural Applications (OEA), through the Applied Information Systems Branch (AISB), maintains a Web-based information system to provide key information on new initiatives. This Web-based information system includes early notice of approved concepts, listings of active PAs and recently published RFAs, and policies related to the clearance of new program initiatives. This information is provided in both public accessible Internet (http://deainfo. nci.nih.gov/funding.htm) and NCI limited-access Intranet versions.

Special Activities in the Office of the Director, DEA

In addition to managing and coordinating the extramural operations described in this report. the DEA Office of the Director (OD) is a focal point and repository of information and policies related to various funding mechanisms for NIH grants, staff and awardee responsibilities, eligibility requirements, receipt dates for all granting mechanisms, and special programs. The DEA OD ensures that NCI meets the congressional mandate to promote increased participation of women, children, and members of minority and medically underserved populations in the research areas of cancer cause, prevention, control, diagnosis, and treatment. The NIH Revitalization Act of 1993 mandates that women and members of minority groups be included as subjects in each research project, unless there are clear scientific or ethical reasons that inclusion is inappropriate with respect to the health of the subject or the purpose of the research. In 1998, an NIH inclusion policy was implemented requiring applicants and grantees to include children (as defined as an individual less than 21 years of age) in clinical research, unless there is strong justification for their exclusion. Administrative procedures allow NCI staff to resolve inclusion problems after initial review of grant applications that are otherwise highly meritorious. In the event that an applicant believes the proposed study does not warrant or require inclusion of women, children, or persons from minority or medically underserved population groups, he or she can apply for a waiver of this requirement. The DEA Director is the Appeals Officer for the NCI and has the authority to grant waivers. In FY2014, 26 applications with preliminary bars to award were received by the DEA. Through corrective action, working with the applicants and program directors, all bars to award were brought into compliance before awards were made.

Additionally, the DEA Director serves as the locus for implementation and oversight of NCI policies concerning extramural research integrity and serves as a resource to all NCI staff with questions in this area. In this role, the DEA Director and designees work to address concerns about extramural research misconduct, misuse of human and animal research subjects, financial mismanagement, and financial conflict of interest involving NCI-supported research. The DEA Director functions as the NCI Research Integrity Officer (RIO) and receives from the appropriate sources all documents related to research misconduct for transmittal and reporting to relevant sources. In FY2014, 12 cases of alleged research misconduct involving NCI funding were opened and under investigation by the Office of Research Integrity. HHS, and referred to the Director, DEA. Six cases were closed, three cases were found to involve research misconduct, and three cases are currently under investigation.*

Extramural Staff Training

Program and Review Extramural Staff Training Office (PRESTO)

The Program and Review Extramural Staff Training Office (PRESTO), which resides in the DEA OD, develops and coordinates the training of Program, Review, and other extramural staff. The mission of PRESTO is to increase the knowledge base of new and experienced staff members and optimize their effectiveness in supporting the goals of the NCI. To accomplish this mission, PRESTO: (1) designs and implements a broad-based curriculum for Program and Review staff; (2) provides training on specialized topics related to understanding of and compliance with NIH policies;

*Cases found to involve research misconduct are published in the Federal Register and NIH Guide for Grants and Contracts.

and (3) identifies and develops resources to facilitate individual learning and performance. Finally, PRESTO tracks the participation of extramural staff in NIH- and NCI-sponsored training activities as well as continuously evaluates the efficacy of these activities.

During FY2014, PRESTO activities included:

- Development and implementation of the Program Official (PO) Basic Training Series, which provides basic training to new program officials with 3 years or less experience as a PO. The series included seven sessions over a 3-week period. The topics included receipt and referral, Funding Opportunity Announcement (FOA) development, PO and principal investigator interactions, the peer review process, pre and post award activities, and commonly used electronic tools. PRESTO plans to provide the PO Basic Training Series every year.
- Production of recorded PRESTO-sponsored training sessions that have been posted on the PRESTO website for employees' use if they were unable to attend in person.
- Organization of forums on core administrative responsibilities, including those related

to Electronic Systems, Human Subjects Protection, Inclusion Policy, and the Inclusion Management System.

- Coordination of State-of-the-Science forums on Complementary and Alternative Medicine: The Interface between Worlds of Clinical Practice and Cancer Research, Big Data: Emerging Practice in Cancer Research, NCI Cancer Clinical Trials Network, and High Risk and High Impact Research Opportunities in Cancer Research: Common Fund.
- Continued enhancement of the PRESTO website (http://deaintranet.nci.nih.gov/ presto/index.htm) on the DEA intranet.

During FY2015, PRESTO will continue to offer a variety of training opportunities for NCI extramural staff, including new Staff Assistants. PRESTO plans to launch a revamped website in the spring of 2015 that will provide improved access to NCI and NIH training resources. The NCI Scientific Review Officer Handbook also will be revised to increase its usability. Various information technology tools will be employed to enhance the effectiveness of PRESTO-sponsored training activities. PRESTO will develop trainings on new and emerging topics of broad interest to NCI extramural staff.

Program Coordination: A Resource for New Funding Initiatives

The DEA performs critical functions in the development of new strategic funding initiatives at the NCI and in the coordination of their publication as Funding Opportunity Announcements (FOAs), which comprise both RFAs and PAs. Members of the Program Coordination and Referral Branch (PCRB) provide expert assistance to NCI Program staff to develop and publish new (or reissue) FOAs. PCRB staff members disseminate various operating policies and procedures pertaining to extramural funding programs. To maintain consistency and completeness, all new and reissued NCI FOAs, Notices, and associated guidelines are reviewed. edited as needed, and cleared through the DEA, under PCRB coordination, before being forwarded to the NIH Office of Extramural Research (OER) for approval and publication in the NIH Guide for Grants and Contracts and on Grants.gov. In these steps, PCRB staff members help to streamline and clarify FOA technical parameters and requirements as well as optimize accuracy, precision, and clarity of their presentation in proper format. PCRB verifies consistency with NIH-wide requirements, provides quality control, and coordinates timelines throughout the development and publication processes. Overall, these services ensure the high quality and timely availability of NCI's funding opportunities for cancer researchers as prospective applicants.

Tables 1a and 1b show the variety of RFAs issued by the NCI in FY2014, and Table 2 lists RFAs issued by other NIH Institutes or Centers (ICs) that the NCI has joined as a participating partner. **Tables 3a** and **3b** show the variety of PAs issued by the NCI in FY2014, and **Table 4** lists PAs issued by other NIH ICs that the NCI has joined as a participating partner.

PCRB staff members continue to provide relevant information and timely updates to all NCI extramural staff members on activities and results related to the requirements for and uses of electronic grant applications. The Branch also serves as a direct source of guidance on this topic for program officials at the NCI and applicants in the extramural scientific community. Staff members in the Referral Office (RO) in PCRB collaborated with NCI information technology staff members and their contractors to successfully develop and deploy an improved Web-based Awaiting Receipt of Application (ARA) management system (permission for special application receipts), which contributes to an improved efficiency of use by NCI staff members and quality of service for the NCI's grant applicants and awardees. In addition to performing their program coordination and referral responsibilities, PCRB Health Scientist Administrators also served as Scientific Review Officers (SROs) in managing the reviews of 348 student loan repayment program (LRP) contract proposals in FY2014 (Table 12).

Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt of Applications

In FY2014, a total of 13,988 grant and cooperative agreement applications were submitted to the NCI for funding with appropriated funds (see Figure 1 and Table 5). Applications encompassed 51 different types of award mechanisms (Appendix E), including investigator-initiated Research Project (R01), Career Development (K series), Research Program Project (P01), Cancer Center Support (P30), Specialized Program of Research Excellence (SPORE, P50), Small Research Project (R03), Exploratory/Developmental Project (R21), Exploratory/Developmental Phase II Project (R33), Small Business Technology Transfer (STTR) (R41/ R42), Small Business Innovation Research (SBIR) (R43/R44), and Cooperative Agreement (U-series) activity codes.

All applications seeking NIH support are initially submitted to the NIH Center for Scientific Review (CSR) Division of Receipt and Referral (DRR), which assigns each application to a specific NIH funding Institute or Center (IC) and the locus of review for the application (i.e., either to a CSR Study Section or within a specific IC). The ICs, in turn, have well-defined processes in place for the internal assignment and review of submitted applications. Upon receipt of applications from CSR, the NCI Referral Officers (ROs) in PCRB: (1) assign all incoming applications to one of the 50 NCI extramural research program areas; (2) track program acceptance of the applications; and (3) if necessary, negotiate transfers of grant applications to and from the NCI to other NIH




Figure 1. Receipt and Referral of NCI Grant Applications FY2010 – 2014

*Includes NCI Primary and Secondary applications received and referred.

Grant Referral: A First Point of Contact for NCI Grant Applicants and Applications ____

ICs and even other HHS research funding agencies, such as the Agency for Healthcare Research and Quality (AHRQ), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA).

The first point of contact for applicants seeking NCI support for their research is often a PCRB RO who provides the investigators with information related to funding opportunities, peer review policies and process, and contact information of an NCI Program staff member who can provide guidance through the application process. In addition, the RO assists members of the extramural community in navigating NIH and NCI Web pages to obtain current information, forms, and guidelines. PCRB also is the information and coordinating center for the submission of applications for the Academic Research Enhancement Award (AREA, R15) grants for research at institutions and organizations that have little or no current NIH grant support.

For certain FOAs, in particular Program Projects and specialized initiatives, applicants are encouraged to submit a Letter of Intent (LOI) to the PCRB prior to the submission of their application. The LOI typically provides the name of the contact principal investigator and other participating key investigators, a listing of the specific aims and a brief description of the research, an approximate cost and years to be requested, and any additional information requested in the FOA. In most instances, the LOI is not mandatory or binding, but provides the Institute with an estimate of the number of applications that might be submitted in response to a specific FOA.

All applications requesting \$500,000 or more in direct costs in any year require prior agreement by NIH staff to accept the assignment of that application to that IC unless stated otherwide in the FOA. This is accomplished by the applicant contacting Program staff well in advance of the anticipated submission date. If the Program agrees to accept the application, the Program must submit an Awaiting Receipt of Applications (ARA) form to CSR DRR. The ARA form also facilitates requests for assignments from ICs and other information that needs to be connected to a specific application. For additional guidance on this process, refer to NOT-OD-02-004 "Revised Policy on the Acceptance for Review of Unsolicited Applications That Request \$500,000 or More in Direct Costs."

Peer Review—The Next Step

Once an application is referred to the NCI and the appropriate program, it must be reviewed. The high caliber of NCI-sponsored research is maintained through a rigorous peer review process in which established experts in the appropriate scientific fields review and evaluate the scientific and technical merit of research grant applications, cooperative agreements, and contract proposals. The peer review process helps to ensure that the NCI uses its resources wisely and supports highly meritorious research that has the potential to make a significant contribution and impact in science and medicine. The NCI's extramural programs and activities are funded primarily through peer reviewed grants and cooperative agreements. Programs that are funded through research and development (R&D) contracts also are subject to peer review, including contract-supported projects conducted within the intramural research program.

The NIH peer review system consists of two sequential levels of review mandated by statute and regulation. The first level of review is managed by Scientific Review Officers (SROs) who serve as the Designated Federal Officer (DFO) and are conducted in either an NIH CSR study section, a chartered NCI Initial Review Group (IRG), or an NCI Special Emphasis Panel (SEP). The purpose of this initial review is to evaluate the scientific and technical merit, protection of human subjects, inclusion plans, animal welfare, and budget and/or administrative issues of the applications or cooperative agreements under review. The second level of review, which is not a re-review of scientific merit but a validation of the initial review and an evaluation of program relevance, is conducted by the National Cancer Advisory Board (NCAB).

Most investigators are familiar with the functions of an NIH CSR study section, which has the primary responsibility for the peer review of most investigator-initiated Research Program Grants (RPGs) (R01) and Fellowship (F) applications. What is less widely known, however, is that grant applications requesting more than 50 percent of the NCI's overall extramural budget are reviewed by chartered NCI IRGs and SEPs that are conducted within the DEA. The locus of the peer review, whether by the CSR or the DEA, is usually determined by the type of grant mechanism of the application under review.

Although the NCI has no direct input into the selection of CSR study section reviewers, members of NCI IRGs and SEPs are selected by DEA Review staff, with suggestions from NCI Program staff. NCI IRGs and SEPs provide advice on the scientific and technical merit of applications for research, research training, education, and career development; cooperative agreements; and contract proposals relating to scientific areas relevant to cancer.

All chartered IRG Subcommittee members are approved by the Director, DEA, based on their knowledge and demonstrated expertise in various disciplines and fields related to cancer. The NCI currently has four specialized IRG Subcommittees. Subcommittee A reviews Cancer Center Support grant (CCSG) applications. Subcommittee F reviews Institutional Training and Education applications. Subcommittee I reviews Transition to Independence applications, and Subcommittee J reviews Career Development applications. NCI IRG members are appointed for varying terms of service, which may be up to 6 years. DEA SEPs are selected *ad hoc* on a one-time, as-needed basis to review specific grant and cooperative agreement applications received in response to RFAs, PAs, PARs, other specialized applications, or R&D contract proposals received in response to RFPs.

The peer review of grant applications and contract proposals generally occurs in the fall, winter, and spring prior to the January, May, and October NCAB meetings, respectively. The membership of NCI-chartered subcommittees may be found in Appendix C and at http://deainfo.nci.nih.gov/ advisory/irg/irg.htm, and information about NCI SEPs can be accessed at http://deainfo.nci.nih.gov/ advisory/sep/sep.htm.


Review Workload

In FY2014, DEA organized, managed, and reported the review of a total of 4,795 research grant and cooperative agreement applications (Table 6) and 512 contract proposals (Table 12) assigned to the NCI for funding with appropriated dollars. The total number of grant applications, cooperative agreements, and contract proposals reviewed in FY2014 was 5,307 (Figure 2). In addition, the DEA conducted 12 Cancer Center site visits, 12 IRG Subcommittee review meetings, 155 SEPs to review grant applications and contract proposals, and 51 other review-associated meetings, such as orientation teleconferences. Tables 7 and 12 provide a summary of the applications and proposals reviewed by NCI IRG Subcommittees and SEPs. Approximately 2,400 peer reviewers served on the NCI DEA-managed IRG Subcommittees, SEPs, and workgroups in FY2014 (see Appendixes C and D). Members were selected on the basis of their demonstrated experience and expertise in relevant fields of biomedical research or their informed consumer perspectives.

Peer Review Functions

The Office of Referral, Review, and Program Coordination (ORRPC) is responsible for the coordination and management of the review of NCI grant applications, cooperative agreements, and contract proposals. ORRPC is composed of four review branches, a coordination and referral branch, and the Office of the Associate Director. The review branches are responsible for organizing, managing, and reporting the results of scientific peer review of grant and cooperative applications or proposals for a wide variety of grant mechanisms and topics. Reviews of grant applications are conducted by either one of four NCI IRG Subcommittees or by specially convened SEPs as shown in Table 7. Contract proposals and Small Business





Innovation Research (SBIR) Special Topics are reviewed by SEPs as shown in Table 12.

The **Resources and Training Review Branch** (RTRB) is primarily responsible for the peer review of multicomponent (*aka* "complex") Cancer Center Support as well as single component Training, Education, and Career Development grant applications (see **Table 6**). The RTRB also has responsibility for the management of the four NCI IRG Subcommittees (see **Appendix D**).

The **Research Programs Review Branch** (RPRB) has primary responsibility for review of unsolicited multicomponent Program Project (P01) and Special Program of Research Excellence (SPORE) (P50) translational research applications focused on various disease sites.

In February 2014, as a result of significant increases in the total number of research and special initiative applications received by DEA for review, the previous Special Review Logistics Branch (SRLB) was reorganized and split into two new review branches, the Special Review Branch (SRB) and the **Research Technology and Contract Review Branch** (RTCRB). The SRB is primarily responsible for the peer review of grant applications submitted in response to NCI issued RFAs (e.g., NCI Provocative Questions) and PAs/PARs (e.g., NCI Omnibus R03/R21) as well as other special initiatives. The RTCRB is primarily responsible for the peer review of Small Business Innovation Research (SBIR)/ Small Business Technology Transfer (STTR) grant applications and Special Topics, technology-related applications, and R&D contract proposals submitted in response to Request for Proposals (RFPs). All review meetings managed by SRB and RTCRB are conducted using SEPs.

Resources and Training Review Branch (RTRB)

The RTRB has primary responsibility for review of Cancer Center Support, Training and Education, and Career Development applications. RTRB is also responsible for the management of the four NCI IRG Subcommittees A, F, I, and J (Appendix D).

The review of Cancer Center Support Grant (CCSG) applications involves a two-tier initial


peer review process. Normally, the first tier of the review involves a site visit to the applicant institution by a non-FACA working group review panel. The site visit reviewers serve as a fact-finding body of experts to obtain updated information and/or clarification of any issues identified in the written application through an onsite face-to-face discussion with the Cancer Center investigators with focus on addressing CCSG-specific review criteria, thereby enhancing the review process. The site visit committee prepares a site visit review report that is presented, along with the written CCSG application, to the NCI IRG Subcommittee A for discussion, evaluation, and final impact scoring of the application. Final scoring by Subcommittee A provides a more uniform evaluation of individual CCSG applications than scoring based solely on the initial site visit review group. In FY2014, new guidelines were implemented in which Cancer Centers may elect not to have a site visit. In this case, the review will be based only on the information provided in the written application (i.e., "paper" review) with final evaluation and impact scoring by NCI Subcommittee A. During FY2014, Subcommittee A reviewed 12 CCSG applications.

Training and Career Development (CD)

Career Development and Training and Education grant applications are reviewed by IRG Subcommittees F, I, and J. The number of CD applications decreased slightly from 474 in 2010 to 438 in 2011, stabilized in 2012, and increased to 527 in 2014. The number of Training and Education grant applications has remained fairly constant from 2010 (157) to 2013 (141) with a slight decrease to 107 applications in 2014 (Figure 3).

NCI Community Oncology Research Program (NCORP)

Late in 2012, the NCI initiated efforts to develop a national network of investigators, cancer care providers, academic institutions, and other health-related organizations for the conduct of multi-site cancer clinical trials and studies in diverse populations with the establishment of the NCI Community Oncology Research Program (NCORP). NCORP integrated two prior networks:





the NCI Community Clinical Oncology Program (Community Clinical Oncology Programs and Minority-Based CCOP, Research Bases), and NCI Community Cancer Centers Program (NCCCP) for the conduct of clinical research in the community setting. The goal of NCORP is to facilitate the design and conduct of clinical trials to improve cancer prevention, cancer control, screening for early cancers, and post-treatment surveillance; and the delivery of cancer care and performance of comparative effectiveness research. In addition, NCORP seeks to facilitate access to treatment and imaging trials conducted by the National Clinical Trials Network (NCTN). In November 2013, three FOAs were issued soliciting cooperative agreement applications for NCORP Research Bases; Community Sites; and Minority/Underserved Community Sites. In April of FY2014, the DEA received and reviewed 76 applications for 10 (7 single project UG1 and 3 complex structure UM1) Research Bases, 45 (34 UG1 and 11 UM1) Community Sites, and 21 (12 UG1 and 9 UM1) Minority/Underserved Community Sites.

Other RTRB Activities


To assist reviewers in their participation for RTRB peer review, Reviewer Guides are maintained for all of the different types of applications reviewed by the RTRB. Reviewer Guides were updated for the newly reissued FOAs and for the electronic submission of grant applications. Reviewer Guides also contain general information on peer review and NIH policies regarding the use of human subjects in research, as well as specific instructions for each of the mechanisms to be reviewed. These mechanism-specific guides have been completed for all Training, Education, and Career Development and Cancer Center Support applications. This resource is especially helpful for IRG Subcommittee members who often participate in the review of single component Training, Education, and Career Development grant applications or multicomponent CCSG grant applications, each with their own specific review criteria.

Research Programs Review Branch (RPRB)

Program Project (P01) Applications

A significant effort of RPRB during FY2014 was the review of unsolicited multicomponent Program Project (P01) applications. P01 applications are typically reviewed using a one-tier, "paper only" review process. The applications are grouped based on their scientific focus and typically clustered into three to four groups of up to 10 applications each. The groupings vary depending on the number of applications received and the science proposed. The applications often represent a continuum of research from basic through translational to preclinical and clinical studies. All P01 review panels are constituted as SEPs, with reviewers recruited based on the scientific expertise needed for the applications being reviewed. The SEP review committees evaluate the technical and scientific merit of the individual projects and supporting core resource facilities, determine the level of program integration and leadership, and then assign an overall impact score to each application. During FY2014, RPRB managed the review of 57 new, renewal (competing), resubmitted (amended), and revised (competitive supplement) P01 applications (Figure 4 and Table 8). Twenty-three (40%) of the applications proposed new multidisciplinary research programs, 13 (23%) of the applications were amended (Table 8), and 10 (17%) included multiple Principal Investigators (PIs). Twentyeight (49%) of the 57 applications were referred to NCI's Division of Cancer Treatment and Diagnosis (DCTD) (see Table 9). The 57 applications requested \$121,582,570 in total costs for the first year (see Table 9) and \$617,087,370 in total costs for 5 years.





Specialized Programs of Research Excellence (SPORE, P50)

Another major responsibility of RPRB is the review of NCI Specialized Programs of Research Excellence (SPORE) P50 applications. These complex. multidisciplinary translational applications focus on research directly applicable to human disease in various organ sites. In FY2014, RPRB organized and managed six SEPs for the review of 40 SPORE applications (Figure 4). The applications addressed multiple organ sites, with the following distribution of applications: Brain (3); Breast (5); Cervical (1); Endometrial (1); Gastrointestinal (2); Head and Neck (3); Kidney (2); Leukemia (1); Lymphoma (3); Lung (6); Mesothelioma (1); Myeloma (1); Ovarian (2); Pancreas (3); Prostate (4); Skin (1); and Thyroid (1). Overall, 24 (60%) of the 40 applications were submitted for new SPOREs, and 16 (40%) were renewal applications. The disease sites addressed in the SPORE applications vary from round to round. Nine applications addressing four different disease sites were reviewed for the January 2014 NCAB cycle, 26 applications addressing 15 disease sites were reviewed for the May 2014 NCAB cycle, and five applications addressing four disease sites were reviewed for the October 2014 NCAB meeting. The applications requested \$100, 074,110 in total costs for the first year of support and \$496,484,706 in total costs for 5 years.

Potential applicants for P01 and P50 grant submissions are strongly encouraged to participate in a pre-submission conference with the appropriate NCI Program and DEA Review staff members so that they can fully understand the guidelines, requirements, and goals of these complex applications. SROs from RPRB routinely participate in these pre-submission conferences to assist the applicants in the application formatting requirements, the review process, the special review criteria, and the scoring paradigms for these applications.

Special Review Branch (SRB)

The SRB organizes and manages the peer review of applications submitted in response to NCI-issued RFAs, PAs, and PARs. Following approval of RFA

concepts by the NCI Scientific Program Leaders (SPL) and the Board of Scientific Advisors (BSA), Program staff prepares RFAs for publication in the NIH Guide for Grants and Contracts. DEA PCRB staff, including DEA SROs, assist in critically reading the draft documents and in providing recommendations for clarity relative to application requirements and review criteria. In an RFA, a specific, published dollar amount is set aside by the Institute, whereas for a PA/PAR, there is no dollar set-aside and no requirement for BSA review. Table 10 summarizes the number of applications submitted for the RFAs and Table 11 summarizes the number of applications submitted in response to PAs or PARs and reviewed by DEA. During FY2014, the DEA reviewed a total of 4,795 applications received in response to 43 RFAs (1,216 applications) (Table 10) and 62 PAs/PARs (3,579 applications) (Table 11). The review of these applications was conducted by SEPs and involved the recruitment of scientists with the appropriate expertise for each review meeting.

Research Answers to NCI's Provocative Questions (PQ)

Following input from the scientific community through focus groups, forums, and online postings, 28 perplexing scientific questions were identified and grouped, 4-6 questions each, into five thematic cancer areas: Cancer Prevention and Risk (Group A); Mechanisms of Tumor Development or Recurrence (Group B); Tumor Detection, Diagnosis, and Prognosis (Group C); Cancer Therapy and Outcomes (Group D); and Clinical Effectiveness (Group E). There were 371 R01 Research Project application and 231 R21 Exploratory/Developmental applications submitted in response to 18 RFAs (Table 10). Applications were peer reviewed in nine face-to-face SEP review meetings to assess the scientific and technical merit and assign a final impact score to each application.

Exploratory/Developmental Research

In FY2014, the DEA reviewed 1,945 R21 applications submitted for the NCI Omnibus Exploratory/ Developmental Research Grant Program (Table 11). The applications are initially grouped based on their scientific focus and typically reviewed in 11 to 14 SEPs. The groupings varied depending on the number of applications received and the science proposed. The applications represent a continuum of research from basic through translational to preclinical and clinical studies. The Omnibus applications were reviewed in a total of 38 SEPs over the three review cycles.

Small Grant Programs

Several small grant (R03) PAR program initiatives in the areas of cancer prevention (PAR11-079), cancer epidemiology (PAR12-039), and NCI Omnibus R03 for cancer research (PAR12-144 and PAR14-007) stimulated increased interest in the applicant community. In FY2014, 625 applications were submitted and reviewed by the DEA in response to these initiatives.

Research Technology and Contract Review Branch (RTCRB)

The RTCRB organizes and manages the peer review of SBIR/STTR applications and Special Topics, technology-related applications, and R&D contract proposals submitted in response to RFPs.

SBIR/STTR and Technology Research Applications

The SBIR program supports Phase I feasibility applications (R43), Phase II applications (R44), and Fast-Track applications (R43/R44). In 2009, the first issued SBIR Phase II Bridge Award RFA was designed to "bridge the gap" between the end of the Phase II award and commercial development. That program continued in FY2014 with the review of 12 R44 SBIR Phase II Bridge Award applications. The majority of technology research initiatives use the R21 Exploratory/Developmental award mechanism and the R33 Exploratory/Developmental Phase II award mechanism. The R21 mechanism is intended to encourage exploratory/developmental research by providing support for exploratory pilot projects in the early stages of project development. The R33 mechanism is suitable for projects where "proof-of-principle" of the proposed technology or methodology already has been established and supportive preliminary data are available. Both of these mechanisms are well suited for technology development. In 2014, 276 technology applications (Figure 5) for Exploratory/Developmental grants (R21) and Exploratory /Developmental Phase II grants (R33) were reviewed for the Innovative Molecular Analysis Technologies (IMAT) for Cancer Research program (RFA-CA14-003 [R21] and RFA CA14-004 [R33]) as well as the Innovative Technologies for Biospecimen Science program (RFA-CA14-005 [R21] and RFA CA14-006 [R33]).

Research and Development (R&D) Contract Proposals

In FY2014, RTCRB received and reviewed 512 contract proposals, including 348 Loan Repayment L30 and L40 proposals, in response to 20 RFPs (Table 12). During review, specific elements of each proposal are individually evaluated and scored, with the combined score indicating the overall merit. After negotiations, contract awards are made for the RFP solicitation. Phase II SBIR proposals are submitted to Topics and are openly announced in a Broad Agency Agreement Announcement.

Other RTCRB Activities

In FY2014, RTCRB participated in the critical reading and editing of pre-publication drafts for Funding Opportunity Announcements (PAs, PARs, RFAs) and research contract acquisition plans that are published as Requests for Proposals (RFPs), and were a part of presentations to prospective applicants during pre-application webinars and teleconferences. Members of the branch also assisted in the review of applications for initiatives that were coordinated by the SRB, including the NCI Provocative Questions Initiative, the NCI Omnibus Exploratory (R21) Grant program, and the Small Grant (R03) program.




Figure 5. Technology Initiatives Applications Reviewed* FY2010 - 2014

*Withdrawn applications are not included.

NCI Grant and RFA Funding

The Board of Scientific Advisors (BSA) is responsible for advising the NCI Director on the extramural program and the future direction and funding of each Division's extramural research. As such, the BSA provides concept review for NCI-sponsored RFAs. Figures 6 and 7 show total NCI Grant and RFA funding according to scientific concept area in FY2013 and FY2014. Figure 8 shows RFA concepts that the BSA approved from FY2010 through FY2014 according to the sponsoring NCI Division, Office, and Center.

Table 13 presents a summary of total funding of NCI grant awards by mechanism for FY2014. In Table 14, a comparison is made of the average cost

and number of NCI R01, P01, R03, R13, R21, P30, P50, U01, U10/ U19, and U54 grants and cooperative agreements awarded in FY2010 through FY2014 according to the extramural Divisions, Offices, and Centers.

Trends in grant funding according to scientific discipline and organ site are provided in Tables 15 and 16. Table 17 reports NCI's funding of foreign research grants in FY2014, and Table 18 reports foreign components of U.S. domestic research grants in FY2014. Note: Some grant awards made during a fiscal year may have been for grant applications reviewed in a prior fiscal year.




Figure 6. NCI Grant and RFA Funding Percentages by Concept Area FY2013

Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants. Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)




Figure 7. NCI Grant and RFA Funding Percentages by Concept Area **FY2014**

Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants. Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)




Figure 8. BSA-Approved RFA Concept Set-Asides by **Division/Office/Center**

NCI (DCCPS, DCP), Trans-NIH * Indicates co-funding among NCI Divisions/Offices/Centers.

NCI (DCCPS, DCB), Trans-NIH

OD-OHAM OD-CSSI

OD-OBBR OD-SBIRDC

TRANS-1

TRANS-2

Office of the Director - Center for Strategic Scientific Initiatives Office of the Director - Office of Biorepositories and Biospecimen Research

Office of the Director - Small Business Innovation Research Development Center

Supporting Peer Review Consultants

Ensuring that highly qualified individuals are available for expert review of grant applications and contract proposals requires an efficient administrative support system. The DEA's Scientific Review and Evaluation Activities (SREA) unit, residing within the NCI Committee Management Office (CMO), supports the NCI peer review process by compensating consultants for their services on the NCI IRG Subcommittees and SEPs and by reimbursing them for their travel and other expenses (Appendixes C and D). The SREA staff also approves and/or processes payments for other activities related to review, including hotel contracts, teleconferencing services, and contractsupported ticketing services.

The NCI SREA unit is a multi-million dollar management program. SREA staff members oversee the successful reconciliation of peer review costs charged against the SREA account, identify erroneous charges, and maintain an extensive tracking system of all costs related to approximately 179 peer review associated meetings to successfully manage the budget. CMO is able to provide the DEA Director with a clear picture of funds spent against the SREA budget throughout the year to ensure sufficient funds are available to cover all NCI peer review activities.

On October 1, 2013, the U.S. Federal Government shut down for 16 days, due to the absence of either an FY 2014 appropriation or a Continuing Resolution for the Department of Health and Human Services (HHS). This had a significant impact on NCI DEA. During this period, 16 peer review meetings were cancelled and the DEA was responsible for contacting consultants participating in each peer review meeting and alerting them that meetings were cancelled, contacting hotels to cancel lodging and meeting space and contacting World Travel Service (WTS) to cancel consultant travel arrangements. Immediately upon the reopening of the Federal Government, SREA provided SROs with guidance on what was required for amending and renegotiating hotel contracts,

Federal Register Notices, and consultant travel for their rescheduled meetings. SROs faced unfamiliar situations with amendments of their hotel contracts. Factors included (1) need for a change in the location due to unavailable lodging and meeting space for the rescheduled meeting date(s); (2) change in U.S. General Services Administration (GSA) *per diem* rate for lodging due to meeting(s) being held in a different month; (3) prior approved AEA Memos; and (4) decrease or increase in the number of meeting attendees. SREA worked closely with the DEA Director, Associate Director, ORRPC, SROs, and the Committee Management Officer to ensure the rescheduled review meetings were still held during the current review cycle and prior to the scheduled January 2014 Council Round to ensure that the original funding obligations were appropriately used and there was no interruption of NCI funding or stoppage of critical research efforts of external Investigators.

During FY2014, approximately 2,400 expert consultants were reimbursed honoraria and flat-rate payment for serving at more than 179 peer review meetings (Appendix D). The SREA staff works diligently to reimburse reviewers in a timely manner or contact those reviewers with an unpaid or returned reimbursement status. The SREA staff also assists reviewers in completing their Secure Payee Registration System (SPRS) registration. Due to these proactive efforts by the SREA staff, only 20 out of the 3,737 (0.5%) instances of honoraria and flat-rate payments to NCI peer review consultants were not paid in FY2014.

Throughout the year, the SREA staff ensures the timely review and submission of hotel contracts for processing to secure lodging and meeting room space for face-to-face peer review meetings. In FY2014, 106 hotel contracts were processed by the SREA staff. The SREA also is responsible for ensuring all meeting logistic invoices (i.e., hotels, World Travel Service, and teleconference services charges) are accurate and valid before being processed for payment. All discrepancies

Supporting Peer Review Consultants _

are immediately addressed with the appropriate vendor and a revised invoice is requested.

The CMO received and responded to several requests from the NIH Freedom of Information Act (FOIA) office. SREA staff was instrumental in the collection and review of one request that involved pulling approximately 601 rosters from the Committee Management IMPACII module and reviewing each to see if the roster met the criteria of the FOIA request. The SREA staff was able to complete this task in 14 calendar days.

The SREA staff collaborates with the Associate Director, ORRPC, NCI DEA Branch Chiefs, CMO, and SROs on the development of NCI SREA policies and procedures. On an ongoing basis, they monitor and evaluate current SREA activities and initiate changes and improvements when warranted.

In addition, CMO and SREA collaborates with the Program and Review Extramural Staff Training

Office (PRESTO) staff to ensure the training needs of DEA review and support staff are met for all aspects of CMO and SREA activities. SREA created new training materials and the following training sessions were conducted in FY2014:

- For Program Analysts (PAs) and Staff Assistants (SAs) – How to properly obtain, review, and process a BPA hotel contract for peer review meetings.
- For All Review Staff How to prepare the Official Meeting File for FACA NCI peer review meetings.

All CMO and SREA documents related to peer review meeting activities are sent to PRESTO to be posted on the "NCI/DEA Peer Review Reference Guide for Staff Assistants" page on the PRESTO website. The documents are then utilized by NCI DEA SROs, PAs, and SAs. These training tools are imperative to the peer review process and the integrity of NCI's mission.

DEA's Role in Advisory Activities

Beyond its central role in coordinating the referral of grants and peer review, perhaps the most farreaching role that the DEA plays across the NCI is the coordination and administration of NCI's nine chartered Federal advisory committees (Appendix C). The memberships and activities of these advisory bodies are coordinated by the Office of the Director, DEA, and the Committee Management Office, DEA, in consultation with the NCI **Director**. A primary responsibility of the DEA is coordination of the activities of the NCAB, whose members are appointed by the President and whose responsibilities include the second-level review of grant and cooperative agreement applications, as well as advising the NCI Director on policy for the conduct of the National Cancer Program. The DEA also coordinates administration of the BSA, the body responsible for the oversight and concept review of the extramural programs and initiatives of the NCI, and FNLAC, which reviews research activities of the FNLCR. Under the various chartered committees, working groups are formed to address and make recommendations on important areas of cancer research related to basic research, clinical trials, diverse populations, cancer advocacy, treatment, cancer control, drug development, prevention, communication, education, and so on. As such, the DEA plays a major role in the development and issuance of PAs, PARs, and RFAs, the major extramural program initiatives used by the NCI to fund extramural research. The DEA Director serves as Executive Secretary to the NCAB and the BSA. (See Appendices A and B for highlights of the activities of these Boards in FY2014 and Appendix C for a list of current chartered committee members.)

Major NCI Advisory Bodies Administered by the DEA

National Cancer Advisory Board (NCAB). NCI's principal advisory body is the presidentially appointed NCAB. The NCAB advises the HHS Secretary and the NCI Director on issues related to the entire National Cancer Program and provides a second level of review for grant applications

referred to the NCI and for the Food and Drug Administration (FDA) (Appendix A).

President's Cancer Panel (PCP). The PCP consists of three members appointed by the President, who by virtue of their training, experience, and background, are exceptionally qualified to appraise the National Cancer Program. At least two members of the Panel are distinguished scientists or physicians, and the third member is a nationally recognized cancer research advocate. The Panel monitors the development and execution of the activities of the National Cancer Program and reports directly to the President. Any delays or hindrances in the rapid execution of the Program are immediately brought to the attention of the President.

Board of Scientific Advisors (BSA). The BSA represents the scientific community's voice in NCI-supported extramural science. The BSA, composed of distinguished scientists from outside the NCI and representatives from the advocacy community, advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The BSA evaluates NCI extramural programs and policies, and it reviews concepts for new research opportunities and solicitations to ensure that those concepts are meritorious and consistent with the Institute's mission (Appendix B).

Boards of Scientific Counselors (BSCs) for Basic Sciences, and for Clinical Sciences and Epidemiol-ogy. The two BSCs, managed through the Office of the Director (OD), NCI, advise the NCI leadership on the progress and future direction of NCI's Intramural Research Program residing in the Center for Cancer Research (CCR) and the Division of Cancer Epidemiology and Genetics (DCEG). The two BSCs, composed of scientific experts from outside the NCI, evaluate the performance and productivity of NCI Intramural Principal Investigators and Staff Scientists through periodic site visits to the intramural laboratories and provide evaluation and advice on the course of research for each Laboratory and Branch. **NCI Council of Research Advocates (NCRA).** The NCRA, previously known as the Director's Consumer Liaison Group (DCLG), advises the NCI Director with respect to promoting research outcomes that are in the best interest of cancer patients. To this end, the NCRA conducts these activities with the intent to identify new approaches, promote innovation, recognize unforeseen risks or barriers, and identify unintended consequences that could result from NCI decisions or actions. Additionally, the NCRA will provide insight into enhancing input, optimizing outreach, and promoting strong collaborations, all with respect to non-scientist stakeholders.

Clinical Trials and Translational Research Advisory Committee (CTAC). The CTAC advises and makes recommendations to the NCI Director, NCI Deputy Directors, and the NCI Division/Office/Center (DOC) Directors on the NCI-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trials process. In addition, CTAC makes recommendations regarding the effectiveness of NCI's translational research management and administration program, including needs and opportunities across disease sites, patient populations, translational developmental pathways, and the range of molecular mechanisms responsible for cancer development. CTAC also will advise on the appropriate magnitude for dedicated translational research priorities and recommend allocation of translational research operations across organizational units, programs, disease sites, populations, developmental pathways, and molecular mechanisms. This responsibility encompasses oversight of all clinical trials, both extramural and intramural. The Committee provides broad scientific and programmatic advice on the investment of taxpaver dollars in clinical trials and related science.

Frederick National Laboratory Advisory Council (**FNLAC**). The FNLAC provides advice and makes recommendations to the Director, NCI, and the Associate Director, NCI-Frederick, on the optimal use of the NCI-Frederick facility to rapidly meet the most urgent needs of the Institute. The NCI facility in Frederick, Maryland, was established in 1972 as a Government-owned Contractor-operated facility. In 1975, the facility was designated as a Federally Funded Research and Development Center (FFRDC) to provide a unique national resource for the development of new technologies and the translation of basic science discoveries into novel agents for the prevention, diagnosis, and treatment of cancer and AIDS. The FFRDC has been renamed as the Frederick National Laboratory for Cancer Research (FNLCR). FNLAC reviews new projects proposed to be performed at NCI-Frederick and advises the Director, NCI, and the Associate Director, NCI-Frederick, about the intrinsic merit of the projects and about whether they should be done at the Frederick facility.

NCI Initial Review Groups (IRGs). The NCI IRGs. composed of four active subcommittees, review grant applications for Cancer Centers, research projects, and Training, Education, and Career Development activities in the areas of cancer cause, prevention, diagnosis, treatment, and control. IRG members may be appointed as standing committee members with overlapping terms of up to 6 years. or as "temporary" ad hoc members. Ad hoc members have all of the rights and obligations of IRG committee membership, including the right to vote on recommendations in which the individual fully participated as a reviewer for a specific meeting. Consultants also may be invited to serve as special experts to provide information or advice. These individuals generally serve on site visit groups or work groups providing critical information to the chartered advisory subcommittees responsible for initial peer review.

NCI Special Emphasis Panels (SEPs). The SEPs advise the NCI Director and the DEA Director regarding research grant and cooperative agreement applications, contract proposals, and concept reviews relating to basic, preclinical, and clinical sciences, and applied research and development programs of special relevance to the NCI. Membership on a SEP is fluid, with experts designated to serve "as needed" for individual review meetings rather than for fixed terms. The SEP individuals have all of the rights and obligations of IRG committee membership, including the right to vote on recommendations. The NCI Committee Management Office (CMO) is critical to the continued success of all National Cancer Institute (NCI) Federal advisory committee activities, including Boards, Advisory Committees, subcommittees, working groups, and review panels. The CMO is located in in the Office of the Director, Division of Extramural Activities (DEA), NCI. The CMO provides expert advice to the Director, NCI; Deputy Directors, NCI; the Director, DEA, NCI; and other senior-level Institute/Center/Client staff on all rules, regulations, guidelines, policies, and procedures governing the Federal Advisory Committee Act (FACA). The CMO is also an established Service Center for the management of other Institutes' Federal advisory committees. Currently, the CMO serves as the Service Center for the NIH Council of Councils (CoC) located in the Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health, and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The CMO began providing committee management support to NIAAA in April 2014. NIAAA has seven Federal Advisory committees, which include an Advisory Council, a BSC, four IRG Subcommittees, and a SEP.

The CMO is also responsible for providing logistical planning and support of the following: four NCAB meetings, three BSA meetings, and two NFAC meetings as well as numerous subcommittees and working groups. The office also continues to manage the Division's SREA Program, which includes reimbursement of thousands of peer review consultants, processing and payment of hotel contracts, teleconferences, and reconciliation of the SREA budget.

As a service center for the Office of the Director, NIH, and NIAAA, the CMO continued to provide exceptional service to these Client-Institutes on the management of their Federal advisory committees. The CMO effectively manages a comprehensive ethics program in support of CoC. Ethics services include analysis and review of Special Government Employee OGE-450s of new CoC advisory committee members and preparation of recusal lists and waivers of current members. Additionally, the CMO prepares charter renewals, analyzes potential nominees, and prepares nomination slates, *Federal Register* notices, and annual and fiscal year reports for its Service Center Clients.

Highlights of CMO activities in FY2014 include the following:

- The NCI Director requested the names of two NCI Federal Advisory Committees be changed to better reflect their purpose. They were the Frederick National Laboratory Advisory Committee (formerly NCI-Frederick Advisory Committee) and NCI Council of Research Advocates (formerly the NCI Director's Consumer Liaison Group). The CMO worked expeditiously with the NIH OFACP and GSA to ensure that the charters of each advisory committee were processed quickly.
- At the request of the NCI Director, the CMO processed the appointment of a new NCRA member. This appointment required a very quick turnaround so that the NCI Director could make a formal announcement of the appointment at a White House press conference later that week. Total turnaround time on the nomination slate was 3 days.
- The following training sessions were given by the CMO to various Federal and non-Federal audiences over the course of the year:
 - 1) PAN Webinar Training to Public Affairs Specialists at various Universities/Institutions on the activities of the NCAB and BSA
 - 2) SRO Retreat Presentation to SROs on Committee Management and SREA Activities

- Working Group Overview and Subcommittee Overview Training to newly assigned Designated Federal Officers (DFOs) working with various subcommittees and working
- 4) Groups of the NCAB, BSA, FNLAC, NCRA, and CTAC.
- FACA Training to new NCRA and CoC Designated Federal Officials (DFOs).
- The 1810-1 NIH Manual Policy Issuance titled "Procedures for Avoiding Conflict of Interest for Special Government and other Federal Employees Serving as Advisory Committee Members" was revised and released this year. The CMO participated in the OFACP Working Group to revise this policy. There were several major changes, including the SGE COI Update Schedule that was changed from updating on a meeting basis to a calendar year updating system.
- Freedom of Information Act (FOIA) Requests Received and responded to several requests

from the NIH FOIA office. One request involved information regarding Special Emphasis Panel FACA meeting rosters for CY 2009-2013. The SREA staff pulled ~601 rosters from the Committee Management IMPAC II module and reviewed each roster to see if they met the criteria of the FOIA request.

- Oversaw travel authorizations and vouchering of more than 100 SGE travel instances.
- The Committee Management IMPAC II Module is an integral part of the day-to-day activities in the management of advisory committees. As such, the CMO continues to evaluate the current database system and provide feedback to the Committee Management Users Group Representative on potential modifications to the Module.
- Responded to requests from senior NCI and Client staff on various non-FACA meetings and working group concerns.

Portfolio Tracking and Analysis

The DEA's Research Analysis and Evaluation Branch (RAEB) is the officially designated contact for scientific information on NCI-supported research. The NCI needs to collect and maintain consistent budget-linked scientific information across all of its scientific programs to analyze the Institute's research funding portfolio, make budget projections, and disseminate information about cancer. The DEA conducts analyses to project future NCI research expenditures and to provide budget justifications to Congress. The work of the RAEB allows the DEA to respond immediately to requests for information from NCI staff, the broader NIH community, and requesters nationally and worldwide regarding the NCI Funded Research Portfolio. The RAEB reviews both unfunded applications and funded extramural grants supported by the NCI to consistently link scientific categories to budget categories on all Institute programs. These capabilities are based on a sophisticated system of indexing in which research documentation staff members analyze grant applications to classify each project for its degree of relevance to Special Interest Category (SIC) and Organ Site Codes (SITE). SIC Codes are meant to describe in a consistent way the major scientific disciplines that are of stated or growing interest to the NIH, HHS, Congress, and the public. A critical characteristic of these data is comparability from one fiscal year to the next.

Trends in funding from FY2010 through FY2014 for selected organ sites and SIC Codes are presented in Tables 15 and 16. In addition, RAEB staff members serve as DEA or NCI representatives on NCI or NIH-wide scientific reporting initiatives. These groups and committees deal with various aspects of NIH grants and contracts or tracking and reporting on areas of special interest to the NIH, NCI, and/or Congress.

In FY2014, the RAEB provided numerous portfolio analyses, for example:

• Office of Government & Congressional Relations: Pancreatic Cancer Funding, FY2010 – FY2013; Pediatric Cancer Funding, FY2010 – FY2013; Stomach Cancer Funding, FY2010 – FY2013. These reports were available at RAEB online on DEA's Intranet at http://deaintranet/nci.nih.gov/

- Exclusive Pediatric Cancer R01 Grant Applications, FY2007 – FY2013
- NCI Office of Budget and Finance: Pediatric Brain Cancer Funding, FY2003 – FY2013
- Supplied Office of the Director with funding data on NCI microbiome research
- Provided scientific indexing for NCI-funded and unfunded extramural projects and contracts.
- Supported the International Cancer Research Partners (ICRP), a group of international cancer research funding organizations, by coding NCI extramural projects and cancer grants funded by other NIH institutes to the Common Scientific Outline (CSO) and by participating in the ICRP.
- Continued coordination with the NCI Office of Budget and Finance (OBF) to update and align budget reporting categories.
- Chaired the NCI Accrual Working Group for biennial reporting of NCI compliance with congressional Health Disparities reporting requirements.
- Served as NCI subject matter expert on the NIH Inclusion Operating Procedures Working Group and its Policy subgroup.
- Served as DEA representative to the NCI Communications Committee.
- Served as DEA representative to the NCI Planning and Evaluation Special Interest Group (SIG).

Extramural Research by Foreign Research Institutions and Extramural NCI Research Grants With a Foreign Research Component

In FY2014, the NCI allocated \$15.1 million to support 42 grants and contracts received by foreign research institutions. These foreign grants are listed by country, mechanism, disease area, and total

funding support in Table 17. Canadian institutions received the most funding from the NCI, with 21 grants and contracts totaling \$9.5 million. RO1s were the most common mechanisms funded, with 21 grants receiving \$6.3 million. Disease areas receiving the most NCI funding to foreign institutions were Not Site Specific (\$3.7 million), Breast (\$3.5 million), and Lung (\$1.9 million).

FY2014 Funding of Foreign Institutions (See Table 17 for more information.)


Country	Grants #	Funding \$
Canada	21	\$9,530,686
France	4	\$2,055,181
United Kingdom	6	\$1,578,337
Israel	4	\$974,929
Australia	3	\$402,672
Japan	1	\$209,449
India	1	\$189,801
Belgium	1	\$179,358
Sweden	1	\$48,190
Totals	42	\$15,168,603

In FY2014, the NCI supported 296 U.S. domestic grants with 509 foreign components. These grants are listed in Table 18 by country, mechanism, and

number of grants. Because many grants have multiple foreign contributors, the total count is greater than the total number of grants. Institutions in Canada (74), the United Kingdom (47), Australia (33), Germany (33), and China (27) were the NCI's most frequent collaborators. R01 is the most common funding mechanism used for collaborations, with 275 grants, followed by U24 (60) and U01 (58).

Success Rates of Extramural Science Categories

The RAEB assigns scientific indexing to both funded and unfunded applications, so it is possible to calculate success rates for funding in scientific categories. For example, the following graphs and tables illustrate FY2014 success rates for high incidence cancers (Figure 9) and for selected Special Interest Categories (SIC) (Figure 10). The highest incidence cancer rankings are from the SEER rank of top 15 cancer sites, 2004-2008, age-adjusted incidence for all races and sexes. Success rates were calculated by dividing the total number of newly funded applications in 2014 (Type 1 and 2 grants) for that research category (SIC or Organ Site) by the total number of applications for that research category (see Figures 9 and 10).





Selected Oncology Sites	SEER Rank*	Types 1 & 2 Funded in 2014 for This Site	Total Applications Received in 2014 for This Site	2014 Success Rate for This Site	Total Funding for Types 1 & 2 in 2014 for This Site
Stomach	14	30	65	46.15%	\$4,016,544
Bladder	5	55	137	40.15%	\$8,846,964
Uterus	9	42	107	39.25%	\$4,629,183
Non-Hodgkins Lymphoma	7	124	370	33.51%	\$26,887,255
Kidney	8	51	155	32.90%	\$5,995,262
Leukemia	10	193	646	29.88%	\$68,151,644
Colon, Rectum	4	189	819	23.08%	\$43,958,523
Melanoma	6	116	518	22.39%	\$28,696,896
Pancreas	11	139	653	21.29%	\$37,955,513
Liver	15	75	377	19.89%	\$14,555,209
Lung	3	193	1,018	18.96%	\$53,847,501
Thyroid	12	15	83	18.07%	\$4,410,551
Prostate	1	166	982	16.90%	\$45,877,910
Breast	2	375	2,266	16.55%	\$125,678,774
Oral cavity and pharynx	13	13	88	14.77%	\$3,240,428

*SEER rank of top 15 cancer sites 2004-2008 age-adjusted incidence for all races and sexes.




Figure 10. FY2014 Success Rates for Applications in Selected Special Interest Categories (SIC) Sorted by Success Rate

Special Interest Category	Type 1 & 2 Funded in 2014 for This SIC	Total Applications Received in 2014 for This SIC	2014 Success Rate for This SIC	Total Funding for Types 1 & 2 in 2014 for This SIC
Prevention	268	827	32.41%	\$140,401,111
Genomics	271	896	30.25%	\$77,305,241
Oncogene	373	1,276	29.23%	\$93,514,679
Inflammation	135	495	27.27%	\$25,408,709
Angiogenesis	75	312	24.04%	\$13,543,130
Biomarkers	364	1532	23.76%	\$82,283,928
Early Detection	163	721	22.61%	\$63,991,157
Therapy	1,060	4,910	21.59%	\$540,797,213
Obesity	56	266	21.05%	\$12,114,009
Metastasis	333	1,608	20.71%	\$83,900,498
Diagnosis	378	1,837	20.58%	\$164,017,364

Information Resources Management

The **Applied Information Systems Branch** (AISB) provides integrated computer support, information technology expertise, and information systems development for the DEA. The AISB maintains and monitors the DEA Internet and Intranet websites; designs, develops, and maintains Division-specific software applications; administers and maintains various DEA servers; provides help desk support; provides oversight of hardware and connectivity; and serves as a liaison with the NIH Center for Information Technology (CIT) and the NCI Center for Biomedical Informatics and Information Technology (CBIIT). Its mission is critical to the Division in communicating current information technology activities and new developments to all components of the NCI and NIH as well as to external reviewer and applicant communities.

DEA's Information Technology and Information Systems contracts are managed by the AISB. The AISB has a computer support team to track staff requests, manage the Division's computer equipment inventory, and provide computer-related training, as needed. Specific projects utilizing the technologies and services provided by the AISB are described under the appropriate functions of the DEA throughout this report.

For FY2014, specific AISB accomplishments are highlighted below.

System Administration and Desktop Support

- Secured 30 iPads for use as e-readers for NCAB closed sessions and an imaging cart to deploy and manage all 30 devices. The first rollout for a closed session was an overall success, which drastically reduced document duplication and a substantive reduction in overall costs.
- Awarded new software and systems support contracts for the DEA Information System (DEAIS) and Fiscal Linked Analysis of Research Emphasis (FLARE).
- Partnered with NCI's Center for Bioinformatics and Information Technology (CBIIT)

to purchase Windows tablets for evaluation as possible substitution for laptops. Worked closely with the CBIIT imaging team and DEA staff to work through technical issues.

- Performed PC/laptop upgrades, bringing the DEA into compliance with a 3-year equipment refresh cycle.
- Developed new alliances and better working relationships with several CBIIT teams (Server Management, Equipment Imaging, Service Now Team) as a result of a newly established CBIIT liaison position.
- Set up and configured new servers for the FLARE production database, DEAIS configuration management, DEAIS Oracle production, and DEAIS production applications.
- Migrated local Oracle databases with eRA's change of the character set in the eRA/IMPAC II databases to UTF-8 (UCS Transformation Format – 8 bit) to support Unicode characters, primarily based on business requests to handle Greek characters.
- Upgraded the development and production databases to 11G, then 12C (installed Oracle software, created and configured databases, and loaded and tested data).
- Security Assessment and Authorization (SA&A)
 - Worked with NCI staff and contractors in support of SA&A packages for DEA GSS (General Support System) and FLARE, low and moderate applications respectively. Remediated deficiencies under AISB's control and documented NIH inherited controls. Documented responses to Plan of Actions and Milestones (POA&M). Documented changes for the Annual Assessment Review for control families, contingency plans, and participated in table-top exercises.
 - In addition to regular annual activity, the following reports and documentation were updated for DEA GSS and FLARE systems SA&A: Contingency Plan, CP Testing,

CP Training, Risk Assessment, Annual Assessment, System Security Plan, and E-Authentication/FIPS-199.

 Planned, organized, and worked with the Independent Validation and Verification team (IV&V) from the SRA contractor for FLARE's Re-Certification and FY2014 Annual Assessment requirements.

Application Development Projects

- After a successful pilot, the custom-developed Funding Patterns Summary and Blog website became fully operational. It readily manages funding report information and accepts and manages comments from the public. New content can be readily loaded while structured archives of both content and comments are retained and available.
- The Concept to Award Tracking System (CATS) notification implementation plan was developed and readied for deployment.
- All end-user requirements were incorporated, and the NCI Grant-Related Directory (NGRAD) application was promoted to full production.
- The Staff Listing application was adjusted to draw on the NIH Electronic Directory (NED) as the data source, provisioned with an administrative module, and updated to incorporate the DEA Web graphic user interface look and feel.
- Major revisions were made to the administrative and end-user modules of the Extramural Science Administrator Training – Tracking System (ESATTS).

User Training

- Developed a training workshop coupled with the preparation of an 83-page manual for the Cisco WebEx virtual meeting service. Presented the material to staff.
- Played a large role in transitioning NIH/ AISB telecommunication towards a Cisco WebEx platform; helped PRESTO conduct

21 WebEx seminars and meetings, 5 webinars, and 10 training sessions.

DEA Website Development

• Implemented final changes to the new President's Cancer Panel (PCP) website and launched the PCP Annual Report. AISB provided essential management and input in the design and display of the PCP website, hosted on DEA's Internet.

Development and Support of Software Applications for the Research Analysis and Evaluation Branch (RAEB) Scientific Coding and Analysis

- Performed the following upgrades and maintenance to the FLARE system and environment:
 - Upgraded to Oracle 11G
 - Enhanced the Women's Health report (by subproject)
 - Ran FLARE under the NIH Login/PIV in the test environment
 - Allowed users to index non-NCI grants (duals and joint-funded) for FY2013 grants
 - Refined and enhanced reports (using 'BIRT' tool), which replaced the current Excelbased Crystal reports; met the goal of eliminating usage of the Crystal reports.
 - Completed development for version 1.0 production release of RAEB Online, to be initially available to internal NCI staff (Program Officers and SROs) for showing success rates and statistical analysis of RAEB disease coding data, which included a new menu, additional Division/Office/Center datasets, separation of grants and contracts in the charts, additional stacked charts, and numerous new features and bug fixes. Provided a demonstration to the new NCI CBIIT Director. An SPL demonstration is expected in 2015.

AISB Staff Involvement

Represented the needs and concerns of DEA staff through active participation in the following groups:

- Frederick Security Team
- CBIIT Process Improvement Team
- NCI Computer Upgrade Project Technology Refresh Program
- NIH Mobile Device Policy Team
- NCI Conference Room Special Interest Group (SIG)

- Service Now SIG
- NCI Division IT Contacts Meeting
- Science Management Workspace (SMW)
- DEA Brown Bag seminars
- International Cancer Research Portfolio (ICRP) Data Meetings
- NCI BAD codes (Basic and Applied) Working Group
- NCI Coding QA/QC Team
- NIH eRA Technical Users Group (eTUG)
- Shady Grove IT and Server Consolidation Planning Team

Office of the Director

- Directs and administers the operations of the Division, including those activities relating to grant review and administration, contract review, referral and program coordination of FOAs, and Advisory Committee and Board activities.
- Directly coordinates and manages the NCAB and the BSA.
- Coordinates coding of NCI's grant portfolio.
- Initiates, coordinates, and implements Institute policies and procedures relating to grants and contracts reviews.
- Oversees the NCI's Committee Management Office.
- Implements NCI policies regarding extramural research integrity.
- Advises the Scientific Program Leadership (SPL) Committee, NCI, on extramural guidelines, review, advisory activities, and implementation strategies.
- Coordinates NCI extramural staff training requirements with the NIH.
- Represents the NCI on the NIH-wide Extramural Program Management Committee (EPMC) with responsibility for development of extramural policy and procedures across all NIH Institutes and Centers.
- Oversees inclusion of gender, minority, and children.
- Serves as the NCI Research Integrity Office.
- Coordinates, develops, and implements extramural policy.

Paulette Gray, Ph.D.	Director
Vacant	Deputy Director
Peter Wirth, Ph.D.	Assistant Director
Dawn William	Senior Program Analyst
Kathy Tiong	Program Analyst
Judi Ziegler	Secretary

DEA Processing and Distribution Unit (DPDU)*

• Provides services to DEA staff, including the coordination, consolidation, purchasing of supplies, tracking of expenditures, and preparation of meeting folders, Board book and orientation documents, and annual reports. In conjunction with the establishment of this unit, the number of DEA Purchase Cards was reduced from 15 to 6. This change has minimized hoarding of office supplies and overall reduction in dollar costs associated with the use of DEA Purchase Cards.

Ricardo Rawle	Special Assistant to the Director
Clara Murphy	Program Specialist
Adrian Bishop	Staff Assistant
Sanjeeb Choudhry	Staff Assistant
Robert Kruth	

^{*}Established in February 2014.

Committee Management Office, OD

- Coordinates functionally related Federal advisory committee activities across the Institute and its client-Institutes. The office manages NCI advisory committees and serves as an NIH service center for the NIH Council of Councils, the NIH, and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to ensure that appropriate policies and procedures are in place to conduct the designated mission of each committee.
- Provides policy guidance to the NCI and client-Institute staff on administrative and technical aspects of Federal advisory committees; coordinates activities with all other NCI advisory committees; implements policies and procedures designed to avoid conflicts in the nomination, selection, and recruitment of board members; implements CM Module guidelines and procedures to ensure that all committee-related data are correctly entered into the database for preparation and submission of required annual reports to the President of the United States, HHS, and NIH; provides logistical support for NCAB, FNLAC, and BSA meetings, subcommittees, and work groups; and facilitates NCAB and BSA committee-related travel.
- Researches and evaluates conflict of interest and foreign activities issues for client-Institutes and provides advice on resolutions affecting advisory committee members serving as Special Government Employees.
- Provides administrative support for the peer review system by compensating consultants for their services on NCI IRG Subcommittees and SEPs, reimbursing consultants for travel and other expenses, and approving and processing payments for other activities related to review such as hotel contracts and teleconferencing.

Claire Harris	Committee Management Officer
Janet Craigie	Deputy Committee Management Officer
Malaika Staff	Senior Committee Management Specialist
Etsegenet Abebe	Committee Management Specialist
Natasha Copeland	Committee Management Specialist
Darnetta King	Committee Management Specialist
Alonda Lord	Committee Management Specialist
Rosalind Niamke*	Committee Management Specialist

*Joined in February 2014.

Program and Review Extramural Staff Training Office

- Develops and implements both broad-based and focused curricula for NCI Program and Review staff.
- Coordinates training for other extramural staff upon request.
- Identifies and develops resources (electronic and human) to facilitate learning and optimal individual, group, and organizational performance.
- Collaborates with NCI Divisions, Offices, Centers, and groups both internal and external to the NCI, to provide customized job-related training and career development opportunities.
- Tracks participation of extramural staff in NIH- and NCI-sponsored training activities.

Michael Small, Ph.D.	Chief
Scot Chen, Ph.D.,.	Health Scientist Administrator
Ivan Ding, M.D	Health Scientist Administrator
Gregory Jones	Program Analyst
Destiny Mercado	Program Analyst
Cecily Nelson, M.S*	Program Analyst
Denise Santeufemio	Program Analyst

*Left April 2014.

Office of Referral, Review, and Program Coordination

- Coordinates program concept development; publication functions; and receipt, referral, and assignment of all NCI applications.
- Coordinates review activities of the RTRB, RPRB, SRB, RTCRB, and PCRB.

Shamala Srinivas, Ph.D.	Associate Director
Paul Gallourakis*	Special Assistant to the Associate Director
Catherine Battistone	. Program Analyst
Linda Brown	Program Specialist
Linda Coleman †	Committee Management Specialist

*Moved to RTCRB in February 2014.

[†]Moved to NIH Clinical Center in 2014.

Special Review and Logistics Branch*

- Plans, manages, and assists in the scientific and technical merit review of applications received in response to RFAs, PAs, and PARs and contract proposals received in response to RFPs.
- Identifies and recommends appropriate review committee members as required for the review of assigned applications and proposals.
- Provides the SROs and other support staff for the technical review committees.
- Serves as the information and coordination center for all grant applications and contract proposals pending review by the Branch.
- Provides input and advice on grant and contract review policy and procedures, application and proposal patterns, and research trends and other related information, as required.

Thomas Vollberg, Ph.D.†	. Acting Chief
Kenneth Bielat, Ph.D. [†]	. Scientific Review Officer
Eun-Ah Cho, Ph.D. [‡]	. Scientific Review Officer
Donald Coppock, Ph.D. [†]	. Scientific Review Officer
Jeffrey DeClue, Ph.D. [†]	. Scientific Review Officer
Gerald Lovinger, Ph.D.†	. Scientific Review Officer
Joyce Pegues, Ph.D.†	. Scientific Review Officer
Marvin Salin, Ph.D. ‡	. Scientific Review Officer
Ellen Schwartz, D.Ed.†	. Scientific Review Officer
Viatcheslav Soldatenkov, Ph.D. [‡]	. Scientific Review Officer
Adriana Stoica, Ph.D.§	. Scientific Review Officer
Thomas Winters Ph.D. [‡]	. Scientific Review Officer
Zhiqiang Zou, Ph.D. [‡]	. Scientific Review Officer
Thu Nguyen [‡]	. Program Analyst
Rosalind Niamke**	. Lead Staff Assistant
Donnell Wilson [†]	. Lead Staff Assistant
Alicia Craig [†]	. Staff Assistant
Bratati Chowdhury [‡]	. Staff Assistant
Grace Hughitt (Tato)**	. Staff Assistant
Hanh "Julie" Hoang†	. Staff Assistant
Adrian Bishop ^{‡‡}	. Mail and File Clerk
Sanjeeb Choudhry ^{‡‡}	
Robert Kruth ^{‡‡}	
Clara Murphy ^{‡‡}	. Program Assistant

*Abolished in February 2014.

[†]Moved to RTCRB in February 2014.

[‡]Moved to SRB in February 2014.

[§] Moved to RTRB in February 2104.

^{**}Moved to CMO in February 2014.

[#]Moved to DPDU in February 2014.

Special Review Branch (SRB)*

- Plans, manages, and assists in the scientific and technical review of grant and cooperative agreement applications received in response to RFAs, PAs, and PARs
- Identifies and recommends appropriate review committee members as required for the review of assigned applications.
- Provides the SROs and other support staff for the technical review committees.
- Serves as the information and coordination center for all grant applications and cooperative agreements pending review by the Branch.
- Provides input and advice on grant review policy and procedures, application patterns, research trends, and other related information, as required.

Eun-Ah Cho, Ph.D	Acting Chief
Marvin Salin, Ph.D.†	Scientific Review Officer
Cliff Schweinfest, Ph.D	Scientific Review Officer
Viatcheslav Soldatenkov, Ph.D.	Scientific Review Officer
Thomas Winters Ph.D.	Scientific Review Officer
Zhiqiang Zou, Ph.D	Scientific Review Officer
Thu Nguyen	Program Analyst
Bratati Chowdhury	Staff Assistant
Imela Gradington-Jones [‡]	Staff Assistant
Tonya Miller§	Lead Staff Assistant
Nakessha Mendez Modeste [‡]	Staff Assistant

*Established in February 2014.

†Retired in May 2014.

[‡]Joined in December 2014.

§ Joined in August 2104.

Research Technology and Contract Review Branch (RTCRB)*

- Plans, manages, and assists in the scientific and technical merit review of grant and cooperative agreement applications received in response to RFAs and PARs and contract proposals received in response to RFPs.
- Identifies and recommends appropriate review committee members as required for the review of assigned applications and proposals.
- Provides the SROs and other support staff for the technical review committees.
- Serves as the information and coordination center for all technology-related grant applications and contract proposals pending review by the Branch.
- Provides input and advice on grant and contract review policy and procedures, application and proposal patterns, and research trends and other related information, as required.

Thomas Vollberg, Ph.D	Chief
Kenneth Bielat, Ph.D.	Scientific Review Officer
Donald Coppock, Ph.D.	Scientific Review Officer
Jeffrey DeClue, Ph.D.	Scientific Review Officer
Gerald Lovinger, Ph.D.	Scientific Review Officer
Joyce Pegues, Ph.D. [†]	Scientific Review Officer
Ellen Schwartz, D.Ed	Scientific Review Officer
Paul Gallourakis	Program Analyst
Donnell Wilson	Lead Staff Assistant
Alisha Craig	Staff Assistant
Hanh "Julie" Hoang	Staff Assistant
Lauren McLaughlin	Staff Assistant
Kimberly Millner [‡]	Staff Assistant

*Established in February 2014.

[‡]Joined in December 2013.

[†]Retired in July 2014.

Program Coordination and Referral Branch

- Serves as the information and coordination point within the NCI for the development, clearance, publication, and tracking of all NCI extramural program (funding) initiatives, which include all RFAs, PAs, and Notices submitted for publication in the *NIH Guide for Grants and Contracts,* and also on Grants.gov, which is a Federal-wide online portal for electronic submission of grant applications.
- Coordinates the development and periodic revision of referral (i.e., application assignment) guidelines within the NCI for both external and internal use.
- Coordinates the development of shared (referral) interest statements with other NIH Institutes and Centers (ICs) so that grant applications of possible or real mutual interest can be properly assigned for receipt, review, and/or funding.
- Serves as the liaison to the Center for Scientific Review (CSR), NIH, to ensure the appropriate referrals (i.e., assignments) of grant applications to the Institute and the transfers of grant applications between the NCI and other NIH ICs.
- Refers new (Type 1) applications to the appropriate cancer activity area(s) according to the NCI Internal Referral Guidelines that define the program interests of each of the 50 cancer activity areas (which typically represent program branches in the NCI extramural divisions).
- Semi-automatically refers resubmission (A1) and renewal (Type 2) applications to the cancer activity area that accepted the previously submitted application (with quality control measures performed to ensure the accuracy of referrals).
- Coordinates requests from Program staff for application status changes (including corrections of application assignments and numbers, which is done in collaboration with NCI Program staff, CSR referral staff, and referral staff of other ICs and agencies) and for acceptance of grant assignments.
- Serves as the NCI contact point and liaison to involved parties at the NIH for approval of the use of cooperative agreement mechanisms and for conversion of grants to cooperative agreements.
- Works with NCI Program and Review staff and with NIH referral liaisons to address unresolved referral and review issues with the CSR and other NIH ICs.
- Receives and distributes advance copies of applications to Review and Program staff.
- Receives Letters of Intent (LOI) from applicants (principal investigators) intending to submit large budget grants (including, but not limited to, program projects and cooperative agreements for clinical trials).
- By handling communications with applicants and NCI Program staff members, coordinates approvals (and disapprovals) of the NCI to sponsor the submission of individual conference (R13) grant applications.
- Serves as the primary point of contact and provides assistance at the NCI for applicants who want to apply for an Academic Research Enhancement Award (i.e., the NIH R15 AREA grant mechanism).
- Processes and tracks requests for submissions of large-budget grant applications that allow them to be received at the NIH, peer reviewed, and possibly awarded by the NCI.
- Maintains database records of prospective large-budget grant and conference grant applications for each council round.
- Serves as the primary NCI information and referral point for the extramural scientific community on a broad range of subjects, including grant guidelines, application information, new initiatives announced as RFAs or PAs, and the review process.

- Assists the extramural community in navigating the NIH and NCI Web pages to help users obtain current information, forms, and guidelines.
- Directs applicants to the appropriate SROs and Program Officers for information regarding the status of the review and award of their grant applications.
- Tracks and analyzes trends of CSR referral to study sections and resultant review outcomes.
- Provides data and data analyses on funding opportunities and on the receipt and referral of grant applications to NCI senior staff members and committees.

Christopher L. Hatch, Ph.D	. Chief
David Contois	. Referral Officer, NCI/NIH Referral Liaison
Anandarup Gupta, Ph.D	. RFA/PA Coordinator, Scientific Review Officer
Leota Hall	. Referral Officer, NCI/NIH Referral Liaison
Bratin Saha, Ph.D.	. Referral Officer, Scientific Review Officer
Jan Woynarowski, Ph.D	RFA/PA Coordinator, Scientific Review Officer
Natacha P. Lassègue	Program Analyst
Dianne Johnson*	•

*Joined in August 2014.

Research Programs Review Branch

- Plans, coordinates, and manages the scientific merit review of program project grants, specialized centers, and other grant mechanisms, as necessary, by Special Emphasis Panels.
- Identifies and recommends appropriate review committee members for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, research trends, and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions/Offices/Centers and other DEA Branches.

Caron Lyman, Ph.D.	. Chief
Shakeel Ahmad, Ph.D.	. Scientific Review Officer
Caterina Bianco Ph.D.	. Scientific Review Officer
Majed Hamawy, Ph.D., M.B.A	. Scientific Review Officer
Wlodek Lopaczynski, M.D., Ph.D	. Scientific Review Officer
David Ransom, Ph.D	. Scientific Review Officer
Delia Tang, Ph.D	Scientific Review Officer
Charles Choi	. Program Analyst
Monica Congo*	. Program Analyst
Shannon Harley†	. Staff Assistant
Deneen Mattocks	. Lead Staff Assistant
Kenneth Nock†	. Staff Assistant

*Left in December 2013.

[†]Joined in September 2014.

Resources and Training Review Branch

- Plans, coordinates, and manages the scientific merit review of cancer center, training, education, and career development grant and cooperative agreement applications by chartered IRG committees and Special Emphasis Panels.
- Arranges for and participates in onsite assessments (site visits) of the research capabilities and facilities of selected applicants (i.e., Cancer Centers).
- Identifies and recommends appropriate review committee members and site visitors, as required, for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, and research trends and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions/Offices/Centers, other DEA Branches, and the Center for Scientific Review.

Robert E. Bird, Ph.D.	Chief
Lynn Amende, Ph.D.*	Scientific Review Officer
Ilda Melo, Ph.D	Scientific Review Officer
Timothy Meeker, M.D.	Scientific Review Officer
Sergei Radaev, Ph.D	Scientific Review Officer
Sonya Roberson, Ph.D	Scientific Review Officer
Adriana Stoica, Ph.D.†	Scientific Review Officer
Sheila Hester	Program Specialist
Linda Edwards	Staff Assistant
Gelia Holloway	Lead Staff Assistant
Leslie Kinney	Staff Assistant
Bridgette Wilson	Staff Assistant

*Retired in July 2014.

[†]Moved from SRLB to RTRB in February 2014.

Office of Extramural Applications

- Coordinates activities of the Research Analysis and Evaluation Branch (RAEB) and the Applied Information Systems Branch (AISB)
- Provides budget-linked research portfolio data and coordinates the information management of extramural NCI-supported research.

Amir Sahar-Khiz, Ph.D., M.B.A., PMP	Associate Director
Justin Rhoderick	Program Analyst

Research Analysis and Evaluation Branch (RAEB)

- Serves as the Institute's officially designated, centralized source of scientific information and science-based budget information on NCI-supported research.
- Analyzes and classifies the science content of all Institute-supported research projects.
- Analyzes the distribution of funds among research areas; these analyses serve as a basis for budget projections.
- Reports and answers inquiries on the scientific and budgetary aspects of Institute-funded research, including research grants, center grants, training grants, and research contracts.
- Maintains liaisons with other organizations involved in related classification activities.
- Documents the need for proposed RFAs by comparing RFA concepts with existing NCI-supported research and with unsolicited applications.

Marilyn Gaston.....Chief Edward Kyle.....Deputy Chief

Research Documentation

- Analyzes and indexes grants and contracts for the Branch's computerized systems.
- Analyzes extramural projects for relevance to Special Interest Categories (SICs) and Anatomic Sites to determine the officially reported figures for Institute support and to provide a basis for budget projections.
- Maintains liaison with other offices within the Institute to ensure consistent reporting of data.
- Monitors the results of NCI's grant-supported research.
- Assists other NCI organizations by indexing NCI research projects for attributes other than SICs and Sites, for example, Common Scientific Outline (CSO) Codes and AIDS Categories.

Edward Kyle	Lead Biologist/Team Leader
Beth Buschling	Biologist
Beverly Johnson, M.S*.	Biologist
Bernard Whitfield	Biologist
Tyrone Wilson	Biologist

*Left in June 2014.

Technical Operations, Inquiry, and Reporting

- Provides specialized data querying, archiving, and reporting functions for the Division and the Institute.
- Coordinates Institute data reporting with the NCI Office of Budget and Financial Management, NIH Population Tracking and Inclusion Committee, and others.
- Answers inquiries from Congress, the public, the press, and others concerning any phase of Institute-supported work.
- Conducts in-depth analyses of extramural research data, including trends analyses.
- Identifies emerging priority areas for data collection and analysis.
- Ensures that terms and categories for indexing are updated and reflect current trends in cancer research, and maintains a thesaurus of term definitions.

- Manages RAEB's FLARE grants documentation and indexing database, ensuring reliability and completeness of its contents.
- Maintains and updates archival document files.
- Works with contractors and the AISB to refine RAEB's computer applications to meet the Branch's needs and resolve FLARE computer application problems for the Branch.
- Represents the DEA as its communications coordinator in the Office of Communications and Education Steering Committee.

Gail Blaufarb, M.S	Lead Biologist/Team Leader
William Clark, M.S	Biologist
Clarissa Douglas	Program Specialist
Rajasri Roy, Ph.D.	Epidemiologist

Applied Information Systems Branch (AISB)

- Fulfills the information technology (IT) requirements of the Division by coordinating information resources management (IRM) activities with other relevant NCI and NIH units, and by providing high-quality information analysis, design, development, and coordination of applications in support of the Division's business processes.
- Serves as the focal point for the Division in the development, deployment, and application of specialized software and databases required for the conduct of review, referral, coding, advisory, and other extramural applications.
- Serves as the liaison with the NCI Center for Biomedical Informatics and Information Technology (CBIIT) staff; NCI computer professionals; NCI units charged with execution of extramural IRM functions; trans-NIH functional units such as the CSR, Office of Policy for Extramural Research Administration (OPERA), and Office of Extramural Research (OER); and the IMPAC II and NIH eRA (electronic Research Administration) staff and systems.
- Supports connectivity and design of Internet and Intranet applications.
- Establishes, administers, and monitors commercial support contracts to provide design, production, and maintenance for microcomputer equipment and information storage and retrieval systems that are not covered by CBIIT.
- Formulates DEA-specific office automation policy.
- Provides staff/lead users with technical support and training for DEA IT applications.
- Coordinates general user support and training with NCI and NIH services.
- Provides Division-specific applications of video teleconferencing and audiovisual services in support of review and Board activities.
- Provides management with recommendations for establishing and implementing policies for conducting Division computer-assisted presentations, as necessary.
- Reviews user-created applications and recommends and/or designs changes to improve efficiency and effectiveness.

Gregory Fischetti Chief

Application Development Team

- Analyzes and coordinates life-cycle software development for the Division.
- Develops and designs applications to support the Division's business processes, including user guides.
- Coordinates security assessment and authorization for the Division's general support system applications.
- Develops, administers, and monitors contracts for acquisition, support, and maintenance of database systems.
- Formulates system development policy, and oversees eRA/IMPAC II operations for the Division.
- Coordinates internal user groups and training for specific DEA applications.

Todd Hardin	. Team Leader
Teresa Park	Information Technology Specialist
Vivien Yeh	Information Technology Specialist

Information Management Team

- Designs and maintains the Division's Intranet and Internet sites and pages, and identifies documents to be placed on the NCI website to make Division information more accessible to the public.
- Coordinates security assessment and authorization for systems and applications developed and implemented for the Research Analysis and Evaluation Branch (RAEB).
- Develops new Web-based software applications that will enhance the productivity and efficiency of extramural processes within the DEA and the distribution of Division information throughout the NCI.
- Coordinates application development and supports the RAEB in the areas of scientific coding and analysis.
- Administers and implements purchasing for the Division's computer hardware/software, maintenance, and supplies.
- Establishes partnerships and ongoing communications with staff and external customers to foster openness and collaboration in accomplishing the information initiatives of the Division.
- Works with DEA staff to ensure the current utility and linkages of documents placed on the Web.

Elaine Taylor	Team Leader
Michael Hu	Information Technology Specialist
Joshua Rhoderick	Information Technology Specialist
Lorrie Smith	Information Technology Specialist

Operations Team

- Administers and maintains the Division's application, database, and Web servers.
- Oversees and provides guidance for IT security policies and regulations.
- Coordinates and implements the Division's security assessment and authorization policies for the server environment.
- Manages the software application environment for development, testing, and production.
- Coordinates network connectivity for the Division with CBIIT.
- Provides user and technical support and training for desktop and laptop computers, office automation products, and applications.
- Plans and recommends purchases of all IT-related equipment for the Division.
- Maintains an accountable IT equipment inventory for the Division.
- Develops and maintains policies for the use of office automation technology.

Richard Florence	Team Leader
Roderick James	Information Technology Specialist
Raymond Vidal	Information Technology Specialist

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2014 Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
10/25/2013	CA13-010	U54	Sub-Saharan African Collaborative HIV and Cancer Consortia	OHAM
10/30/2013	CA13-015	UH2, UH3	Cancer Detection, Diagnostic, and Treatment Technologies for Global Health	GCHR
11/4/2013	CA14-001	U54	Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Revision to Enhance the Collection of Cervical Cancer Screening Data	DCCPS
	CA13-014	UM1	NCI Community Oncology Research Program (NCORP) - Minority/ Underserved Community Sites	DCP
11/8/2013	CA13-013	UM1	NCI Community Oncology Research Program (NCORP) - Community Sites	DCP
	CA13-012	UM1	NCI Community Oncology Research Program (NCORP) Research Bases	DCP
	CA14-003	R21	Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research	CSSI
12/20/2013	CA14-004	R33	Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research	CSSI
12/20/2013	CA14-005	R21	Early-Stage Development of Innovative Technologies for Biospecimen Science	CSSI
	CA14-006	R33	Validation and Advanced Development of Emerging Technologies for Biospecimen Science	CSSI
	CA14-007	R01	Using Social Media to Understand and Address Substance Use and Addiction	DCCPS
1/3/2014	CA14-009	R21	Using Social Media to Understand and Address Substance Use and Addiction	DCCPS
	CA14-008	R01	Using Social Media to Understand and Address Substance Use and Addiction	DCCPS
2/12/2014	CA14-002	R44	SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	SBIRDC
6/5/2014	CA14-501	U24	Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN)	DCTD
	CA14-010	U01	Molecular and Cellular Characterization of Screen-Detected Lesions	DCP
6/6/2014	CA14-011	U01	Molecular and Cellular Characterization of Screen-Detected Lesions - Coordinating Center and Data Management Group	DCP
7/17/2014	CA14-013	U54	Centers of Cancer Nanotechnology Excellence (CCNEs)	DCP
7/31/2014	CA14-012	U01	Cancer Intervention and Surveillance Modeling Network (CISNET)	DCCPS
8/8/2014	CA14-502	UM1	Limited Competition: AIDS Malignancy Clinical Trials Consortium	OHAM
9/4/2014	CA14-503	U01	Limited Competition: International Agency for Research on Cancer (IARC) Monographs Program	DCB
9/5/2014	CA14-019	U01	Pediatric Preclinical Testing Consortium: Coordinating Center	DCTD
9/3/2014	CA14-018	U01	Pediatric Preclinical Testing Consortium: Research Programs	DCTD

Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2014

Sorted by Division, Office, and Center

Division, Office, and Center	RFA	Mechanism	Title	Date of Publication
	CA14-003	R21	Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research	_
CSSI	CA14-004	R33	Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research	10/00/0010
0001	CA14-005	R21	Early-Stage Development of Innovative Technologies for Biospecimen Science	- 12/20/2013
	CA14-006	R33	Validation and Advanced Development of Emerging Technologies for Biospecimen Science	
DCB	CA14-503	U01	Limited Competition: International Agency for Research on Cancer (IARC) Monographs Program	9/4/2014
	CA14-001	U54	Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Revision to Enhance the Collection of Cervical Cancer Screening Data	11/4/2013
DCCPS	CA14-007	R01		
20010	CA14-008	R01	Using Social Media to Understand and Address Substance Use and Address	1/3/2014
	CA14-009	R21		
	CA14-012	U01	Cancer Intervention and Surveillance Modeling Network (CISNET)	7/31/2014
	CA13-012	UM1	NCI Community Oncology Research Program (NCORP) Research Bases	11/8/2013
	CA13-013	UM1	NCI Community Oncology Research Program (NCORP) - Community Sites	
DCP	CA13-014	UM1	NCI Community Oncology Research Program (NCORP) - Minority/ Underserved Community Sites	
	CA14-010	U01	Molecular and Cellular Characterization of Screen-Detected Lesions	6/6/0014
	CA14-011	U01	Molecular and Cellular Characterization of Screen-Detected Lesions - Coordinating Center and Data Management Group	6/6/2014
	CA14-013	U54	Centers of Cancer Nanotechnology Excellence (CCNEs)	7/17/2014
	CA14-018	U01	Pediatric Preclinical Testing Consortium: Research Programs	0/5/2014
DCTD	CA14-019	U01	Pediatric Preclinical Testing Consortium: Coordinating Center	9/5/2014
	CA14-501	U24	Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN)	6/5/2014
GCHR	CA13-015	UH2, UH3	Cancer Detection, Diagnostic and Treatment Technologies for Global Health	10/30/2013
OHAM	CA13-010	U54	Sub-Saharan African Collaborative HIV and Cancer Consortia	10/25/2013
	CA14-502	UM1	Limited Competition: AIDS Malignancy Clinical Trials Consortium	8/8/2014
SBIRDC	CA14-002	R44	SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization	2/12/2014

Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs)in FY2014

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
12/4/2013	HG14-001	U54	BD2K-LINCS-Perturbation Data Coordination and Integration Center (DCIC)	ALL DIVISIONS	NIH
12/10/2013	RM14-001	R01	Computational Analyses Exploiting Reference Epigenomic Maps	ALL DIVISIONS	NIH-RM
	AI14-009	R01	U.SSouth Africa Program for Collaborative Biomedical	OHAM	NIH
12/13/2013	AI14-010	R21	Research	O I A M	
	HL14-031	U24	Development of an NIH Data Discovery Index Coordination Consortium	DCCPS	NIH
	RM13-015	U54	NIH Coordination and Evaluation Center for Enhancing the Diversity of the NIH-Funded Workforce Program		
	RM13-016	U54	NIH Building Infrastructure Leading to Diversity (BUILD) Initiative		
	RM13-017	U54	NIH National Research Mentoring Network (NRMN)		
12/19/2013	RM13-020	R33	Validation and Advanced Development of Technologies for the Study of Biological Properties of Single Cells	ALL DIVISIONS	NIH-RM
	RM13-021	R21	Exceptionally Innovative Tools and Technologies for Single Cell Analysis		
	RM13-022	R01	Revisions to Add Single Cell Analysis to Active Research		
	RM13-023	U01	Projects		
1/15/2014	HG14-007	K01	Mentored Career Development Award in Biomedical Big Data Science for Clinicians and Doctorally Prepared Scientists		
1/16/2014	HG14-008	R25	Courses for Skills Development in Biomedical Big Data Science	DCCPS	NIH
	HG14-009	R25	Open Educational Resources for Biomedical Big Data		
1/17/2014	RM13-019	DP7	NIH Directors Biomedical Research Workforce Innovation Award: Broadening Experiences in Scientific Training (BEST)	ALL DIVISIONS	NIH-RM
1/24/2014	AI14-018	U01	U.S-South Africa Program for Collaborative Biomedical Research	OHAM	NIH
	OD14-002	R01	Empirical Research on Ethical Issues Related to Central IRBs and Consent for Research Using Clinical Records and Data	DCCPS	NIH
2/12/2014	RM14-002	U01	Limited Competition: Renewal Applications for Technology Development for New Affinity Reagents Against the Human Proteome	ALL DIVISIONS	NIH-RM
4/18/2014	RM14-005	R21	Undiagnosed Diseases Gene Function Research		
	HG14-004	T32	Predoctoral Training in Biomedical Big Data Science		
4/22/2014	HG14-005	T32	Revisions to Add Biomedical Big Data Training to Active Institutional Training Grants	DCCPS	NIH

continued

Table 2 (cont'd).NCI Participation in Trans-NIH Requests for Applications (RFAs)in FY2014

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	lssuing NIH-IC
4/24/2014	OD14-004	SI2	Lasker Clinical Research Scholars Program	CCR	NIH
4/25/2014	OD14-005	U01	NIH Research Evaluation and Commercialization Hub (REACH) Awards	DCCPS	NIH
7/16/2014	AI14-057	R01	U.SChina Program for Research Toward a Cure for HIV/ AIDS	OHAM	NIAID
7/24/2014	RM14-003	R01	NIH Transformative Research Awards	ALL DIVISIONS	NIH-RM
8/7/2014	TW14-001	U01	Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) Research	DCCPS	NIH
8/8/2014	TW14-002	U2R	Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) Research Training		CDC
8/28/2014	GM15-006	R25	Training Modules to Enhance Data Reproducibility	ССТ	NIH
	RM14-006	U54	Nuclear Organization and Function Interdisciplinary Consortium (NOFIC)		
	RM14-007	U01	Nucleomics Tools		
9/24/2014	RM14-008	U01	Study of Nuclear Bodies and Compartments	ALL	NIH-RM
9/24/2014	RM14-009	U01	4D Nucleome Imaging Tools	DIVISIONS	ואוח-חואו
	RM14-010	U01	4D Nucleome Network Organizational Hub		
	RM14-011	U01	4D Nucleome Network Data Coordination and Integration Center		
9/26/2014	RM14-016	U54	Model Organisms Screening Center for the Undiagnosed Diseases Network (UDN)	ALL DIVISIONS	NIH-RM
	RM14-012	R34	Data Integration and Analysis Tools: Accessible Resources for Integration and Analysis of Carbohydrate and Glycoconjugate Structural, Analytical, and Interaction Data in the Context of Comparable Gene, Protein, and Lipid Data	jugate xt of ALL DIVISIONS	NIH-RM
9/30/2014	RM14-013	U01	Novel and Innovative Tools to Facilitate Identification,		
	RM14-014	R21	Tracking, Manipulation, and Analysis of Glycans and Their Functions		
	RM14-015	U01	Facile Methods and Technologies for Synthesis of Biomedically Relevant Carbohydrates		

Table 3a. Program Announcements (PAs) Published by the NCI in FY2014 Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
10/17/2013	PAR13-371	P20	Planning for a National Center for Particle Beam Radiation Therapy Research	DCTD
10/21/2013	PA13-378 PA13-377	R21 R01	Research on Malignancies in the Context of HIV/AIDS	DCB, OHAM DCCPS
11/7/2013	PAR13-386	P30	Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers	OD
11/21/2013	PAR14-007	R03	NCI Small Grants Program for Cancer Research (NCI Omnibus)	ALL DIVISIONS
12/11/2013	PAR14-031	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014	DCTD DCP
1/9/2014	PAR14-067	U01	Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control	DCCPS
	PAR14-085	R01		
2/4/2014	PAR14-086	U01	Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy	DCB
	PAR14-087	P01		
2/19/2014	PAR14-013	R21	Early Phase Clinical Trials in Imaging and Image-Guided Interventions	DCTD
2/26/2014	PAR14-116	U01	Quantitative Imaging for Evaluation of Response to Cancer Therapies	DCTD
3/10/2014	PAR14-152	P20	Feasibility Studies to Build Collaborative Partnerships in Cancer Research	CRCHD
3/19/2014	PAR14-160	U01	Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	DCCPS
3/28/2014	PAR14-166	R01	Early Phase Clinical Trials in Imaging and Image-Guided Interventions	DCTD
4/1/2014	PAR14-169	U54	Physical Sciences-Oncology Centers	DCB
	PAR14-239	U24	Oncology Models Forum	
5/30/2014	PAR14-240	R01	Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01)	DCB
	PAR14-241	R01	Research Projects to Enhance Applicability of Mouse Models for Translational Research	-
6/3/2014	PAR14-242	R01	Role of the Microflora in the Etiology of Gastro-Intestinal Cancer	DCB, DCP
6/16/2014	PAR14-260	R01	Interventions for Health Promotion and Disease Prevention in Native American Populations	DCCPS
6/18/2014	PAR14-261	333	Innovation Corps (I-Corps) Team Training Pilot Program for NIH Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp)	OSP
6/27/2014	PAR14-267	R35	Outstanding Investigator Award	DCB
7/17/2014	PAR14-285	U01	Innovative Research in Cancer Nanotechnology (IRCN)	CSSI
8/7/2014	PAR14-314	U01	New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers	DCB
9/26/2014	PAR14-353	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015 and 2016	DCTD, DCP

Table 3b. Program Announcements (PAs) Published by the NCI in FY2014

Sorted by Division, Office, and Center

Division, Office, and Center	RFA	Mechanism	Title	Date of Publication
ALL DIVISIONS	PAR14-007	R03	NCI Small Grants Program for Cancer Research (NCI Omnibus)	11/21/2013
CRCHD	PAR14-152	P20	Feasibility Studies to Build Collaborative Partnerships in Cancer Research	3/10/2014
CSSI	PAR14-285	U01	Innovative Research in Cancer Nanotechnology (IRCN)	7/17/2014
	PAR14-085	R01		
	PAR14-086	U01	Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy	2/4/2014
	PAR14-087	P01	·····	
	PAR14-169	U54	Physical Sciences-Oncology Centers	4/1/2014
	PAR14-239	U24	Oncology Models Forum	
DCB	PAR14-240	R01	Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01)	5/30/2014
	PAR14-241	R01	Research Projects to Enhance Applicability of Mouse Models for Translational Research	
	PAR14-267	R35	Outstanding Investigator Award	6/27/2014
	PAR14-314	U01	New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers	8/7/2014
DCB,	PA13-377	R01		10/21/2013
DCCPS OHAM	PA13-378	R21	Research on Malignancies in the Context of HIV/AIDS	
DCB, DCP	PAR14-242	R01	Role of the Microflora in the Etiology of Gastro-Intestinal Cancer	6/3/2014
	PAR14-067	U01	Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control	1/9/2014
DCCPS	PAR14-160	U01	Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	3/19/2014
	PAR14-260	R01	Interventions for Health Promotion and Disease Prevention in Native American Populations	6/16/2014
	PAR13-371	P20	Planning for a National Center for Particle Beam Radiation Therapy Research	10/17/2013
DCTD	PAR14-013	R21	Early Phase Clinical Trials in Imaging and Image-Guided Interventions	2/19/2014
	PAR14-116	U01	Quantitative Imaging for Evaluation of Response to Cancer Therapies	2/26/2014
	PAR14-166	R01	Early Phase Clinical Trials in Imaging and Image-Guided Interventions	3/28/2014
DCTD	PAR14-031	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014	12/11/2013
DCP	PAR14-353	P50	Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015 and 2016	9/26/2014
OD	PAR13-386	P30	Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers	11/7/2013
OSP	PAR14-261	333	Innovation Corps (I-Corps) Team Training Pilot Program for NIH Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp)	6/18/2014

Table 4. NCI Participation in Trans-NIH Program Announcements (PA/PARs)in FY2014

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	lssuing NIH-IC
10/17/2013	PAR13-374	R01	Modeling Social Behavior	DCCPS	NIH
10/18/2013	PAR13-375	R01	Nutrigenetics and Nutrigenomics Approaches for Nutrition Research	DCP	NIH
10/24/2013	PA13-381	333	Administrative Supplements to NIH Awards for Validation Studies of Analytical Methods for Natural Products	DCP	NIH
10/30/2013	PAR13-382	R21	Analysis of Genome-Wide Gene-Environment (G x E) Interactions	DCCPS	NIH
11/13/2013	PAR13-390	R03	Indo-U.S. Collaborative Program on Affordable Medical Devices	CGH	NIH
11/14/2013	PA14-003	333	Collaborative Activities to Promote Metabolomics Research	DCB	NIH
	PA14-015	T32	Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent)	ССТ	_
12/6/2013	PAR14-017	SC2	Support of Competitive Research (SCORE) Pilot Project Award	CRCHD	NIH
	PAR14-019	SC1	Support of Competitive Research (SCORE) Research Advancement Award	CCT	-
12/10/2013	PA14-024	333	NIH/PEPFAR Collaboration for Implementation Science	OHAM	NIAID
12/11/2013	PA14-027	333	Administrative Supplements for Research on Sex/Gender Differences	OD DCCPS	- NIH
12/11/2013	PAR14-028	R21	Mobile Health: Technology and Outcomes in Low and Middle Income Countries		
12/13/2013	PA14-040	333	Administrative Supplement to Existing NIH Directors Biomedical Research Workforce Innovation Award: Broadening Experiences in Scientific Training (BEST)	ALL DIVISIONS	NIH
12/17/2013	PAR14-041	P30	Centers for AIDS Research and Developmental Centers for AIDS Research	OHAM	NIAID
	PA14-042	K99, R00	NIH Pathway to Independence Award (Parent)		
	PA14-046	K08	Mentored Clinical Scientist Research Career Development Award (Parent)		
12/19/2013	PA14-047	K24	Midcareer Investigator Award in Patient-Oriented Research (Parent)	ССТ	NIH
	PA14-048	K25	Mentored Quantitative Research Development Award (Parent)		
	PA14-049	K23	Mentored Patient-Oriented Research Career Development Award (Parent)		
1/17/2014	PA14-071	R43, R44	PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR)	SBIRDC	NIH CDC FDA ACF
1/17/2014	PA14-072	R41, R42	PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR)		
1/29/2014	PA14-078	777	Change of Grantee Organization (Type 7 Parent)	N/A	NIH

Table 4 (cont'd).NCI Participation in Trans-NIH Program Announcements (PA/PARs)in FY2014

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	lssuing NIH-IC
1/30/2014	PA14-077	333	Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp)	N/A	NIH
	PA14-079	666	Successor-in-Interest (Type 6 Parent)		
2/5/2014	PAR14-088	R44	Direct Phase II SBIR Grants to Support Biomedical Technology Development	SBIRDC	NIH
2/6/2014	PAR14-092	R01	Bioengineering Research Partnerships (BRP)	DCTD	NIH
2/24/2014	PA14-114	R01	Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care	DCCPS	NIH
3/5/2014	PA14-146	333	Additional Research Training Positions for NIAAA-, NIDA-, or NCI-Supported NRSA Institutional Training (T32) Grants	CCT DCCPS	NIH
	PA14-147	F31	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent)	ССТ	
	PA14-148	F31	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent-Diversity)	CRCHD	-
3/7/2014	PA14-149	F32	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent)		NIH
	PA14-150	F30	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral MD/PhD or Other Dual-Doctoral Degree Fellowship (Parent)	CCT	
	PA14-151	F33	Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Senior Fellowship (Parent)		
	PA14-155	R01	Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science		
3/14/2014	PA14-156	R01	Extended Development, Hardening and Dissemination of Technologies in Biomedical Computing, Informatics and Big Data Science	DCB	NIH
4/24/2014	PAR14-191	U41	Genomic Resource Grants for Community Resource Projects	DCCPS	NIH / NCI
5/2/2014	PAR14-201	333	Administrative Supplements for Research on Dietary Supplements	DCP	NIH
	PAR14-210	UH2, UH3	Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules		
E/10/0014	PAR14-211	UH3	Limited Competition for NIH-Industry Program: Discovering	DOTD	NIH
5/12/2014	PAR14-212	UH2, UH3	New Therapeutic Uses for Existing Molecules	DCTD	FDA
	PAR14-213	X02	Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules		
5/15/2014	PAR14-225	R01	Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain	DCP	NIH
	PAR14-230	R21, R33	Exploratory Studies of Smoking Cessation Interventions for	DOODO	NULL
5/19/2014	PAR14-231	R33	People with Schizophrenia	DCCPS	NIH

continued

Table 4 (cont'd).NCI Participation in Trans-NIH Program Announcements (PA/PARs)in FY2014

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	lssuing NIH-IC
6/10/2014	PAR14-255	R01	Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection	DCB	NIH
	PA14-276	R01	Ethical, Legal, and Social Implications (ELSI) of Genomic Research Regular Research Program		
7/10/2014	PA14-277	R03	Ethical, Legal, and Social Implications (ELSI) of Genomic	DCCPS	NIH
	PA14-278	R21	Research Small Research Grant Program		
7/11/2014	PAR14-279	R01	Discovery of In Vivo Chemical Probes	DCTD	NIH
7/17/0014	PAR14-283	R21	R21 High Throughput Screening (HTS) to Discover Chemical		NILL
7/17/2014	PAR14-284	R01	Probes	DCTD	NIH
	PA14-320	333	Administrative Supplements for Tobacco Regulatory Research on the Role and Impact of Flavors in Cigarettes, Cigars, E-Cigarettes and Smokeless Tobacco (Admin Supp)		
8/12/2014	PAR14-315	R01	Testing Interventions for Health-Enhancing Physical Activity	DCCPS	NIH
	PAR14-321	R21, R33	Developing Interventions for Health-Enhancing Physical Activity		
8/28/2014	PA14-328	333	Administrative Supplements for U.SBrazil Biomedical Collaborative Research	OSPO	NIH
9/5/2014	PA14-334	R01	Advancing Interventions to Improve Mediaction Adherence	DCCPS	NILL
9/5/2014	PA14-335	R21	 Advancing Interventions to Improve Medication Adherence 	DUCPS	NIH

Table 5. Applications Received for Referral by the NCI/DEA in FY2014 Sorted by Mechanism

			Арр	lications NCAB	s by	
Mechanism	Activity Code	Total by Activity	Jan	May	Oct	Total Costs Requested First Year
International Training Grants in Epidemiology (FIC)	D43	16	16	0	0	\$5,996,762
NIH Director's Pioneer Award (NDPA)	DP1	2	0	2	0	\$5,000,000
NIH Director's New Innovator Awards	DP2	11	0	11	0	\$16,500,000
Early Independence Award	DP5	1	0	0	1	\$436,882
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA)	F30	121	33	41	47	\$0
Predoctoral Individual National Research Service Award	F31	414	136	150	128	\$0
Postdoctoral Individual National Research Service Award	F32	296	96	111	89	\$0
Research Scientist Development Award – Research and Training	K01	41	7	24	10	\$5,463,220
Research Scientist Award	K05	11	4	2	5	\$928,77
Academic/Teacher Award	K07	68	20	27	21	\$9,874,36
Clinical Investigator Award	K08	80	24	23	33	\$13,240,02
Physician Scientist Award (Program)	K12	6	6	0	0	\$1,819,89
Career Transition Award	K22	108	39	38	31	\$16,553,73
Mentored Patient-Oriented Research Development Award	K23	27	11	10	6	\$4,824,81
Midcareer Investigator Award in Patient-Oriented Research	K24	8	2	2	4	\$1,330,18
Mentored Quantitative Research Career Development	K25	10	0	5	5	\$1,471,09
Career Transition Award	K99	237	67	119	51	\$26,215,42
Research Program Projects	P01	57	14	26	17	\$121,582,57
Exploratory Grants	P20	24	2	0	22	\$7,317,10
Center Core Grants	P30	20	14	3	3	\$69,443,63
Biotechnology Resource Grant Program	P41	1	0	0	1	\$1,548,34
Specialized Center	P50	45	13	27	5	\$100,074,10
Research Project	R01	5,731	2,164	1,775	1,792	\$2,804,835,75
Small Research Grants	R03	703	218	259	226	\$54,987,12
Conferences	R13	100	37	31	32	\$3,140,32
Academic Research Enhancement Awards (AREA)	R15	287	104	106	77	\$118,549,82
Exploratory/Developmental Grants	R21	3,384	1,191	999	1,194	\$765,906,01
Education Projects	R25	55	21	25	9	\$15,191,44
Exploratory/Developmental Grants Phase II	R33	101	31	27	43	\$45,796,58
Method to Extend Research in Time (MERIT) Award	R37	3	3	0	0	\$1,025,12

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (413) were not included in the total count.

Table 5 (cont'd). Applications Received for Referral by the NCI/DEA in FY2014 Sorted by Mechanism

			Арр	lication: NCAB	s by	
Mechanism	Activity Code	Total by Activity	Jan	May	Oct	Total Costs Requested First Year
Small Business Technology Transfer (STTR) Grants – Phase I	R41	216	67	70	79	\$43,851,480
Small Business Technology Transfer (STTR) Grants - Phase II	R42	27	6	12	9	\$13,686,641
Small Business Innovation Research Grants (SBIR) – Phase I	R43	801	252	269	280	\$160,134,426
Small Business Innovation Research Grants (SBIR) - Phase II	R44	202	52	62	88	\$114,976,092
High Priority, Short Term Project Award	R56	5	1	4	0	\$0
Research Enhancement Award	SC1	3	2	1	0	\$1,036,965
Pilot Research Project	SC2	1	0	0	1	\$134,250
Intramural Clinical Scholar Research Award	SI2	5	5	0	0	\$0
Institutional National Research Service Award	T32	68	29	24	15	\$30,384,707
Research Project (Cooperative Agreements)	U01	214	72	101	41	\$135,539,004
Research Program (Cooperative Agreement)	U19	22	1	21	0	\$24,769,925
Resource-Related Research Project (Cooperative Agreements)	U24	19	11	8	0	\$14,438,672
Resource-Related Research Multi-Component Projects and Centers Cooperative Agreements	U2C	1	1	0	0	\$3,199,868
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase I	U43	13	13	0	0	\$2,409,844
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase II	U44	2	2	0	0	\$1,405,981
Specialized Center (Cooperative Agreements)	U54	195	0	190	5	\$419,858,266
Clinical Research Cooperative Agreements – Single Project	UG1	53	0	53	0	\$150,436,624
Exploratory/Developmental Cooperative Agreement Phase I	UH2	94	0	94	0	\$46,231,288
Research Project With Complex Structure Cooperative Agreement	UM1	67	37	30	0	\$96,503,460
Pre-application	X02	12	0	12	0	\$0
Overall Totals		13,988	4,824	4,794	4,370	\$5,478,050,620

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (413) were not included in the total count.

Table 6. Grant and Cooperative Agreement Applications Reviewed
by the NCI/DEA in FY2014

Sorted by Mechanism

			Applica	ations by		
Mechanism	Activity Code	Total by Activity	Jan	Feb	Oct	Total Costs Requested First Year
Research Scientist Development Award - Research and Training	K01	32	7	15	10	\$4,042,583
Research Scientist Award	K05	11	4	2	5	\$928,773
Academic/Teacher Award	K07	68	20	27	21	\$9,874,369
Clinical Investigator Award	K08	75	22	21	32	\$12,451,904
Physician Scientist Award (Program)	K12	6	6	0	0	\$1,819,891
Career Transition Award	K22	108	39	38	31	\$16,553,731
Mentored Patient-Oriented Research Development Award	K23	25	10	9	6	\$4,426,643
Midcareer Investigator Award in Patient-Oriented Research	K24	7	2	2	3	\$1,213,706
Mentored Quantitative Research Career Development	K25	9	0	5	4	\$1,332,277
Career Transition Award	K99	192	57	94	41	\$21,820,190
Research Program Projects	P01	57	14	26	17	\$121,582,570
Exploratory Grants	P20	24	2	0	22	\$7,317,108
Center Core Grants	P30	13	7	3	3	\$54,746,070
Specialized Center	P50	45	13	27	5	\$100,074,100
Research Project	R01	442	313	5	124	\$246,712,939
Small Research Grants	R03	620	194	239	187	\$47,857,000
Conferences	R13	67	19	26	22	\$1,739,481
Exploratory/Developmental Grants	R21	2,365	798	651	916	\$536,506,498
Education Projects	R25	37	18	10	9	\$11,709,657
Exploratory/Developmental Grants Phase II	R33	91	31	27	33	\$41,992,634
Small Business Innovation Research Grants (SBIR) – Phase II	R44	12	0	0	12	\$12,867,282
Institutional National Research Service Award	T32	64	26	24	14	\$24,404,267
Research Project (Cooperative Agreements)	U01	150	48	67	35	\$89,576,469
Research Program (Cooperative Agreement)	U19	1	1	0	0	\$3,979,423
Resource-Related Research Project (Cooperative Agreements)	U24	19	11	8	0	\$14,438,672
Resource-Related Research Multi-Component Projects and Centers Cooperative Agreements	U2C	1	1	0	0	\$3,199,868
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase I	U43	13	13	0	0	\$2,409,844
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase II	U44	2	2	0	0	\$1,405,981
Specialized Center (Cooperative Agreements)	U54	26	0	22	4	\$21,034,161
Clinical Research Cooperative Agreements – Single Project	UG1	53	0	53	0	\$150,436,624
Exploratory/Developmental Cooperative Agreement Phase I	UH2	94	0	94	0	\$46,231,288
Research Project With Complex Structure Cooperative Agreement	UM1	66	36	30	0	\$94,015,676
Overall Totals		4,795	1,714	1,525	1,556	\$1,708,701,679

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (181) were not included in the total count.

Table 7. Applications Reviewed by NCI IRG Subcommittees and
Special Emphasis Panels (SEPs) in FY2014

NCI IRG Subcommittee	Types of Applications Reviewed	Number of Applications	Total Costs Requested First Year
A - Cancer Centers	P30	12	\$51,683,977
F - Institutional Training and Education	K12, R25, T32	105	\$37,382,041
I - Transition to Independence	K01, K22, K25, K99	247	\$30,213,522
J - Career Development	K05, K07, K08, K23, K24	183	\$28,406,471
Totals - NCI IRG Subcommittees		547	\$147,686,011
Total SEPs	K01, K07, K08, K22, K23, K4, K99, P01, P20, P30, P50, R01,R03, R13, R21, R33, R44, T32, U01, U19, U24, U2C, U43, U44, U54, UG1, UH2, UM1	4,248	\$1,561,015,668
TOTAL		4,795	\$1,708,701,679

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (204) were not included in the total count.

Table 8. Summary of Investigator-Initiated P01 Applications Reviewed in FY2014

	Applications by Board								
Type of Application	February 2014	June 2014	September 2014	FY 2014 Total					
New	5	10	8	23					
Resubmitted New	0	0	1	1					
Renewal	4	7	7	18					
Resubmitted Renewal	5	6	1	12					
Revisions	0	3	0	3					
Total	14	26	17	57					

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications.

Table 9. Summary of Investigator-Initiated P01 Applications Reviewed,Sorted by NCI Program Division, in FY2014

Program Division	Number of Applications	Total Costs Requested First Year	Total Costs for Requested Period
Division of Cancer Biology (DCB)	20	\$41,134,611	\$212,298,800
Division of Cancer Control and Population Sciences (DCCPS)	4	\$9,444,993	\$47,527,552
Division of Cancer Prevention (DCP)	5	\$14,272,467	\$72,099,538
Division of Cancer Treatment and Diagnosis (DCTD)	28	\$56,730,499	\$285,161,480
Total	57	\$121,582,570	\$617,087,370

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications.

Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEAin FY2014

			Арр	olication	Applications by NCAB			
Title of Initiative	RFA Number	Activity Code	Totals	Jan	May	Oct	Requested First Year	
	CA12-015	Dod	80	80	0	0	\$44,314,42 ⁻	
Research Answers to NCI's Provocative Questions –	CA13-016	- R01	13	0	0	13	\$6,906,813	
Group A	CA12-016	Dod	54	54	0	0	\$11,994,564	
	CA13-017	R21	5	0	0	5	\$1,174,78 ⁻	
	CA12-017	DO1	73	73	0	0	\$40,790,38	
Research Answers to NCI's Provocative Questions -	CA13-018	- R01	19	0	0	19	\$11,285,990	
Group B	CA12-018	Dod	47	47	0	0	\$10,669,99	
	CA13-019	R21	9	0	0	9	\$1,969,850	
	CA12-019	Dod	70	70	0	0	\$40,255,92	
Research Answers to NCI's Provocative Questions –	CA13-020	- R01	14	0	0	14	\$8,223,05	
Group C	CA12-020	Dod	46	46	0	0	\$10,379,60	
	CA13-021	R21	16	0	0	16	\$3,415,61	
	CA12-021	504	84	84	0	0	\$42,605,45	
Research Answers to NCI's Provocative Questions – Group D	CA13-022	- R01	14	0	0	14	\$7,355,34	
	CA12-022	DO1	46	46	0	0	\$10,586,67	
	CA13-023	R21	7	0	0	7	\$1,687,22	
Research Answers to NCI's Provocative Questions –	CA13-024	R01	4	0	0	4	\$2,536,15	
Group E	CA13-025	R21	1	0	0	1	\$266,55	
Early-Stage Innovative Molecular Analysis Technology	CA13-001	Dod	87	33	54	0	\$23,565,61	
Development for Cancer Research	CA14-003	R21	55	0	0	55	\$14,258,12	
Validation and Advanced Development of Emerging	CA13-002	Doo	45	24	21	0	\$20,321,49	
Molecular Analysis Technologies for Cancer Research	CA14-004	- R33	23	0	0	23	\$10,967,37	
Early-Stage Development of Innovative Technologies for	CA13-003	Dod	18	8	10	0	\$4,664,43	
Biospecimen Science	CA14-005	R21	11	0	0	11	\$3,213,70	
Validation and Advanced Development of Emerging	CA13-004	Doo	13	7	6	0	\$6,110,56	
Technologies for Biospecimen Science	CA14-006	- R33	10	0	0	10	\$4,593,20	
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN)	CA13-006	UM1	21	21	0	0	\$17,845,41	
Collaborative Human Tissue Network (CHTN)	CA13-007	UM1	9	9	0	0	\$9,997,72	
Person-Centered Outcomes Research Resource	CA13-008	U2C	1	1	0	0	\$3,199,86	
Sub-Saharan African Collaborative HIV and Cancer Consortia	CA13-010	U54	16	0	16	0	\$11,878,74	
NCI Community Oncology Research Program (NCORP)	CA13-012	UG1	7	0	7	0	\$63,722,26	
Research Bases	CA13-012	UM1	3	0	3	0	\$12,958,674	

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (127) were not included in the total count.

Table 10 (cont'd). Requests for Applications (RFAs) Reviewed by the NCI/DEAin FY2014

			Ар	olication	ns by NC	AB	Total Costs
Title of Initiative	RFA Number	Activity Code	Totals	Jan	May	Oct	Requested First Year
NCI Community Oncology Research Program (NCORP)	CA13-013	UG1	34	0	34	0	\$72,989,201
- Community Sites	CA13-013	UM1	11	0	11	0	\$15,149,099
NCI Community Oncology Research Program (NCORP)	CA13-014	UG1	12	0	12	0	\$13,725,159
- Minority/Underserved Community Sites	CA13-014	UM1	9	0	9	0	\$10,635,022
Cancer Detection, Diagnostic and Treatment Technologies for Global Health	CA13-015	UH2	94	0	94	0	\$46,231,288
Limited Competition: Adult Brain Tumor Consortium (ABTC)	CA13-501	UM1	1	1	0	0	\$2,000,000
Limited Competition: Pediatric Brain Tumor Consortium	CA13-502	UM1	1	1	0	0	\$2,590,000
Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Revision to Enhance the Collection of Cervical Cancer Screening Data	CA14-001	U54	6	0	6	0	\$3,898,765
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization	CA14-002	R44	12	0	0	12	\$12,867,282
Using Social Media to Understand and Address	CA14-008	R01	58	0	0	58	\$31,476,085
Substance Use and Addiction	CA14-009	R21	57	0	0	57	\$12,099,069
Totals			1,216	605	283	328	\$687,376,578

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (127) were not included in the total count.

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEAin FY2014

			Applic	Applications by NCAB			Total Costs
Title of Initiative	RFA Number	Activity Code	Totals	Jan	May	Oct	Requested First Year
Ruth L. Kirschstein National Research Service Award	PA11-184	TOO	50	26	24	0	\$19,581,478
(NRSA) Institutional Research Training Grants	PA14-015	T32	14	0	0	14	\$4,822,789
Mentored Clinical Scientist Research Career Development	PA11-193	K08	39	18	21	0	\$6,322,887
Award	PA14-046	NU0	31	0	0	31	\$5,289,790
Mentored Patient-Oriented Research Career Development	PA11-194	K23	17	8	9	0	\$3,092,238
Award	PA14-049	NZ3	4	0	0	4	\$694,811
Mideorook Investigator Award in Dationt Oriented Descarab	PA11-195	K24	4	2	2	0	\$752,172
Midcareer Investigator Award in Patient-Oriented Research	PA14-047	N24	3	0	0	3	\$461,534
Mentored Quantitative Research Development Award	PA11-196	K25	5	0	5	0	\$726,757
	PA14-048	KZ0	4	0	0	4	\$605,520
NILL Dathway to Indopondence Award	PA11-197	K99	151	57	94	0	\$17,243,262
NIH Pathway to Independence Award	PA14-042	K99	41	0	0	41	\$4,576,928
Dessarch Draiget Crant	PA11-260	D01	4	4	0	0	\$3,914,171
Research Project Grant	PA13-302	R01	6	0	4	2	\$6,317,874
	PA11-261	R21	0	0		0	¢0.
NIH Exploratory/Developmental Research Grant Program	PA13-303		0	0	0	0	\$0
NIH Support for Conferences and Scientific Meeting	PA12-212	R13	19	19	0	0	\$442,103
NIN Support for Conterences and Scientific Meeting	PA13-347	nıə	48	0	26	22	\$1,297,378
National Cancer Institute (NCI) Cancer Education and Career	PAR10-165	R25	10	10	0	0	\$4,054,481
Development Program	PAR12-049	nzj	27	8	10	9	\$7,655,176
Cancer Diagnostic and Therapeutic Agents Enabled by	PAR10-286	U43	13	13	0	0	\$2,409,844
Nanotechnology (SBIR)	FAN 10-200	U44	2	2	0	0	\$1,405,981
Cancer Prevention Research Small Grant Program	PAR11-079	R03	87	42	45	0	\$6,561,340
Quantitative Imaging for Evaluation of Responses to Cancer Therapies	PAR11-150	U01	38	11	18	9	\$25,603,615
Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	PAR11-167	UM1	11	4	7	0	\$22,839,735
		P01	14	14	0	0	\$32,209,610
National Cancer Institute Program Project Applications	PAR12-005	U19	1	1	0	0	\$3,979,423
	PAR13-321	P01	42	0	25	17	\$89,142,774
Small Grants Program for Cancer Epidemiology	PAR12-039	R03	104	35	35	34	\$8,225,908
NCI Mentored Research Scientist Development Award to Promote Diversity	PAR12-050	K01	32	7	15	10	\$4,042,583

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (77) were not included in the total count.

Table 11 (cont'd).Program Announcements (PAs) Reviewed by the NCI/DEAin FY2014

			Appli	cation	s by N	CAB	Total Costs
Title of Initiative	RFA Number	Activity Code	Totals	Jan	May	Oct	Requested First Year
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity	PAR12-051	K08	5	4	0	1	\$839,227
NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity	PAR12-052	K23	4	2	0	2	\$639,594
Limited Competition: Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)	PAR12-055	U54	4	0	0	4	\$5,256,656
The NCI Transition Career Development Award to Promote Diversity	PAR12-062	K22	15	7	4	4	\$2,219,119
NCI Established Investigator Award in Cancer Prevention and Control	PAR12-065	K05	11	4	2	5	\$928,773
Cancer Prevention, Control, Behavioral Sciences and Population Sciences Career Development Award	PAR12-067	K07	68	20	27	21	\$9,874,369
The NCI Transition Career Development Award	PAR12-121	K22	93	32	34	27	\$14,334,612
NCI Small Grants Program for Cancer Research (NCI	PAR12-144	DOO	276	117	159	0	\$21,379,336
Omnibus R03)	PAR14-007	R03	153	0	0	153	\$11,690,416
Revisions for Early-Stage Development of Informatics	PAR12-286	R01	3	2	1	0	\$731,266
Technology	PAR12-289	U01	3	2	1	0	\$835,388
	PAR12-287		11	11	0	0	\$8,053,911
Advanced Development of Informatics Technology	PAR13-294	U24	8	0	8	0	\$6,384,761
Early-Stage Development of Informatics Technology	PAR12-288	U01	31	8	23	0	\$12,444,442
Specialized Programs of Research Excellence (SPOREs) in	PAR12-296	DEO	35	9	26	0	\$87,292,593
Human Cancer for Years 2013 and 2014	PAR14-031	P50	5	0	0	5	\$11,499,998
Cancer Center Support Grants (CCSGs) for NCI-designated	PAR12-298	Doo	10	7	3	0	\$34,411,734
Cancer Centers	PAR13-386	P30	3	0	0	3	\$20,334,336
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research	PAR13-036	U01	30	13	0	17	\$18,929,419
Bridging the Gap Between Cancer Mechanism and Population Science	PAR13-081	U01	8	0	8	0	\$5,209,793
Planning for a National Center for Particle Beam Radiation	PAR13-096	DOO	2	2	0	0	\$996,457
Therapy Research	PAR13-371	P20	6	0	0	6	\$2,998,929
NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)	PAR13-146	R21	1,906	564	587	755	\$426,560,690
The Role of Microbial Metabolites in Cancer Prevention and Etiology	PAR13-159	U01	7	0	7	0	\$4,631,124
Revisions Applications to P50 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	PAR13-170	P50	2	2	0	0	\$513,064

continued

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (77) were not included in the total count.

Table 11 (cont'd).Program Announcements (PAs) Reviewed by the NCI/DEAin FY2014

			Appli	cation	Total Costs		
Title of Initiative	RFA Number	Activity Code	Totals	Jan	May	Oct	Requested First Year
Revision Applications to U01 Awards on Detection of Pathogen-Induced Cancer (DPIC)	PAR13-173	U01	1	1	0	0	\$231,750
Revision Applications to P50 Awards for Research on	PAR13-174	P50	2	2	0	0	\$508,200
Imaging and Biomarkers for Early Cancer Detection	PAR13-318	F90	1	0	1	0	\$260,245
Revision Applications to U01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	PAR13-176	U01	2	1	1	0	\$507,388
Collaborative Research in Integrative Cancer Biology	PAR13-184	U01	21	12	9	0	\$15,287,617
Paul Calabresi Career Development Award for Clinical Oncology	PAR13-201	K12	6	6	0	0	\$1,819,891
Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	PAR13-317	P01	1	0	1	0	\$230,186
Opportunities for Collaborative Research at the NIH Clinical Center	PAR13-358	U01	9	0	0	9	\$5,895,933
Feasibility Studies to Build Collaborative Partnerships in Cancer Research	PAR14-152	P20	16	0	0	16	\$3,321,722
Totals			3,579	1,109	1,242	1,228	\$1,021,325,101

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (77) were not included in the total count.

Table 12. Requests for Proposals (RFPs) and SBIR Topics Reviewed by the NCI/DEA in FY2014*

Announcement/ Topic Number	Announcement Title	Work- Ioad Round	No. of Proposals
Topic 326	Development of Novel Therapeutic Agents That Target Cancer Stem Cells	May-14	27
Topic 327 (Phase I & FastTrack)	Reformulation of Failed Chemotherapeutic Drugs	May-14	16 (1 FT)
Topic 328 (Phase I & FastTrack)	Validation of 3D Human Tissue Culture Systems That Mimic the Tumor Microenvironment	May-14	24 (3 FT)
Topic 329 (Phase I & FastTrack)	Proteomic Analysis of Single Cells Isolated From Solid Tumors	May-14	1
Topic 330 (Phase I & FastTrack)	Generation of Site-Specific Phospho-Threonine Protein Standards for Use in Cancer Assays	May-14	8
Topic 331 (Phase I & FastTrack)	Development of a Biosensor-Based Core Needle Tumor Biopsy Device	May-14	9
Topic 332 (Phase I & FastTrack)	Development of Radiation Modulators for Use During Radiotherapy	May-14	22 (5 FT)
Topic 333 (Phase I & FastTrack)	Software Tools for the Development of Environmental Measures Related to Cancer Health Behaviors and Resources	May-14	14 (1 FT)
Phase II Topics from I	Earlier Phase I Awards		
Topic 255	Development of Anticancer Agents	Oct-14	2
Topic 277	Development of Companion Diagnostics	Oct-14	2
Topic 300	Reformulation of Cancer Therapeutics Using Nanotechnology	Oct-14	2
Topic 312	Generation and Qualification of Site-Specific Post-Translationally Modified Proteins for Use as Calibrators in Pharmacodynamic (PD) Assays	Oct-14	1
Topic 291	Development of Radiation Modulators for Use During Radiotherapy	Oct-14	1
Topic 301	Probing Tumor Microenvironment Using In Vivo Nanotechnology-Based Sensors	Oct-14	2
Topic 305	Novel Digital X-ray Sources for Cancer Imaging Applications	Oct-14	1
Topic 306	Development of Innovative Algorithms for Processing & Analysis of In Vivo Images	Oct-14	2
Topic 307	Novel Imaging Agents to Expand the Clinical Toolkit for Cancer Diagnosis, Staging, and Treatment	Oct-14	5
Topic 308	Automated Collection, Storage, Analysis, and Reporting Systems for Dietary Images	Oct-14	3
Topic 309	Development of Low Cost, Small Sample Multi-Analyte Technologies for Cancer Diagnosis, Prognosis and Early Detection	Oct-14	5
Topic 314	Development of Human Tissue Culture Systems That Mimic the Tumor Microenvironment	Oct-14	2
Other Solicitations R	eviewed in DEA		
N01 CO42400-80	Cancer Genomics Cloud Pilots	Oct-14	14
N01 CP41003-72	Support for Epidemiological Studies of Cancer Among Atomic Bomb Survivors (Sole Source)	Oct-14	1
L30 (OD13-081)	Loan Repayment Program for Clinical Researchers	Oct-14	267
L40 (OD13-083)	Loan Repayment Program for Pediatirc Researchers	Oct-14	81
TOTAL			512

* The proposals were in response to SBIR Contract Solicitations - Phase I (111) and Fast Track-Phase I/II (10), Phase II (28), RFPs (N01) (15) and Loan Repayment (L30/L40) (348). Source: Office of Referral, Review and Program Coordination.

Table 13. Summary of NCI Grant Awards by Mechanism in FY2014*

Fund Type: Appropriated				% of N Gra	CI Total ints		Fiscal Year: 2014	
Cost Centers Mechanisms	Awards Count	Awards Dollars	Average Cost	Number	Dollars	Competing Requested	Competing Awarded	Success Rate
Research Project Grants Traditional Research Grants – R01/RL1	3,085	1,166,410,039	378,091	48.41%	38.1 %	3,849	578	15.02%
Program Projects – P01	109	211,170,561	1,937,345	1.71%	6.9 %	54	18	33.33%
Small Grants – R03	194	15,078,085	77,722	3.04%	0.49%	627	93	14.83%
Exploratory/Developmental Research – R21	551	102,957,573	186,856	8.65%	3.36%	2,539	302	11.89%
Phased Innovation Grant (Phase 2) – R33	0	0	0	0.0 %	0.0 %	0	0	0.0 %
Pathway to Independence – R00	84	19,652,434	233,958	1.32%	0.64%	0	0	0.0 %
Exploratory/Development Cooperative Agreements – UH2/UH3	1	627,224	627,224	0.02%	0.02%	0	0	0.0 %
Merit Awards – R37	25	11,391,328	455,653	0.39%	0.37%	5	2	40.0 %
NIH Director Pioneer Award (NDPA) – DP1	4	4,024,293	1,006,073	0.06%	0.13%	0	0	0.0 %
NIH Director New Innovator Awards – DP2	3	7,488,829	2,496,276	0.05%	0.24%	3	3	100.0 %
NIH Director's Early Independence Awards – DP5	6	2,317,871	386,312	0.09%	0.08%	0	0	0.0 %
Academic Research Enhancement Awards (AREA) – R15	23	9,875,442	429,367	0.36%	0.32%	228	23	10.09%
Multi-Component Research Project Cooperative Agreements – UM1	15	29,648,844	1,976,590	0.24%	0.97%	15	4	26.67%
Cooperative Agreements – U01/U19	133	76,039,169	571,723	2.09%	2.48%	205	45	21.95%
Request for Applications	263	96,030,511	365,135	4.13%	3.14%	959	119	12.41%
Cooperative Agreements – RFA – U01/U19	101	105,070,580	1,040,303	1.58%	3.43%	55	20	36.36%
Small Business Innovative Research – R43/R44	171	66,878,234	391,101	2.68%	2.18%	727	129	17.74%
Small Business Technology Transfer – R41/R42	46	14,962,728	325,277	0.72%	0.49%	176	42	23.86%
Program Evaluation – R01	0	72,936,000	72,936,000	0.0 %	2.38%	0	0	0.0 %
Subtotal Research Project Grants	4,814	2,012,559,745	418,064	75.54%	65.73%	9,442	1,378	14.59%
Other Research Clinical Cooperative Groups – U10/ UG1	102	263,347,218	2,581,835	1.6 %	8.6 %	135	101	74.81%
Clinical Cooperative Groups – U10 Specials	0	3,800,000	3,800,000	0.0 %	0.12%	0	0	0.0 %
Clinical Cooperative Groups – CCCT	0	4,487,361	4,487,361	0.0 %	0.15%	0	0	0.0 %
Conference Grants – R13	54	758,248	14,042	0.85%	0.02%	63	42	66.67%
International Research Training Grants Conference – D43	0	958,051	958,051	0.0 %	0.03%	0	0	0.0 %
Continuing Education Training Grants – T15/RL9	1	100,323	100,323	0.02%	0.0 %	0	0	0.0 %
Cancer Education Awards – R25	96	32,932,180	343,044	1.51%	1.08%	47	18	38.3 %
Research/Resource Grant – R24/U24/ U2C	25	55,897,698	2,235,908	0.39%	1.83%	21	7	33.33%
Invalid Budget Mechanism	0	6,000,000	6,000,000	0.0 %	0.2 %	0	0	0.0 %
Subtotal Other Research	278	368,281,079	1,324,752	4.36%	12.03%	266	168	63.16%

continued

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award. Source: Office of Extramural Finance and Information Analysis.

Table 13 (cont'd). Summary of NCI Grant Awards by Mechanism in FY2014*

Fund Type: Appropriated				% of N Gra			Fiscal Year: 2014	
Cost Centers Mechanisms	Awards Count	Awards Dollars	Average Cost	Number	Dollars	Competing Requested	Competing Awarded	Success Rate
Centers	00	070 570 000	0.010.045	1.050/	0.000/	00	00	
Core/Planing – P20/P30 Core – CCCT	<u> </u>	276,579,866	3,216,045	1.35% 0.0 %	9.03% 0.17%	<u> </u>	23	58.97% 0.0 %
Center for AIDS Research – CFAR – OHAM – P30	0	<u>5,241,314</u> 24,045	5,241,314 24,045	0.0 %	0.17%	0	0	0.0 %
Invalid Budget Mechanism	0	1,084,000	1,084,000	0.0 %	0.04%	0	0	0.0 %
Spore Grants – P50	50	104,601,905	2,092,038	0.78%	3.42%	42	11	26.19%
Other P50/P20	11	18,203,343	1,654,849	0.17%	0.59%	0	0	0.0 %
Specialized Center (Cooperative Agreement)	111	138,509,205	1,247,831	1.74%	4.52%	25	13	52.0 %
Subtotal Centers	258	544,243,678	2,109,472	4.05%	17.78%	106	47	44.34%
National Research Service Awards (NR NRSA Institution – T32/T35	ISA) 139	49,704,248	357,585	2.18%	1.62%	61	28	45.9 %
NRSA Fellowships – F31/F32	485	19,512,900	40,233	7.61%	0.64%	680	196	28.82%
Subtotal NRSA	624	69,217,148	110,925	9.79%	2.26%	741	224	30.23%
Careers Mentored Clinical Scientist – K08	100	16,018,409	160,184	1.57%	0.52%	67	18	26.87%
Preventive Oncology Award – K07	59	8,745,014	148,221	0.93%	0.29%	66	12	18.18%
Mentored Career Award – K12	15	11,647,327	776,488	0.24%	0.38%	6	2	33.33%
Mentored Research Scientist Development Awards/Mentored Career Development/Temin – K01	49	6,243,040	127,409	0.77%	0.2 %	32	10	31.25%
Clinical Research Track – K22	27	4,481,622	165,986	0.42%	0.15%	114	15	13.16%
Mentored Patient-Oriented Research Career Dev A – K23	31	5,166,481	166,661	0.49%	0.17%	28	5	17.86%
Mid-Career Investigator in Patient- Oriented Research Award – K24	17	2,921,508	171,853	0.27%	0.1 %	5	4	80.0 %
Mentored Quantitative Research Career Development Award – K25	15	2,103,468	140,231	0.24%	0.07%	11	4	36.36%
Established Investigator Award in Cancer Prevention & Control – K05	15	1,787,792	119,186	0.24%	0.06%	8	3	37.5 %
Pathway to Independence – K99	71	8,410,172	118,453	1.11%	0.27%	179	46	25.7 %
Subtotal Careers	399	67,524,833	169,235	6.26%	2.21%	516	119	23.06%
Total:	6,373	3,061,826,483	480,437	100.0 %	100.0 %	11,071	1,936	17.49%

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

Source: Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project GrantAwards Sorted by Division, Office, Center, and MechanismFrom FY2010 – FY2014

Budget Mechnism/	FY 2	2010	FY 2	2011	FY 2	2012	FY 2013		FY 2014		Percent 2010 -	Change 2014
Division	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
	R01 Average Cost of Award											
NCI Overall	3,655	362	3,648	365	3,526	374	3,306	358	3,085	378	-15.6 %	4.42%
DCB	1,783	313	1,748	317	1,660	323	1,555	312	1,441	330	-19.2 %	5.3 %
DCP	261	399	258	400	245	421	226	389	201	434	-23.0 %	8.9 %
DCTD	1,107	336	1,141	343	1,139	355	1,078	342	1,041	362	-6.0 %	7.8 %
DCCPS	486	561	485	553	468	559	436	521	391	542	-19.5 %	-3.5 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	18	911	16	901	14	924	11	1,221	11	1,343	-38.9 %	47.4 %
P01 Average C	P01 Average Cost of Award											
NCI Overall	140	2,004	129	2,010	122	1,997	124	1,868	109	1,937	-22.14%	-3.34%
DCB	56	1,783	53	1,804	54	1,771	54	1,612	45	1,708	-19.6 %	-4.2 %
DCP	7	1,737	8	1,814	8	1,579	7	1,414	7	1,652	0.0 %	-4.9 %
DCTD	64	2,188	58	2,164	49	2,194	53	2,063	48	2,018	-25.0 %	-7.8 %
DCCPS	12	2,161	10	2,298	11	2,502	10	2,517	9	2,836	-25.0 %	31.2 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	1	2,576	0	638	0	306	0	155	0	343	-100.0 %	-86.7 %
R03 Average C		ard										
NCI Overall	181	78	127	76	172	76	199	77	194	78	7.18%	0.0 %
DCB	8	78	3	75	10	76	11	75	22	76	175.0 %	-2.8 %
DCP	56	78	38	75	61	78	63	77	48	78	-14.3 %	-0.7 %
DCTD	10	77	6	76	10	78	15	76	24	78	140.0 %	0.7 %
DCCPS	107	79	80	77	91	75	110	77	100	78	-6.5 %	-0.6 %
R21 Average C		1										
NCI Overall	415	202	442	200	439	197	441	188	551	187	32.77%	-7.43%
DCB	77	188	79	181	80	187	90	185	138	188	79.2 %	0.0 %
DCP	50	187	51	183	54	188	54	181	44	172	-12.0 %	-8.3 %
DCTD	198	218	207	220	188	215	190	194	242	194	22.2 %	-10.9 %
DCCPS	82	185	80	178	89	176	78	179	93	174	13.4 %	-5.9 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	8	217	25	205	28	186	29	195	34	182	325.0 %	-15.8 %

continued

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

†In thousands.

Source: Office of Extramural Finance and Information Analysis.

Table 14 (cont'd). Average Total Cost* \dagger and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2010 - FY2014

Budget	FY 2	2010	FY 2	2011	FY	2012	FY 2	2013	FY	2014	Percent 2010 -	
Mechnism/ Division	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
U01/U19 Avera	ige Cost o	f Award										
NCI Overall	131	1,091	130	1,062	132	989	115	1,093	79	988	-39.69%	-9.44%
DCB	28	776	29	721	28	714	28	665	1	1,065	-96.4 %	37.3 %
DCP	35	741	35	671	36	681	36	674	35	546	0.0 %	-26.3 %
DCTD	28	1,461	26	1,313	23	939	5	3,621	1	3,820	-96.4 %	161.6 %
DCCPS	23	1,598	23	1,752	22	1,761	22	1,593	16	1,570	-30.4 %	-1.8 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	17	1,039	17	1,135	23	1,119	24	1,235	26	1,113	52.9 %	7.1 %
R13 Average C	ost of Aw	ard										
NCI Overall	95	76	92	65	64	89	57	15	54	14	-43.16%	-81.58%
DCB	36	9	35	4	22	6	24	5	22	6	-38.9 %	-33.6 %
DCP	8	12	9	15	5	19	6	18	3	34	-62.5 %	183.3 %
DCTD	19	12	16	11	14	14	15	8	18	6	-5.3 %	-44.8 %
DCCPS	17	20	17	14	11	21	7	19	8	21	-52.9 %	2.0 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	15	418	15	349	12	418	5	69	3	84	-80.0 %	-80.0 %
U10 Average C	ost of Aw	ard		'								
NCI Overall	131	1,937	135	1,801	128	1,789	120	1,958	49	3,637	-62.6 %	87.76%
DCP	71	1,330	77	1,160	75	1,165	75	1,130	0	11,012	-100.0 %	728.0 %
DCTD	60	2,655	58	2,653	53	2,671	45	3,337	49	3,412	-18.3 %	28.5 %
P30 Average C	ost of Awa	ard			1				1			
NCI Overall OD (CRCHD,	66	4,446	66	4,168	67	4,134	68	3,823	68	4,098	3.03%	-7.83%
OCAM, CSSI, CCT, OHAM, etc.)	66	4,446	66	4,168	67	4,133	68	3,823	68	4,098	3.0 %	-7.8 %
P50 Average C	ost of Aw	ard		1	1	1	1	1	1	1		
NCI Overall	75	2,081	74	1,979	69	2,010	66	1,895	61	2,012	-18.67%	-3.32%
DCP	0	400	0	400	0	400	0	388	0	388	0.0 %	-3.0 %
DCTD	65	2,101	64	1,999	59	2.044	59	1,907	56	2,032	-13.8 %	-3.3 %
DCCPS	10	1.847	10	1,739	10	1.686	- 3 3 - 7	1,651	5	1,676	-50.0 %	-3.3 % -9.2 %
OD (CRCHD,	10	1,077	10	1,703	10	1,000	,	1,001	5	1,070	-50.0 /0	-0.2 /0
OCAM, CSSI, CCT, OHAM, etc.)	0	617	0	701	0	813	0	600	0	138	0.0 %	-77.6 %
continued												

continued

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award. † In thousands.

Source: Office of Extramural Finance and Information Analysis.

Table 14 (cont'd).Average Total Cost*† and Number of Research Project Grant
Awards Sorted by Division, Office, Center, and Mechanism
From FY2010 – FY2014

Budget Mechnism/	FY 2	010	FY 2	2011	FY	2012	FY 2	2013	FY	2014		Change 2014
Division	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
SBIR Average	Cost of Av	vard										
NCI Overall	180	411	123	587	151	422	132	444	171	391	-5.0 %	-4.87%
CRCHD	0	85	0	83	0	0	0	0	0	0	0.0 %	-100.0 %
DCTD	0	0	0	0	0	0	0	0	0	66	0.0 %	100.0 %
DCCPS	0	0	0	32	0	0	0	0	0	0	0.0 %	0.0 %
SBIRDC	180	411	123	586	151	422	132	444	171	391	-5.0 %	-4.9 %
STTR Average	Cost of A	ward										
NCI Overall	27	431	21	562	39	350	27	469	46	325	70.37%	-24.59%
SBIRDC	0	0	21	562	39	350	27	469	46	325	100.0 %	100.0 %
STTRDC	27	431	0	0	0	0	0	0	0	0	-100.0 %	-100.0 %
U54 Average C	ost of Aw	ard										
NCI Overall	93	1,453	101	1,523	103	1,709	106	1,316	99	1,268	6.45%	-12.73%
CRCHD	51	1,066	47	1,152	49	1,110	50	940	49	978	-3.9 %	-8.2 %
CSSI	18	2,776	21	2,468	21	3,630	21	2,155	9	2,343	-50.0 %	-15.6 %
DCB	20	1,492	22	1,400	22	1,441	24	1,343	30	1,288	50.0 %	-13.7 %
DCCPS	4	230	11	1,551	11	1,244	11	1,365	11	1,626	175.0 %	607.0 %

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the average cost of an award.

[†]In thousands.

Source: Office of Extramural Finance and Information Analysis.

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars [†]	2010	2011	2012	2012	2014	Average Percent Change/Yr
	Number of Grants	9	6	6	3	3	
Adrenal	Relevant Grant Dollars	908,434	557,068	694,479	334,332	440,344	
	<i>Total Count</i> Total Relevant Dollars	9 908,434	6 557,086	6 694,479	3 334,332	3 440,344	-8.54
		,		,		· ·	-0.04
	<i>Number of Grants</i> Relevant Grant Dollars	14 1,996,111	16 2,740,690	18 2,539,326	19 3,730,597	19 3,860,964	
	Number of Contracts	1,990,111	2,740,090 3	2,009,020	3,730,397 ‡	3,000,904 ‡	
Anus	Relevant Contract Dollars	*	446,435	÷	÷	:	
	Total Count	14	19	18	19	19	
	Total Relevant Dollars	1,996,111	3,187,125	2,539,326	3,730,597	3,860,964	22.44
	Number of Grants	208	176	143	124	147	
	Relevant Grant Dollars	18,941,518	15,777,763	18,493,415	15,767,632	23,221,839	
Bladder	Number of Contracts	3	1	1	1	* *	
	Relevant Contract Dollars Total Count	25,113 211	176,266 177	749,947 144	561,614 125	‡ 147	
	Total Relevant Dollars	18.966.631	15.954.029	19,243,362	16,329,246	23,221,839	7.95
	Number of Grants	92	76	55	67	40	1
- ··	Relevant Grant Dollars	13,124,422	17,343,897	8,938,608	8,109,194	6,186,065	
Bone Marrow	Total Count	92	76	55	67	40	
	Total Relevant Dollars	13,124,422	17,343,897	8,938,608	8,109,194	6,186,065	-12.33
	Number of Grants	<i>98</i>	90	72	68	54	
	Relevant Grant Dollars	18,014,359	14,539	10,824,238	7,034,582	4,313,783	
Bone, Cartilage	Number of Contracts Relevant Contract Dollars	+	*	+ ‡	+ +	‡ *	
	Total Count	* 98	* 90	* 72	* 68	÷ 54	
	Total Relevant Dollars	18,014,359	14,539,162	10,824,238	7,034,582	4,313,783	-29.63
	Number of Grants	498	500	512	544	557	
	Relevant Grant Dollars	131,178,363	143,786,108	148,032,345	152,082,930	162,133,244	
Brain	Number of Contracts	3	3	5	2	2	
Dian	Relevant Contract Dollars	217,734	698,895	672,916	1,639,630	422,895	
	<i>Total Count</i> Total Relevant Dollars	501 131,396,097	503 144,485,003	517 148,705,261	546 153,722,560	559 162,556,139	5.50
	Number of Grants						0.00
	Relevant Grant Dollars	1,934 569,062,367	1,859 552,999,395	1,835 536,444,140	1,792 501,581,607	1,811 478,792,611	
-	Number of Contracts	32 32	20	25	20	470,752,011 10	
Breast	Relevant Contract Dollars	7,908,595	9,370,644	12,810,843	11,117,661	5,422,635	
	Total Count	1,966	1,879	1,860	1,812	1,821	
	Total Relevant Dollars	576,970,962	562,370,039	549,254,983	512,699,268	483,879,269	-4.27
	Number of Grants	43	35	51	59	48	
Control Non rous	Relevant Grant Dollars	6,255,071	5,370,246	4,169,107	3,630,469	1,739,620	
Central Nervous System	Number of Contracts Relevant Contract Dollars	+ +	+ + +	+ +	÷ *	+ + +	
System	Total Count	* 43	* 35	* 51	* 59	* 48	
				V1			

continued

^{*}Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

 $[\]dagger$ Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Anatomical Site	Counts and Relevant Dollars [†]	2010	2011	2012	2012	2014	Average Percent Change/Yr.
Que in	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	298 61,579,940 5	295 60,341,462 4	298 58,198,274 3	283 50,597,621 1	305 52,183,192 1	
Cervix	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	4,759,619 303 66,339,559	4,729,585 299 65,071,047	3,366,401 <i>301</i> 61,564,675	2,280,313 284 52,877,934	740,476 306 52,923,668	-5.33
Childhood Leukemia	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count	148 49,924,922 ‡ ‡ 1 48	157 33,329,128 ‡ ‡ 157	178 51,786,291 ‡ ‡ 178	151 51,230,678 ‡ ‡ 151	159 36,743,720 1 45,000 160	
	Total Relevant Dollars	49,924,922	33,291,283	51,786,291	51,230,678	36,788,720	-1.76
	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	984 245,295,756 16	951 242,486,775 11	937 227,386,183 14	916 213,714,476 9	866 198,038,574 6	
Colon, Rectum	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	6,412,331 <i>1,000</i> 251,708,087	4,299,256 <i>962</i> 246,786,031	6,246,343 951 233,632,526	4,230,994 925 217,945,470	3,024,309 872 201,062,883	-5.44
Connective Tissue	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i>	51 10,417,011 51	56 9,999,338 56	44 8,185,709 44	21 3,310,900 21	13 3,141,987 13	
	Total Relevant Dollars	10,417,011	9,999,338	8,185,709	3,310,900	3,141,987	-21.70
Embryonic Tissue, Cells	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i>	10 1,477,847 10	8 1,325,565 8	5 368,936 5	3 340,919 3	2 145,522 2	
Cells	Total Relevant Dollars	1,477,847	<i>a</i> 1,325,565	368,936	3 340,919	2 145,522	-36.85
Esophagus	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	100 25,599,073 ‡ ‡ 100 25,599,073	118 28,238,207 1 20,000 119 28,258,207	147 23,801,157 2 229,905 149 24,031,062	175 23,146,386 1 12,726 176 23,159,112	117 24,631,620 ‡ ‡ 117 24,631,620	-0.46
Eye	Number of Grants Relevant Grant Dollars Total Count Total Relevant Dollars	13 2,168,685 13 2,168,685	12 2,161,882 12 2,161,882	14 2,008,983 14 2,008,983	16 2,362,025 16 2,362,025	17 2,855,615 17 2,855,615	7.77
Gall Bladder	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i> Total Relevant Dollars	1 212,356 1 212,356	16 199,485 16 199,485	2 156,086 2 156,086	2 146,805 2 146,805	2 * 2 *	-11.25
Gastrointestinal Tract	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count	51 8,649,596 ‡ ‡ 51	48 8,306,179 ‡ ‡ 48	50 9,181,848 ‡ \$ 50	45 7,398,956 ‡ ‡ 45	35 5,831,855 ‡ ‡ 35	
	Total Relevant Dollars	8,649,596	8,306,179	9,181,848	7,398,956	5,831,855	-8.51

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site. [‡]Coding not required or requested.

•				•		,	
Anatomical Site	Counts and Relevant Dollars [†]	2010	2011	2012	2012	2014	Average Percent Change/Yr.
	Number of Grants	12	19	38	43	74	
	Relevant Grant Dollars	1,255,368	1,708,702	2,136,318	2,875,521	1,800,605	
Genital System,	Number of Contracts	5	1	‡	*	*	
Female	Relevant Contract Dollars	336,493	187,496	\$	\$	‡	
	Total Count	17	20	38	43	74	7.05
	Total Relevant Dollars	1,591,861	1,896,198	2,136,318	2,875,521	1,800,605	7.25
	Number of Grants	6	5	6	2	2	
A B B A	Relevant Grant Dollars	549,031	334,581	350,827	237,891	241,644	
Genital System,	Number of Contracts	5	Į.	Ţ	Į.	Ţ	
Male	Relevant Contract Dollars	336,493	‡	÷	\$	÷	
	<i>Total Count</i> Total Relevant Dollars	11 885,524	5 334,581	6 350,827	2 237,891	2 241,644	-21.99
		000,024		330,027	237,091	241,044	-21.99
	Number of Grants	204	201	217	248	226	
	Relevant Grant Dollars	41,468,691	39,623,318	37,034,455	33,677,355	33,439,973	
Head and Neck	Number of Contracts	7	3	7	5	3	
	Relevant Contract Dollars	1,897,174	1,337,385	4,032,932	717,810	1,733,390	
	<i>Total Count</i> Total Relevant Dollars	211 43,365,865	204 40,960,703	224 41,067,387	253 34,395,165	229 35,173,363	-4.82
		43,303,005	40,900,703	41,007,307	34,395,105		-4.02
	Number of Grants	15	16	12	10	7	
Heart	Relevant Grant Dollars	2,148,483	1,737,287	1,971,428	1,792,289	1,344,822	
	Total Count	15	16	12	10	7	0.00
	Total Relevant Dollars	2,148,483	1,737,287	1,971,428	1,792,289	1,344,822	-9.93
	Number of Grants	54	77	94	83	51	
	Relevant Grant Dollars	9,846,229	8,994,562	9,649,890	9,563,149	10,262,763	
Hodgkins Lymphoma	Number of Contracts	\$	+	+	‡	‡	
riougiano Eymphonia	Relevant Contract Dollars	1		Ŧ	\$	Ŧ	
	Total Count	54	77	94	83	51	1.00
	Total Relevant Dollars	9,846,229	8,994,562	9,649,890	9,563,149	10,262,763	1.26
	Number of Grants	92	87	82	77	76	
	Relevant Grant Dollars	17,444,041	20,205,869	19,241,042	18,354,076	20,860,705	
Kaposi Sarcoma	Number of Contracts	\$	+	‡	‡	‡	
	Relevant Contract Dollars	*	*	Ŧ	*	Ŧ	
	Total Count	92	87	<i>82</i>	77	76	F 00
	Total Relevant Dollars	17,444,041	20,205,869	19,241,042	18,354,076	20,860,705	5.03
	Number of Grants	226	241	246	250	237	
	Relevant Grant Dollars	26,734,935	29,194,089	32,449,153	31,320,199	21,146,275	
Kidney	Number of Contracts	2	2	‡	‡ +	‡	
	Relevant Contract Dollars	274,436	390,889	\$	‡	‡	
	Total Count	228	243	246	250	237	1.10
	Total Relevant Dollars	27,009,371	29,584,978	32,449,153	31,320,199	21,146,275	-4.19
	Number of Grants	3	4	6	6	7	
Larynx	Relevant Grant Dollars	99,159	203,215	464,533	1,259,413	1,535,331	
Larynx	Total Count	3	4	6	6	7	
	Total Relevant Dollars	99,159	203,215	464,533	1,259,413	1,535,331	106.64

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site. [‡]Coding not required or requested.

Anatomical Site	Counts and Relevant Dollars [†]	2010	2011	2012	2012	2014	Average Percent Change/Yr.
	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	680 210,799,140 3	683 199,610,401 4	724 208,324,142 2	755 209,330,335 7	781 212,414,621 4	
Leukemia	Relevant Contract Dollars	1,495,139	1,098,646	213,752	3,612,561	1,775,197	
	<i>Total Count</i> Total Relevant Dollars	683 212,294,279	687 200,709,047	726 208,537,894	762 212,942,896	785 214,189,818	0.29
	<i>Number of Grants</i> Relevant Grant Dollars	294 60,616,338	302 54,071	322 52,508,097	321 48,910,887	306 49,666,458	
Liver	Number of Contracts	00,010,330 ‡	54,071 1	52,506,097 2	40,910,007 8	49,000,430 ‡	
Liver	Relevant Contract Dollars	‡	299,353	115,700	4,653,688	‡	
	<i>Total Count</i> Total Relevant Dollars	294 60,616,338	303 54,370,763	324 52,623,797	329 53,564,575	306 49,666,458	-4.75
	Number of Grants	965	968	993	1,003	977	
Lung	Relevant Grant Dollars <i>Number of Contracts</i>	243,602,747 23	260,155,893 16	268,028,541 26	243,708,636 21	219,322,515 11	
Lung	Relevant Contract Dollars	7,815,307	4,919,129	12,146,630	11,323,702	6,163,921	
	<i>Total Count</i> Total Relevant Dollars	988 251,418,054	984 265,075,022	1,019 280,175,171	1,024 255,032,338	988 225,486,436	-2.36
	Number of Grants	15	13	9	9	4	
Lymph Node	Relevant Grant Dollars Total Count	2542477 15	2,017,737 13	1,975,041 9	608,275 9	316,561 4	
	Total Relevant Dollars	2,542,477	2,017,737	1,975,041	608,275	316,561	-34.98
	<i>Number of Grants</i> Relevant Grant Dollars	4 472,471	5 788,609	4 803,722	3 489,999	3 397,376	
Lymphatic System	Total Count	4	5	4	3	3	
	Total Relevant Dollars	472,471	788,609	803,722	489,999	397,376	2.72
	<i>Number of Grants</i> Relevant Grant Dollars	457 85,429,532	435 96,537,993	423 99,713,846	474 101,678,996	502 106,822,745	
Melanoma	Number of Contracts	4	1	2	2	‡	
molarionia	Relevant Contract Dollars Total Count	698,413 461	50,000 436	1,349,977 425	1,764,768 476	‡ 502	
	Total Relevant Dollars	401 86,127,945	96,587,993	425 101,063,823	476 103,443,764	106,822,745	5.60
	Number of Grants	15	16	18	19	25	
Mesothelioma	Relevant Grant Dollars Total Count	5,530,460 15	3,457,493 16	4,863,814 18	4,452,535 19	7,157,480 25	
	Total Relevant Dollars	5,530,460	3,457,493	4,863,814	4,452,535	7,157,480	13.87
	<i>Number of Grants</i> Relevant Grant Dollars	37 6,049,875	48 8,018,193	58 6,914,232	41 3 361 305	10 862,759	
Muscle	Total Count	0,049,875 37	6,016,193 48	0,914,232 58	3,361,305 41	002,759 10	
	Total Relevant Dollars	6,049,875	8,018,193	6,914,232	3,361,305	862,759	-26.74
	<i>Number of Grants</i> Relevant Grant Dollars	234 41,740,236	242 48,195,056	249 52,667,345	160 37,120,602	174 37,800,248	
Muslama	Number of Contracts	41,740,230 1	+0,130,000 ‡	52,007,545 1	\$	07,000,240 ‡	
Myeloma	Relevant Contract Dollars	199,860	‡	1,499,746	‡	‡	
	Total Count	235	242	250	160	174	

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site. [‡]Coding not required or requested.

,	, ,	0			, ,	,	
Anatomical Site	Counts and Relevant Dollars [†]	2010	2011	2012	2012	2014	Average Percent Change/Y
	Number of Grants	30	28	26	24	24	
	Relevant Grant Dollars Number of Contracts	5,271,048 +	6,787,090 1	6,438,816 +	4,163,832 *	4,421,874 *	
Nervous System	Relevant Contract Dollars	‡ ‡	8,250	* *	* *	I ‡	
	Total Count	30	29	26	24	24	
	Total Relevant Dollars	5,271,048	6,795,340	6,438,816	4,163,832	4,421,874	-1.37
	Number of Grants	98	98	105	<i>99</i>	104	
	Relevant Grant Dollars Number of Contracts	17,861,575 +	20,974,714 +	24,697,656 1	16,492,753 +	21,130,521	
Neuroblastoma	Relevant Contract Dollars	*	* *	299,993	* * *	* ‡	
	Total Count	98	98	106	99	104	
	Total Relevant Dollars	17,861,575	20,974,714	24,997,649	16,492,753	21,130,521	7.68
	Number of Grants	455	472	473	480	452	
Non Hodalino	Relevant Grant Dollars	97,937,059 *	101,566,115	93,857,913	89,044,122	93,955,405	
Non-Hodgkins Lymphoma	Number of Contracts Relevant Contract Dollars	*	1 1,500,000	1 125,000	1 749,986	* *	
Lymphoma	Total Count	455	473	474	481	452	
	Total Relevant Dollars	97,937,059	103,066,115	93,982,913	89,794,108	93,955,405	-0.85
	Number of Grants	14	8	10	10	9	
Nose, Nasal	Relevant Grant Dollars	1,627,236	904,491	1,117,904	987,215	890,916	
Passages	<i>Total Count</i> Total Relevant Dollars	14 1,627,236	8 904,491	10 1,117,904	10 987,215	9 890,916	-10.57
	Number of Grants	2,079	1,952	1.889	1,727	1,747	10.07
	Relevant Grant Dollars	608,746,346	573,631,342	572,734,563	495,343,572	621,155,734	
Not Site Specific §	Number of Contracts	162	166	192	201	181	
Not Site Specific 3	Relevant Contract Dollars	191,360,124	192,657,199	187,026,369	205,498,650	212,411,501	
	Total Count	2,241	2,118	2,081	<i>1,928</i>	<i>1,928</i>	1 50
	Total Relevant Dollars	800,106,470	766,288,541	759,760,932	700,842,222	833,567,235	1.53
	<i>Number of Grants</i> Relevant Grant Dollars	52 11,138,288	49 8,209,050	59 11,657,227	66 10,151,964	<i>66</i> 8,835,614	
	Number of Contracts	11,130,200	0,209,000	11,057,227	10,131,904	0,000,014 ‡	
Oral Cavity	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	52	49	59	66	66	
	Total Relevant Dollars	11,138,288	8,209,050	11,657,227	10,151,964	8,835,614	-2.54
	Number of Grants	413	413	385	384	380	
	Relevant Grant Dollars Number of Contracts	96,565,010 11	96,600,440 <i>6</i>	95,732,146 7	85,110,664 5	79,194,763 2	
Ovary	Relevant Contract Dollars	5,217,503	2,015,726	2,496,203	3,421,603	1,182,604	
	Total Count	424	419	392	389	382	
	Total Relevant Dollars	101,782,513	98,616,166	98,228,349	88,532,267	80,377,367	-5.65
	Number of Grants	424	417	421	465	494	
	Relevant Grant Dollars	90,502,908	91,095,822	97,245,213	93,541,191	109,038,628	
Pancreas	Number of Contracts Relevant Contract Dollars	1 159,140	3 673,594	3 306,780	2 1,249,838	5 6,483,207	
	Total Count	425	420	424	1,249,000 467	0,403,207 499	

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

⁶Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies. There is no cancer site focus; however, it is relevant to cancer research.) Source: Research Analysis and Evaluation Branch.

^{*}Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

Anatomical Site	Counts and Relevant Dollars [†]	2010	2011	2012	2012	2014	Average Percent Change/Yr.
Parathyroid	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i>	2 ‡ 2	1 ‡ 1	2 216,587 2	2 199,513 2	3 401,380 3	
	Total Relevant Dollars	\$	‡	216,587	199,513	401,380	46.65
Penis	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i>	5 2,667,920 5	6 2,249,216 6	6 2,424,675 6	6 2,435,008 6	8 2,652,760 8	
	Total Relevant Dollars	2,667,920	2,249,216	2,424,675	2,435,008	2,652,760	0.37
Dhorupy	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	14 1,521,576 ‡	18 1,692,375 ‡	74 3,427,507 ‡	63 4,442,944 ‡	25 1,881,045 ‡	
Pharynx	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	‡ 14 1,521,576	‡ 18 1,692,375	‡ 74 3,427,507	‡ 63 4,442,944	‡ 25 1,881,045	21.43
Pituitary	Number of Grants Relevant Grant Dollars Total Dount	7 627,219 7	7 1,032,440 7	5 695,788 5	6 649,567 6	4 458,773 4	
	Total Relevant Dollars	627,219	1,032,440	695,788	649,567	458,773	-1.00
Prostate	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	1,030 265,054,420 24	960 254,592,786 13	968 231,897,860 10	923 223,571,212 12	866 187,129,390 5	
Tiosiale	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	8,108,959 1,054 273,163,379	5,670,388 973 260,263,174	3,076,292 978 234,974,152	6,244,033 935 229,815,245	6,350,291 871 193,479,681	-8.11
Reticuloendothelial System	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i>	24 4,220,047 24	23 4,207,337 23	12 3,007,301 12	9 1,097,687 9	8 1,318,507 8	
	Total Relevant Dollars	4,220,047	4,207,337	3,007,301	1,097,687	1,318,507	-18.05
Respiratory System	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i>	3 400,921 3	5 433,241 5	4 424,144 4	** * * *	* * * *	
,	Total Relevant Dollars	400,921	433,241	424,144	‡	\$	2.98
Retinoblastoma	Number of Grants Relevant Grant Dollars Total Count	20 2,599,952 20	14 2,291,465 14	13 2,335,494 13	14 2,225,018 14	16 3,538,181 16	11.00
	Total Relevant Dollars	2,599,952	2,291,465	2,335,494	2,225,018	3,538,181	11.09
	<i>Number of Grants</i> Relevant Grant Dollars	5 281,931	2 122,931	3 582,113	3 515,075	2 45,316	
Salivary Glands	Total Count	5	2 122,931	3	3	2	

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

Relevant Dollars = portion of the funded amount relevant to a specific site.
Coding not required or requested.

Anatomical Site	Counts and Relevant Dollars [†]	2010	2011	2012	2012	2014	Average Percent Change/Yr
	<i>Number of Grants</i> Relevant Grant Dollars	227 43,190,271	206 39,781,606	209 38,979,774	205 36,075,772	192 35,045,052 *	
Skin	<i>Number of Contracts</i> Relevant Contract Dollars	*	1 999,000	1 299,993	1 608,798	+ * +	
	Total Count	227	207	210	206	192	
	Total Relevant Dollars	43,190,271	40,780,606	39,279,767	36,684,570	35,045,052	-5.08
	<i>Number of Grants</i> Relevant Grant Dollars	19	21	22	19	13	
Small Intestine	Total Count	2,154,757 19	2,523,663 21	2,601,072 22	2,440,030 19	1,954,527 13	
	Total Relevant Dollars	2,154,757	2,523,663	2,601,072	2,440,030	1,954,527	-1.48
	Number of Grants	3	1	‡	‡	2	
Spleen	Relevant Grant Dollars	243,170	41,226	‡ *	* + +	136,258	
·	<i>Total Count</i> Total Relevant Dollars	3 243,170	1 41,226	+ + +	* *	2 136,258	73.73
	Number of Grants	65	58	46	43	63	
	Relevant Grant Dollars	10,776,732	9,227,080	8,068,624	8,064,193	8,597,660	
Stomach	Number of Contracts	‡ *	#	2	‡ + +	* * *	
	Relevant Contract Dollars Total Count	‡ 65	‡ 58	85,605 48	.∔ 43	.↓ 63	
	Total Relevant Dollars	10,776,732	9,227,080	8,154,229	8,064,193	8,597,660	-5.12
	Number of Grants	27	23	12	8	8	
	Relevant Grant Dollars	4,216,762	2,966,075	3,825,536	3,850,005	3,880,838	
Testis	<i>Number of Contracts</i> Relevant Contract Dollars	‡ ‡	+ +	+ +	+ +	+ *	
	Total Count	* 27	÷ 23	* 12	* 8	* 8	
	Total Relevant Dollars	4,216,762	2,966,075	3,825,536	3,850,005	3,880,838	0.19
	Number of Grants	4	4	4	5	5	
Thymus	Relevant Grant Dollars Total Count	397,192 4	504,940 4	615,252 4	609,747 5	449,070 5	
	Total Relevant Dollars	3 97,192	5 04,940	615,252	609,747	449,070	5.43
	Number of Grants	52	51	48	52	61	
	Relevant Grant Dollars	10,900,704	10,394,218	10,082,148	14,641,877	17,516,816	
Thyroid	<i>Number of Contracts</i> Relevant Contract Dollars	* *	* *	‡ *	1 95313	*	
	Total Count		51	* 48	53 53	61	
	Total Relevant Dollars	10,900,704	10,394,218	10,082,148	14,737,190	17,516,816	14.35
	Number of Grants	2	4	3	3	3	
Trachea, Bronchus	Relevant Grant Dollars Total Count	112,364 2	927,176 4	707,722 3	523,065 3	279,944 3	
	Total Relevant Dollars	∠ 112,364	4 927,176	3 707,722	523,065	3 279,944	157.23
	Number of Grants	80	90	107	104	101	
	Relevant Grant Dollars	12,006,415	13,617,358	16,911,090	15,653,222	13,467,035	
Uterus	Number of Contracts	+ + +	* + +	‡ + +	1	‡ +	
	Relevant Contract Dollars Total Count	‡ 80	‡ 90	↓ 107	142712 105	↓ 101	
	Total Relevant Dollars	12,006,415	13,617,358	16,911,090	15,795,934	13,467,035	4.07

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

natomical Site	Counts and Relevant Dollars [†]	2010	2011	2012	2012	2014	Average Percent Change/Yr.
	Number of Grants	4	5	5	4	4	
Vagina	Relevant Grant Dollars	275,471	284,762	336,623	317,026	286,298	
	Total Count	4	5	5	4	4	
	Total Relevant Dollars	275,471	284,762	336,623	317,026	286,298	1.52
	Number of Grants	55	48	40	30	19	
Vacaular	Relevant Grant Dollars	3,792,626	3,166,418	2,563,467	1,341,539	3,843,112	
Vascular	Total Count	15	17	14	7	9	
	Total Relevant Dollars	3,792,626	3,166,418	2,563,467	1,341,539	3,843,112	25.81

(This table reports funding for grants and contracts only; intramural projects are excluded.)

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site. [‡]Coding not required or requested. Source: Research Analysis and Evaluation Branch.

(This table repo	orts funding f	for grants and	contracts only; intrai	mural projects are exclud	ed.)
1			· · · · · · · · · · · · · · · · · · ·		/

Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Adoptive Cell	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	249 71,169,780 ‡	226 68,415,543 1	231 64,459,206 ‡	216 55,186,231 1	211 52,024,707 ‡	
Immunotherapy	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	; 249 71,169,780	247,568 227 68,663,021	; 231 64,459,206	1,499,971 217 56,686,202	; 211 52,024,707	-7.48
	Number of Grants Relevant Grant Dollars	1,100,700 15 3,285,087	13 2,770,889	2,945,075	7 2,460,945	2,295,195	1.10
Advanced Manufacturing Technology	Number of Contracts Relevant Contract Dollars Total Count	1 106,000 16	_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1 498,626 11	_,, ‡ ‡ 7	* * 8	
	Total Relevant Dollars	3,391,087	2,770,889	3,443,701	2,460,945	2,295,195	-7.32
	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	<i>1,066</i> 113,349,368 7	854 99,438,832 5	689 79,998,304 2	577 69,649,282 1	420 57,171,560 1	
Aging	Relevant Contract Dollars Total Count	2,424,616 <i>1,073</i>	631,073 859	82,113 691	27,250 578	31,046 421	
	Total Relevant Dollars	115,773,984	100,069,905	80,080,417	69,676,532	57,202,606	-16.11
	Number of Grants Relevant Grant Dollars Number of Contracts	412 91,837,776 3	65 13,092,878 ‡	60 12,538,472 ‡	45 10,917,513 ‡	35 10,442,198 ‡	
AIDS	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	504,083 415	‡ 65	‡ 60	‡ 45	‡ 35	00.00
	Number of Grants	92,341,859 373	13,092,878 347	12,538,472 343	10,917,513 304	10,442,198 317	-26.83
Alternative Medicine,	Relevant Grant Dollars Number of Contracts	89,420,040 2	83,106,708 ‡	73,033,996 3	57,639,318 ‡	52,792,542 2	
Direct	Relevant Contract Dollars Total Count	1,149,412 375	‡ 347	266,500 346	‡ 304	3,552,516 319	
	Total Relevant Dollars Number of Grants	90,569,452	83,106,708 47	73,300,496 31	57,639,318 23	56,345,058 24	-10.91
Alternative Medicine, Indirect	Relevant Grant Dollars Total Count	8,714,472 44	8,363,143 47	6,981,196 <i>31</i>	4,798,508 23	4,098,399 24	
	Total Relevant Dollars	8,714,472	8,363,143	6,981,196	4,798,508	4,098,399	-16.60
Alzheimers Dementia	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i>	4 508,810 4	4 565,699 4	3 96,204 3	3 186,357 3	2 294,069 2	
	Total Relevant Dollars	508,810	565,699	96,204	186,357	294,069	19.92
	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	3 684,462 †	3 692,817 ‡	5 570,649 1	7 1,048,649 †	8 1,141,359 †	
Arctic Research	Relevant Contract Dollars Total Count	* ‡ 3	‡ 3	471,532 6	* * 7	* * 8	
	Total Relevant Dollars	684,462	692,817	1,042,181	1,048,649	1,141,359	15.28

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

* Relevant Dollars = portion of the funded amount relevant to a specific site.
* Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Arthritis	Number of Grants Relevant Grant Dollars Total Count	4 400,562 4	5 396,477 5	7 1,066,691 7	6 881,952 6	6 864,304 6	
	Total Relevant Dollars	400,562	396,477	1,066,691	881,952	864,304	37.18
Asbestos	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i> Total Relevant Dollars	11 3,428,084 11 3,428,084	12 2,591,109 12 2,591,109	13 3,609,082 13 3,609,082	13 2,872,753 13 2,872,753	12 2,937,531 12 2,937,531	-0.82
Ataxia Telangiectasia	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i> Total Relevant Dollars	19 2,938,837 19 2,938,837	17 1,769,222 17 1,769,222	11 1,369,928 11 1,369,928	7 1,238,529 7 1,238,529	6 309,072 6 309,072	-36.75
Automimmune Diseases	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i> Total Relevant Dollars	37 4,320,535 37 4,320,535	35 4,076,442 35 4,076,442	33 3,767,007 33 3,767,007	28 2,747,501 28 2,747,501	22 1,403,677 22 1,403,677	-22.30
Behavior Research	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	1,104 314,205,359 10 3,248,062 1,116 318,626,425	1,098 322,649,017 12 7,177,481 1,110 329,826,498	1,106 328,483,291 18 7,750,198 1,124 336,233,489	1,093 288,411,741 19 11,278,961 1,112 299,690,702	1,032 239,765,778 5 3,018,920 1,037 242784698	-6.10
Bioengineering	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	543 143,101,038 19 5,212,765 562 148,313,803	478 136,659,850 28 7,104,296 506 143,764,146	471 128,170,758 14 7,721,382 485 135,892,140	438 116,606,055 14 6,142,128 452 122,748,183	551 139,804,609 9 3,567,443 560 143,372,052	-0.35
Bioinformatics	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	613 175,538,540 16 18,412,975 629 193,951,515	620 195,579,757 20 20,328,761 640 215,908,518	691 220,626,261 25 20,993,037 716 241,619,298	655 188,164,686 31 24,968,039 686 213,132,725	649 183,215,139 29 24,606,810 678 207,821,949	2.24
Biological Carcinogenesis, Non-Viral	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	65 13,043,584 ‡ \$ 65 13,043,584	68 14,509,921 ‡ \$ 68 14,509,921	75 15,387,505 ‡ ‡ 75 15,387,505	77 14,300,282 ‡ ‡ 77 14,300,282	78 15,804,902 ‡ ‡ 78 15,804,902	5.19

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

Average **Special Interest** Counts and 2010 2011 2012 2013 2014 Percent Relevant Dollars† Categories Change/Yr. Number of Grants 1.900 1.668 1.484 1.353 1.188 Relevant Grant Dollars 670,058,289 603,303,533 530,129,682 477,320,267 289,423,470 **Biologics/Biological** Number of Contracts 22 15 10 10 5 **Response Modifiers** Relevant Contract Dollars 21,405,546 16,939,205 10,691,980 9.671.661 5,894,582 1,683 Total Count 1,494 1,363 1,193 1,922 Total Relevant Dollars 691,463,835 620,242,738 540,821,662 486,991,928 295,318,052 -18.10 Number of Grants 141 114 104 94 84 Relevant Grant Dollars 21,212,069 17,519,246 15,414,009 12,137,705 14,254,502 **Biomaterials** Number of Contracts 4 2 3 ŧ İ Research Relevant Contract Dollars 1,548,783 1,186,186 797,035 t Total Count 145 114 106 97 84 Total Relevant Dollars 22,760,852 17,519,246 16,600,195 12,934,740 14,254,502 -10.04 Number of Grants 532 542 596 588 595 **Relevant Grant Dollars** 137,845,989 144,567,142 164,726,922 161,506,346 190,278,426 Number of Contracts 19 30 31 35 24 **Biomedical Computing Relevant Contract Dollars** 37,914,467 61,163,296 76,247,799 53,261,742 24,933,240 Total Count 572 627 619 551 623 **Total Relevant Dollars** 199,009,285 217,988,664 199,420,813 215,211,666 2.27 220,814,941 Number of Grants 64 56 46 33 30 Relevant Grant Dollars 12,310,466 10,773,700 8,086,859 5,021,213 4,403,949 Birth Defects Total Count 46 64 56 33 30 Total Relevant Dollars 12,310,466 8,086,859 4,403,949 -21.91 10,773,700 5,021,213 Number of Grants 140 146 112 130 115 **Relevant Grant Dollars** 54,507,621 50,005,537 37,328,235 39,871,538 35,750,541 Bone Marrow Number of Contracts İ İ ‡ 1 t İ İ İ Transplantation **Relevant Contract Dollars** t Total Count 115 140 146 112 130 **Total Relevant Dollars** 54,507,621 50,005,537 37,328,235 39,871,538 35,750,541 -9.28 Number of Grants 498 458 441 411 385 Relevant Grant Dollars 99,759,605 91,023,962 88,105,336 81,666,201 75,065,760 Breast Cancer Number of Contracts 13 15 12 Δ 1 Detection Relevant Contract Dollars 5,863,578 3,543,475 3,632,816 6,478,783 1,100,000 Total Count 453 511 473 415 386 Total Relevant Dollars 103,392,421 93,968,914 85,209,676 -7.31 97,502,745 76,165,760 Number of Grants 225 196 197 180 180 **Relevant Grant Dollars** 47,143,457 48,915,492 46,685,468 43,528,756 43,117,642 Breast Cancer Early Number of Contracts 3 4 6 2 1 **Relevant Contract Dollars** Detection 1,506,703 2,561,486 3,764,617 2,295,819 1,100,000 Total Count 228 200 203 182 181 Total Relevant Dollars 48,650,160 51,476,978 50,450,085 45,824,575 44,217,642 -2.21 Number of Grants 149 131 117 106 102 **Breast Cancer Relevant Grant Dollars** 16,743,662 16,114,826 13,390,623 9,550,272 4,699,015 Education Total Count 149 131 117 106 102 Total Relevant Dollars 16,743,662 16,114,826 13,390,623 9,550,272 4,699,015 -25.03

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

*Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

,	,					,	
Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Breast Cancer	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	189 64,674,588 5	195 67,767,559 1	215 79,021,942 2	219 74,082,885 6	210 65,139,979 1	
Epidemiology	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	336,493 194 65,011,081	1,620,669 196 69,388,228	1,728,711 217 80,750,653	3,348,609 225 77,431,494	125,000 211 65,264,979	0.82
	Number of Grants	453	482	510	509	498	
Breast Cancer	Relevant Grant Dollars Number of Contracts	116,708,177 5	116,790,479 6	130,302,574 5	116,592,352 4	107,994,765 ‡	
Genetics	Relevant Contract Dollars Total Count	2,418,766 458	2,277,691 488	2,143,190 515	2,739,232 513	‡ 498	
	Total Relevant Dollars	119,126,943	119,068,170	132,445,764	119,331,584	107,994,765	-2.05
	<i>Number of Grants</i> Relevant Grant Dollars	211 20,573,617	193 19,425,993	190 18,454,078	182 18,639,346	180 16,628,036	
Breast Cancer Prevention	<i>Number of Contracts</i> Relevant Contract Dollars	*	2 161745	1 35,700	1 68,000	1 1,478,927	
	Total Relevant Dollars	211	195	191	183	181	0.11
	Number of Grants	20,573,617 165	19,587,738 180	18,489,778 169	18,707,346 160	18,106,963 130	-3.11
Breast Cancer	Relevant Grant Dollars Number of Contracts	23,414,402 ‡	23,491,341 ‡	23,354,588 ‡	19,304,588 1	16,034,148 ‡	
Rehabilitation	Relevant Contract Dollars	‡	‡	\$	200,000	‡	
	<i>Total Count</i> Total Relevant Dollars	165 23,414,402	180 23,491,341	169 23,354,588	161 19,504,588	130 16,034,148	-8.63
	<i>Number of Grants</i> Relevant Grant Dollars	194 22,564,554	178 24,098,034	178 26,090,155	170 24,889,715	142 20,751,155	
Breast Cancer	Number of Contracts	:	1	1	1	1	
Screening	Relevant Contract Dollars Total Count	‡ 194	1,599,992 179	1,400,000 179	1,300,000 171	1,100,000 143	
	Total Relevant Dollars	22,564,554	25,698,026	27,490,155	26,189,715	21,851,155	-0.11
	<i>Number of Grants</i> Relevant Grant Dollars	699 191,699,483	671 182,244,051	679 151,868,982	664 142,815,791	687 138,560,818	
Breast Cancer Treatment	<i>Number of Contracts</i> Relevant Contract Dollars	11 1,962,093	3 461,244	8 4,169,128	5 2,525,833	4 2,065,223	
	<i>Total Count</i> Total Relevant Dollars	710 193,661,576	674 182,705,295	687 156,038,110	669 145,341,624	691 140,626,041	-7.59
	Number of Grants	781	758	744	767	855	
Proact Concor Pooio	Relevant Grant Dollars Number of Contracts	168,864,512 <i>9</i>	168,911,481 2	175,587,977 5	164,833,399 <i>3</i>	167,569,592 3	
Breast Cancer-Basic	Relevant Contract Dollars Total Count	1,977,194 790	648,203 760	1,013,726 749	1,431,744 770	653,485 858	
	Total Relevant Dollars	170,841,706	169,559,684	176,601,703	166,265,143	168,223,077	-0.32
	<i>Number of Grants</i> Relevant Grant Dollars	627 233,784,991	669 244,829,411	669 247,349,527	628 245,984,817	568 169,414,751	
Cancer Survivorship	<i>Number of Contracts</i> Relevant Contract Dollars	7 2,202,035	11 10,974,854	13 12,698,851	15 11,019,708	1 997,190	
	Total Count	634	680	682	643	569	6.00
	Total Relevant Dollars	235,987,026	255,804,265	260,048,378	257,004,525	170,411,941	-6.20

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

^{*} Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget. * Relevant Dollars = portion of the funded amount relevant to a specific site. * Coding not required or requested. Source: Research Analysis and Evaluation Branch.

Average Special Interest Counts and 2010 2011 2012 2013 2014 Percent Relevant Dollars† Categories Change/Yr. Number of Grants 1.316 1.237 1.163 1.116 1.041 **Relevant Grant Dollars** 395,790,431 384,795,833 367,617,534 313,980,620 273,042,396 Carcinogenesis, Number of Contracts 19 9 13 17 11 Environmental Relevant Contract Dollars 7,165,859 3,411,768 4,057,751 5,565,513 3,879,202 Total Count 1,335 1,246 1,176 1,052 1,133 388,207,601 Total Relevant Dollars 402,956,290 371,675,285 319,546,133 276,921,598 -8.82 Number of Grants 49 44 39 30 34 Cervical Cancer **Relevant Grant Dollars** 6,669,506 6,289,116 6,569,930 4,529,757 6,077,658 Education Total Count 49 44 39 30 34 6,289,116 **Total Relevant Dollars** 6,669,506 6,569,930 4,529,757 6,077,658 0.47 Number of Grants 554 513 521 490 429 110,334,008 Relevant Grant Dollars 110,809,302 106,270,652 97,428,457 84,243,372 Number of Contracts 9 9 9 6 6 Chemoprevention **Relevant Contract Dollars** 14,907,908 12,224,778 7,745,895 8.399,689 15,066,511 Total Count 563 522 530 496 435 Total Relevant Dollars 122,558,786 114,016,547 105,828,146 99,309,883 -5.71 125,717,210 Number of Grants 136 129 129 118 91 **Relevant Grant Dollars** 31,292,583 30,974,445 26,207,896 24,973,361 14,722,116 Chemoprevention, Number of Contracts 2 4 5 İ İ İ Clinical **Relevant Contract Dollars** 1,568,183 6,660,343 1,809,372 Total Count 91 134 118 138 133 **Total Relevant Dollars** 32,860,766 37,634,788 28,017,268 24,973,361 14,722,116 -15.73 Number of Grants 1.265 1.268 1,309 1.232 1.087 Relevant Grant Dollars 486,445,892 487,783,247 483,927,715 439,082,427 250,373,415 Number of Contracts 23 23 21 18 12 Chemotherapy Relevant Contract Dollars 16,237,585 15,509,777 15,400,076 10,450,686 9,970,324 Total Count 1.099 1,288 1.291 1.330 1.250 Total Relevant Dollars -13.18 502,683,477 503,293,024 499,327,791 449,533,113 260,343,739 Number of Grants 122 180 146 132 123 **Relevant Grant Dollars** 35,485,301 30,619,348 29,367,355 23,265,126 24,830,888 Number of Contracts 1 1 3 5 2 Child Health Relevant Contract Dollars 632.000 177,670 100.000 500.000 2,181,318 Total Count 135 181 147 128 124 Total Relevant Dollars 29,999,355 25,008,558 -8.26 35,585,301 31,119,348 25,446,444 Number of Grants 495 517 532 525 493 **Relevant Grant Dollars** 166,272,586 165,281,278 177,934,130 155,945,246 173,785,934 Number of Contracts 1 1 2 3 2 Childhood Cancers Relevant Contract Dollars 2,938,868 2,791,925 2,999,993 4,212,177 3,007,558 Total Count 496 518 534 528 495 Total Relevant Dollars 169,211,454 168,073,203 180,934,123 160,157,423 176,793,492 1.47 Number of Grants 129 143 143 143 132 Chronic **Relevant Grant Dollars** 33,259,274 40,413,091 38,980,403 36,692,865 36,189,051 Myeloproliferative Total Count 129 143 143 143 132 Disorders **Total Relevant Dollars** 33,259,274 40,413,091 38,980,403 36,692,865 36,189,051 2.68

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

		•		•			
Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Clinical Trials,	Number of Grants Relevant Grant Dollars Number of Contracts	158 49,365,161 14	157 50,104,212 3	142 38,090,132 2	136 30,815,744 3	146 45,889,734 1	
Diagnosis	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	21,295,518 172 70,660,679	4,929,393 160 55,033,605	2,264,053 144 40,354,185	1,651,880 139 32,467,624	1,728,293 147 47,618,027	-5.42
Clinical Trials, Other	Number of Grants Relevant Grant Dollars Number of Contracts	231 64,532,028 3	220 69,256,696 4	241 73,756,321 8	115 40,042,677 ‡	279 149,612,281 3	
,	Relevant Contract Dollars Total Count Total Relevant Dollars	2,199,778 234 66,731,806	5,627,105 224 74,883,801	4,870,009 249 78,626,330	‡ 115 40,042,677	7,962,288 282 157,574,569	65.41
Clinical Trials, Prevention	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars	162 56,851,445 4 10,044,105	227 142,302,439 6 11,401,878	140 51,726,135 8 2,682,866	115 40,042,677 ‡ ‡	114 35,417,115 4 7,423,381	
Flevention	Total Relevant Dollars	10,044,103 166 66,895,550	233 153,704,317	2,002,000 148 54,409,001	, 115 40,042,677	7,423,381 118 42,840,496	11.44
Clinical Trials, Therapy	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i> Relevant Contract Dollars	636 383,892,811 17 43,398,794	523 321,816,935 20 57,748,533	574 326,779,192 16 38,008,573	532 323,103,308 14 22,662,279	546 315,511,818 11 18,485,764	
	Total Relevant Dollars	653 427,291,605	543 379,565,468	590 364,787,765	546 345,765,587	557 333,997,582	-5.92
Combined Treatment	Number of Grants Relevant Grant Dollars Number of Contracts	679 366,302,744 4	769 388,561,125 7	922 407,422,052 8	1,022 412,395,044 8	<i>1,056</i> 241,467,906 <i>6</i>	
Modalities	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	3,372,144 683 369,674,888	6,442,620 776 395,003,745	7,776,273 930 415,198,325	7,259,529 1,030 419,654,573	7,488,672 1,062 248,956,578	-6.91
Cost Effectiveness	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars	173 27,186,831 2 186,230	177 29,938,700 1 248,461	181 29,528,911 1 2,479,561	155 23,509,038 ‡ ‡	139 22,816,491 ‡ ‡	
	<i>Total Count</i> Total Relevant Dollars	175 27,373,061	178 30,187,161	182 32,008,472	155 23,509,038	139 22,816,491	-3.30
Diabetes	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count	47 3,530,526 ‡ ‡ 47	36 4,851,425 ‡ ‡ 36	49 7,823,131 ‡ ‡ 49	68 9,846,534 1 207,952 69	77 8,622,303 ‡ ‡ 77	
	Total Relevant Dollars	3,530,526	4,851,425	7,823,131	10,054,486	8,622,303	28.24
Diagnosis	Number of Grants Relevant Grant Dollars Number of Contracts	1,855 553,036,713 66	1,779 559,531,772 51	1,758 538,315,913 52	<i>1,695</i> 492,426,013 <i>54</i>	1,686 529,392,958 39	
	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	38,373,345 1,921 591,410,058	24,273,760 1,830 583,805,532	32,848,866 1,810 571,164,779	40,112,891 1,749 532,538,904	30,979,563 1,725 560,372,521	-1.25

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

^{*} Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget. *Relevant Dollars = portion of the funded amount relevant to a specific site. *Coding not required or requested. Source: Research Analysis and Evaluation Branch.

Average Special Interest Counts and 2010 2011 2012 2013 2014 Percent Relevant Dollars[†] Categories Change/Yr. Number of Grants 2 3 3 3 2 210,443 330,257 323,182 308,506 263,724 **Relevant Grant Dollars** Number of Contracts 5 İ Diethylstilbestrol İ t **Relevant Contract Dollars** 1,345,965 İ Total Count 3 3 3 2 7 308,506 Total Relevant Dollars 1,556,408 330.257 323,182 263,724 -24.99 Number of Grants 12 13 9 8 7 Relevant Grant Dollars 1,736,256 869,725 936,088 612,850 631,714 Dioxin Total Count 12 13 9 8 Total Relevant Dollars 1,736,256 869,725 936,088 612,850 631,714 -18.43 Number of Grants 600 555 540 512 494 **Relevant Grant Dollars** 128,813,944 122,952,777 102,121,375 99,797,181 111,276,907 Number of Contracts 2 ‡ İ 1 **DNA Repair Relevant Contract Dollars** 399.599 ţ 999,596 İ ‡ 541 494 Total Count 602 555 512 Total Relevant Dollars 129,213,543 122,952,777 102,121,375 99,797,181 -6.21 112,276,503 Number of Grants 2.091 2,095 2,233 2,310 2,393 Relevant Grant Dollars 550,899,818 582,044,480 593,685,849 583,484,075 604,291,255 Number of Contracts 82 84 69 39 64 **Drug Development** Relevant Contract Dollars 50,932,059 44,439,383 58,367,271 43,062,404 36,749,532 Total Count 2,173 2,179 2,302 2,374 2,432 Total Relevant Dollars 601,831,877 626,483,863 652,053,120 626,546,479 641,040,787 1.64 Number of Grants 377 380 426 423 432 **Relevant Grant Dollars** 74,170,074 83,662,149 71,551,561 77,078,178 76,661,475 Number of Contracts 18 11 7 14 3 Drug Discovery Relevant Contract Dollars 11,779,829 2,805,286 2,752,844 5,018,328 298,072 Total Count 433 435 395 391 437 **Total Relevant Dollars** 85,949,903 79,831,022 83,960,221 -0.25 74,356,847 81,679,803 Number of Grants 634 638 697 712 785 **Relevant Grant Dollars** 117,323,805 126,166,864 137,912,021 133,575,885 148,056,783 Number of Contracts 2 2 2 3 1 **Drug Resistance** Relevant Contract Dollars 388,667 399.349 3.198.559 1.000.000 395.550 Total Count 636 640 699 715 786 Total Relevant Dollars 117,719,355 126,555,531 138,311,370 136,774,444 149,056,783 6.17 Number of Grants 640 603 577 556 490 **Relevant Grant Dollars** 143,114,167 140,027,475 123,779,207 109,888,176 71,095,657 Drugs - Natural Number of Contracts ‡ 4 5 2 ‡ İ 1,375,565 ‡ Products **Relevant Contract Dollars** 1,298,440 396,938 Total Count 644 608 579 556 490 Total Relevant Dollars 144,489,732 141,325,915 124,176,145 109,888,176 71,095,657 -15.28 Number of Grants 839 799 788 755 748 Relevant Grant Dollars 227,060,938 231,169,872 220,140,713 204,867,734 225,248,442 Number of Contracts 9 17 10 17 14 Early Detection Relevant Contract Dollars 21,353,066 9,463,743 15,164,662 13,803,863 8,393,779 Total Count 856 809 805 769 757 Total Relevant Dollars 248,414,004 240,633,615 235,305,375 218,671,597 233,642,221 -1.39

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

[†]Relevant Dollars = portion of the funded amount relevant to a specific site. [‡]Coding not required or requested.

^{*}Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

Source: Research Analysis and Evaluation Branch.

Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr
Effectiveness	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	199 59,933,366	241 88,645,132 2	329 95,620,963	318 90,764,479	296 80,220,580	
Research	Relevant Contract Dollars	2 560,081 201	2 303,094 243	7 5,463,193 336	8 12,172,772 326	1 10,500 297	
	Total Relevant Dollars	60,493,447	88,948,226	101,084,156	102,937,251	80,231,080	10.11
	<i>Number of Grants</i> Relevant Grant Dollars	716 144,586,939	669 134,691,456	619 127,583,367	572 111,913,229	539 107,069,679	
Endocrinology	<i>Number of Contracts</i> Relevant Contract Dollars	5 1 045 065	2 365,780	4 813,140	1 207 500	1 479 550	
	Total Count	1,345,965 721	671	613,140 623	1,307,520 573	1,478,552 540	
	Total Relevant Dollars	145,932,904	135,057,236	128,396,507	113,220,749	108,548,231	-7.08
	<i>Number of Grants</i> Relevant Grant Dollars	104 30,844,556	105 33,474,016	112 32,621,115	91 27,758,787	86 23,971,943	
Energy Balance	Number of Contracts	1	\$	‡	1	‡	
Energy balance	Relevant Contract Dollars	4,885	‡ 105	‡ 110	31,250	‡	
	<i>Total Count</i> Total Relevant Dollars	105 30,849,441	105 33,474,016	112 32,621,115	92 27,790,037	86 23,971,943	-5.65
	Number of Grants	238	248	257	245	233	
	Relevant Grant Dollars	58,955,769	58,456,327	75,023,578	76,193,758	81,439,737	
Epidemiology	Number of Contracts Relevant Contract Dollars	12 7,967,822	9 6,370,296	19 13,162,987	42 42,219,232	33 38,502,206	
	Total Count	250	257	276	287	266	
	Total Relevant Dollars	66,923,591	64,826,623	88,186,565	118,412,990	119,941,943	17.12
	<i>Number of Grants</i> Relevant Grant Dollars	544 207,004,532	513 196,371,213	525 200,458,114	516 183,330,345	495 169,955,392	
Epidemiology,	Number of Contracts	207,004,352 9	190,071,210 10	200,430,114 10	4	109,900,092 1	
Biochemical	Relevant Contract Dollars	22,230,209	27,302,955	32,063,034	12,320,111	2,160,252	
	<i>Total Count</i> Total Relevant Dollars	553 229,234,741	523 223,674,168	535 232,521,148	520 195,650,456	496 172,115,644	-6.59
	Number of Grants	487	442	402	380	336	0.00
	Relevant Grant Dollars	169,765,154	158,195,340	146,924,987	117,386,653	107,915,202	
Epidemiology, Environmental	<i>Number of Contracts</i> Relevant Contract Dollars	16	10 00 000 401	14 27,082,561	6	5 0 754 701	
Environmental	Total Count	24,953,396 503	22,833,401 452	27,002,501 416	13,262,667 386	3,754,701 341	
	Total Relevant Dollars	194,718,550	181,028,741	174,007,548	130,649,320	111,669,903	-12.59
	Number of Grants	771	859	893	901	943	
.	Relevant Grant Dollars Number of Contracts	161,834,223 3	182,952,932 ‡	197,448,892 1	183,377,930 1	187,566,016 ‡	
Epigenetics	Relevant Contract Dollars	549,598	;	80,000	80,000	‡	
	<i>Total Count</i> Total Relevant Dollars	774 162,383,821	859 182,952,932	894 197,528,892	902 183,457,930	943 187,566,016	3.94
	Number of Grants	436	402	349	283	237	0.01
	NUMBER OF GLAINS						
Gene Mapping,	Relevant Grant Dollars Total Count	158,894,763	149,903,735	112,977,260	75,989,190	61,585,479	

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

				•		,	
Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr
Gene Mapping,	<i>Number of Grants</i> Relevant Grant Dollars	243 37,746,569	215 35,807,176	183 30,805,418	157 24,907,163	130 14,858,944	
Non-Human	<i>Total Count</i> Total Relevant Dollars	243 37,746,569	215 35,807,176	183 30,805,418	157 24,907,163	130 14,858,944	-19.65
Gene Transfer,	Number of Grants Relevant Grant Dollars	28 8,086,568	33 8,242,594	28 6,398,890	23 5,731,303	22 4,272,656	
Clinical	Total Count Total Relevant Dollars	28 8,086,568	33 8,242,594	28 6,398,890	23 5,731,303	4,272,656	-14.08
	<i>Number of Grants</i> Relevant Grant Dollars	335 115,367,220	286 97,622,451	250 78,970,309	195 60,583,797	154 42,299,385	
Genetic Testing	Number of Contracts	3 113,307,220	97,022,431 4	70,970,309 4	\$	42,299,303 1	
Research, Human	Relevant Contract Dollars	1,325,744	1,531,022	2,838,423	\$	660,000	
	<i>Total Count</i> Total Relevant Dollars	338 116,692,964	290 99,153,473	254 81,808,732	195 60,583,797	155 42,959,385	-21.89
	Number of Grants	837	936	1.090	1,113	1,182	
	Relevant Grant Dollars	276,653,749	312,504,344	355,990,253	315,909,113	323,758,372	
Genomics	Number of Contracts	9	10	9	8	2	
	Relevant Contract Dollars Total Count	2,573,478 846	3,992,902 946	3,769,491 1,099	3,463,628 1,121	972,912 1,184	
	Total Relevant Dollars	279,227,227	316,497,246	359,759,744	319,372,741	324,731,284	4.37
	Number of Grants	93	104	107	106	98	
	Relevant Grant Dollars Number of Contracts	21,151,000	23,322,845	25,702,360	20,195,573	18,558,771	
Health Literacy	Relevant Contract Dollars	1 2,225,682	1 2.034.678	1 2,026,250	1 2,298,614	* * *	
	Total Count	<u>94</u>	105	108	107	98	
	Total Relevant Dollars	23,376,682	25,357,523	27,728,610	22,494,187	18,558,771	-4.64
	Number of Grants	535	492	459	434	378	
	Relevant Grant Dollars Number of Contracts	156,169,759 12	158,653,454 5	152,900,603 <i>9</i>	125,530,387 6	107,111,437 7	
Health Promotion	Relevant Contract Dollars	8,239,835	4,853,740	5,078,162	7,193,454	4,712,166	
	Total Count	547	497	468	440	385	
	Total Relevant Dollars	164,409,594	163,507,194	157,978,765	132,723,841	111,823,603	-8.92
	Number of Grants	323	361	370	360	398	
	Relevant Grant Dollars Number of Contracts	99,249,496 9	111,213,954 10	116,521,815 12	108,978,920 14	218,923,687 3	
Health Care Delivery	Relevant Contract Dollars	4,637,640	6,239,884	6,285,437	12,762,591	2,221,373	
	Total Count	332	371	382	374	401	04.00
	Total Relevant Dollars	103,887,136	117,453,838	122,807,252	121,741,511	221,145,060	24.60
	<i>Number of Grants</i> Relevant Grant Dollars	34 8,078,008	33 8,081,826	32 7,685,880	31 6,972,140	29 6,799,315	
LL P. L.	Number of Contracts	\$,070,000	0,001,020 ‡	000,000,1 ‡	0,972,140 ‡	0,799,315 ‡	
Helicobacter	Relevant Contract Dollars	;	‡	‡	‡	‡	
	Total Count	34	33	32	31	29	4.45
	Total Relevant Dollars	8,078,008	8,081,826	7,685,880	6,972,140	6,799,315	-4.15

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

*Relevant Dollars = portion of the funded amount relevant to a specific site.

Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yi
	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	1,472 466,847,932 6	1,423 464,441,339 6	1,440 454,740,603 7	1,411 428,144,424 9	1,336 432,281,168 4	
Hematology	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	1,967,879 <i>1,478</i> 468,815,811	2,797,458 1,429 467,238,797	3,100,209 1,447 457,840,812	5,851,583 1,420 433,996,007	1,775,197 <i>1,340</i> 434,056,365	-1.89
	Number of Grants Relevant Grant Dollars	396 113,380,226	407,238,797 465 122,611,326	437,040,812 449 105,983,734	433,990,007 431 101,488,276	434,030,303 397 87,079,722	-1.09
Hematopoietic	Number of Contracts	113,300,220 1	122,011,320	100,900,704	101,400,270	01,019,122 ‡	
Stem Cell Research	Relevant Contract Dollars	999,936	\$	‡	‡	\$	
	<i>Total Count</i> Total Relevant Dollars	397 114,380,162	465 122,611,326	449 105,983,734	431 101,488,276	397 87,079,722	-6.20
Hormone	<i>Number of Grants</i> Relevant Grant Dollars	33 3,175,346	31 3,987,675	23 2,695,611	21 2,396,798	17 1,621,562	
Replacement	Total Count	3,175,340 33	3,967,075 31	2,095,011 23	2,390,798 21	1,021,302 17	
Therapy	Total Relevant Dollars	3,175,346	3,987,675	2,695,611	2,396,798	1,621,562	-12.56
	<i>Number of Grants</i> Relevant Grant Dollars	45 9,344,380	33 8,276,000	34 7,183,290	31 5,960,311	26 6,718,944	
Hospice	Number of Contracts	1	\$	‡	¢,000,011 ‡	‡	
Tiospice	Relevant Contract Dollars	999,998	\$	\$	‡	\$	
	<i>Total Count</i> Total Relevant Dollars	46 10,344,378	33 8,276,000	34 7,183,290	31 5,960,311	26 6,718,944	-9.37
	Number of Grants	533	631	762	831	889	
	Relevant Grant Dollars Number of Contracts	224,387,803 2	262,277,096 2	303,194,306 4	285,048,104 <i>6</i>	288,232,403 2	
Human Genome	Relevant Contract Dollars	2,260,666	1,398,722	1,744,057	2,922,371	972,912	
	<i>Total Count</i> Total Relevant Dollars	535 226,648,469	633 263,675,818	766 304,938,363	837 287,970,475	891 289,205,315	6.71
	Number of Grants	220,040,409	203,073,010 247	264	207,970,473 240	209,200,010 255	0.71
	Relevant Grant Dollars	61,577,955	62,271,326	70,740,383	63,359,024	62,665,069	
latrogenesis	<i>Number of Contracts</i> Relevant Contract Dollars	5 1 045 065	3	4	15 0.050.004	11 500 700	
	Total Count	1,345,965 262	487,983 250	1,406,258 268	9,252,324 255	11,590,700 271	
	Total Relevant Dollars	62,923,920	62,759,309	72,146,641	72,611,348	74,255,769	4.40
	<i>Number of Grants</i> Relevant Grant Dollars	1,045 298,744,722	1012 309,142,019	1,014 287,214,478	977 262,826,270	1,020 303,333,609	
Imaging	Number of Contracts	230,744,722 32	309,142,019 20	14	202,020,270 18	505,555,009 15	
Imaging	Relevant Contract Dollars	21,851,672	7,316,896	7,351,691	13,479,943	9,601,975	
	<i>Total Count</i> Total Relevant Dollars	1,077 320,596,394	1032 316,458,915	<i>1,028</i> 294,566,169	995 276,306,213	1,035 312,935,584	-0.29
	Number of Grants	442	449	469	443	432	
	Relevant Grant Dollars	116,267,543 +	122,814,703	127,780,151	108,339,472	104,548,325	
Immunization	Number of Contracts Relevant Contract Dollars	+ ‡	4 3,429,651	1 1,996,084	5 8,810,556	4 4,894,582	
	Total Count	442	453	470	448	436	
	Total Relevant Dollars	116,267,543	126,244,354	129,776,235	117,150,028	109,442,907	-1.23

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

Average **Special Interest** Counts and 2010 2011 2012 2013 2014 Percent Relevant Dollars† Categories Change/Yr. Number of Grants 418 467 532 594 611 81,746,863 99,553,973 113,039,549 **Relevant Grant Dollars** 107,278,269 109.966.955 Number of Contracts ‡ İ ‡ 1 3 Inflammation ‡ t t 3.652,516 **Relevant Contract Dollars** 318,141 Total Count 418 467 532 595 614 Total Relevant Dollars 81,746,863 99,553,973 113,039,549 107,596,410 113,619,471 9.03 Number of Grants 861 835 787 755 739 Relevant Grant Dollars 231,787,714 237,305,178 247,159,725 224,368,430 217,876,571 Information Number of Contracts 38 36 56 22 8 Dissemination Relevant Contract Dollars 72,642,039 70,246,091 76,556,706 19,915,843 14,567,395 Total Count 843 899 871 747 777 Total Relevant Dollars 304,429,753 307,551,269 323,716,431 244,284,273 232,443,966 -5.78 Number of Grants 1,527 1.534 1.543 1,550 1.545 **Relevant Grant Dollars** 361,870,802 381,229,457 370,139,067 339,242,680 340,009,556 Number of Contracts 7 6 6 6 3 Metastasis **Relevant Contract Dollars** 1,325,290 1,024,332 3,434,990 2,322,483 961,421 Total Count 1.534 1,540 1.549 1.556 1.548 Total Relevant Dollars 363,196,092 373,574,057 341,565,163 340,970,977 -1.42 382,253,789 Number of Grants 59 75 83 83 78 **Relevant Grant Dollars** 17,883,028 16,149,064 18,436,251 13,881,407 11,783,092 Number of Contracts ‡ 2 İ Mind/Body Research Relevant Contract Dollars 89,759 İ ‡ İ Total Count 75 83 85 78 59 Total Relevant Dollars 17,883,028 16,149,064 18,526,010 13,881,407 11,783,092 -8.79 Number of Grants 4,962 4,879 4,945 5,158 5,466 Relevant Grant Dollars 1,670,263,492 1,660,747,605 1,646,243,216 1,611,962,239 1,679,313,384 Number of Contracts 31 34 45 35 49 Molecular Disease Relevant Contract Dollars 9,144,621 14,337,338 19,893,543 30.025.697 30,765,834 Total Count 4,993 4,914 4,979 5.207 5.511 **Total Relevant Dollars** 1,679,408,113 1,675,084,943 1,666,136,759 1,641,987,936 1,710,079,218 0.48 Number of Grants 650 701 724 672 620 **Relevant Grant Dollars** 164,707,342 184,280,121 152,907,543 181,500,075 160,435,399 Number of Contracts 15 5 3 15 4 Molecular Imaging Relevant Contract Dollars 4,042,324 5,602,005 798,078 2,940,739 1,942,675 Total Count 716 728 623 665 677 Total Relevant Dollars 168,749,666 187,102,080 185,078,199 163,376,138 154,850,218 -1.79 Number of Grants 232 252 248 269 260 **Relevant Grant Dollars** 39,235,184 47,765,297 47,214,496 48,209,422 44,556,081 Molecular Targeted Number of Contracts 1 1 2 2 2 Prevention **Relevant Contract Dollars** 74,750 248,461 212,500 1,647,216 2,979,162 Total Count 253 249 271 262 234 Total Relevant Dollars 5.35 39.309.934 48,013,758 47,426,996 49,856,638 47,535,243 1,775 Number of Grants 1.515 1.577 1.888 2.044 Relevant Grant Dollars 407,096,513 442,319,529 475,531,951 470,992,018 523,857,998 Molecular Targeted Number of Contracts 21 18 18 12 12 Therapy **Relevant Contract Dollars** 6,175,491 7,588,080 12,174,642 8,499,344 8,863,954 Total Count 1,793 1,900 2,056 1,536 1,595 Total Relevant Dollars 6.67 413,272,004 449,907,609 487,706,593 479,491,362 532,721,952

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

^{*}Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Special Interest Categories	Counts and Relevant Dollars †	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Nanotechnology	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	461 122,072,696 20	444 119,336,493 11	480 121,450,044 14	476 109,920,780 6	455 111,516,643 5	
ranolechnology	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	7,338,362 481 129,411,058	5,161,598 455 124,498,091	7,104,793 494 128,554,837	2,045,407 482 111,966,187	5,326,115 460 116,842,758	-2.27
Neurofibromatosis	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i> Total Relevant Dollars	34 7,560,557 34 7,560,557	15 2,915,817 15 2,915,817	15 2,745,637 15 2,745,637	11 1,584,767 11 1,584,767	8 1,376,362 8 1,376,362	-30.68
Nursing Research	<i>Number of Grants</i> Relevant Grant Dollars <i>Total Count</i> Total Relevant Dollars	54 13,918,717 54 13,918,717	49 11,599,142 49 11,599,142	45 11,366,624 45 11,366,624	37 9,407,781 37 9,407,781	35 8,475,918 35 8,475,918	-11.45
Nutrition-Fiber	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	19 2,058,728 ‡ ‡ 19 2,058,728	19 3,019,322 ‡ ‡ 19 3,019,322	13 1,881,369 1 56,250 14 1,937,619	10 1,147,521 ‡ 10 1,147,521	7 1,084,354 <i>‡</i> 7 1,084,354	-8.86
Nutrition	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	830 198,165,748 14 13,792,873 844 211,958,621	779 201,597,394 5 9,069,226 784 210,666,620	735 176,394,674 19 12,900,479 754 189,295,153	698 152,339,204 9 11,924,668 707 164,263,872	638 131,807,340 9 4,372,361 647 136,179,701	-10.27
Nutrition Monitoring	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	45 11,311,406 ‡	42 15,194,549 ‡	36 9,995,060 7	30 10,354,902 2	30 8,955,163 3	
	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	‡ 45 11,311,406	‡ 42 15,194,549	1,107,515 43 11,102,575	1,277,146 32 11,632,048	2,210,544 33 11,165,707	2.04
Obesity	Total Count	45 11,311,406 251 47,992,367 ‡ ‡ 251	42 15,194,549 251 58,308,346 3 689394 254	43 11,102,575 258 63,008,280 4 1,012,349 262	32	33 11,165,707 290 63,637,392 1 1,478,927 291	2.04
Obesity Occupational Cancer	Total Count Total Relevant Dollars Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count	45 11,311,406 251 47,992,367 ‡ ‡	42 15,194,549 251 58,308,346 3 689394	43 11,102,575 258 63,008,280 4 1,012,349	32 11,632,048 283 62,423,989 ‡ ‡ 283	33 11,165,707 290 63,637,392 1 1,478,927	

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

*Relevant Dollars = portion of the funded amount relevant to a specific site.

Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr
_	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	2,031 515,190,558 3	1,934 498,144,267 5	1,883 473,323,034 8	1,828 413,130,527 6	1,784 404,601,468 1	
Oncogenes	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	2,074,867 2,034 517,265,425	1,072,456 <i>1,939</i> 499,216,723	2,534,277 <i>1,891</i> 475,857,311	5,307,498 <i>1,834</i> 418,438,025	111,706 <i>1,785</i> 404,713,174	-5.88
	Number of Grants	182	194	164	175	151	-5.00
Organ Transplant	Relevant Grant Dollars Number of Contracts	66,404,117 ‡	67,155,158 ‡	49,923,229 ‡	55,542,375 ‡	48,657,932 ‡	
Research	Relevant Contract Dollars	‡	÷	÷	‡	\$	
	<i>Total Count</i> Total Relevant Dollars	182 66,404,117	194 67,155,158	164 49,923,229	175 55,542,375	151 48,657,932	-6.42
	<i>Number of Grants</i> Relevant Grant Dollars	8 411,172	6 317,668	6 925,324	5 722,771	7 1,471,815	
Osteoporosis	Total Count		6 סטט, דו ס	525,524 6	5	7,471,013	
	Total Relevant Dollars	411,172	317,668	925,324	722,771	1,471,815	62.57
	<i>Number of Grants</i> Relevant Grant Dollars	147 16,468,439	152 16,300,996	154 18,155,638	159 17,703,099	132 12,405,393	
Pain	Number of Contracts	2 1 0,400,403	10,000,000	10,100,000	17,700,000 1	\$	
ran	Relevant Contract Dollars Total Count	1,299,610 149	‡ 152	‡ 154	100,000 <i>160</i>	‡ 120	
	Total Relevant Dollars	17,768,049	16,300,996	18,155,638	17,803,099	132 12,405,393	-7.28
	Number of Grants	161	153	153	152	129	
	Relevant Grant Dollars Number of Contracts	20,897,707 2	21,247,383 <i>1</i>	21,916,672 1	18,689,924 1	15,149,837 1	
Palliative Care	Relevant Contract Dollars	2,198,445	52,655	21,000	53,991	10,500	
	Total Count	163	154	154	153	130	0.00
	Total Relevant Dollars	23,096,152	21,300,038	21,937,672	18,743,915	15,160,337	-9.62
	<i>Number of Grants</i> Relevant Grant Dollars	106 10,627,523	105 11,695,680	111 11,312,785	98 10,168,380	81 5,542,465	
Pap Testing	Number of Contracts	1	‡ +	* + +	* + +	‡ +	
1 5	Relevant Contract Dollars Total Count	45,000 107	.↓ 105	‡ 111	‡ 98	‡ 81	
	Total Relevant Dollars	10,672,523	11,695,680	11,312,785	10,168,380	5,542,465	-12.32
	Number of Grants	685	581	636	681	623	
	Relevant Grant Dollars Number of Contracts	212,337,590 7	146,844,741 2	179,363,922 5	193,100,899 8	209,529,822 4	
Pediatric Research	Relevant Contract Dollars	4,384,833	3,291,925	3,631,993	6,488,808	3,185,228	
	<i>Total Count</i> Total Relevant Dollars	692 216,722,423	583 150,136,666	641 182,995,915	689 199,589,707	627 212,715,050	1.70
	Number of Grants	630	638	685	661	664	
	Relevant Grant Dollars	183,230,229	180,445,101	184,951,025	164,974,350	155,335,886	
Personalized Health Care	<i>Number of Contracts</i> Relevant Contract Dollars	21 37,543,010	17 32,351,821	20 37,283,739	12 8,158,581	1 224,999	
Cale	Total Count	651	655 655	705	673	665	
	Total Relevant Dollars	220,773,239	212,796,922	222,234,764	173,132,931	155,560,885	-7.86

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Relevant Dollars = portion of the funded amount relevant to a specific site. *Coding not required or requested.

^{*}Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr.
	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	12 531,371 2	13 471,294 *	10 460,087 +	4 59,725 +	1 § ‡	
Pesticides	Relevant Contract Dollars Total Count	2 224,000 14	‡ 13	* * 10	+ ‡ 4	* ‡ 1	
	Total Relevant Dollars	755,371	471,294	460,087	59,725	§	-42.33
Pharmacogenetics	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	312 53,813,379 ‡	276 52,795,552 1	266 54,346,257 2	248 49,570,728 ‡	226 41,541,959 ‡	
i namaoogonoaco	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	‡ 312 53,813,379	193,637 277 52,989,189	670,000 268 55,016,257	‡ 248 49,570,728	‡ 226 41,541,959	-5.95
	<i>Number of Grants</i> Relevant Grant Dollars	<i>1,246</i> 324,621,692	1,220 332,988,470	1,235 338,729,425	1,240 324,824,552	1,221 366,837,607	
Prevention	Number of Contracts Relevant Contract Dollars	28,993,208	23 30,211,780	35 25,780,603	27 30,875,471	23 32,958,496	
	Total Relevant Dollars	<i>1,266</i> 353,614,900	<i>1,243</i> 363,200,250	<i>1,270</i> 364,510,028	<i>1,267</i> 355,700,023	<i>1,244</i> 399,796,103	3.26
	<i>Number of Grants</i> Relevant Grant Dollars	564 105,713,144	648 128,504,517	718 143,749,069	700 133,187,112	680 132,200,036	
Proteomics	Number of Contracts Relevant Contract Dollars Total Count	13 3,710,715 577	12 2,364,169 <i>660</i>	8 3,506,652 726	14 5,364,611 714	3 465,439 <i>683</i>	5 40
	Total Relevant Dollars Number of Grants	109,423,859 5	130,868,686	147,255,721 2	138,551,723 1	132,665,475 1	5.49
Radiation, Electromagnetic Fields	Relevant Grant Dollars Total Count	794,902 5	274,880 5	208,400 2	195,214 <i>1</i>	207,149 1	
	Total Relevant Dollars	794,902	274,880	208,400	195,214	207,149	-22.45
Dediction legising	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	137 24,942,689 ‡	118 22,587,580 ‡	109 20,437,132 1	99 15,415,636 1	91 13,527,344 1	
Radiation, Ionizing	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	‡ 137 24,942,689	‡ 118 22,587,580	91,808 110 20,528,940	95,313 100 15,510,949	209,449 <i>92</i> 13,736,793	-13.61
	Number of Grants	284	288	297	291	301	
Radiation, Ionizing	Relevant Grant Dollars <i>Number of Contracts</i>	67,228,830 2	83,355,570 <i>6</i>	78,440,948 4	69,835,784 <i>6</i>	67,671,200 3	
Diagnosis	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	1,127,414 286 68,356,244	3,682,723 294 86,038,293	2,664,706 301 81,105,654	4,565,381 297 74,401,165	4,153,185 304 71,824,385	2.10
	<i>Number of Grants</i> Relevant Grant Dollars	605 197,773,842	594 215,668,304	595 178,645,894	578 168,829,680	510 105,995,072	2.10
Radiation, Ionizing Radiotherapy	Number of Contracts Relevant Contract Dollars Total Count	3 226,116 608	6 852,523 600	<i>6</i> 1,860,053 <i>601</i>	14 7,299,204 592	1 1,499,978 511	
	Total Relevant Dollars	197,999,958	216,520,827	180,505,947	176,128,884	107,495,050	-12.17

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

§No Cost Extension.

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest	Counts and	0010	0044	0040	0040	0011	Average
Categories	Relevant Dollars [†]	2010	2011	2012	2013	2014	Percent Change/Yi
	Number of Grants	16	15	11	8	7	Ŭ
	Relevant Grant Dollars	3,564,004	2,684,415	2,790,815	1,703,359	760,210	
Radiation, Low-Level	Number of Contracts	‡	\$; ;	‡	‡	
lonizing	Relevant Contract Dollars	*	\$	‡	\$	‡	
	Total Count	16	15 0.004.415	11	8	7	00.70
	Total Relevant Dollars	3,564,004	2,684,415	2,790,815	1,703,359	760,210	-28.76
	Number of Grants	309	311	316	302	322	
Radiation, Magnetic	Relevant Grant Dollars Number of Contracts	71,053,694 2	72,516,747 3	66,373,621 4	71,059,404 3	83,520,731 ‡	
Resonance Imaging	Relevant Contract Dollars	625,760	810.966	4 1,649,709	3 813,452	* ‡	
lesonance imaging	Total Count	311	314	320	305	, 322	
	Total Relevant Dollars	71,679,454	73,327,713	68,023,330	71,872,856	83,520,731	4.23
	Number of Grants	211	186	183	173	153	
	Relevant Grant Dollars	26,824,376	30,249,026	29,124,083	27,564,637	23,148,908	
Radiation,	Number of Contracts	1	2	1	1	1	
Mammography	Relevant Contract Dollars	999,985	1,845,486	1,400,000	1,300,000	1,100,000	
	Total Count	212	188	184	174	154	0.74
	Total Relevant Dollars	27,824,361	32,094,512	30,524,083	28,864,637	24,248,908	-2.74
	Number of Grants	167	160	149	129	130	
Radiation,	Relevant Grant Dollars	26,918,563	26,910,915	25,283,118	21,566,717	24,739,055	
Non-Ionizing	<i>Number of Contracts</i> Relevant Contract Dollars	3 476,414	1 999.000	1 137,350	+ +	* *	
Non-Ionizing	Total Count	470,414 170	161	150	, 129	130	
	Total Relevant Dollars	27,394,977	27,909,915	25,420,468	21,566,717	24,739,055	-1.87
	Number of Grants	471	467	491	469	474	
Radiation,	Relevant Grant Dollars	125,702,669	131,948,820	126,670,584	114,249,805	130,723,063	
Non-Ionizing	Number of Contracts	9	5	6	6	3	
Diagnosis	Relevant Contract Dollars	1,675,452	1,260,269	2,735,231	4,045,191	679,250	
- 3	<i>Total count</i> Total Relevant Dollars	480 127,378,121	472 133,209,089	497 129,405,815	475 118,294,996	477 131,402,313	1.05
							1.05
	Number of Grants	195	190	187 45.869.628	187	193	
Radiation,	Relevant Grant Dollars Number of Contracts	40,077,552 3	48,439,155 ‡	45,869,6∠8 1	42,314,931 2	51,128,011 5	
Non-Ionizing	Relevant Contract Dollars	599,386	<i>†</i> ‡	1,499,896	1,573,324	1,044,592	
Radiotherapy	Total Count	198	190	188	189	198	
	Total Relevant Dollars	40,676,938	48,439,155	47,369,524	43,888,255	52,172,603	7.10
	Number of Grants	149	144	133	121	114	
	Relevant Grant Dollars	23,686,597	24,555,465	23,909,838	20,530,426	22,589,958	
Radiation, UV	Number of Contracts	3	1	1	‡	*	
	Relevant Contract Dollars	476,414	‡ 1 45	137,350	Į	‡	
	<i>Total Count</i> Total Relevant Dollars	152 24,163,011	145 25,554,465	134 24,047,188	121 20,530,426	114 22,589,958	-1.18
							1.10
	<i>Number of Grants</i> Relevant Grant Dollars	2 48,624	3 326,441	5 490,407	4 399,608	4 417,728	
Radon	Total Count	40,0∠4 2	3∠0,441 3	490,407 5	099,008 4	417,720 A	
		48,624	326,441	5	399,608	417,728	151.90

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

*Relevant Dollars = portion of the funded amount relevant to a specific site. *Coding not required or requested.

		•		•			
Special Interest Categories	Counts and Relevant Dollars†	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Rare Diseases	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count	140 29,192,350 ‡ ‡ 140	119 23,592,946 ‡ ‡ 119	100 18,712,924 ‡ 100	73 12,159,075 1 74,592 74	62 10,866,928 1 312,912 63	
	Total Relevant Dollars	29,192,350	23,592,946	18,712,924	12,233,667	11,179,840	-20.78
Rehabilitation	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	221 38,584,600 2 76,452 223 38,661,052	230 40,748,671 1 52,655 231 40,801,326	234 45,308,533 1 21,000 235 45,329,533	229 40,076,940 4 475,141 233 40,552,081	210 47,474,572 2 1,007,690 212 48,482,262	6.41
Rural Populations	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	103 35,157,309 12 10,416,108 115 45,573,417	103 34,658,560 10 8,535,867 113 43,194,427	100 31,874,931 8 7,269,316 108 39,144,247	91 28,293,909 ‡ \$ 91 28,293,909	118 51,131,320 ‡ ‡ 118 51,131,320	9.60
Sexually Transmitted Diseases	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	183 30,488,788 2 4,439,576 185 34,928,364	185 29,789,110 1 3,836,717 186 33,625,827	175 28,189,148 1 870,317 176 29,059,465	154 21,439,368 ‡ 154 21,439,368	130 17,283,985 ‡ 130 17,283,985	-15.73
Sleep Disorders	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	70 9,183,149 ‡ 70 9,183,149	64 7,810,486 ‡ ‡ 64 7,810,486	54 6,729,657 1 300,000 55 7,029,657	46 5,420,968 3 550,000 49 5,970,968	48 6,930,386 1 78,195 49 7,008,581	-5.66
Small Molecules	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	407 70,693,138 10 2,203,593 417 72,896,731	416 81,708,151 9 3,726,105 425 85,434,256	513 100,631,305 4 1,449,375 517 102,080,680	556 95,910,356 6 1,140,627 562 97,050,983	609 109,485,605 4 1,389,150 613 110,874,755	11.50
Smokeless Tobacco	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	34 6,896,702 1 453,965 35 7,350,667	19 4,743,669 1 385,000 20 5,128,669	24 5,175,673 1 385,000 25 5,560,673	33 4,087,588 1 332,500 34 4,420,088	29 1,359,152 1 420,000 30 1,779,152	-25.52
Smoking, Passive	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	24 3,459,579 1 453,965 25 3,913,544	15 2,250,884 1 385,000 16 2,635,884	14 2,491,604 1 385,000 15 2,876,604	18 3,160,590 1 332,500 19 3,493,090	20 3,771,941 1 420,000 21 4,191,941	4.48

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

†Relevant Dollars = portion of the funded amount relevant to a specific site.

^{*}Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

Coding not required or requested. Source: Research Analysis and Evaluation Branch.

ι.	, , ,	, ,			, ,	,	
Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Structural Biology	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	1,337 269,191,027 11	1,242 258,099,045 15	1,199 235,455,633 3	1,103 206,932,623 4	1,048 196,164,921 ‡	
Structural biology	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	1,512,388 1,348 270,703,415	1,522,607 1,257 259,621,652	615,101 <i>1,202</i> 236,070,734	1,595,591 1,107 208,528,214	‡ 1,048 196,164,921	-7.69
	<i>Number of Grants</i> Relevant Grant Dollars	327 72,591,577	333 85,655,815	328 76,917,479	326 77,598,007	300 48,740,495 +	
Surgery	Number of Contracts Relevant Contract Dollars Total Count	2 1,200,000 <i>329</i>	2 373,417 335	3 545,979 331	5 2,527,184 331	‡ 300	
	Total Relevant Dollars	73,791,577	86,029,232	77,463,458	80,125,191	48,740,495	-7.28
	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	305 73,441,347 1	285 70,198,681 ‡	273 60,447,024 1	270 52,963,267 ‡	222 17,879,201 ‡	
Taxol	Relevant Contract Dollars	50,000	‡	199,714	÷ ‡	÷	
	Total Count	306	285	274	270	222	04.05
	Total Relevant Dollars	73,491,347	70,198,681	60,646,738	52,963,267	17,879,201	-24.25
	Number of Grants Relevant Grant Dollars Number of Contracts	351 83,738,070 10	311 76,191,259 11	292 76,478,419 7	288 65,169,688 7	283 64,593,337 6	
Telehealth	Relevant Contract Dollars	12,502,513	11,912,660	9,755,606	9,541,363	10,473,269	
	Total Count Total Relevant Dollars	361 96,240,583	322 88,103,919	299 86,234,025	295 74,711,051	289 75,066,606	-5.87
	Number of Grants	3,668	3,626	3,738	3,838	4,057	
	Relevant Grant Dollars	1,289,919,675	1,295,238,778	1,293,761,000	1,246,559,964	1,366,836,549	
Therapy	Number of Contracts Relevant Contract Dollars	102	94	92	104	67 80,749,732	
	Total Count	97,314,391 3,770	93,641,732 3,720	88,810,315 <i>3,830</i>	71,823,475 3,942	00,749,732 4,124	
	Total Relevant Dollars	1,387,234,066	1,388,880,510	1,382,571,315	1,318,383,439	1,447,586,281	1.21
	Number of Grants	470	449	416	417	381	
	Relevant Grant Dollars Number of Contracts	121,389,946 8	127,614,366 4	122,594,345 4	98,441,413 8	80,787,427 5	
Tobacco	Relevant Contract Dollars	2,479,840	1,419,652	1,302,350	2,268,519	1,335,500	
	<i>Total Count</i> Total Relevant Dollars	478 123,869,786	453	420	425	386	-9.25
			129,034,018	123,896,695	100,709,932	82,122,927	-9.20
	Number of Grants Relevant Grant Dollars	250 81,176,603	239 83,456,895	259 87,985,064	276 73,128,257	274 64,136,938	
Tobacco Use Behavior	Number of Contracts Relevant Contract Dollars	4 1,868,571	2 1,320,000	4 1,302,350	6 2,066,485	5 1,335,500	
	Total Count	254	241	263	282	279	
	Total Relevant Dollars	83,045,174	84,776,895	89,287,414	75,194,742	65,472,438	-5.33
	Number of Grants	29	25	21	16	15	
	Relevant Grant Dollars Number of Contracts	6,535,704 ‡	5,619,635 ‡	5,588,012 ‡	2,226,158 ‡	2,968,168 ‡	
Tropical Diseases	Relevant Contract Dollars	÷ ‡	‡	‡	÷	÷ ‡	
	<i>Total Count</i> Total Relevant Dollars	29 6 525 704	25 5 610 625	21	16	2 069 169	10.05
	IUIAI MEIEVAI IL DOIIAIS	6,535,704	5,619,635	5,588,012	2,226,158	2,968,168	-10.35

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

^{*}Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

^{*}Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested. Source: Research Analysis and Evaluation Branch.

Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr.
Tumor Markers	<i>Number of Grants</i> Relevant Grant Dollars <i>Number of Contracts</i>	731 189,955,095 12	626 161,691,676 4	508 124,259,866 3	393 88,015,396 ‡	298 59,605,975 ‡	
	Relevant Contract Dollars <i>Total Count</i> Total Relevant Dollars	4,365,645 743 194,320,740	2,569,530 <i>630</i> 164,531,206	2,693,245 511 126,953,111	‡ 393 88,015,396	‡ 298 59,605,975	-25.28
Underserved Populations	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	607 210,560,355 21 12,245,405 628 222,805,760	595 210,385,470 16 10,306,244 611 220,691,714	585 216,074,187 16 11,469,992 601 227,544,179	556 189,290,919 2,354,483 558 191,645,402	610 245,809,745 ‡ 610 245,809,745	3.66
Vaccine Development	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	163 21,218,754 ‡ 163 21,218,754	159 21,105,678 1 199,988 160 21,305,666	151 20,714,291 ‡ 151 20,714,291	130 17,452,232 1 739,425 131 18,191,657	112 15,119,199 1 458,635 113 15,577,834	-7.23
Vaccine Production	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	8 1,046,919 ‡ # 8 1,046,919	6 661,049 1 1,499,001 7 2,160,050	3 589,530 ‡ 3 589,530	2 152,239 1 739,425 3 891,664	1 ‡ ‡ 1 ‡	28.29
Vaccine Research	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	201 33,377,072 1 23,100 202 33,400,172	195 34,117,779 2 1,502,003 197 34,619,782	183 31,279,880 1 1,996,084 184 33,275,964	167 25,866,062 3 5,831,735 170 31,697,797	149 25,518,109 ‡ 149 25,518,109	-6.12
Vaccine Testing	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	130 21,759,604 1 4,394,576 131 26,154,180	111 18,745,944 1 3,836,717 112 22,582,661	101 17,217,816 1 870,317 102 18,088,133	82 13,797,753 ‡ \$2 13,797,753	70 14,265,015 3 4,435,947 73 18,700,962	-5.44
Virus Cancer Research	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count Total Relevant Dollars	541 153,628,908 3 4,549,461 544 158,178,369	505 142,438,045 1 3,836,717 506 146,274,762	481 133,815,083 4 4,066,305 485 137,881,388	458 123,611,800 2 2,478,454 460 126,090,254	442 124,977,046 1 740,476 443 125,717,522	-5.53
Virus – Epstein-Barr	Number of Grants Relevant Grant Dollars Number of Contracts Relevant Contract Dollars Total Count	110 24,362,117 ‡ ‡ 110	104 24,499,924 ‡ ‡ 104	96 22,756,337 ‡ \$ 96	81 20,096,683 ‡ ‡ 81	75 17,304,516 ‡ ‡ 75	0.00
	Total Relevant Dollars	24,362,117	24,499,924	22,756,337	20,096,683	17,304,516	-8.03

(This table reports funding for grants and contracts only; intramural projects are excluded.)

continued

^{*} Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget. *Relevant Dollars = portion of the funded amount relevant to a specific site. *Coding not required or requested. Source: Research Analysis and Evaluation Branch.

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr.
	Number of Grants	4	4	3	‡ +	‡	
Virus – Genital Herpes	Relevant Grant Dollars Total Count	379,575 4	372,188 4	290,654 3	‡ ‡	‡ ‡	
nerpes	Total Relevant Dollars	379,575	372,188	290,654	* * *	*	-11.93
	Number of Grants	51	50	42	39	39	
Virus – Hepatitis B	Relevant Grant dollars	11,337,066	6,370,613	4,928,799	3,929,183	4,816,519	
virus – nepalilis D	Total Count	51	50	42	39	39	
	Total Relevant Dollars	11,337,066	6,370,613	4,928,799	3,929,183	4,816,519	-16.03
	Number of Grants	34	31	40	<i>39</i>	34	
	Relevant Grant Dollars Number of Contracts	5,719,779 †	4,600,379 ‡	5,332,014 †	3,990,130 †	3,507,767 †	
Virus – Hepatitis C	Relevant Contract Dollars	* * *	÷	* * *	* * *	‡	
	Total Count	34	31	40	39	34	
	Total Relevant Dollars	5,719,779	4,600,379	5,332,014	3,990,130	3,507,767	-10.23
	Number of Grants	206	190	182	163	157	
	Relevant Grant Dollars	47,274,246	48,127,519	44,080,597	41,683,291	42,315,552	
Virus – Herpes	Number of Contracts Relevant Contract Dollars	‡ +	‡ ‡	‡ ‡	‡ ‡	‡ ‡	
	Total Count	* 206	+ 190	* 182	* 163	, 157	
	Total Relevant Dollars	47,274,246	48,127,519	44,080,597	41,683,291	42,315,552	-2.63
	Number of Grants	87	78	74	66	65	
	Relevant Grant Dollars	18,532,843	17,725,584	15,764,211	18,719,752	19,671,059	
Virus – HHV8	Number of Contracts	‡ *	* *	‡ *	* * *	‡ ‡	
	Relevant Contract Dollars Total Count	÷ 87	.⊹ 78	+ 74	÷ 66	÷ 65	
	Total Relevant Dollars	18,532,843	17,725,584	15,764,211	18,719,752	19,671,059	2.10
	Number of Grants	22	24	22	20	22	
	Relevant Grant Dollars	6,183,612	6,171,762	6,563,215	3,679,947	4,627,662	
Virus – HTLV-I	Number of Contracts	*	‡ + +	‡ *	‡ + +	‡ *	
	Relevant Contract Dollars Total Count	‡ 22	‡ 24	‡ 22	‡ 20	‡ 22	
	Total Relevant Dollars	6,183,612	6,171,762	6,563,215	3,679,947	4,627,662	-3.01
	Number of Grants	+	2	1	1	1	
Virus – HTLV-II	Relevant Grant Dollars	*	2,000	171,471	160,325	151,718	
VIIUS – HILV-II	Total Count	‡	2	1	1	1	
	Total Relevant Dollars	\$	2,000	171,471	160,325	151,718	2820.56
	Number of Grants	169	168	165	162	176	
	Relevant Grant Dollars	46,214,177	43,559,761	41,276,749	40,445,208 2	43,808,063 1	
Virus – Papilloma	Number of Contracts Relevant Contract Dollars	1 4.394,576	1 3,836,717	3 3,866,401	2 2,478,454	740,476	
	Total Count	4,034,070 170	169	168	2,470,404 164	177	
	Total Relevant Dollars	50,608,753	47,396,478	45,143,150	42,923,662	44,548,539	-3.06

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget. †Relevant Dollars = portion of the funded amount relevant to a specific site. ‡Coding not required or requested. Source: Research Analysis and Evaluation Branch.

Special Interest Categories	Counts and Relevant Dollars [†]	2010	2011	2012	2013	2014	Average Percent Change/Yr.
	Number of Grants	207	200	190	185	196	
	Relevant Grant Dollars	55,528,827	52,541,742	49,415,531	49,217,700	50,340,929	
Virus – Papova	Number of Contracts	2	1	3	2	1	
indo i apora	Relevant Contract Dollars	4,544,576	3,836,717	3,866,401	2,478,454	740,476	
	Total Count	209	201	193	187	197	0.05
	Total Relevant Dollars	60,073,403	56,378,459	53,281,932	51,696,154	51,081,405	-3.95
	Number of Grants	29	25	21	15	7	
Virus – SV40	Relevant Grant Dollars	5,171,617	5,163,432	3,525,677	3,313,239	356,763	
1100 0110	Total Count	29	25	21	15	7	
	Total Relevant Dollars	5,171,617	5,163,432	3,525,677	3,313,239	356,763	-31.78
	Number of Grants	66	55	42	40	31	
	Relevant Grant Dollars	8,863,103	9,150,008	6,336,364	6,714,906	4,342,551	
Vitamin A	Number of Contracts	1	1	‡	‡	‡	
VitaminA	Relevant Contract Dollars	391,285	99,917	‡	‡	‡	
	Total Count	67	56	42	40	31	
	Total Relevant Dollars	9,254,388	9,249,925	6,336,364	6,714,906	4,342,551	-15.23
	Number of Grants	21	15	16	11	7	
Vitamin C	Relevant Grant Dollars	1,843,823	1,106,973	1,323,825	1,327,243	993,313	
	Total Count	21	15	16	11	7	
	Total Relevant Dollars	1,843,823	1,106,973	1,323,825	1,327,243	993,313	-11.32
	Number of Grants	45	70	76	70	81	
	Relevant Grant Dollars	11,837,723	20,457,495	20,791,513	17,759,137	17,167,368	
Vitamin D	Number of Contracts	Į	‡ *	1	1	* * *	
	Relevant Contract Dollars	+	+	56,250	918,685	\$	
	<i>Total Count</i> Total Relevant Dollars	45 11.837.723	70	77	71	81	14.00
		11,037,723	20,457,495	20,847,763	18,677,822	17,167,368	14.06
	Number of Grants	55	44	25	15	8	
	Relevant Grant Dollars	12,310,882	10,076,781	6,252,528	4,252,163	3,199,595	
Vitamins, Other	Number of Contracts	*	‡	1	‡	+	
	Relevant Contract Dollars	*	‡	56,250	\$	‡	
	Total Count	55	44	26	15	8	00.00
	Total Relevant Dollars	12,310,882	10,076,781	6,308,778	4,252,163	3,199,595	-28.22

(This table reports funding for grants and contracts only; intramural projects are excluded.)

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.

[†]Relevant Dollars = portion of the funded amount relevant to a specific site.

[‡]Coding not required or requested.

Table 17. NCI Funding of Foreign Research Grants in FY2014

(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)

Country/ Cancer Site	Mechanism														
AUSTRALIA	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals					
Grants & Contracts # Funding \$	1 45,000	1 134,377			1 223,295					2 402,672					
Breast Hodgkins Lymphoma Leukocytes Myeloma Childhood Leukemia Non-Hodgkins Lymphoma	45,000	134,377			37,960 111,648 35,727 37,960				134,377 37,960 111,648 35,727 45,000 37,960						
BELGIUM	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals					
Grants & Contracts # Funding \$							1 179,358			1 179,358					
Bone, Cartilage Brain Breast Central Nervous System Cervix							4,679 3,119 51,467 1,560 3,119			4,679 3,119 51,467 1,560 3,119					
Childhood Leukemia Colon, Rectum Esophagus Head and Neck							21,835 6,238 1,560 1,560			21,835 6,238 1,560 1,560					
Kidney Leukemia Liver							3,119 21,835 1,560			3,119 21,835 1,560					
Lung Neuroblastoma Non-Hodgkins Lymphoma							12,477 3,119 1,560			12,477 3,119 1,560					
Not Site Specific* Ovary Pancrea							12,477 4,679 1,560			12,477 4,679 1,560					
Pharynx Prostate Uterus							1,560 17,156 3,119			1,560 17,156 3,119					

*Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies and has no cancer site focus; however, it is relevant to cancer research.) Source: Research Analysis and Evaluation Branch.

Table 17 (cont'd). NCI Funding of Foreign Research Grants in FY2014

(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)

Country/ Cancer Site				ľ	lechanism	ı				
CANADA	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals
Grants & Contracts # Funding \$	1 798,409	13 4,046,552	1 68,062	2 348,173		1 257,249	1 3,314,493	1 296,351	1 401,397	2 9,530,68
Bladder		19,836					165,725			185,56
Brain							165,725			165,72
Breast		1,211,738	68,062				1,325,796			2,605,59
Cervix							82,862			82,86
Childhood Leukemia		159,959								159,95
Colon, Rectum							132,580			132,58
Esophagus							66,290			66,29
Head and Neck							165,725			165,72
Kidney							165,725			165,72
Leukemia		727,096					124,293			851,38
Liver							33,145			33,14
Lung		808,094					165,725			973,819
Myeloma							82,862			82,86
Non-Hodgkins Lymphoma							124,293			124,29
Not Site Specific*	798,409	745785		103,360				296,351	401,397	2,345,30
Ovary	,			,		257,249	165,725	,	,	422,97
Pancreas				244,813		- , -	66,290			311,10
Prostate		374.044		,			165,725			539,76
Stomach							33,145			33,14
Uterus							82,862			82,862
FRANCE	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals
Grants & Contracts #				1		3				
Funding \$				126,247		1,928,934				2,055,18
Bladder						124,289				124,28
Kidney				126,247		329,259				455,50
Lung						895,370				895,370
Not Site Specific*						580,016				580,010
INDIA	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals
Grants & Contracts #		1								
Funding \$		189,801								189,80
Breast		189,801								189,80
ISRAEL	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals
Grants & Contracts #		3			1					074.00
Funding \$		753,516			221,413					974,92
Breast		48,482			221,413					269,89
Colon, Rectum		48,482								48,482
Lung		48,482								48,482
Not Site Specific*		459,899								459,899
Ovary		99,689								99,68
Skin		48,482								48,48

continued

*Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies and has no cancer site focus; however, it is relevant to cancer research.) Source: Research Analysis and Evaluation Branch.

Table 17 (cont'd). NCI Funding of Foreign Research Grants in FY2014

(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)

Country/ Cancer Site				I	Vlechanism	ı				
JAPAN	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals
Grants & Contracts # Funding \$	1 209,449									1 209,449
Not Site Specific*	209,449									209,449
SWEDEN	N01	R01	R03	R21	R37	U01	U10	U24	UM1	Totals
Grants & Contracts # Funding \$			1 48,190							1 48,190
Bone, Cartilage Brain Childhood Leukemia Leukemia Liver Neuroblastoma Non-Hodgkins Lymphoma Retinoblastoma Sarcoma, Soft Tissue Wilms Tumor UNITED KINGDOM	N01	R01	4,819 4,819 4,819 4,819 4,819 4,819 4,819 4,819 4,819 4,819 R03	R21	R37	U01	U10	U24	UM1	4,819 4,819 4,819 4,819 4,819 4,819 4,819 4,819 4,819 4,819 4,819
Grants & Contracts # Funding \$	1 50,218	3 1,188,279				1 97,149		1 242,691		6 1,578,337
Breast Eye Melanoma Myeloma Not Site Specific* Thyroid	50,218	215,945 380,739 380,739 210,856				97,149		242,691		215,945 380,739 380,739 210,856 147,367 242,691
Total Grants & Contracts	4	21	2	3	2	5	2	2	1	42
Total \$ Per Grant & Contract type	1,103,076	6,312,525	116,252	474,420	444,708	2,283,332	3,493,851	539,042	401,397	15,168,603

*Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies and has no cancer site focus; however, it is relevant to cancer research.) Source: Research Analysis and Evaluation Branch.

Table 18. Foreign Components of U.S. Domestic Research Grants in FY2014

(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)

	Funding Mechanism F30 F31 F32 K01 K05 K07 K08 K23 K99 P01 R00 R01 R03 R13 R21 R25 R37 R43 R44 U01 U24 U54 UG1 UH2 UM1																							
Country	F30	F31	F32	K01	K05	K07 I	K08	K23	K99 I	P01	R00 R0	1 R0	3 R	13 R2	1 R25	5 R37	R43	8 R44	U01	U24	U54 U(31 UH	2 UM1	Sub- Total
Africa (unspecified)											1													1
Argentina				1							1									1				3
Asia (unspecified											2	1												3
Australia				1	1						22			2					3	3			1	33
Austria											1						1			1				3
Bangladesh											1													1
Belgium											2									1				3
Benin											1													1
Botswana																					1			1
Brazil											2			1	1				1	1		1		7
Cameroon											1		_											1
Canada					1					1	43			66	2		1	1	8	3	-		1	74
Caribbean (unspecified)											1													1
Central America (unspecified)											1													1
Chile											1													1
China		1				1					13	3		2					2	2			3	27
Columbia											2			1						1		1		5
Costa Rica																			1					1
Czech Republic																			1	1				2
Denmark			1								7			1					1	1				11
Egypt											1									1				2
El Salvador											1													1
Europe (unspecified)											1	1												2
Finland											2								1	1				4
France											7	2		2					5	1				17
Germany									1		24			1					4	2		1		33
Greece											3													3
Honduras												1												1
Hungary																				2				2
Iceland																			1					1
India			1		1						5	1								1		1		10
Iran																				1				1
Ireland											1									2				3
Israel		1									1 7				1	1		1	1	2				15
Italy	1				1						8	1							2	2				15
Jamaica														1										1
Japan											9	1		1						1				12
Kenya	1										4								1		1			7
Kuwait																				1				1
Malawi											1			1							1			3

Table 18 (cont'd). Foreign Components of U.S. Domestic Research Grants in FY2014

(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)

											Fund	ng N	Mec	hanisn	n											
Country	F30	F31	F32	K01	K05	K07	K08	K23	K99	P01	R00 R()1 R	03	R13 R	21	R25	R37	R43	R44	U01	U24	U54	UG1	UH2 U	M1	Sub- Total
Malaysia																					1					1
Mexico				1							4	-			2						1					8
Middle East (unspecified)																										1
Netherlands		1								1	1	1			1		1			5	1					21
New Zealand											3	}			1						3					7
Nicaragua													1													1
Nigeria															1									1		2
North America (unspecified)											1															1
Norway											6	;	2							3						11
Oceania (unspecified)											i															1
Pakistan																					1					1
Panama																					1					1
Paraguay															1											1
Peru													1											1		2
Philippines																								1		1
Poland											-										1					2
Portugal																					1					2
Romania																				1						1
Russia																				1	1					2
Rwanda																						1				1
Saudi Arabia																					1					1
Singapore									1		(;	1								1				1	10
Slovenia																					1					1
South Africa																				1	2			1		4
South America (unspecified)											-															1
South Korea											-										1					2
Spain											7	,			1	1					2					11
Sweden											(;								4	2					12
Switzerland							1				Ę	i	1							1	2					10
Taiwan											4										1					5
Tanzania											-											1				2
Thailand											2	2														2
Turkey	1	1																			1					4
Uganda		1						1			3	}								1		3				9
United Kingdom		1									3		3		3	1				8	1					47
Uraguay																					1					1
Venezuela																					1					1
Vietnam											-															1
Zambia											2															2
Zimbabwe																				1						1
Totals	3	6	2	3	4	1	1	1	2	2	1 27	52	20	8 2	27	6	2	2	2	58	60	8	1	8	6	509*

* Because many grants and contracts have multiple foreign contributors, the total count (509) is greater than the total number of grants and contracts (296). Source: Research Analysis and Evaluation Branch.

Appendix A: Activities of the National Cancer Advisory Board

Originally established as the National Advisory Cancer Council in 1937, the NCAB consists of 18 members who are appointed by the President and 12 nonvoting ex officio members. The NCAB advises, assists, consults with, and makes recommendations to the Secretary, HHS, and to the NCI Director with respect to the activities carried out by and through the Institute and on policies pertaining to these activities. It is authorized to recommend support for grants and cooperative agreements following technical and scientific peer review. The Director of the DEA serves as Executive Secretary of the NCAB. In fulfilling its role as the locus for second-level review of all peer reviewed applications, the Board reviewed a total of 6,712 applications in FY2014 requesting \$2,752,500,251 in direct costs with appropriated funds from a total of 13,071 applications requesting \$3,792,650,570.

The Board heard presentations, discussed, and provided advice on a variety of topics and NCI activities in FY2014, such as:

- NCI Director's Report
- President's Cancer Panel Report
- Legislative Update
- Report on Study of Cancer Center Budgets
- Annual Delegations of Authority
- Overview of NCI Tobacco Control Research Investment and Partnerships
- Surgeon General's Tobacco Report
- Pathophysiology of Tobacco-Induced Cancers
- New Directions in Cessation of Tobacco Uses: A 2014 Update
- E-Cigarettes: Unanswered Questions
- Global Tobacco Control
- FDA Regulation and the FDA-NIH Regulatory Science Partnership

- Final Report: Cancer Centers Working Group
- Clinical Trials Reporting Policy
- SPORE Program Working Group Report
- Use of Aspirin for Prevention and Treatment of Cancers
- NCI and the Common Fund
- Pediatric Oncology
- Intramural Program: Review of NCI Report to the NIH
- Impact of the New NCI Clinical Trials System
- Cancer Genomics
- Update: Electronic Cigarette
- Reducing the Number of Types of K Awards
- Modular Grants
- Perspective on Cancer Prevention Research and Implementation

As part of its mandate for oversight of NCI activities, the NCAB receives regular updates from the NCI Director, the NCI Office of Legislation and Congressional Activities, and the President's Cancer Panel.

Another major role of the Board is to monitor the overall advisory and oversight activities of the NCI as a whole. In that regard, it annually reviews the site visit outcomes of intramural review and the extramural RFA and RFP concepts acted on by the BSA. The NCAB also participates in the framing of the annual NCI Bypass Budget and considers the impact of actualized priorities as expressed by the allocation of the annual operating budget.

The full text of recent NCAB meeting summaries is available on the NCI website at http://deainfo. nci.nih.gov/advisory/ncab/ncabmeetings.htm

Appendix B: Activities of the Board of Scientific Advisors

The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, progress, and future direction of NCI's extramural research programs, and concept review of extramural program initiatives.

In addition to approving a number of extramural program initiatives (see below), the BSA also heard presentations on the following in FY2014:

- Report of the NCI Director
- Cancer Genomics
- Clinical Trials Reporting Policy
- Final Report Cancer Centers Working Group
- SPORE Program Working Group Report
- NCI and the Common Fund
- Pediatric Oncology
- Update: Electronic Cigarettes
- Reducing the Types of K Awards
- Modular Grants
- Perspective on Cancer Prevention Research and Implementation

RFA Concept Approved

Division of Cancer Control and Population Sciences

• Using Social Media to Understand and Address Substance Use and Addiction Effort with NIDA and NIAAA

RFP Concept Approved

Division of Cancer Treatment and Diagnosis

• A Prospective Randomized Trial of Carbon Ion Versus Conventional Radiation Therapy for Locally Advanced, Unresectable Pancreatic Cancer

RFA/Cooperative Agreements Approved

Division of Cancer Treatment and Diagnosis

• Biospecimens Banks to Support NCI-Clinical Trials Network (NCTN)

Division of Cancer Prevention

• Chronic Pancreatitis and Pancreatic Cancer Clinical Research or Consortium of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CSCPPC)

Division of Cancer Prevention and Division of Cancer Biology

• Molecular Characterization of Screen-Detected Lesions

RFA/Cooperative Agreements Re-Issuances

Office of the Director

- Innovative Molecular Analysis Technologies (IMAT)
- AIDS Malignancy Clinical Trials Consortium (AMC)
- Centers of Cancer Nanotechnology Excellence
- Research Answers to NCI Provocative Questions

Division of Cancer Treatment and Diagnosis

• Pediatric Preclinical Testing Program (PPTP)

Division of Cancer Control and Population Sciences

- Cancer Intervention and Surveillance Modeling Network (CISNET)
- Breast Cancer and the Environment Research Program

Division of Cancer Prevention

• The Early Detection Network (EDRN)

Division of Cancer Biology

• IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

President's Cancer Panel

Chair

Barbara K Rimer	DrPH MPH	The U	Iniversity of No	rth Carolina at	Chapel Hill
barbara K. Kimer,	, DI.F.I I., WI.F.I I.	i ne c	Juiversity of INO.	fui Caronna at	Chaper I hit

Members

Hill Harper, J.D	Author, Actor, Philanthropist
Owen N. Witte, M.D	University of California, Los Angeles

Executive Secretary

Abby B. Sandler, Ph.D.	National	Cancer	Institute,	NIH
------------------------	----------	--------	------------	-----

National Cancer Advisory Board

Chair

Tyler E. Jacks, Ph.D. Massachusetts Institute of Technology

Members

Victoria I Champion Ph D R N F A A N	Indiana University
David C. Christiani, M.D., M.P.H.	Harvard Medical School
Marcia R. Cruz-Correa, M.D., Ph.D	University of Puerto Rico
Kevin J. Cullen, M.D	University of Maryland, Baltimore
Judy E. Garber, M.D., M.P.H.	Harvard Medical School
William H. Goodwin, Jr., M.B.A.	CCA Industries, Inc.
Waun K. Hong, M.D.	he University of Texas MD Anderson Cancer Center
Elizabeth M. Jaffee, M.D	Johns Hopkins University
Beth Y. Karlan, M.D.	University of California, Los Angeles
Ms. Mary Vaughan Lester	University of California, San Francisco Foundation
	Duke University
Olufunmilayo F. Olopade, M.B.B.S., F.A.C.P.	The University of Chicago
	Vanderbilt University
Mack Roach III, M.D., F.A.C.R.	University of California, San Francisco
Jonathan M. Samet, M.D., M.S.	University of Southern California
Charles L. Sawyers, M.D	Weill Cornell Medical College of Cornell University
William R. Sellers, M.D.	Novartis Institutes for BioMedical Research, Inc.

Ex Officio Members of the National Cancer Advisory Board

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S	National Institute of Environmental
	Health Sciences, NIH
The Honorable Sylvia M. Burwell	. U.S. Department of Health and Human Services
Francis S. Collins, M.D., Ph.D.	National Institutes of Health
Margaret A. Hamburg, M.D	U.S. Food and Drug Administration

John P. Holdren, Ph.D Office of Science and Technology I	Policy
John Howard, M.D., M.P.H., J.D., L.L.M National Institute for Occupational Safety and H	Iealth
Gina McCarthy, M.SU.S. Environmental Protection Ag	gency
The Honorable Thomas E. PerezU.S. Department of I	Labor
Robert A. Petzel, M.DU.S. Department of Veterans A	۱ffairs
The Honorable Kathleen Sebelius, M.P.A U.S. Department of Health and Human Ser	rvices
Inez Tenenbaum, M.EdU.S. Consumer Product Safety Comm	ission
Sharlene Weatherwax, Ph.D U.S. Department of E	nergy
Jonathan Woodson, M.D U.S. Department of De	efense

Alternates to Ex Officio Members of the National Cancer Advisory Board

Robert T. Anderson, Ph.D	U.S. Department of Energy
Michael A. Babich, Ph.D	U.S. Consumer Product Safety Commission
Patricia Bray, M.D., M.P.H	OSHA/U.S. Department of Labor
Vincent J. Cogliano, Ph.D.	U.S. Environmental Protection Agency
Michael Kelley, M.D., F.A.C.P.	U.S. Department of Veterans Affairs
Aubrey Miller, M.D	National Institute of Environmental Health Sciences, NIH
Richard Pazdur, M.D., F.A.C.P.	U.S. Food and Drug Administration
Craig D. Shriver, M.D., F.A.C.S., COL	, M.C U.S. Department of Defense
Kerry Souza, Sc.D., M.P.H	National Institute for Occupational Safety and Health
Michael Stebbins, Ph.D	Office of Science and Technology Policy
Lawrence A. Tabak, D.D.S., Ph.D	National Institutes of Health
Richard J. Thomas, M.D., M.P.H	OSHA/U.S. Department of Labor

Executive Secretary

Paulette S. Gray, Ph.D.	National	Cancer	Institute,	NIH
-------------------------	----------	--------	------------	-----

Frederick National Laboratory Advisory Committee to NCI

(formerly the NCI-Frederick Advisory Committee)

Chair

Joe W. Gray, Ph.D. Oregon Health & Science University

Members

J. Carl Barrett, Ph.D.	AstraZeneca Pharmaceuticals LP
_	
	Brown University
Levi A. Garraway, M.D., Ph.D.	
Beatrice H. Hahn, M.D.	University of Pennsylvania
Monica J. Justice, Ph.D.	
Lawrence J. Marnett, Ph.D	Vanderbilt University Medical Center
Jill P. Mesirov, Ph.D.	The Broad Institute of MIT and Harvard University
Garry P. Nolan, Ph.D.	Stanford University
Kenneth J. Pienta, M.D.	Johns Hopkins University
Steven T. Rosen, M.D., F.A.C.P.	City of Hope National Medical Center

Appendix C: List of Chartered Committees _____

Representatives

Elizabeth M. Jaffee, M.D The Sid	dney Kimmel Comprehensive Cancer Center at
	Johns Hopkins University
Alexandra L. Joyner, Ph.D	Memorial Sloan Kettering Cancer Center
Cheryl Willman, M.D.	The University of New Mexico

Ex Officio Members of the Frederick National Laboratory Advisory Committee to the NCI

Stephen J. Chanook, M.D	National Cancer Institute, NIH
James H. Doroshow, M.D.	National Cancer Institute, NIH
Paulette S. Gray, Ph.D	National Cancer Institute, NIH
Douglas R. Lowy, M.D.	National Cancer Institute, NIH
Alan S. Rabson, M.D.	National Cancer Institute, NIH
Craig W. Reynolds, Ph.D.	National Cancer Institute, NIH
Robert H. Wiltrout, Ph.D.	National Cancer Institute, NIH

Executive Secretary

Thomas M. Vollberg, Sr., Ph.D.	. National	Cancer Institute, NIH
--------------------------------	------------	-----------------------

NCI Board of Scientific Advisors

Chair

Todd R. Golub, M.D Ine Broad Institute of MIT and Harvard University	Todd R. Golub, M.D.	The Broad Institute of MIT and Harvard University
--	---------------------	---

Members

Francis Ali-Osman, D.Sc	Duke University Medical Center
	New York University School of Medicine
	The University of North Carolina at Chapel Hill
Sangeeta N. Bhatia, M.D., Ph.D.	Massachusetts Institute of Technology
	Columbia University Medical Center
Arul M. Chinnaiyan, M.D., Ph.D.	University of Michigan
Curt. I. Civin, M.D.	University of Maryland, Baltimore
	Washington University in St. Louis
Chi V. Dang, M.D., Ph.D.	University of Pennsylvania
Joseph M. DeSimone, Ph.D.	The University of North Carolina at Chapel Hill
Daniel C. DiMaio, M.D., Ph.D.	Yale University
Jeffrey A. Drebin, M.D., Ph.D., F.A.C.S.	University of Pennsylvania
	Oregon Health & Science University
Karen M. Emmons, Ph.D.	
Betty R. Ferrell, Ph.D., R.N., F.A.A.N.	City of Hope National Medical Center
Kathleen M. Foley, M.D.	Memorial Sloan Kettering Cancer Center
Stanton L. Gerson, M.D.	Case Western Reserve University
Joe W. Gray, Ph.D.	Oregon Health & Science University
Chanita Hughes-Halbert, Ph.D	Medical University of South Carolina
Joshua LaBaer, M.D., Ph.D.	Arizona State University

Appendix C: List of Chartered Committees

	University of Michigan Canary Foundation
	University of California, San Diego
	The University of Texas Southwestern Medical Center
Diane Z. Quale, J.D.	Bladder Cancer Advisory Network
	St. Jude Children's Research Hospital
Mary L. Smith, J.D., M.B.A.	Research Advocacy Network
Lincoln Stein, M.D., Ph.D.	Ontario Institute for Cancer Research
	Cold Spring Harbor Laboratory
Frank M. Torti, M.D., M.P.H.	University of Connecticut Health Center
	A.S
Irving L. Weissman, M.D.	
-	
Kevin P. White, Ph.D	

Paulette S. Gray, Ph.D	.National	Cancer Institute, NIH
------------------------	-----------	-----------------------

Clinical Trials and Translational Research Advisory Committee

Chair

James L. Abbruzzese, M.D., F.A.C.PI	Juk	se l	Univers	sity
-------------------------------------	-----	------	---------	------

Members

Susan G. Arbuck, M.D., M.Sc., F.A.C.P.	Susan G. Arbuck M.D., LLC
David F. Arons, J.D.	National Brain Tumor Society
Susan M. Blaney, M.D.	Texas Children's Hospital
Monica M. Bertagnolli, M.D.	Dana-Farber Cancer Institute
Curt I. Civin, M.D.	University of Maryland, Baltimore
Kevin J. Cullen, M.D.	University of Maryland, Baltimore
Walter J. Curran, M.D., Ph.D.	
Nancy E. Davidson, M.D.	University of Pittsburgh
J. Philip Kuebler, M.D., Ph.D.	Columbus Oncology Associates, Inc.
Michael L. LeBlanc, Ph.D.	University of Washington
Scott M. Lippman, M.D.	University of California, San Diego
David A. Mankoff, M.D., Ph.D.	University of Pennsylvania
Mary S. McCabe, R.N., M.A.	
Edith P. Mitchell, M.D., F.A.C.P.	Thomas Jefferson University
Nikhil C. Munshi, M.D.	Harvard Medical School
Lisa A. Newman, M.D., M.P.H., F.A.C.S.	University of Michigan
Peter G. Shields, M.D.	The Ohio State University
George W. Sledge, Jr., M.D.	Stanford University
Chris H. Takimoto, M.D., Ph.D., F.A.C.P.	Janssen Pharmaceuticals, Inc.
Gillian M. Thomas, M.D., F.R.C.P.C., F.R.C.R.	University of Toronto
Frank M. Torti, M.D., M.P.H.	University of Connecticut Health Center
Miguel A. Villalona-Calero, M.D	The Ohio State University
George J. Weiner, M.D.	The University of Iowa

Ex Officio Members

James H. Doroshow, M.D.	National Cancer Institute, NIH
Paulette S. Gray, Ph.D.	National Cancer Institute, NIH
Rosemarie B. Hakim, Ph.D., M.S.	U.S. Centers for Medicare and Medicaid Services
Lee J. Helman, M.D.	National Cancer Institute, NIH
Michael J. Kelley, M.D., F.A.C.P.	U.S. Department of Veterans Affairs
Richard Pazdur, M.D., F.A.C.P.	U.S. Food and Drug Administration
Alan S. Rabson, M.D.	National Cancer Institute, NIH

Board of Scientific Counselors for Clinical Sciences and Epidemiology, NCI

Chair

Louis M. Weiner, M.D.Georgetown University Medical Center

Members

Edgar Ben-Josef, M.D	University of Pennsylvania
Jonine L. Bernstein, Ph.D.	Memorial Sloan Kettering Cancer Center
Arthur W. Blackstock, Jr., M.D	
E. Julie Buring, Sc.D.	Brigham and Women's Hospital
Tim Byers, M.D., M.P.H.	University of Colorado Cancer Center
Nicola J. Camp, M.D., Ph.D.	University of Utah
Graham Casey, Ph.D.	University of Southern California
	The University of Chicago
Laurence J.N. Cooper, M.D., Ph.D	The University of Texas MD Anderson Cancer Center
John F. DiPersio, M.D., Ph.D., F.A.C.P	Washington University in St. Louis
Kojo S.J. Elenitoba-Johnson, M.D	University of Michigan Medical School
Elizabeth T. H. Fontham, Dr.P.H., M.P.H.	Louisiana State University Health Science Center
Michael L. Freeman, Ph.D.	
Marc T. Goodman, Ph.D, M.P.H	Cedars-Sinai Medical Center
Nancy Goodman, J.D	Kids V Cancer
Bernard Harlow, Ph.D	University of Minnesota
Carl June, M.D	University of Pennsylvania
Karen L. Kelly, M.D.	University of California, Davis
Hongzhe Lee, Ph.D	University of Pennsylvania
Alexandra M. Levine, M.D., M.A.C.P	City of Hope National Medical Center
Sanford Markowitz, M.D., Ph.D	Case Western Reserve University
David A. Norris, M.D	University of Colorado
Augusto Ochoa, M.D	Louisiana State University
Kenneth Offit, M.D., M.P.H.	Memorial Sloan Kettering Cancer Center
Raphael E. Pollock, M.D., Ph.D.	The Ohio State University
David Poplack, M.D	Baylor College of Medicine
	Johns Hopkins University
Jeremy N. Rich, M.D., M.H.Sc	Case Western Reserve University
Thomas Rohan, M.D., Ph.DA	lbert Einstein College of Medicine of Yeshiva University
A. Oliver Sartor, M.D	
	The University of Southern California
Walter M. Stadler, M.D., F.A.C.P.	The University of Chicago Medical Center
	American Cancer Society
	University of Wisconsin, Madison
Cheryl L. Willman, M.D	The University of New Mexico Cancer Research Facility

Brian E. Wojcik, Ph.D.	National	Cancer	Institute, N	NIH
------------------------	----------	--------	--------------	-----

Board of Scientific Counselors for Basic Sciences, NCI

Chair

Joan W. Conaway, Ph.D. Stowers Institute for Medical Research

Members

Amnon Altman, Ph.D.	La Jolla Institute for Allergy and Immunology
Paul D. Bieniasz, Ph.D.	
	University of Colorado, Denver
	Fred Hutchinson Cancer Research Center
Sara A. Courtneidge, Ph.D	Sanford Burnham Prebys Medical Discovery Institute
Alan D'Andrea, Ph.D	Dana-Farber Cancer Institute
,	University of Wisconsin, Madison
Errol Friedberg, M.D.	The University of Texas Southwestern Medical Center
Joanna Groden, Ph.D.	The Ohio State University
Daria J. Hazuda, Ph.D	Merck & Company Inc.
	Emory University
	The University of Texas at Austin
Alexandra L. Joyner, Ph.D	Memorial Sloan Kettering Cancer Center
Marcelo G. Kazanietz, Ph.D	University of Pennsylvania
	University of Massachusetts Medical School
,	University of Nebraska Medical Center
	Northwestern University Feinberg School of Medicine
Sergio A. Lira, M.D., Ph.D.	Icahn School of Medicine at Mount Sinai
Ian G. Macara, Ph.D	Vanderbilt University Medical Center
Roeland Nusse, Ph.D.	Stanford University
Suzanne Ostrand-Rosenberg, Ph.D	University of Maryland, Baltimore County
	University of California, Irvine
Kenneth L. Rock, M.D.	University of Massachusetts Medical School
Daniel Romo, Ph.D.	Texas A&M University
James A. Wells, Ph.D.	University of California, San Francisco
Tzyy-Choou Wu, M.D., Ph.D., M.P.H	Johns Hopkins University
Wayne M. Yokoyama, M.D	Washington University in St. Louis
Virginia A. Zakian, Ph.D.	Princeton University
Dong-Er Zhang, Ph.D.	University of California, San Diego

Mehrdad Tondravi, Ph.D	National	Cancer	Institute,	NIH
------------------------	----------	--------	------------	-----

NCI Council of Research Advocates

(formerly NCI Director's Consumer Liaison Group)

Chair

Max N. Wallace, J.D.	Accelerate Brain Cancer Cure
----------------------	------------------------------

Members

Gregory H. Aune, M.D., Ph.D	National Brain Tumor Society The University of Texas Health Science Center The V Foundation for Cancer Research
	U.S. Department of Health and Human Services
	Cancer Support Community
Jeffrey A. Kaufman, M.B.A, M.I.A	Adenoid Cystic Carcinoma Research Foundation
Ms. Mila McCurrach	The Lustgarten Foundation
Michelle T. McMurry-Heath, M.D., Ph.D	U.S. Food and Drug Administration
Shelley F. Nasso, M.P.P	
Senaida F. Poole, Ph.D	University of California
Jon G. Retzlaff, M.P.A., M.B.A	American Association for Cancer Research
Mr. Josh Sommer	The Chordoma Foundation
Andrea E. Ferris Stern, M.B.A	LUNGevity Foundation
Regina M. Vidaver, Ph.D	National Lung Cancer Partnership

Kelley Landy, M.P.A.	National	Cancer Institute, NIH
----------------------	----------	-----------------------

NCI Initial Review Group Scientific Review Committees

Subcommittee A—Cancer Centers

Chair

Members

Lucile L. Adams-Campbell, Ph.D	Georgetown University
Alex A. Adjei, M.D., Ph.D., F.A.C.P	
Terrance L. Albrecht, Ph.D.	
Howard H. Bailey, M.D.	University of Wisconsin, Madison
Donald J. Buchsbaum, Ph.D	The University of Alabama at Birmingham
William E. Carson III, M.D.	The Ohio State University
Moon S. Chen, Jr., Ph.D., M.P.H	University of California, Davis
Margie L. Clapper, Ph.D	Fox Chase Cancer Center
Robert S. DiPaola, M.D	Rutgers Biomedical and Health Sciences
	University of Colorado, Denver
Dennis E. Hallahan, M.D., F.A.S.T.R.C	D Washington University in St. Louis
Helen E. Heslop, M.D	Baylor College
5	University of Kansas
	Thomas Jefferson University
King C. Li, M.D., M.B.A Wake I	Forest University Health Sciences & Baptist Medical Center
Beverly S. Mitchell, M.D	Stanford University
	Northwestern University
Jerome Ritz, M.D.	Dana-Farber Cancer Institute
	St. Jude Children's Research Hospital
Victoria L. Seewaldt, M.D	Duke University
	Albert Einstein College of Medicine of Yeshiva University
	University of California, San Francisco
Eduardo M. Sotomayor, M.D	H. Lee Moffit Cancer Center & Research Institute
	e University of Texas Health Science Center at San Antonio
•	BPW Consulting Services
Patti Wiley, M.B.A.	On the Wings of Angels Pediatric Cancer Foundation

Sonya V. Roberson, Ph.D	. National	Cancer Institute, NIH
-------------------------	------------	-----------------------

Subcommittee F—Institutional Training & Education

Chair

Nipun B. Merchant, M.D., F.A.C.S.	Vanderbilt University
-----------------------------------	-----------------------

Members

Lisa K. Denzin, Ph.D.	Rutgers, The State University of New Jersey
	North Carolina State University
Jennifer J. Hu, Ph.D.	University of Miami Miller School of Medicine
Aminah Jatoi, M.D.	
Molly F. Kulesz-Martin, Ph.D.	Oregon Health & Science University
Primo N. Lara Jr., M.D.	University of California, Davis
Stephen L. Lessnick, M.D., Ph.D.	University of Utah
Jesse D. Martinez, Ph.D.	The University of Arizona
Deborah B. McGuire, Ph.D., R.N., F.A.A.N	Virginia Commonwealth University
Karen M. Meneses, Ph.D., R.N., F.A.A.N.	The University of Alabama at Birmingham
	ne University of Texas MD Anderson Cancer Center
Polly A. Newcomb, Ph.D	University of Washington
Daniel P. Normolle, Ph.D	University of Pittsburgh
Fiemu E. Nwariaku, M.DTh	e University of Texas Southwestern Medical Center
Mark P. Pfeifer, M.D.	University of Louisville
Gavin P. Robertson, Ph.D.	
Kathryn H. Schmitz, Ph.D., M.P.H.	University of Pennsylvania
	University of Kansas Medical Center
Gayle E. Woloschak, Ph.D.	Northwestern University

Timothy C. Meeker, M.D	National	Cancer	Institute,	NIH
------------------------	----------	--------	------------	-----

Subcommittee I—Transition to Independence

Chair

Neil Osheroff, Ph.D	Vanderbilt	University	y Medical	Center
---------------------	------------	------------	-----------	--------

Members

Emmanuel T. Akporiaye, Ph.D	Providence Portland Medical Center
Deepak Bastia, Ph.D.	Medical University of South Carolina
Lawrence H. Boise, Ph.D.	Emory University
Amy H. Bouton, Ph.D.	University of Virginia
Jennifer P. Clarke, Ph.D.	University of Nebraska–Lincoln
Andrei Goga, M.D., Ph.D.	University of California, San Francisco
Charles Keller, M.D.	Oregon Health & Science University
Kenneth A. Krohn, Ph.D	University of Washington
Sophie A. Lelievre, D.V.M., Ph.D., LL.M(PH)	Purdue University
Anna E. Lokshin, Ph.D	University of Pittsburgh
	Wayne State University
Daniela E. Matei, M.D	. Indiana University–Purdue University Indianapolis
	Dartmouth College
	University of Oklahoma Health Science Center
	University of Maryland, Baltimore
Tiffany N. Seagroves, Ph.D.	The University of Tennessee Health Science Center
David B. Solit, M.D	Memorial Sloan Kettering Cancer Center
Bakhos A. Tannous, Ph.D.	Harvard Medical School
E. Aubrey Thompson, Ph.D.	Mayo Clinic, Jacksonville
Shizhen E. Wang, Ph.D	City of Hope National Medical Center
Michael A. White, Ph.D.	The University of Texas
Robert A. Winn, M.D	University of Illinois at Chicago
Wen-Cheng Xiong, Ph.D.	Medical College of Georgia
Yu-Chung Yang, Ph.D.	Case Western Reserve University

Sergei Radaev, Ph.D.	National	Cancer	Institute,	NIH
----------------------	----------	--------	------------	-----

Subcommittee J—Career Development

Chair

Christopher H. Lowrey, M.D. Dartmouth-Hitchcock Medical Center

Members

Virginia F. Borges, M.D., M.M.Sc.	University of Colorado Denver
Deborah W. Bruner, Ph.D., R.N	Emory University
John C. Byrd, M.D.	The Ohio State University
Fernando A. Ferrer, M.D.	University of Connecticut School of Medicine
Christopher R. Friese, Ph.D., R.N., A.O.C.N.	University of Michigan
Michael E. Hagensee, M.D., Ph.D	Louisiana State University
Heather S.L. Jim, Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Santosh Kesari M.D., Ph.D	University of California, San Diego
Alexander S. Krupnick, M.D	Washington University in Saint Louis
Gertraud Maskarinec, M.D., Ph.D., M.P.H	University of Hawaii
Chaya S. Moskowitz, Ph.D	Memorial Sloan Kettering Cancer Center
Daniel C. Mullins, Ph.D	University of Maryland, Baltimore
Scott A. Waldman, M.D., Ph.D.	Thomas Jefferson University
Zuo-Feng Zhang, M.D., Ph.D	University of California, Los Angeles

Ilda F.S. Melo, Ph.D	National	Cancer Institute, NIH
----------------------	----------	-----------------------

Appendix D: NCI Initial Review Group Consultants

1. Consultants Serving as Temporary Members on IRG Subcommittees in FY2014

A

Andersen, Bogi, M.D.	University of California, Irvine
Arceci, Robert J., M.D., Ph.D.	
Axelrod, David E., Ph.D.	Rutgers, The State University of New Jersey

B

Bae-Jump, Victoria L., M.D., Ph.D	The University of North Carolina
Basu, Sujit, M.D., Ph.D.	
Baumgartner, Kathy B., Ph.D.	University of Louisville
Behbod, Fariba, Pharm.D., Ph.D.	University of Kansas Medical Center
Berwick, Marianne, Ph.D., M.P.H.	
Bjornsti, Mary-Ann, Ph.D.	The University of Alabama at Birmingham
Brock, Malcolm V., M.D.	Johns Hopkins University
Buchsbaum, Donald J., Ph.D.	The University of Alabama at Birmingham
Byers, Stephen W., Ph.D.	Georgetown University

C

Cannon, Martin J., Ph.D.	University of Arkansas for Medical Sciences
Chen, Moon S., Ph.D., M.P.H.	University of California, Davis
Chiao, Elizabeth, M.D., M.P.H.	Baylor College of Medicine
Coleman, William B., Ph.D.	The University of North Carolina at Chapel Hill
Cooney, Kathleen A., M.D.	University of Michigan
Corey, Seth J., M.D., M.P.H.	Northwestern University
Corry, Peter M., Ph.D.	University of Arkansas for Medical Sciences
Creighton, Chad, Ph.D.	Baylor College of Medicine

D

Datta, Kaustubh, Ph.D.	University of Nebraska Medical Center
Davis, Ian J., M.D., Ph.D.	. The University of North Carolina at Chapel Hill
Davis, Scott C., Ph.D.	Dartmouth College

F

Figlin, Re	obert A., M.D.	Cedars-	Sinai	Medical	Center
------------	----------------	---------	-------	---------	--------

G

Garza, Mary A., M.D.	. Yale University
Girardi, Michael, M.D.	. Yale University

_ Appendix D-1: Consultants Serving as Temporary Members on IRG Subcommittees in FY2014

Goydos, James S., M.D.	Rutgers Cancer Institute of New Jersey
Graves, Kristi D., Ph.D.	Georgetown University

H

_

Hackett, Lauren, M.P.A	
Hawkins, William G., M.D.	Washington University in St. Louis
Hezel, Aram F., M.D.	University of Rochester
Hohl, Raymond J., M.D., Ph.D.	Penn State Milton S. Hershey Medical Center
Hong, Chi-Chen, Ph.D.	Roswell Park Cancer Institute
Hwang, Rosa F., M.D.	The University of Texas MD Anderson Cancer Center

J

Jim, Heather S.L., Ph.D.	. H. Lee Moffitt Cancer Center & Research Institute
Jones, Kevin B., M.D	University of Utah

K

Kalinski, Pawel, M.D., Ph.D.	
Kalyanaraman, Balaraman, Ph.D	
Kazak, Anne E., Ph.D	Nemours Alfred I. duPont Hospital for Children
Kesler, Shelli R., Ph.D.	The University of Texas MD Anderson Cancer Center
Kessel, David, Ph.D	
Khan, Shafiq A., Ph.D.	Clark Atlanta University
Kline, Justin P., M.D.	
Krohn, Kenneth, Ph.D	University of Washington

L

Lannigan,	, Deborah, Ph.D	Vanderbilt	University
Loffredo,	Christopher A., Ph.D.	Georgetown	University

M

Ma, Xiaomei, Ph.D.	
Majumdar, Adhip P. N., D.Sc., Ph.D.	
Malafa, Mokenge P., M.D.	H. Lee Moffitt Cancer Center & Research Institute
Malkas, Linda H., Ph.D.	City of Hope National Medical Center
Manjili, Masoud H., D.V.M., Ph.D.	Virginia Commonwealth University
Martinez, Jesse D., Ph.D.	The University of Arizona
Matthay, Katherine K., M,D.	University of California, San Francisco
Mermelstein, Robin J., Ph.D.	University of Illinois at Chicago
Michor, Franziska, Ph.D.	Dana-Farber Cancer Institute
Morel, Penelope A., M.D.	University of Pittsburgh
Mortimer, Joanne E., M.D.	City of Hope National Medical Center
Mukhtar, Hasan, Ph.D.	University of Wisconsin, Madison

N

Neugut, Alfred I., M.D., Ph.D., M.P.H.	Columbia	University
--	----------	------------

0

O'Connor, Kathleen L., Ph.D.	University of Kentucky
· · ·	
Olshan, Andrew, Ph.D.	The University of North Carolina at Chapel Hill

Ρ

Pagel, John M., M.D., Ph.D.	Fred Hutchinson Cancer Research Center
Patankar, Manish S., Ph.D.	Eastern Virginia Medical School
Paterson, Yvonne J., Ph.D.	University of Pennsylvania

Q

Quarles,	Christopher C., Ph.D	Vanderbilt	University
----------	----------------------	------------	------------

R

Rall, Glenn F., Ph.D.	Fox Chase Cancer Center
Rathmell, Wendy K., M.D., Ph.D.	The University of North Carolina
Reginato, Mauricio J., Ph.D.	Drexel University College of Medicine
Reid, Mary E., Ph.D.	
Ritz, Jerome, M.D.	Dana-Farber Cancer Institute
Rubenstein, James L., M.D., Ph.D.	University of California, San Francisco

S

Sausville, Edward A., M.D., Ph.D	University of Maryland, Baltimore
Scaglioni, Pier P., M.D.	The University of Texas Southwestern Medical Center at Dallas
Schmidt, Edward E., Ph.D	Montana State University, Bozeman
Spruck, Charles H., Ph.D.	Sanford Burnham Prebys Medical Discovery Institute
Steel, Jennifer L., Ph.D.	University of Pittsburgh
Steidl, Ulrich G., M.D., Ph.D	Albert Einstein College of Medicine of Yeshiva University
Sweet-Cordero, Eric A., M.D	Stanford University School of Medicine
Syngal, Sapna, M.D., M.P.H.	Dana-Farber Cancer Institute

T

Tan, Ming T., Ph.D.	Georgetown University
-	
	The University of Texas MD Anderson Cancer Center

U

Uittenbogaart, Christel H., M.D. University of California, Los Angeles

W

Walter, Roland B., M.D., Ph.D	Fred Hutchinson Cancer Research Center
Wang, Shizhen E., Ph.D.	City of Hope National Medical Center
Watson, Dennis K., Ph.D.	Medical University of South Carolina
Welch, Danny R., Ph.D.	University of Kansas Medical Center
White, Michael A., Ph.D.	. The University of Texas Southwestern Medical Center at Dallas
White, Rebekah, M.D.	Duke University
Williams, Karen P., Ph.D.	Michigan State University

Y

Z

Zhang, Rugang, Ph.D.	
	Texas Tech University Health Sciences Center
Zhang, Yanping, Ph.D.	
Zheng, Lei, M.D., Ph.D.	Johns Hopkins University

Total Number of Reviewers: 97

2. Consultants Serving as *Ad Hoc* Committee Members on IRG Site Visit Teams in FY2014

A

Abate-Shen, Cory, Ph.D.	Columbia University Medical Center
Adams-Campbell, Lucile L., Ph.D.	Georgetown University
Agarwal, Rajesh, Ph.D.	University of Colorado Denver
Ahn, Chul W., Ph.D.	. The University of Texas Southwestern Medical Center
Albertson, Donna G., Ph.D.	New York University

B

University of California, Los Angeles
The Ohio State University
City of Hope National Medical Center
The University of Alabama at Birmingham
Icahn School of Medicine at Mount Sinai
University of Vermont and State Agricultural College
Baylor College of Medicine
Boston University Medical Campus
Memorial Sloan Kettering Cancer Center

C

Chaudhary, Preet M., M.D., Ph.D.	University of Southern California
Chen-Kiang, Selina Y., Ph.D.	Weill Cornell Medical College
Chernoff, Jonathan D., M.D., Ph.D.	Fox Chase Cancer Center
Chu, Edward, M.D.	University of Pittsburgh
Cody, Vivian, Ph.D.	.Hauptman-Woodward Medical Research Institute
Cooney, Kathleen A., M.D.	University of Michigan

D

Debinski, Waldemar, M.D., Ph.D	Wake Forest University Health Sciences &
	Baptist Medical Center
Deininger, Michael W., M.D., Ph.D.	. The University of Texas MD Anderson Cancer Center
Djeu, Julie Y., Ph.D	H. Lee Moffitt Cancer Center & Research Institute
Dowlati, Afshin, M.D	Case Western Reserve University
Duckett, Colin S., Ph.D.	University of Michigan
Duli, Anne, M.P.A.	Case Western Reserve University

Ε

Earp, Henry S., M.D.	The University of North Carolina at Chapel Hill
Eaton, Kathryn A., D.V.M., Ph.D.	University of Michigan
El-Deiry, Wafik S., M.D., Ph.D.	Fox Chase Cancer Center

F

Ferris, Robert L., M.D., Ph.D.	University of Pittsburgh
Ferrone, Soldano, M.D., Ph.D.	Massachusetts General Hospital
Formenti, Silvia C., M.D.	New York University School of Medicine
Friedman, Debra L., M.D., R.N.	. Fred Hutchinson Cancer Research Center
Futscher, Bernard W., Ph.D.	The University of Arizona

G

Gao, Allen C., M.D., Ph.D	University of California, Davis
Gapstur, Susan M., Ph.D., M.P.H.	American Cancer Society, Inc.
Gerlach, Robert W., M.P.A	Dartmouth College
Gewirtz, David A., Ph.D	Virginia Commonwealth University
Gillanders, William E., M.D	Washington University in St. Louis
Gimotty, Phyllis A., Ph.D	University of Pennsylvania
Ginder, Gordon D., M.D	Virginia Commonwealth University
Gmitro, Arthur F., Ph.D	
Gruber, Stephen B., M.D., Ph.D., M.P.H	University of Southern California

H

Hackett, Lauren, M.P.A	
Harrison, Anita L., M.P.A.	Medical University of South Carolina
Heguy, Adriana, Ph.D	New York University School of Medicine
Hoopes, Jack, D.V.M., Ph.D.	Dartmouth College
Houghton, Janet A., Ph.D.	Cleveland Clinic Lerner College of Medicine
Huang, Tim H., Ph.D.	The University of Texas Health Science Center at San Antonio
Hung, Mien-Chie, Ph.D.	The University of Texas MD Anderson Cancer Center
Hussain, Maha H., M.D.	University of Michigan
Hyslop, Terry, Ph.D.	Duke University

J

Jensen, Roy A., M.D.	University of Kansas
Jones, David A., Ph.D.	Oklahoma Medical Research Foundation
Jones, Richard J., M.D.	Johns Hopkins University

K

Kane, Madeleine A., M.D., Ph.D.	University of Colorado Denver
Kelley, Mark R., Ph.D.	Indiana University–Purdue University Indianapolis
Kerr, William G., Ph.D.	State University of New York Upstate Medical University
Keyomarsi, Khandan, Ph.D.	The University of Texas MD Anderson Cancer Center
Khuri, Fadlo R., M.D.	Emory University
	The University of New Mexico Health Sciences Center
Knudsen, Karen E., Ph.D.	
Kumar, Nagi B., Ph.D.	

L

Lang, Frederick F., M.D.	The University of Texas MD Anderson Cancer Center
Le Beau, Michelle M., Ph.D.	The University of Chicago
Lenkinski, Robert E., Ph.D The second secon	he University of Texas Southwestern Medical Center at Dallas
Lubaroff, David M., Ph.D.	
Lynch, Thomas J., M.D.	

M

	University of Maryland, Baltimore
Marzluff, William F., Ph.D.	The University of North Carolina at Chapel Hill
Mayne, Susan T., Ph.D.	
McCarthy, James B., Ph.D.	University of Minnesota
McWeeney, Shannon K., Ph.D.	Oregon Health & Science University
Meneses, Karen M., Ph.D., R.N	The University of Alabama at Birmingham
Mermelstein, Robin J., Ph.D	University of Illinois at Chicago
Mikkelsen, Tom, M.D	Henry Ford Health System
Moley, Jeffrey F., M.D.	Washington University in St. Louis
Mori, Motomi, Ph.D.	Oregon Health & Science University
Munster, Pamela N., M.D	University of California, San Francisco

0

O'Connor, Kathleen L., Ph.D.	University of Kentucky
	The University of North Carolina at Chapel Hill
Oeffinger, Kevin Charles, M.D.	Memorial Sloan Kettering Cancer Center
Olshan, Andrew, Ph.D.	The University of North Carolina at Chapel Hill

P

Partridge, Edward E., M.D.	The University of Alabama at Birmingham
Pasche, Boris, M.D., Ph.D Wake Fo	rest University Health Sciences & Baptist Medical Center
Perez, Raymond P., M.D.	University of Kansas Medical Center
Piazza, Gary A., Ph.D.	University of South Alabama
Pieper, Russell O., Ph.D.	University of California, San Francisco
Platanias, Leonidas C., M.D., Ph.D.	Northwestern University
Porter, Peggy L., M.D.	Fred Hutchinson Cancer Research Center
Prossnitz, Eric R., Ph.D.	The University of New Mexico Health Sciences Center

Q

Quaranta, Vito, M.D	University of Pennsylvani
---------------------	---------------------------

R

Redmond, Carol K., Sc.D., Ph.D.	. University of Pittsburgh
Resnicow, Ken A., Ph.D.	University of Michigan

Rosner, Marsha R., Ph.D. The University of Chicago

S

Schwartz, Ann G., Ph.D., M.P.H.	Wayne State University
Serody, Jonathan S., M.D.	The University of North Carolina at Chapel Hill
Shea, Thomas C., M.D.	The University of North Carolina at Chapel Hill
Shyr, Yu, Ph.D.	Vanderbilt University
Singh, Rakesh K., Ph.D.	University of Nebraska Medical Center
Sotomayor, Eduardo M., M.D H	I. Lee Moffitt Cancer Center & Research Institute
Stauffacher, Cynthia V., Ph.D.	Purdue University
Stein, Gary S., Ph.DUni	iversity of Vermont and State Agricultural College

T

Tanzer, Linda L., B.S	Rutgers Biomedical and Health Sciences
Tycko, Benjamin, M.D., Ph.D	Gordon Research Conferences

V

Van Breemen, Richard B., Ph.D.	University of Illinois at Chicago
Van Etten, Richard A., M.D., Ph.D	University of California, Irvine
Vertino, Paula M., Ph.D	Emory University
	Sanford Burnham Prebys Medical Discovery Institute

W

Weiner, George J., M.D.	The University of Iowa
Weiss, Geoffrey R., M.D.	-
Welch, Danny R., Ph.D.	
Wilburn, Louella S., M.S.	People Living With Cancer

Z

Zhang, Zhong-Yin, Ph.D	Indiana University–Purdue University Indianapolis
Zutter, Mary M., M.D	

Total Number of Reviewers: 118

3. Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

A

Abdulkadir, Sarki A., M.D., Ph.D.	Northwestern University
Abounader, Roger, M.D., Ph.D.	
Abraham, George N., M.D., Ph.D.	University of Rochester
Abrams, Scott I., Ph.D.	Roswell Park Cancer Institute
Acharya, Raj S., Ph.D.	The Pennsylvania State University
Acharya, Samir, Ph.D	The Ohio State University
Achilefu, Samuel, Ph.D.	Washington University in St. Louis
Acosta, Michelle C., Ph.D.	National Development and Research Institutes
	Georgetown University
Adebamowo, Clement A., Sc.D	University of Maryland, Baltimore
Adejare, Adeboye, Ph.D.	University of the Sciences
Adjei, Alex A., M.D., Ph.D., F.A.C.P.	Roswell Park Cancer Institute
Adler, Adam J., Ph.D	University of Connecticut School of Dental Medicine
	Washington University in St. Louis
Agah, Masoud, Ph.D.	Virginia Polytechnic Institute and State University
Agarwal, Rajesh, Ph.D.	University of Colorado Denver
Ahmed, Khalil, Ph.D	University of Minnesota
Ahsan, Habibul, M.D	The University of Chicago
Akabani, Gamal, Ph.D	Texas A&M University
Akbari, Omid, Ph.D.	University of Southern California
Al'Absi, Mustafa N., Ph.D.	University of Minnesota
Albertson, Donna G., Ph.D.	New York University
Albrecht, Terrance L., Ph.D.	
Aldape, Kenneth D., M.D.	University Health Network
Alexandrakis, Georgios, Ph.D.	
Alexandrow, Mark G., Ph.D.	H. Lee Moffitt Cancer Center & Research Institute
Almasan, Alexandru, Ph.D	Cleveland Clinic Lerner College of Medicine
	of Case Western Reserve University
Altman, Norman H., V.M.D.	University of Miami Miller School of Medicine
Altomare, Deborah A., Ph.D	University of Central Florida
Alvarez, Ronald D., M.D.	The University of Alabama at Birmingham
Amaravadi, Ravi K., M.D.	University of Pennsylvania
Amatruda, James F., M.D., Ph.D.	The University of Texas Southwestern Medical Center
	at Dallas
Amos, Christopher I., Ph.D.	Dartmouth College
Anant, Shrikant, Ph.D.	University of Kansas Medical Center
Anchordoquy, Thomas, Ph.D.	University of Colorado Denver
Andersen, M. Robyn, Ph.D., M.P.H.	Fred Hutchinson Cancer Research Center
	University of Pittsburgh
	University of Florida
Anderson, Karen S., M.D., Ph.D.	Arizona State University, Tempe
	Oregon Research Institute
· · · · · · · · · · · · · · · · · · ·	

Androphy Elliot I MD	Indiana University–Purdue University, Indianapolis
5, ,	
1 / /	Rush University Medical Center
, , ,	
, , , ,	Johns Hopkins University
0, ,	
	Louisiana State University Health Science Center, Shreveport
, , ,	
, , ,	
, , ,	
· · ·	
Athar, Mohammad, Ph.D	
Atkins, Michael B., M.D	
Atkins, William M., Ph.D	University of Washington
Attisano, Liliana, Ph.D	University of Toronto
Au, Jessie L. S., Pharm.D., Ph.D	Optimum Therapeutics, LLC
Audrain-McGovern, Janet E., Ph.I	DUniversity of Pennsylvania
	University of Wisconsin, Madison
S	Albert Einstein College of Medicine of Yeshiva University
	D Georgetown University
	Colorado State University-Fort Collins
	ake Forest University Health Sciences & Baptist Medical Center
, , , ,	The University of Oklahoma Health Sciences Center
· · · · ·	Rutgers, The State University of New Jersey
	The University of Texas Health Science Center at Houston
Azcarate-Peril, M. Andrea, Ph.D.	The University of North Carolina at Chapel Hill

B

Georgia Institute of Technology
The University of North Carolina at Chapel Hill
The Mount Sinai Hospital
University of Pittsburgh
University of Pittsburgh
University of Illinois at Urbana-Champaign
The University of Arizona
Stanford University
St. Jude Children's Research Hospital
University of Kansas
The University of Alabama at Birmingham

Balgley Brian M Ph D	
· · · · ·	University of Kansas Medical Center
· · · · ·	LumaMed, LLC
	University of Nebraska Medical Center
, , ,	
, , ,	
	State University of New York at Buffalo
, , ,	C.N., F.A.A.N University of Michigan
	Dana-Farber Cancer Institute
, 1,	
Basu, Sujit, M.D., Ph.D.	
Batra, Surinder K., Ph.D.	University of Nebraska Medical Center
Batt, Carl A., Ph.D.	
Bearden, James D., M.D.	Spartanburg Regional Medical Center
Beauchamp, Robert D., M.D	
Bechara, Antoine, Ph.D	University of Southern California
Becich, Michael J., M.D., Ph.D	University of Pittsburgh
Beck, George R., Ph.D	Emory University
Beck, John R., M.D.	Fox Chase Cancer Center
Beck, William T., Ph.D	University of Illinois at Chicago
Becker, Dorothea, Ph.D	University of Pittsburgh
	University of Rochester
	The University of Oklahoma Health Sciences Center
	Penn State Milton S. Hershey Medical Center
	Albert Einstein College of Medicine of Yeshiva University
	Lovelace Biomedical Environmental Research Institute
	e Forest University Health Sciences & Baptist Medical Center
	University of Pennsylvania
	University of Cincinnati
· · · · · · · · · · · · · · · · · · ·	McGill University
	Baylor College of Medicine
bergan, Kaymond C., M.D.	Northwestern University

Bergen, Harold R., Ph.D.	
e ,	Case Western Reserve University School
8	University of California, San Francisco
Berliner, Lawrence J., Ph.D	University of Denver
Bernstam, Elmer V., M.D	The University of Texas Health Science Center at Houston
Bernstein, Emily, Ph.D.	
Berry, Donna L., Ph.D.	Dana-Farber Cancer Institute
Bertino, Joseph R., M.D.	
Bhansali, Shekhar, Ph.D	Florida International University
Bhatia, Ravi, M.D	City of Hope National Medical Center
Bhaumik, Sukesh R., Ph.D	Southern Illinois University, Carbondale
Bhowmick, Neil A., Ph.D	Cedars-Sinai Medical Center
Bhujwalla, Zaver M., Ph.D	Johns Hopkins University
Bickell, Nina A., M.D., M.P.H	The Mount Sinai Hospital
Bilby, Curt, Ph.D	
Binder, Robert J., Ph.D	University of Pittsburgh
Birt, Diane F., Ph.D	Iowa State University
Bissell, Mina, Ph.D	Lawrence Berkeley National Laboratory
Biswal, Shyam, Ph.D	Johns Hopkins University
Black, Jennifer D., Ph.D	University of Nebraska Medical Center
Blair, Sarah L., M.D	University of California, San Diego
Bland, Kirby I., M.D	The University of Alabama at Birmingham
Blaney, Susan M., M.D	Baylor College of Medicine
Blankenberg, Francis G., M.D	Stanford University
Bloom, Joan R., Ph.D	University of California, Berkeley
	RTI International
	Loyola University, Chicago
Bock, Beth C., Ph.D.	The Miriam Hospital
	Wayne State University
	State University of New York Upstate Medical University
, ,	
Boise, Lawrence H., Ph.D	Emory University
	University Hospitals Case Medical Center
	University of California, Davis
	Children's National Medical Center
	Christiana Care Health Services, Inc.
	University of California, Los Angeles
	Baylor College of Medicine
	Weill Cornell Medical College of Cornell University
	The University of Arizona
, , ,	University of Colorado Denver
	Mayo Clinic, Arizona
	University of Colorado Denver
	Northern California Institute of Research Education
Boussiotis, Vassiliki A., M.D., Ph.D	Beth Israel Deaconess Medical Center

Bouton Amy H Ph D	
· · ·	
, , ,	
	The University of Texas Southwestern Medical Center at Dallas
5, 5,	
5, , ,	University of Arkansas for Medical Sciences
5 /	
	. The University of Texas Health Science Center at San Antonio
	Dana-Farber Cancer Institute
	University of California, San Francisco
	University of Nebraska Medical Center
, , , ,	
· · · ·	Oregon Health & Science University
	Bend Research, Inc.
Brem, Steven, M.D.	H. Lee Moffitt Cancer Center & Research Institute
	Albert Einstein College of Medicine of Yeshiva University
Brewer, Molly A., D.V.M., M.D	
Bright, Robert K., Ph.D.	
Brock, Kristy, Ph.D	University of Michigan
Brody, James P., Ph.D.	University of California, Irvine
Bromberg, Jacqueline F., M.D., Ph	.D Memorial Sloan Kettering Cancer Center
Brooks, James D., M.D.	Stanford University
Brown, John M., Ph.D	Stanford University
Brown, Stuart M., Ph.D	New York University School Medicine
Browning, Christopher R., Ph.D.	
Bruchez, Marcel P., Ph.D	Carnegie Mellon University
Brufsky, Adam M., M.D., Ph.D	University of Pittsburgh
Bruner, Deborah W., Ph.D., R.N.,	F.A.A.NEmory University
Buchsbaum, Donald J., Ph.D	The University of Alabama at Birmingham
Bui, Jack D., M.D., Ph.D	University of California, San Diego
Buller, David B., Ph.D	
Buolamwini, John K., Ph.D	Rosalind Franklin University of Medicine and Science
Burchiel, Scott W., Ph.D	The University of New Mexico Health Sciences Center
	Acoustic MedSystems, Inc.
	Albert Einstein College of Medicine of Yeshiva University
· · · · · · · · · · · · · · · · · · ·	Worcester Polytechnic Institute
	The University of Iowa
Burns, Linda J., M.D	University of Minnesota
	Yale University
	The University of Texas Health Science Center at Houston
Butler, Lesley M., Ph.D	University of Pittsburgh

Butterfield, Lisa H., Ph.D.	University of Pittsburgh
Buttyan, Ralph, Ph.D.	The University of British Columbia
Byers, Stephen W., Ph.D.	Georgetown University

C

Cabot. Myles C., Ph.D.	East Carolina University
	The University of Vermont and State Agricultural College
	University of Rochester
	The University of Southern California
	The University of Texas MD Anderson Cancer Center
	St. Jude Children's Research Hospital
	University of Michigan
Cantor, Sharon B., Ph.D.	
	Johns Hopkins University
Carey, Robert, M.B.A.	
Carlin, Bradley P., Ph.D.	University of Minnesota
Caron, Marc G., Ph.D.	Duke University
Carrier, France, Ph.D.	University of Maryland, Baltimore
Carroll, Kathleen M., Ph.D.	
Carson, James A., Ph.D.	University of South Carolina, Columbia
Carter, Kenneth C., Ph.D.	
Casillas, Jacqueline, M.D	University of California, Los Angeles
Cassidy, Pamela B., Ph.D.	Oregon Health & Science University
Castilla, Lucio H., Ph.D	University of Massachusetts Medical School
Castro, Maria G., Ph.D	University of Michigan
Celebi, Julide T., M.D.	The Mount Sinai Hospital
Celi, Francesco S., M.D.	Virginia Commonwealth University
Celis, Esteban, M.D., Ph.D.	Georgia Regents University
Cesarman, Ethel, M.D., Ph.D.	Weill Cornell Medical College of Cornell University
Chagpar, Anees B., M.D., M.P.H.	
Chaillet, J. Richard, M.D., Ph.D.	University of Pittsburgh
Chak, Amitabh, M.D	Case Western Reserve University
Chalmers, Jeffrey J., Ph.D.	The Ohio State University
Chamberlain, Marc C., M.D.	University of Washington
Champlin, Richard E., M.D.	The University of Texas MD Anderson Cancer Center
Chan, Andrew T., M.D., M.P.H.	Massachusetts General Hospital
	Duke University
Chandra, Joya, Ph.D	The University of Texas MD Anderson Cancer Center
Chang, Chawnshang, Ph.D.	University of Rochester
Chang, Eric C., Ph.D.	Baylor College of Medicine
	The University of Texas MD Anderson Cancer Center
	Duke University
Chaplin, David D., M.D., Ph.D.	The University of Alabama at Birmingham
Chapman, Paul B., M.D.	Memorial Sloan Kettering Cancer Center

Chauhan, Abhay S., Ph.D.,	Concordia University Wisconsin
· · · · · · · · · · · · · · · · · · ·	D
, , ,	Massachusetts General Hospital
	I
, 6	University of Washington
, ,	
, , ,	
	D
	City of Hope National Medical Center
, 8 (Wake Forest University Health Sciences & Baptist Medical Center
	City of Hope National Medical Center
, ,	
, , , ,	
	Indiana University
<u>e</u> ,	Northwestern University
, , ,	D
	The University of Texas Southwestern Medical Center at Dallas
	Boston University Medical Campus
	Boston College
, , , ,	
Choi. Hak S., Ph.D.	Beth Israel Deaconess Medical Center
	University of Kansas Medical Center
	H The University of Texas MD Anderson Cancer Center
	The University of Texas Southwestern Medical Center at Dallas
- · · · ·	Dartmouth College
	Brigham Young University
	Cedars-Sinai Medical Center
	A.P.H
	Diagnostic Photonics, Inc.
	University of Connecticut Health Center
,	·

Clarke, Jennifer G., M.D., M.P.H.	Rhode Island Hospital
, , , ,	
	Penn State Milton S. Hershey Medical Center
· · · · · · · · · · · · · · · · · · ·	Children's Research Institute
57	University of Minnesota
	George Washington University
Cleeland, Charles S., Ph.D	The University of Texas MD Anderson Cancer Center
	PixelMed Publishing, LLC
Cobb, Melanie H., Ph.D	The University of Texas Southwestern Medical Center at Dallas
Cochran, Brent H., Ph.D	
Cody, Vivian, Ph.D	Hauptman-Woodward Medical Research Institute
Cohen, Trevor, Ph.D	
	University of Kentucky
Colcher, David M., Ph.D	City of Hope National Medical Center
Cole, Michael D., Ph.D.	Dartmouth College
Comai, Lucio, Ph.D	University of Southern California
	University of Virginia
	The University of Chicago
. ,	Stanford University
, , , ,	The University of Chicago
	The University of North Carolina at Chapel Hill
5/ I /	
	Case Western Reserve University
	Cleveland Clinic Taussig Cancer Institute
.	Mayo Clinic, Jacksonville
	Northwestern University
, , ,	Brigham and Women's Hospital
	BioTex Medical, Inc.
	The University of Texas MD Anderson Cancer Center
, , , ,	
Cowan, Ronald L., M.D., Ph.D.	
	Albert Einstein College of Medicine of Yeshiva University
	Oak Ridge Institute for Science and Education University of Colorado Denver
Cronan Thereasa A Ph D	
$\bigcirc \mathbf{W} = \mathbf{W} $	Capitai I Italtii Mitultai Celltei

Appendix D-3: Consultants Serving on Special Emphasis Panels (SEPs) in FY2014

Cukierman, Edna, Ph.D.	Fox Chase Cancer Center
Cunningham, John M., M.D.	The University of Chicago
Cutler, Stephen J., M.D., Ph.D.	The University of Vermont
Czerniak, Bogdan A., M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Czyzyk-Krzeska, Maria F., M.D., Ph.D	

D

D'Ambrosio, Steven M., PhD	
	University of California, Berkeley
	University of Kentucky
D'Souza, Warren D., Ph.D.	University of Maryland, Baltimore
Daaka, Yehia, Ph.D.	University of Florida
Dahiya, Rajvir, Ph.D	Northern California Institute of Research & Education
Daly, Mary B., M.D., Ph.D.	Fox Chase Cancer Center
Damodaran, Chendil, Ph.D.	
Dang, Nam H., M.D., Ph.D.	University of Florida
Daniel, Larry W., Ph.DWake Fo	rest University Health Sciences & Baptist Medical Center
Daniulaityte, Raminta, Ph.D.	
Das, Gokul M., Ph.D.	
Dasgupta, Ramanuj, Ph.D	New York University School of Medicine
Dash, Srikanta, Ph.D.	
Daskalakis, Constantine, Sc.D.	Thomas Jefferson University
Datta, Kamal, M.D.	Georgetown University
Datta, Kaustubh, Ph.D	University of Nebraska Medical Center
Davalos, Rafael V., Ph.D	Virginia Polytechnic Institute and State University
Dave, Sandeep, M.D	Duke University
Davidoff, Andrew M., M.D.	St. Jude Children's Research Hospital
Davidson, Kelly M., M.D.	University of Virginia
Davies, Joanna D., Ph.D.	San Diego Biomedical Research Institute
Davis, Michael J., Ph.D.	University of Missouri
Day, Roger S., Sc.D.	University of Pittsburgh
de Bono, Johann S., M.D., Ph.D.	
De Leon, Marino, Ph.D	Loma Linda University
de Winter, Alex, Ph.D	General Electric Healthcare Ventures
Deapen, Dennis M., Dr.P.H.	University of Southern California
	Boston Children's Hospital
Debinski, Waldemar, M.D., Ph.D	Wake Forest University Health Sciences &
	Baptist Medical Center
Debnath, Asim K., Ph.D.	New York Blood Center
DeClerck, Yves A., M.D.	University of Southern California
DeCoster, Mark A., Ph.D.	Louisiana Tech University
Deiner, Stacie, M.D	The Mount Sinai Hospital
Deininger, Prescott L., Ph.D.	
	Virginia Commonwealth University
Delnevo, Cristine D., Ph.D., M.P.H	Rutgers Biomedical and Health Sciences
Delong, Robert K., Ph.D	

Delva Jorge Ph D	University of Michigan
	New York University School of Medicine
, , ,	
, , ,	
, , ,	
, ,	
, ,	Loyola University, Chicago
, , ,	
, , ,	
S	University of Kentucky
C	Dana-Farber Cancer Institute
Dimri, Goberdhan P., Ph.D	George Washington University
, , , , , , , , , , , , , , , , , , , ,	Georgia Regents University
Dingli, David J., M.D., Ph.D.	
Dino, Geri A., Ph.D.	
Dinov, Ivo D., Ph.D	University of Michigan
DiPersio, C. Michael, Ph.D	Albany Medical College
DiSilvestro, Paul A., M.D.	Women and Infants Hospital of Rhode Island
Distelhorst, Clark W., M.D	Case Western Reserve University
Divgi, Chaitanya R., M.D	Columbia University Health Sciences
Divine, George W., Ph.D	Henry Ford Health System
Djaballah, Hakim, Ph.D	Memorial Sloan Kettering Cancer Center
Djeu, Julie Y., Ph.D	H. Lee Moffitt Cancer Center & Research Institute
Djuric, Zora, Ph.D	University of Michigan
Doherty, Gerard M., M.D	Boston University Medical Campus
Dong, Lei, Ph.D	Scripps Research Institute
	University of Pittsburgh
	The University of Oklahoma Health Sciences Center
	University of Maryland, Baltimore
	University of California, San Diego
	University of Maryland, Baltimore
	Penn State Milton S. Hershey Medical Center
	Case Western Reserve University
	Indiana University–Purdue University, Indianapolis
	University of Rochester
· · · · · · · · · · · · · · · · · · ·	
	Georgetown University
, , ,	Obermayer Rebmann Maxwell & Hippel LLP
	University of Southern California
Duda, Dan G., D.M.D., Ph.D	Massachusetts General Hospital

Dudley, Andrew C., Ph.D	The University of North Carolina at Chapel Hill
Duerksen-Hughes, Penelope J., Ph.D	Loma Linda University
Duffy, David C., Ph.D	Quanterix Corporation
Dunbar, Cynthia E., M.D	National Heart, Lung, and Blood Institute
Dunkel, Ira J., M.D.	Memorial Sloan Kettering Cancer Center
Dunn, William A., Ph.D	University of Florida
Dunton, Genevieve F., Ph.D., M.P.H.	University of Southern California
Dupont, William D., Ph.D	
Dupuy, Adam J., Ph.D	The University of Iowa
Dwinell, Michael B., Ph.D	Medical College of Wisconsin

E

Earle, Craig C., M.D.	Sunnybrook Health Sciences Centre
Eary, Janet F., M.D.	The University of Alabama at Birmingham
Eckelman, William C., Ph.D., M.P.H.	Molecular Tracer, LLC
Eckhart, Walter, Ph.D.	Salk Institute for Biological Studies
Edelen, Maria O., Ph.D.	
Edil, Barish H., M.D.	University of Colorado Denver
Edwards, D. Scott, Ph.D	SciFluor Life Sciences, LLC
	The University of New Mexico
Eheman, Christie R., Ph.D.	U.S. Centers for Disease Control and Prevention
	Consultant
Eibl, Guido E. M., M.D.	University of California, Los Angeles
Eischen, Christine M., Ph.D.	
Eiseman, Julie L., Ph.D.	University of Pittsburgh
, , , ,	Northwestern University
Elashoff, David, Ph.D.	University of California, Los Angeles
El-Ashry, Dorraya, Ph.D.	University of Miami Miller School of Medicine
5 57	Penn State Milton S. Hershey Medical Center
	Fox Chase Cancer Center
	Weill Cornell Medical College of Cornell University
Eley, John W., M.D., M.P.H.	Emory University
	Wayne State University
	Weill Cornell Medical College of Cornell University
Elliott, John T., Ph.D	National Institute of Standards & Technology
, , ,	HealthPartners Institute
Ellis, Nathan A., Ph.D.	The University of Arizona
El-Rifai, Wael, M.D., Ph.D.	
5 / /	University of California, San Francisco
	The University of Alabama at Birmingham
	The University of Texas MD Anderson Cancer Center
	University of Arkansas for Medical Sciences
	The University of Texas at Arlington
	Johns Hopkins University
, , , ,	University of Southern California
	Massachusetts General Hospital
Epplein, Meira, Ph.D.	

Epstein, Alan L., M.D., Ph.D	University of Southern California
Epstein, Jennifer A., Ph.D.	Weill Cornell Medical College of Cornell University
Erdei, Esther, Ph.D., M.P.H	
Erdman, Susan E., D.V.M., M.P.H.	Massachusetts Institute of Technology
Erickson, David, Ph.D	Cornell University
Esser, Karyn A., Ph.D	University of Kentucky
Essner, Jeffrey J., Ph.D	Iowa State University
Etkin, Amit, M.D., Ph.D	Palo Alto Veterans Institute for Research
Evans, Conor L., Ph.D	Massachusetts General Hospital
Evers, Bernard M., M.D	University of Kentucky
Ewing, James R., Ph.D.	Henry Ford Health System
Exner, Agata A., Ph.D	Case Western Reserve University

F

Faddegon, Bruce, Ph.D.	University of California, San Francisco
Fan, Guang, M.D., Ph.D.	Oregon Health & Science University
Fan, Hung Y., Ph.D.	University of California, Irvine
Fan, Rong, Ph.D.	
Fan, Weimin, M.D., M.P.H.	Medical University of South Carolina
Fan, Z. Hugh, Ph.D.	University of Florida
Farag, Sherif S., M.D., Ph.D.	Indiana University–Purdue University, Indianapolis
Fatatis, Alessandro, M.D., Ph.D	Drexel University
Fearon, Eric R., M.D., Ph.D.	University of Michigan
Fedorov, Andriy, Ph.D	Brigham and Women's Hospital
Felding, Brunhilde, Ph.D.	Scripps Research Institute
	Riverside Research Institute
Fennessy, Fiona, M.D., Ph.D.	Harvard Medical School
, , ,	University of Kentucky
Ferrance, Jerome P., Ph.D.	J2F-Engineering
, , ,	New York University School of Medicine
	Massachusetts General Hospital
	Treatment Research Institute, Inc.
Feusner, James, M.D	Children's Hospital & Research Center at Oakland
Figlin, Robert A., M.D.	Cedars-Sinai Medical Center
Figueiredo, Jane C., Ph.D.	University of Southern California
Fisher, Brian D., Ph.D	Simon Fraser University
Fisher, Christopher, Ph.D	
Fisher, Gary J., Ph.D	University of Michigan
Fisher, Joy D., M.A.	Johns Hopkins University
Fisher, Susan G., Ph.D.	
Fishman, David A., M.D.	The Mount Sinai Hospital
Fitzgerald-Bocarsly, Patricia, Ph.D	Rutgers Biomedical and Health Sciences
Flaherty, Lawrence E., M.D	
	University of Colorado Denver
	Beth Israel Deaconess Medical Center
Fleming, Jason B., M.D.	The University of Texas MD Anderson Cancer Center
Fleming, Jonathan J., M.P.A	Oxford Bioscience Partners

Flemington, Erik K., Ph.D. Florez, Karen R., Dr.P.H. Fong, Yiu-Liang, Ph.D. Fonseca, Rafael, M.D. Ford, Eric C., Ph.D. Ford, James M., M.D. Ford, Jean G., M.D.	RAND Corporation Abbott Laboratories Mayo Clinic, Arizona University of Washington Stanford University Johns Hopkins University
Forrest, Marcus L., Ph.D.	• •
Forsyth, Peter A., M.D.	•
Fortina, Paolo M., M.D., Ph.D.	•
Foty, Ramsey A., Ph.D.	
Fraass, Benedick A., Ph.D.	*
Francesconi, Lynn C., Ph.D.	
Franklin, Wilbur A., M.D.	8
Freedland, Stephen J., M.D.	5
Freeman, James W., Ph.D The University of	
Freeman, Michael R., Ph.D.	Cedars-Sinai Medical Center
Freitas, Michael A., Ph.D	The Ohio State University
Freyer, David R., D.O	1 0
Freyer, James P., Ph.D.	•
Fridley, Brooke L., Ph.D	
Friedman, Debra L., M.D., R.N	
Fritsche, Herbert A., Ph.D The Un	5
Fu, Haian, Ph.D	5 5
Fu, Jianping, Ph.D.	, 0
Fu, Mei R., Ph.D., R.N., A.C.N.SB.C., F.A.A.N	
Fu, Pingfu, Ph.D.	5
Fu, Rongwei, Ph.D.	
Fu, Yang-Xin, M.D., Ph.D.	
Fueyo, Juan, M.D The Un	5
Fujita, Mayumi, M.D., Ph.D.	
Fukumura, Dai, M.D., Ph.D.	
Fuloria, Jyotsna, M.B.B.S.	
Fulton, Amy M., Ph.D.	5 5 7
Furdui, Cristina, Ph.D	wake forest University Health Sciences

G

Gabrielson, Edward W., M.D.	Johns Hopkins University
Gabrilovich, Dmitry I., M.D., Ph.D	The Wistar Institute
Gajjar, Amar, M.D	St. Jude Children's Research Hospital
Galban, Craig J., Ph.D	University of Michigan
Galbraith, David W., Ph.D.	
Galipeau, Jacques, M.D	Emory University
Gallagher, Carla J., Ph.D.	Penn State Milton S. Hershey Medical Center
Gallick, Gary E., Ph.D.	The University of Texas MD Anderson Cancer Center

Galloway Robert L. Ph D	
	Georgia Regents University
1 5/	
	University of California, Los Angeles
, 8,	
	University of Washington
, , ,	
, , ,	University of Maryland, Baltimore
	. The University of Texas MD Anderson Cancer Center
1 / /	Beth Israel Deaconess Medical Center
	H. Lee Moffitt Cancer Center & Research Institute
	Brown University
Gau, Vincent, Ph.D.	
Gavai, Ashvinikumar, Ph.D.	Bristol-Myers Squibb Pharmaceutical Research
Geacintov, Nicholas E., Ph.D.	New York University Langone Medical Center
Gebreyes, Wondwossen A., D.V.M., Ph.D.	
	University of Pennsylvania
	Columbia University Health Sciences
Gelovani, Juri G., M.D., Ph.D	Wayne State University
Genkinger, Jeanine M., Ph.D.	Columbia University Health Sciences
George, Steven C., M.D., Ph.D.	Washington University in St. Louis
Gerend, Mary A., Ph.D.	Northwestern University
	University of Utah
Gestwicki, Jason E., Ph.D	University of California, San Francisco
Gewirtz, Abigail, Ph.D	University of Minnesota
Ghandehari, Hamid, Ph.D	University of Utah
, ,	Dana-Farber Cancer Institute
	University of California, Davis
Ghoshal, Kalpana, Ph.D	The Ohio State University
, , ,	Stanford University
	Georgetown University
	S. Uniformed Services University of the Health Sciences
	University of Connecticut, Storrs
	Gibson Consulting
	The University of Chicago
e	Greenville Health System
	University of Rochester
, , ,	H. Lee Moffitt Cancer Center & Research Institute
Gimotty, Phyllis A., Ph.D.	University of Pennsylvania

	Medical College of Wisconsin
Giuliano, Anna R., Ph.D.	
Gius, David, M.D., Ph.D.	Northwestern University
Given, Barbara A., Ph.D., R.N., F.A.A.N	N Michigan State University
Glatstein, Eli J., M.D	University of Pennsylvania
Glazer, Peter M., M.D., Ph.D.	Yale University
Glorioso, Joseph C., Ph.D.	University of Pittsburgh
	Johns Hopkins Hospital
Gmeiner, William H., Ph.D.	Wake Forest University Health Sciences &
	Baptist Medical Center
Gmitro, Arthur F., Ph.D.	The University of Arizona
Goel, Ajay, Ph.D.	Baylor University Medical Center
	Mayo Clinic
	University of California, San Francisco
Gold, David V., Ph.D.	Garden State Cancer Center
Gold, Ellen B., Ph.D.	University of California, Davis
	University of Southern California
	Georgetown University
Goldsmith, Elizabeth J., Ph.D	The University of Texas Southwestern Medical Center
	at Dallas
	Fox Chase Cancer Center
	Children's Hospital Los Angeles
S, ,	University of Kentucky
· · · · · ·	New Mexico Consortium, Inc.
	University of Toronto
	The University of Texas MD Anderson Cancer Center
	Princess Margaret Hospital
	Scripps Research Institute
· · ·	Baylor College of Medicine
	Washington University in St. Louis
	Fred Hutchinson Cancer Research Center
	City of Hope National Medical Center
, , ,	Virginia Commonwealth University
1, ,	Albert Einstein College of Medicine of Yeshiva University
—	. State University of New York Upstate Medical University
-	The University of North Carolina at Charlotte
	Indiana University–Purdue University, Indianapolis
	University of California, Davis
	Children's Hospital Corporation
	University of Arkansas for Medical Sciences
	Cincinnati Children's Hospital Medical Center
Grippo, Paul J., Ph.D.	University of Illinois at Chicago

Grobin, Adam W., Ph.D.	
Grochow, Louise B., M.D., F.A.C.P	Johns Hopkins Hospital
Groden, Joanna L., Ph.D	The Ohio State University
Gronemeyer, Suzanne A., Ph.D	St. Jude Children's Research Hospital
Gross, Cynthia R., Ph.D.	University of Minnesota
Gross, Mitchell E., M.D., Ph.D.	University of Southern California
Gross, Myron D., Ph.D.	University of Minnesota
Grossniklaus, Hans E., M.D.	Emory University
Groutas, William C., Ph.D.	Wichita State University
Gruber, Stephen B., M.D., Ph.D., M.P.	H University of Southern California
Grufferman, Seymour, M.D., Dr.P.H	The University of New Mexico
Grundfest, Warren S., M.D.	University of California, Los Angeles
Gu, Li-Qun, Ph.D.	University of Missouri
Gu, Xiaohui, Ph.D.	North Carolina State University
Gu, Xinbin, M.D., Ph.D.	Howard University
Guan, Jun-Lin, Ph.D.	University of Cincinnati
	University of Nebraska Medical Center
	Roswell Park Cancer Institute
	. Albert Einstein College of Medicine of Yeshiva University
Guidry, Jeffrey J., Ph.D.	Texas A&M University
Gulley, Margaret L., M.D.	The University of North Carolina at Chapel Hill
	Rutgers, The State University of New Jersey
Gupta, Sanj ay, Ph.D	Case Western Reserve University
Gutkind, J. Silvio, Ph.D.	National Institute of Dental and Craniofacial Research
Gutmann, David H., M.D., Ph.D	Washington University in St. Louis
Guttridge, Denis C., Ph.D	The Ohio State University

H

Haab, Brian B., Ph.D.	
Habelhah, Hasem, Ph.D	
Hahn, Elizabeth A., M.A.	Northwestern University
Hahn, William C., M.D., Ph.D.	Dana-Farber Cancer Institute
Haimovitz-Friedman, Adriana, Ph.D	Memorial Sloan Kettering Cancer Center
Haines, Dale S., Ph.D.	
	Duke University
Hambardzumyan, Dolares, Ph.D	Cleveland Clinic Lerner College of Medicine
	of Case Western Reserve University
Hamburger, Anne W., Ph.D.	University of Maryland, Baltimore
Hamilton, Ann S., Ph.D.	University of Southern California
	The University of Texas MD Anderson Cancer Center
Hamilton, Thomas C., Ph.D.	Fox Chase Cancer Center
Hammer, Daniel A., Ph.D.	University of Pennsylvania
	The University of North Carolina at Chapel Hill
Hammons, George J., Ph.D.	Philander Smith College
Han, Sang M., Ph.D.	The University of New Mexico
Hansen, Kirk C., Ph.D.	University of Colorado Denver

Hansen Laura A Ph D	Creighton University
· · · · ·	
	Us TOO International, Inc.
57 5	Johns Hopkins University
	University of California, San Diego
	Indiana University School of Medicine
- · · · · · · · · · · · · · · · · · · ·	East Carolina University
, , ,	Dartmouth-Hitchcock Medical Center
	Boston Medical Center
	H. Lee Moffitt Cancer Center & Research Institute
, 0, ,	University of Michigan
	H. Lee Moffitt Cancer Center & Research Institute
	University of Virginia
, 6,	Fox Chase Cancer Center
	The University of Alabama at Birmingham
Held, Kathryn D., Ph.D.	Massachusetts General Hospital
Hellstrom, Ingegerd E., M.D., Ph.D.	University of Washington
Helzlsouer, Kathy J., M.D.	Mercy Health Services
Henikoff, Steven, Ph.D	Fred Hutchinson Cancer Research Center
Herbst, Roy S., M.D., Ph.D., M.P.H.	Yale University
Herlyn, Meenhard F., D.V.M., D.Sc.	
Gonzalez Hernandez, Graciela, Ph.I	D Arizona State University, Tempe
Hernando, Eva, Ph.D	New York University School of Medicine
Herring, Amy H., Sc.D	
Herrinton, Lisa J., Ph.D	Kaiser Foundation Research Institute
Hersch, Rebekah K., Ph.D	Isa Associates, Inc.
Hesketh, Peter J., Ph.D	Georgia Institute of Technology
Heslop, Helen E., M.D	Baylor College
Heston, Warren D., Ph.D	Cleveland Clinic Foundation
Hettich, Robert L., Ph.D	The University of Tennessee-Oak Ridge National Laboratory
Heymach, John V., M.D., Ph.D	The University of Texas MD Anderson Cancer Center
Hiatt, Robert A., M.D., Ph.D	University of California, San Francisco
Hickey, Robert J., Ph.D	City of Hope National Medical Center
Higgins, Paul J., Ph.D.	Albany Medical College
	Georgetown University
Hill, David E., Ph.D	Dana-Farber Cancer Institute
Hill, Elizabeth G., Ph.D	Medical University of South Carolina
	East Tennessee State University
	Tufts University
	University of Kentucky
	Genesys Research Institute, Inc.
	Los Alamos National Laboratory
Ho, Alan L., M.D., Ph.D	Memorial Sloan Kettering Cancer Center

Ho. Shuk-Mei. Ph.D	
· · · ·	
	Penn State Milton S. Hershey Medical Center
	Yale University
	Arizona State University, Tempe
	Commonwealth Medical College
1 / 0 /	Dartmouth College
	The University of Texas MD Anderson Cancer Center
Hord, Norman G., Ph.D., M.P.H.	
Hortobagyi, Gabriel N., M.D.	The University of Texas MD Anderson Cancer Center
Houchen, Courtney W., M.D	The University of Oklahoma Health Sciences Center
Houghton, A. McGarry, M.D.	Fred Hutchinson Cancer Research Center
	University of Massachusetts Medical School
Houghton, Peter J., Ph.D.	St. Jude Children's Research Hospital
	Friend for Life Cancer Support Network
	Weill Cornell Medical College of Cornell University
· · · ·	University of Nebraska Medical Center
-	North Carolina State University
	The University of Texas Southwestern Medical Center
	University of California, San Diego
	University of Miami Miller School of Medicine
Huang, Emina H., M.D.	Cleveland Clinic Lerner College of Medicine
	of Case Western Reserve University
	The University of Texas MD Anderson Cancer Center
	Oregon Health & Science University
	The University of Texas MD Anderson Cancer Center
, , ,	,
	The University of Texas MD Anderson Cancer Center
	University of Utah
	The oniversity of onicago

Hussong, Andrea M., Ph.D.	The University of North Carolina at Chapel Hill
Huth, James F., M.D.	The University of Texas Southwestern Medical Center at Dallas
Hutt-Fletcher, Lindsey M., Ph.D	Louisiana State University Health Science, Shreveport
Hwang, Rosa F., M.D.	The University of Texas MD Anderson Cancer Center
Hylemon, Phillip B., Ph.D.	Virginia Commonwealth University
Hyslop, Terry, Ph.D.	Duke University

Iavarone, Antonio, M.D.	Columbia University Health Sciences
Iftimia, Nicusor, Ph.D.	Physical Sciences, Inc.
Inaba, Hiroto, M.D., Ph.D.	St. Jude Children's Research Hospital
Isom, Harriet C., Ph.D.	Penn State Milton S. Hershey Medical Center
Issa, Jean-Pierre J., M.D.	
Ittmann, Michael M., M.D., Ph.D.	
Iversen, Edwin S., Ph.D.	Duke University

J

Jabado, Nada, M.D., Ph.D	
Jackson, Mark W., Ph.D	Case Western Reserve University
Jacobs, Lisa K., M.D	Johns Hopkins University
Jacobs, Michael A., Ph.D.	Johns Hopkins University
Jacobsen, Paul B., Ph.D	University of South Florida
Jacobson, Geraldine M., M.D., M.P.H.	West Virginia University
Jadvar, Hossein, M.D., Ph.D.	University of Southern California
Jaffray, David A., Ph.D.	
Jain, Maneesh, Ph.D	University of Nebraska Medical Center
James, Charles D., Ph.D.	Northwestern University
Jamner, Larry D., Ph.D	University of California, Irvine
Jarrard, David F., M.D.	University of Wisconsin, Madison
Jay, Daniel G., Ph.D.	
Jay, Michael, Ph.D	NanoMed Pharmaceuticals, Inc.
Jeffe, Donna B., Ph.D	Washington University in St. Louis
Jeffery, Elizabeth H., Ph.D	
Jeffrey, Stefanie S., M.D.	Stanford University
Jelicks, Linda A., Ph.D.	Albert Einstein College of Medicine of Yeshiva University
Jensen, Todd R., Ph.D.	Jensen Informatics LLC
Jermaine, Christopher, Ph.D.	Rice University
Jernigan, David, Ph.D	Johns Hopkins University
Jerry, D. Joseph, Ph.D.	University of Massachusetts, Amherst
Jewell, William R., M.D.	University of Kansas Medical Center
Ji, Hanlee, M.D	Stanford University
Jia, Shidong, Ph.D	Genentech, Inc.
Jiang, Binghua, Ph.D	Thomas Jefferson University
Jiang, Feng, M.D., Ph.D.	University of Maryland, Baltimore
	Georgia State University
Jimeno, Antonio, M.D., Ph.D	University of Colorado Denver

Johnson, David G., Ph.D The U	University of Texas MD Anderson Cancer Center
Johnson, Gary L., Ph.D	The University of North Carolina at Chapel Hill
Johnson, Mark E., Ph.D	Mark E. Johnson Consulting, LLC
Johnson, Michael D., Ph.D	Georgetown University
Johnson, William E., Ph.D	Boston University Medical Campus
John-Stewart, Grace C., M.D., Ph.D., M.P.H	University of Washington
Jones, David A., Ph.D	
Jones, Elizabeth C., M.D	National Institutes of Health, Clinical Center
Jones, Kevin B., M.D.	
Jones, Resa M., Ph.D., M.P.H	Virginia Commonwealth University
Joshi, Amit, Ph.D	Baylor College of Medicine
Joshi, Karuna, Ph.D	University of Maryland, Baltimore
Ju, Jingfang, Ph.D	The State University New York at Stony Brook
Judge, Andrew R., Ph.D	University of Florida
Junghans, Richard P., M.D., Ph.D.	Tufts Medical Center

K

	University of Pennsylvania
, ,	
	Cincinnati Children's Hospital Medical Center
, , ,	University of Southern California
· · · · ·	Johns Hopkins University
, , ,	University of Louisville
	University of Pittsburgh
	The University of Texas MD Anderson Cancer Center
1 5 / 5 /	Massachusetts General Hospital
Kaminski, Joseph M., M.D	Medical College of Georgia
, ,	Boston University
Kane, Madeleine A., M.D., Ph.D	University of Colorado Denver
	City of Hope National Medical Center
Kang, Duck-Hee, Ph.D., R.N., F.A.A	A.N The University of Texas Health Science Center
	at Houston
Kang, Min H., Pharm.D.	Texas Tech University Health Sciences Center
Kang, Yibin, Ph.D	Princeton University
Kao, Joseph P. Y., Ph.D	University of Maryland, Baltimore
Kaplan, Alan, Ph.D.	University of Kentucky
Kapur, Reuben, Ph.D.	Indiana University–Purdue University, Indianapolis
Kar, Koushik, Ph.D	
Karchin, Rachel, Ph.D.	Johns Hopkins University
Karellas, Andrew, Ph.D.	
Karnad, Anand, M.D.	Γhe University of Texas Health Science Center at San Antonio
, ,	
1, , ,	
Katsanis, Emmanuel, M.D.	

Katz Stoven I M.D. M.D.	University of Michigan
, , ,	
, , ,	
, , ,	
	University of Michigan
	Indiana University–Purdue University, Indianapolis
	Dartmouth College
Kern, Scott E., M.D.	Johns Hopkins University
Kerr, William G., Ph.D.	State University of New York Upstate Medical University
Kershaw, Trace S., Ph.D.	
	The University of Chicago
Kesler, Shelli R., Ph.D	The University of Texas MD Anderson Cancer Center
Kessel, David, Ph.D	
Kessler, Larry G., D.Sc	University of Washington
	University of Virginia
Khaled, Annette R., Ph.D	University of Central Florida
, , ,	Temple University
	Northwestern University
· · · ·	Harry S. Truman Memorial Veteran's Hospital
	University of Utah
· · · · ·	University of Arkansas for Medical Sciences
	Fred Hutchinson Cancer Research Center
, , ,	
	Northeastern University
, , ,	
-	
, , ,	
	Cornell University
S	The University of New Mexico Health Sciences Center
	Oklahoma Medical Research Foundation
	Solution of the one of the one of the one of the office of

Klein, Alison P, Ph.D. New York University School of Medicine Klesges, Rohert C, Ph.D. The University of Tennessee Health Science Center Kline, Justin P, M.D. The University of Tomsesee Health Science Center Klosky, James, Ph.D. St. Jude Children's Research Hospital Kluger, Harriet M., M.D. Yale University Knoepfler, Paul S, Ph.D. Purdue University Knoepfler, Paul S, Ph.D. University of California, Davis Knoepfler, Paul S, Ph.D. Open Medicine Institute, Inc. Kosparshi, Susumu, M.D., Ph.D. Beth Israel Deaconess Medical Center Kogelnik, Andreas M, M.D., Ph.D. Open Medicine Institute, Inc. Koh, James, Ph.D. University of Miani Miller School of Michigan Koopelit, Fakar R, Ph.D. Vanderbilt University Koonekpour, Shahrar, M.D., M.P.H. University of Michigan Koopelit, Mladen, Ph.D. Roswell Park Cancer Institute Koopelik, Mladen, Ph.D. British Columbia Cancer Agency Korngold, Robert, Ph.D. Louisiana State University of Michigan Kovari, Ladislau C, Ph.D. Louisiana State University of Ponnsylvania Kovari, Ladislau C, Ph.D. Louisiana State University of Ponnsylvania Kovari, Ladislau C, Ph.D. Wayne State Universi	Klassen, Ann C., Ph.D.	Drexel University
Klein, Hannah L., Ph.D		
Klesges, Robert C., Ph.D		
Kline, Justin P, M.D. The University of Chicago Klosky, James, Ph.D. The University of Iowa Klosky, James, Ph.D. St. Jude Children's Research Hospital Kluger, Harriet M., M.D. Yale University Knoepfler, Paul S., Ph.D. Purdue University Knoepfler, Paul S., Ph.D. University of California, Davis Knudsen, Beatrice S., M.D., Ph.D. Beth Israel Deaconess Medical Center Kogelnik, Andreas M., M.D., Ph.D. Beth Israel Deaconess Medical Center Kook, James, Ph.D. Duwersity of Miami Miller School of Medicine Kootekepour, Shabriar, M.D., Ph.D. Duwersity of Miami Miller School of Medicine Kootekepour, Shabriar, M.D., Ph.D. Roswell Park Cancer Institute Koochekpour, Shabriar, M.D., Ph.D. Roswell Park Cancer Institute Koopelanan, Raoul, Ph.D. British Columbia Cancer Agency Korngold, Robert, Ph.D. Hackensack University Medical Center Kosmenic, Constantinos, Ph.D. Luiversity of North Carolina at Chapel Hill Koul, Hari K., Ph.D. Luiversity of Pansylvania Kovari, Ladislau C, Ph.D. Emory University Koara, Richard C, M.D., Ph.D. Roswell Park Cancer Institute Korare, Fred R., Ph.D. Luiversity of Minesota <t< td=""><td></td><td>· · · · · · · · · · · · · · · · · · ·</td></t<>		· · · · · · · · · · · · · · · · · · ·
Klingelhutz, Aloysius J., Ph.D	S	
Klosky, James, Ph.D. St. Jude Children's Research Hospital Kluger, Harriet M., M.D. Pale University Knipp, Gregory T., Ph.D. Purdue University Knoepfler, Paul S., Ph.D. University of California, Davis Knudsen, Beatrice S., M.D., Ph.D. Cedars-Sinai Medical Center Kosgelnik, Andreas M., M.D., Ph.D. D. Open Medicine Institute, Inc. Koh, James, Ph.D. University of Miami Miller School of Medicine Konjeti, Schkar R., Ph.D. University of Miami Miller School of Medicine Koonpeti, Schkar R., Ph.D. University of Miami Miller School of Medicine Koonpeti, Schkar R., Ph.D. University of Miami Miller School of Medicine Koonpeti, Schkar R., Ph.D. University of Miami Miller School of Medicine Koonpeti, Schkar R., Ph.D. University of Michigan Kopelman, Raoul, Ph.D. Ho. University of Michigan Kopelman, Raoul, Ph.D. Ho. University of Michigan Kopelman, Raoul, Ph.D. Ho. University of Michigan Kopelman, Raoul, Ph.D. Ho. Heither Michigan Kopelman, Raoul, Ph.D. Louisiana State University Medical Center Kosorok, Michael R., Ph.D. Louisiana State University of North Caroline A Chapel Hill Kovari, Ladislau C., Ph.D. Louisiana State University of Pennsylvania Kovari, Ladislau C., Ph.D. Emory University of Pennsylvania Kovari, Ladislau C., Ph.D. Medical College of Wisconsin Kresty, Laura A., Ph.D. Medical College of Wisconsin Kricka, Larry J, B.A. University of Pennsylvania Kridel, Steven J, Ph.D. Medical College of Wisconsin Kricka, Larry J, B.A. University of Pennsylvania Kridel, Steven J, Ph.D. The University of Sciences & Baptist Medical Center Krishnamyth, Smitha, M.D. The University of Texas MD Anderson Cancer Center Krishnamyth, Smitha, M.D. The University of Texas MD Anderson Cancer Center Krishnamyth, Smitha, M.D. The University of Texas MD Anderson Cancer Center Krishnam, Sunil, M.D. Ph.D. The University of Pennsylvania Kirdel, Steven J, Ph.D. The University of Pennsylvania Kirdel, Steven J, Ph.D. The University of Pennsylvania Kirdel, Haris, Ph.D. Compon Health & Science Institute Kudaroli, Hari	, , ,	
Kluger, Harriet M., M.D		
Knipp, Gregory T, Ph.D. Purdue University Knoepfler, Paul S, Ph.D. University of California, Davis Knudsen, Beatrice S, M.D., Ph.D. Beth Israel Deaconess Medical Center Kobayashi, Susumu, M.D., Ph.D. Beth Israel Deaconess Medical Center Koh, James, Ph.D. Open Medicine Institute, Inc. Koh, James, Ph.D. University of Miami Miller School of Medicine Konjeti, Krishna V, M.D. University of Miami Miller School of Medicine Koopman, James S, M.D., M.P.H. University of Michigan Koopenan, Raoul, Ph.D. Roswell Park Cancer Institute Koopman, James S, M.D., M.P.H. University of Michigan Kopelina, Roolu, Ph.D. British Columbia Cancer Agency Korngold, Robert, Ph.D. Hackensack University Medical Center Kosorok, Michael R, Ph.D. Louisiana State University of North Carolina at Chapel Hill Koul, Hari K., Ph.D. Louisiana State University of Pennsylvania Kovari, Ladislau C., Ph.D. Wayne State University Kowari, Ladislau C., M.D. Emory University Kowari, Ladislau C., M.D. Public Health Research Institute Kratzke, Robert A, M.D. University of Minnesota Kried, Steven J., Ph.D. Wake Forest University Health Science & Baptist		
Knoepfler, Paul S., Ph.D. University of California, Davis Knudsen, Beatrice S., M.D., Ph.D. Cedars-Sinai Medical Center Kogelnik, Andreas M., M.D., Ph.D. Deaconess Medical Center Kogelnik, Andreas M., M.D., Ph.D. Open Medicine Institute, Inc. Koh, James, Ph.D. University of Miami Miller School of Medicine Konjeti, Sekhar R., Ph.D. Vanderbilt University Koochekpour, Shahrar, M.D., Ph.D. Roswell Park Cancer Institute Koopelman, Raoul, Ph.D. Roswell Park Cancer Institute Koopelman, Raoul, Ph.D. British Columbia Cancer Agency Kornegl, Robert, Ph.D. Hackensack University Medical Center Kosorok, Michael R., Ph.D. Louisiana State University of North Carolina at Chapel Hill Koul, Hari K., Ph.D. Louisiana State University of North Carolina at Chapel Hill Kovari, Ladislau C., Ph.D. Wayne State University Kovari, Ladislau C., Ph.D. Wayne State University Kratzke, Robert A., M.D. Public Health Research Institute Kratzke, Robert A., M.D. Wake Forest University Health Sciences & Baptist Medical Center Kricka, Larry, J., B.A. University of Minnesota Kricka, Larry, J., B.A. University of Pomsylvania Kricka, Larry, J., B.A.		
Knudsen, Beatrice S., M.D., Ph.D. Cedars-Sinai Medical Center Kogelnik, Andreas M., M.D., Ph.D. Beth Israel Deaconess Medical Center Kogelnik, Andreas M., M.D., Ph.D. Duke University Komanduri, Krishna V., M.D. University of Miami Miller School of Medicine Koopen, Shahra, M.D., Ph.D. Naderbilt University Koonekpour, Shahrar, M.D., Ph.D. Roswell Park Cancer Institute Koopen, James S, M.D., M.P.H. University of Michigan Korbelik, Mladen, Ph.D. Beth Israel Columbia Cancer Agency Korngold, Robert, Ph.D. Hackensack University Medical Center Kosorok, Michael R., Ph.D. Louisiana State University of North Carolina at Chapel Hill Kovari, Ladislau C., Ph.D. Louisiana State University Health Science Center, Shreveport Kowark, I.adislau C., Ph.D. Emory University Krauer, Fred R., Ph.D. Roswell Park Cancer Institute Krauer, Fred R., Ph.D. Emory University Kowark, Ladislau C., M.D., Ph.D. Roswell Park Cancer Institute Krauer, Fred R., Ph.D. Wayne State University of Minnesota Kriekz, Larer A., M.D. University of Minnesota Kriekz, Larer A., Ph.D. Medical Center Krishnamurthi, Smitha, M.D. Kriekz, Larer J., Ph.D. The		
Kobayashi, Susumu, M.D., Ph.D.Beth Israel Deaconess Medical CenterKogelnik, Andreas M., M.D., Ph.D.Open Medicine Institute, Inc.Koh, James, Ph.D.University of Miami Miller School of MedicineKonjeti, Sekhar R., Ph.D.University of Miami Miller School of MedicineKoopelman, Raoul, Ph.D.Roswell Park Cancer InstituteKoopelman, Raoul, Ph.D.Roswell Park Cancer InstituteKoorbekpour, Shahriar, M.D., Ph.D.Roswell Park Cancer InstituteKoorpelik, Mladen, Ph.D.British Columbia Cancer AgencyKorgold, Robert, Ph.D.Hackensack University Medical CenterKosorok, Michael R., Ph.D.The University of North Carolina at Chapel HillKoul, Hari K., Ph.D.Louisiana State University Health Science Center, ShreveportKoumenis, Constantinos, Ph.D.University of PennsylvaniaKovari, Ladislau C., Ph.D.Roswell Park Cancer InstituteKovari, Ladislau C., Ph.D.Roswell Park Cancer InstituteKramer, Fred R., Ph.D.Roswell Park Cancer InstituteKratzke, Robert A., M.D.University of MinnesotaKresty, Laura A., Ph.D.Wake Forest University Health Sciences & Baptist Medical CenterKrishnamurthi, Smitha, M.D.University of Texas MD Anderson Cancer CenterKrishnamurthi, Smitha, M.D.University of Texas MD Anderson Cancer CenterKrishnanswamy, Venkataramanan, Ph.D.Expression Pathology, IncKrohn, Kenneth A., Ph.D.The University of Texas MD Anderson Cancer CenterKrishnanswamy, Venkataramanan, Ph.D.The University of PennsylvaniaKrodeksti, Elizabeth A., Ph.D.The Universi	1 / /	
Kogelnik, Andreas M., M.D., Ph.D		
Koh, James, Ph.D		
Komanduri, Krishna V., M.D		-
Konjeti, Sekhar R., Ph.D	, , ,	
Koochekpour, Shahriar, M.D., Ph.D		e e e e e e e e e e e e e e e e e e e
Koopman, James S., M.D., M.P.H.University of MichiganKopelman, Raoul, Ph.D.University of MichiganKorbelik, Mladen, Ph.D.British Columbia Cancer AgencyKorngold, Robert, Ph.D.Hackensack University Medical CenterKosorok, Michael R., Ph.D.Louisiana State University Health Science Center, ShreveportKoumenis, Constantinos, Ph.D.Louisiana State University Health Science Center, ShreveportKowari, Ladislau C., Ph.D.Wayne State UniversityKovari, Ladislau C., Ph.D.Emory UniversityKovari, Ladislau C., Ph.D.Roswell Park Cancer InstituteKramer, Fred R., Ph.D.Public Health Research InstituteKratzke, Robert A., M.D.University of MinnesotaKresty, Laura A., Ph.D.Wake Forest University Health Sciences & Baptist Medical CenterKrishnamurthi, Smitha, M.D.The University of Texas MD Anderson Cancer CenterKrishnan, Sunil, M.D.The University of Texas MD Anderson Cancer CenterKrishnaswamy, Venkataramanan, Ph.D.Dartmouth CollegeKrizman, David B., Ph.D.Dana-Farber Cancer InstituteKroon, Stephen J., M.D., Ph.D.Dana-Farber Cancer InstituteKrolewski, John J., M.D., Ph.D.The University of PennsylvaniaKrolu, Stephen J., M.D., Ph.D.Rostepher Cancer InstituteKrudrolli, Haris, Ph.D.Rostepher Cancer InstituteKron, Stephen J., M.D., Ph.D.Rostepher Cancer InstituteKron, Stephen J., M.D., Ph.D.Rostepher Cancer InstituteKrudrolli, Haris, Ph.D.Rostepher Cancer InstituteKrudrolli, Haris, Ph.D.Rostepher Cancer Institute </td <td>5 /</td> <td></td>	5 /	
Kopelman, Raoul, Ph.D.University of MichiganKorbelik, Mladen, Ph.D.British Columbia Cancer AgencyKorngold, Robert, Ph.D.Hackensack University Medical CenterKosorok, Michael R., Ph.D.The University of North Carolina at Chapel HillKoul, Hari K., Ph.D.Louisiana State University Health Science Center, ShreveportKourneis, Constantinos, Ph.D.University of PennsylvaniaKovari, Ladislau C., Ph.D.Wayne State UniversityKowalski, Jeanne, Ph.D.Emory UniversityKowalski, Jeanne, Ph.D.Roswell Park Cancer InstituteKratzke, Robert A., M.D.Public Health Research InstituteKratzke, Robert A., M.D.University of MinnesotaKresty, Laura A., Ph.D.Medical College of WisconsinKricka, Larry J, B.A.University of PennsylvaniaKricka, Larry J, B.A.University of PennsylvaniaKricka, Larry J, B.A.University of PennsylvaniaKricka, Larry J, B.A.University of Texas MD Anderson Cancer CenterKrishnamurthi, Smitha, M.D.The University of Texas MD Anderson Cancer CenterKrishnan, Sunil, M.D.Expression Pathology, Inc.Krohn, Kenneth A., Ph.D.University of WashingtonKrolewski, John J, M.D., Ph.D.Dana-Farber Cancer InstituteKrupinski, Elizabeth A., Ph.D.The University of PennsylvaniaKrudrolli, Haris, Ph.D.Dana-Farber Cancer InstituteKrupinski, Elizabeth A., Ph.D.Dana-Farber Cancer InstituteKrudrolli, Haris, Ph.D.Dana-Farber Cancer InstituteKrudrolli, Haris, Ph.D.Dana-Farber Cancer Institute <td>1 <i>1 1 1</i></td> <td></td>	1 <i>1 1 1</i>	
Korbelik, Mladen, Ph.D. British Columbia Cancer Agency Korngold, Robert, Ph.D. Hackensack University Medical Center Kosorok, Michael R., Ph.D. Louisiana State University of North Carolina at Chapel Hill Koul, Hari K., Ph.D. Louisiana State University Health Science Center, Shreveport Koumenis, Constantinos, Ph.D. Louisiana State University Health Science Center, Shreveport Kowalski, Jeanne, Ph.D. Wayne State University Kovalski, Jeanne, Ph.D. Emory University Koya, Richard C., M.D., Ph.D. Emory University Koya, Richard C., M.D., Ph.D. Roswell Park Cancer Institute Kratzke, Robert A., M.D. University of Minnesota Kresty, Laura A., Ph.D. Medical College of Wisconsin Kricka, Larry J., B.A. University Health Sciences & Baptist Medical Center Krishnamurthi, Smitha, M.D. University Hospitals of Cleveland Krishnan, Sunil, M.D. Make Forest University fealth Sciences & Baptist Medical Center Krishnamurthi, Smitha, M.D. D. Dartmouth College Krizman, David B., Ph.D. Band, Ph.D. Louiversity of Texas MD Anderson Cancer Center Krohn, Kenneth A., Ph.D. University of Rochester Kron, Stephen J., M.D., Ph.D. The University of Texas MD Anderson Cancer Institute Krou, Stephen J., M.D., Ph.D. Radiation Monitoring Chicago Krop, Ian E., M.D., Ph.D. Radiation Monitoring Devices, Inc. Kufe, Donald W., M.D. Ph.D. Radiation Monitoring Devices, Inc. Kufe, Donald W., M.D. M.D., Ph.D. Radiation Monitoring Devices, Inc. Kufe, Donald W., M.D., Ph.D. Oregon Health Science Center at San Antonio	- · · · · · · · · · · · · · · · · · · ·	· · ·
Korngold, Robert, Ph.D	1 , ,	, 8
Kosorok, Michael R., Ph.D	, , ,	
Koul, Hari K., Ph.DLouisiana State University Health Science Center, Shreveport Koumenis, Constantinos, Ph.DUniversity of Pennsylvania Kovari, Ladislau C., Ph.D	8, ,	
Koumenis, Constantinos, Ph.DUniversity of Pennsylvania Kovari, Ladislau C., Ph.DWayne State University Kowalski, Jeanne, Ph.D		
Kovari, Ladislau C., Ph.D		
Kowalski, Jeanne, Ph.D	, , , ,	
Koya, Richard C., M.D., Ph.D	, , ,	
Kramer, Fred R., Ph.D	, ,	
Kratzke, Robert A., M.D		
 Kricka, Larry J., B.A. University of Pennsylvania Kridel, Steven J., Ph.D. Wake Forest University Health Sciences & Baptist Medical Center Krishnamurthi, Smitha, M.D. University Hospitals of Cleveland Krishnan, Sunil, M.D. The University of Texas MD Anderson Cancer Center Krishnaswamy, Venkataramanan, Ph.D. Dartmouth College Krizman, David B., Ph.D. Krohn, Kenneth A., Ph.D. Krohn, Kenneth A., Ph.D. University of Washington Kroop, Ian E., M.D., Ph.D. Krupinski, Elizabeth A., Ph.D. Krupinski, Elizabeth A., Ph.D. Krupinski, Elizabeth A., Ph.D. Krupinski, Elizabeth A., Ph.D. Kudrolli, Haris, Ph.D. Kufe, Donald W., M.D. M.D., M.P.H. Wiesz-Martin, Molly F., Ph.D. The University of Minnesota Kulesz-Martin, Molly F., Ph.D. The University of Minnesota Kulesz-Martin, Molly F., Ph.D. 		
Kridel, Steven J., Ph.D	Kresty, Laura A., Ph.D	Medical College of Wisconsin
Krishnamurthi, Smitha, M.D	Kricka, Larry J., B.A	University of Pennsylvania
Krishnamurthi, Smitha, M.D	Kridel, Steven J., Ph.D.	.Wake Forest University Health Sciences & Baptist Medical Center
Krishnaswamy, Venkataramanan, Ph.D		
Krizman, David B., Ph.D	Krishnan, Sunil, M.D	The University of Texas MD Anderson Cancer Center
Krohn, Kenneth A., Ph.D	Krishnaswamy, Venkataramana	n, Ph.DDartmouth College
Krolewski, John J., M.D., Ph.D	Krizman, David B., Ph.D	Expression Pathology, Inc.
Kron, Stephen J., M.D., Ph.D	Krohn, Kenneth A., Ph.D	University of Washington
Krop, Ian E., M.D., Ph.D	Krolewski, John J., M.D., Ph.D	University of Rochester
Krupinski, Elizabeth A., Ph.D	Kron, Stephen J., M.D., Ph.D.	The University of Chicago
Krymskaya, Vera P., M.B.A., Ph.D	Krop, Ian E., M.D., Ph.D	Dana-Farber Cancer Institute
Kudrolli, Haris, Ph.D	Krupinski, Elizabeth A., Ph.D.	The University of Arizona
Kufe, Donald W., M.D	Krymskaya, Vera P., M.B.A., Pł	1.D University of Pennsylvania
Kulasingam, Shalini L., Ph.D., M.P.H		
Kulesz-Martin, Molly F., Ph.D		
Kumar, Addanki P., Ph.D The University of Texas Health Science Center at San Antonio		
	Kulesz-Martin, Molly F., Ph.D.	Oregon Health & Science University
Kumar, Ajit, Ph.DGeorge Washington University		
	Kumar, Ajit, Ph.D	George Washington University

Kumar, Challa S., Ph.D	Louisiana State University Agricultural & Mechanical College
Kumar, Deepak, Ph.D	
Kumar, Nagi B., Ph.D	H. Lee Moffitt Cancer Center & Research Institute
Kumar, Naresh, Ph.D	University of Miami Miller School of Medicine
Kumar, Santosh, Ph.D	University of Memphis
Kumar, Shaji K., M.D	
Kunicki, Thomas J., Ph.D	Children's Hospital of Orange County
Kuo, Macus T., Ph.D	
	La Jolla Institute for Allergy & Immunology
Kuzel, Timothy M., M.D	Northwestern University
Kwiatkowski, David J., M.D., Ph.D.	Brigham and Women's Hospital
Kwock, Lester, Ph.D	
	University of Wisconsin, Madison
Kyprianou, Iacovos S., Ph.D	U.S. Food and Drug Administration
Kyprianou, Natasha, Ph.D	University of Kentucky

L

LaBarge Mark A Ph D	
0 /	
· · · ·	
. ,	SRI International
	Albert Einstein College of Medicine of Yeshiva University
, , ,	Howard University
, , ,	
	British Columbia Cancer Research Centre
	Fred Hutchinson Cancer Research Center
Landgraf, Ralf, Ph.D.	University of Miami Miller School of Medicine
Landowski, Terry H., Ph.D	
Landsittel, Douglas P., Ph.D	University of Pittsburgh
Landsman, David, Ph.D	National Library of Medicine
Lane, Andrew N., Ph.D	University of Kentucky
Lane, Timothy F., Ph.D	University of California, Los Angeles
Langer, Mark P., M.D	Indiana University–Purdue University, Indianapolis
Langer, Steve G., Ph.D	
0 /	Thomas Jefferson University
Lanier, Keith S., M.D	Providence Portland Medical Center
0,	
· · · · · · · · · · · · · · · · · · ·	Thomas Jefferson University
, , ,	Virginia Commonwealth University
Larson, Andrew C., Ph.D.	Northwestern University

Lash Timothy L. D.Sc. M.P.H.	
· · · · ·	
· · · ·	Kaiser Permanente
	Commonwealth Medical College
	The University of Texas Health Science Center at San Antonio
	University of Pittsburgh
, , ,	
	Drexel University
· · · · · ·	University of California, Irvine
, , , ,	
	University of Pennsylvania
· · ·	
, 8	
	Jefferson University
, ,	U.S. Food and Drug Administration
S /	
	Penn State Milton S. Hershey Medical Center
Leong, Stephen, M.D.	
	University of Pennsylvania
Lesinski, Gregory B., Ph.D., M.P.I	H The Ohio State University
	St. Jude Children's Research Hospital
Leung, Yuet-Kin, Ph.D.	University of Cincinnati
Levenson, Richard M., M.D.	
Levine, Alexandra M., M.D	University of California, Los Angeles
Levine, Ellis G., M.D	Roswell Park Cancer Institute
	Columbia University Medical Center
	Baylor College of Medicine
Li, Changqing, Ph.D	University of California, Merced
	University of Louisville
Li, Christopher I., M.D., Ph.D., N	1.P.H Fred Hutchinson Cancer Research Center
Li, Ellen, Ph.D	The State University of New York at Stony Brook

Li Hong VI Ph D	
, , , ,	
	The University of Texas Health Science Center at San Antonio
, ,	Johns Hopkins University
, 8, ,	1 5
, , , ,	
3 ,	Syracuse University
, , ,	
, , ,	University of Rochester
	University of Cincinnati
	The University of Texas MD Anderson Cancer Center
, 5 ,	Nationwide Children's Hospital
, 3	University of Nebraska Medical Center
	The University of Texas MD Anderson Cancer Center
	The University of Texas MD Anderson Cancer Center
, ,	University of Pittsburgh
, , ,	The University of Iowa
	George Mason University
	Stanford University
Lipkin, Steven M., M.D., Ph.D	Weill Cornell Medical College of Cornell University
Lipshultz, Steven E., M.D	
Lisetti, Christine L., Ph.D	Florida International University
Liu, Chunming, Ph.D	University of Kentucky
Liu, Gilbert C., M.D	University of Louisville
Liu, Jonathan T., Ph.D	University of Washington
Liu, Pengyuan, Ph.D	Medical College of Wisconsin
Liu, Song, Ph.D	Roswell Park Cancer Institute
Liu, Yunlong, Ph.D	Indiana University–Purdue University, Indianapolis
Lo, Hui-Wen, Ph.DV	Vake Forest University Health Sciences & Baptist Medical Center
	University of California, San Diego
Loboa, Elizabeth G., Ph.D	North Carolina State University, Raleigh
	The University of Alabama at Birmingham
· · · · ·	
	Indiana University–Purdue University, Indianapolis
· · · · ·	The University of Texas MD Anderson Cancer Center
- · · · · ·	
,	

Lokeshwar, Vinata B., Ph.D
Long, Jirong, Ph.D
Lonsdale, John T., Ph.D
Lord, Edith M., Ph.D
Lorusso, Patricia M., D.O
Loscalzo, Matthew J., L.C.S.W
Lothstein, Leonard, Ph.D
Lounsbury, David W., Ph.DAlbert Einstein College of Medicine of Yeshiva University Lowe, Anson W., M.DStanford University Lu, Chang, Ph.DVirginia Polytechnic Institute and State University Lu, Jianming, Ph.DImmuphargen, LLC Lu, Karen H., M.DThe University of Texas MD Anderson Cancer Center Lubaroff, David M., Ph.D
Lowe, Anson W., M.D
Lu, Chang, Ph.D
Lu, Jianming, Ph.D Immuphargen, LLC Lu, Karen H., M.D The University of Texas MD Anderson Cancer Center Lubaroff, David M., Ph.D The University of Iowa Lue, Neal F., M.D., Ph.D Weill Cornell Medical College of Cornell University Luebeck, Georg E., Ph.D Fred Hutchinson Cancer Research Center
Lu, Karen H., M.D
Lubaroff, David M., Ph.D
Lue, Neal F., M.D., Ph.D Weill Cornell Medical College of Cornell University Luebeck, Georg E., Ph.D
Luebeck, Georg E., Ph.D Fred Hutchinson Cancer Research Center
Lum Lawrence Ph D The University of Texas Southwestern Medical Center
Lum, Lawrence G., M.D
Lunyak, Victoria, Ph.DBuck Institute for Research on Aging
Luo, Juhua, Ph.D Indiana University, Bloomington
Luo, Jun-Li, M.D., Ph.DScripps Research Institute
Luo, Yuling, Ph.D Advanced Cell Diagnostics, Inc.
Luque, John S., Ph.D., M.P.HGeorgia Southern University
Lutters, Wayne G., Ph.D University of Maryland, Baltimore
Lv, Qin, Ph.DUniversity of Colorado Boulder
Lyman, Gary H., M.D., M.P.H Fred Hutchinson Cancer Research Center
Lynch, John P., M.D., Ph.DUniversity of Pennsylvania
Lyon, Debra E., Ph.D University of Florida

Μ

Ma, Cynthia X., M.D., Ph.D.	Washington University in St. Louis
Ma, Grace X., Ph.D.	Temple University
	Reaction Biology Corp.
Ma, Patrick C., M.D.	Cleveland Clinic Lerner College of Medicine
	of Case Western Reserve University
Macoska, Jill A., Ph.D.	University of Massachusetts, Boston
Madabhushi, Anant, Ph.D	Case Western Reserve University
Maggard-Gibbons, Melinda A., M.D	University of California, Los Angeles
Mahadevan-Jansen, Anita, Ph.D	
Mai, Volker, Ph.D	University of Florida
Maihle, Nita J., Ph.D.	Georgia Health Sciences University
Maizels, Nancy, Ph.D.	University of Washington
Majumdar, Adhip P.N., D.Sc., Ph.D	
Majumder, Sadhan, Ph.D.	The University of Texas MD Anderson Cancer Center
Makriyannis, Alexandros, Ph.D	Northeastern University
Maley, Carlo, Ph.D.	University of California, San Francisco

Malkas Linda H. Ph.D.	City of Hope National Medical Center
, , ,	
	Henry M. Jackson Foundation
· · ·	
	Albert Einstein College of Medicine of Yeshiva University
	Virginia Commonwealth University
C ,	
, , ,	
	Baylor College of Medicine
	The University of Alabama College of Arts and Sciences
	e Forest University Health Sciences & Baptist Medical Center
, , , ,	
, , ,	M.P.HUniversity of Hawaii at Manoa
	Emory Healthcare
	Indiana University–Purdue University, Indianapolis
,	Johns Hopkins University
, , ,	The University of Vermont and State Agricultural College
· · · · · · · · · · · · · · · · · · ·	
	Inova Fairfax Hospital
	Indiana University–Purdue University, Indianapolis
	Stanford University

McDaid, Hayley M., Ph.D	Albert Einstein College of Medicine of Yeshiva University
	Indiana University–Purdue University, Indianapolis
McKeon, Frank D., Ph.D.	The Jackson Laboratory
McMahon, Steven B., Ph.D.	
McMillen, Janey S., Ph.D.	
McNeel, Douglas G., M.D., Ph.D	University of Wisconsin, Madison
McNeely, Margaret, Ph.D	University of Alberta
McNitt-Gray, Michael F., Ph.D	University of California, Los Angeles
McQueen, Amy, Ph.D	Washington University in St. Louis
McTiernan, Anne M., M.D., Ph.D	Fred Hutchinson Cancer Research Center
Medhora, Meetha M., Ph.D	Medical College of Wisconsin
	Drexel University
	IIT Research Institute
Mendonca, Paulo R., Ph.D	General Electric Global Research Center
	University of Illinois at Chicago
	Indiana University–Purdue University, Indianapolis
Mesri, Enrique A., Ph.D	University of Miami Miller School of Medicine
Messersmith, Wells A., M.D	University of Colorado Denver
Metallo, Christian M., Ph.D	University of California, San Diego
Metzger, Gregory J., Ph.D.	University of Minnesota
Meyer, Charles R., Ph.D.	University of Michigan
Meyer, Laurence J., M.D., Ph.D	University of Utah
Meyerand, Mary E., Ph.D	University of Wisconsin, Madison
	Penn State Milton S. Hershey Medical Center
· · · · · · · · · · · · · · · · · · ·	University of California, Irvine
	University of Nebraska Medical Center
	Massachusetts General Hospital
· · ·	The State University of New York at Buffalo
	Brown University
	Maine Medical Center
	Mayo Clinic
	Virginia Commonwealth University
, , ,	Pacific Institute for Research and Evaluation
	University of California, Davis
	University of Minnesota
	Stanford University
	University Health Network
	University of Texas Southwestern Medical Center at Dallas
	Van Andel Research Institute
—	University of Texas MD Anderson Cancer Center at Dallas
, , ,	Sanford Research
	Thomas Jefferson University
	Southern Research Institute
Mitsiades, Constantine S., M.D., Ph.D.	Dana-Farber Cancer Institute

Mittal, Vivek, Ph.D	
	University of Colorado Boulder
5 / /	University of Wisconsin, Madison
3 <i>i i i</i>	
, , ,	
	Albert Einstein College of Medicine of Yeshiva University
-	
· · ·	
· · · ·	
, , ,	
, , ,	
, 8	University of Utah
	Virginia Commonwealth University
, 8	
	Oregon Health & Science University
· · · · · · · · · · · · · · · · · · ·	The University of Texas Medical Branch at Galveston
	Los Alamos National Laboratory
Mu, David, Ph.D.	Eastern Virginia Medical School
	North Carolina State University, Raleigh
Muench, Frederick J., Ph.D.	The Feinstein Institute for Medical Research
Muise-Helmericks, Robin C., Ph.D	Medical University of South Carolina
	University of Michigan
	The University of North Carolina at Charlotte
	University of Connecticut School of Dental Medicine
Mukhopadhyay, Debabrata, Ph.D	
	University of Wisconsin, Madison
	University of Michigan
Mullen, Craig A., M.D., Ph.D	University of Rochester
	The University of New Mexico
Mullersman, Jerald E., M.D., Ph.D., N	1.P.HEast Tennessee State University
	Dartmouth College
Mulloy, James C., Ph.D.	Cincinnati Children's Hospital Medical Center

Mulshine, James L., M.D	Rush University Medical Center
Mulvihill, John J., M.D	The University of Oklahoma Health Sciences Center
Munden, Reginald F., M.D	The Methodist Hospital Research Institute
Munger, Karl, Ph.D	Tufts University
	Northwestern University
	U.S. Food and Drug Administration
Murphy, Robert L., M.D	Northwestern University
Murphy, Sheigla B., Ph.D	Scientific Analysis Corporation
Murphy, William J., Ph.D	University of Nevada, Reno
Murray, John J., M.D., Ph.D	Meharry Medical College
Murtaugh, Lewis C., Ph.D	University of Utah
Mustian, Karen M., Ph.D., M.P.H	University of Rochester
Muthusamy, Natarajan, Ph.D	The Ohio State University
Muthuswamy, Senthil K., Ph.D	Cold Spring Harbor Laboratory
• • • •	The University of Texas MD Anderson Cancer Center
Myers, Valerie H., Ph.D	Klein Buendel, Inc.

N

Nabors, Louis B., M.D	The University of Alabama at Birmingham
Nagarkatti, Mitzi, Ph.D	University of South Carolina, Columbia
Nagle, Dale G., Ph.D	The University of Mississippi
Nagrath, Sunitha, Ph.D	University of Michigan
Naidu, Mamta D., Ph.D	GeneSys Research Institute
Najavits, Lisa M., Ph.D	Treatment Innovations, LLC
Nakagawa, Mayumi, M.D., Ph.D	
Nakshatri, Harikrishna, Ph.D	Indiana University–Purdue University, Indianapolis
Nana-Sinkam, Serge P., M.D	The Ohio State University
Napolitano, Melissa A., Ph.D.	George Washington University
Nathanson, Katherine L., M.D	University of Pennsylvania
Naughton, Michelle J., Ph.D., M.P.H.	
Navone, Nora M., Ph.D	The University of Texas MD Anderson Cancer Center
Nelson, Celeste M., Ph.D	Princeton University
Nelson, Sarah J., Ph.D	University of California, San Francisco
Nemenoff, Raphael A., Ph.D	University of Colorado Denver
	Indiana University–Purdue University, Indianapolis
Ness, Scott A., Ph.D	The University of New Mexico Health Sciences Center
Neuhouser, Marian L., Ph.D	Fred Hutchinson Cancer Research Center
Neuwelt, Edward A., M.D.	
Newcomb, Polly A., Ph.D., M.P.H	Fred Hutchinson Cancer Research Center
	University of Wisconsin, Madison
Nickerson, Jeffrey A., Ph.D	University of Massachusetts Medical School
Nickoloff, Jac A., Ph.D	Colorado State University
· · · · ·	University of South Florida
Nieva, Jorge J., M.D	The University of Southern California
Nikiforov, Mikhail, Ph.D	Roswell Park Cancer Institute

Nikitin, Alexander Y., M.D., Ph.D	Cornell University
Nishikawa, Robert M., Ph.D	University of Pittsburgh
Nishimura, Michael I., Ph.D.	Loyola University, Chicago
Nishioka, Gary M., Ph.D	H & N Instruments, Inc.
Nonn, Larisa, Ph.D	University of Illinois at Chicago
Norian, Lyse A., Ph.D.	The University of Iowa
Normolle, Daniel P., Ph.D	University of Pittsburgh
Norris, Jeremy L., Ph.D	Vanderbilt University
Novina, Carl D., M.D., Ph.D	Dana-Farber Cancer Institute
Nucifora, Giuseppina, D.Sc., Ph.D	The University of Chicago
Nusse, Roeland, Ph.D	Stanford University
Nygaard, Peter, Ph.D.	Pacific Institute for Research and Evaluation

0

O'Bryan, John P., Ph.D.	University of Illinois at Chicago
O'Connor, Kathleen L., Ph.D	University of Kentucky
O'Connor, Richard J., Ph.D	Roswell Park Cancer Institute
O'Hara, Michael D., Ph.D.	U.S. Food and Drug Administration
O'Neill, Brian P., M.D.	
Ochs, Michael F., Ph.D.	The College of New Jersey
Odedina, Folakemi T., Ph.D	University of Florida
Oesterle, Sabrina, Ph.D	University of Washington
Ogretmen, Besim, Ph.D	Medical University of South Carolina
	Oregon Health & Science University
Okcu, Mehmet F., M.D., M.P.H	The University of Texas MD Anderson Cancer Center
	Case Western Reserve University
Oliver, Janet M., Ph.D.	The University of New Mexico Health Sciences Center
, , , ,	University of Michigan
Onar-Thomas, Arzu, Ph.D.	St. Jude Children's Research Hospital
	University of Minnesota
	University of Illinois at Chicago
	St. Jude Children's Research Hospital
Orlowski, Robert Z., M.D., Ph.D	The University of Texas MD Anderson Cancer Center
Orsulic, Sandra, Ph.D.	Cedars-Sinai Medical Center
Osheroff, Neil, Ph.D	
Ostrowski, Michael C., Ph.D	The Ohio State University
Ota, David M., M.D	Duke University
	University of Southern California
	Roswell Park Cancer Institute
	Veterans Administration Palo Alto Health Care System
	ne University of Texas Health Science Center at San Antonio
Ozbun, Michelle A., Ph.D.	The University of New Mexico Health Sciences Center

Ρ

Padilla, Geraldine V., Ph.D	University of California, San Francisco
Pagel, Mark D., Ph.D	The University of Arizona

	University of California, Los Angeles
	Children's Hospital Corporation
	University of Wisconsin, Madison
	University of California, San Diego
	The University of Chicago
Pan, Zhen-Qiang, Ph.D	Icahn School of Medicine at Mount Sinai
Pandita, Tej K., Ph.D	
Panepinto, Julie A., M.D.	
Pankratz, V. Shane, Ph.D.	The University of New Mexico Health Sciences Center
, ,	
, , ,	
.	
8, ,	Johns Hopkins University
	The University of Texas Southwestern Medical Center at Dallas
	University of Minnesota
, , ,	., M.P.H
Tarra-Medina, Deborari M., Th.E	at San Antonio
Pares Androw T MD PhD	Northwestern University
	U.S. Food and Drug Administration
	Icahn School of Medicine at Mount Sinai
	University of Washington
	University of California, Berkeley
, , , ,	Pacific Northwest National Laboratory
	University of California, San Francisco
· · ·	American Cancer Society, Inc.
, , , ,	Mayo Clinic, Jacksonville
	D Sanford Burnham Prebys Medical Discovery Institute
Paulos, Chrystal M., Ph.D	Medical University of South Carolina
Paulovich, Amanda G., M.D., Ph	D Fred Hutchinson Cancer Research Center
Paulsen, Keith D., Ph.D	Dartmouth College
Pavlidis, Ioannis, Ph.D	
Pearcey, Robert G., M.D	University of Alberta
Pearse, Roger N., M.D., Ph.D	
	HAmerican Legacy Foundation
	University Of California, Irvine
	Stanford University School of Medicine
6	
· · · ·	
· · ·	
rerez-rerez, Guillermo I., D.Sc.	New York University School of Medicine

Perez-Soler Roman M D	Albert Einstein College of Medicine of Yeshiva University
	Indiana University
, , ,	
	Louisiana State University Health Sciences Center
, , ,	
	U.S. Food and Drug Administration
, , ,	
	University of California, San Diego
-	
· ·	Roswell Park Cancer Institute
	University of California, San Diego
	University of Kentucky
, , ,	
	at San Antonio
Pop. Mihai. Ph.D	
1 , ,	
	University of Utah
	University of Maryland, Baltimore
	Icahn School of Medicine at Mount Sinai
	Lankenau Institute for Medical Research
	The University of Texas MD Anderson Cancer Center
	The University of New Mexico Health Sciences Center
Prywes, Ron M., Ph.D	
Przytycka, Teresa M., Ph.D	

Puduvalli, Vinay K., M.D.	The Ohio State University
Pulsipher, Michael A., M.D.	University of Utah
Pumiglia, Kevin M., Ph.D.	

Q

Qian, Wei, Ph.D.	The University of Texas at El Paso
Quaranta, Vito, M.D.	University of Pennsylvania
Quarles, Christopher C., Ph.D.	Vanderbilt University
Quintero, Gilbert A., Ph.D.	The University of Montana
Quintiliani, Lisa M., Ph.D.	Boston Medical Center

R

Raber, Jacob, Ph.D	
	University of Pennsylvania
	Fred Hutchinson Cancer Research Center
Rae, James M., Ph.D.	University of Michigan
Raffel, Glen D., M.D., Ph.D.	
Rafii, Shahin, M.D.	Weill Cornell Medical College of Cornell University
Raghavan, Derek, M.D., Ph.D.	Carolinas Healthcare System
Rahimi, Nader, Ph.D.	Boston University Medical Campus
Rajasekaran, Ayyappan K., Ph.D	Lankenau Institute for Medical Research
Ramakrishnan, Viswanathan, Ph.D	Medical University of South Carolina
Ramesh, Rajagopal, Ph.D.	University of Oklahoma Health Sciences Center
Rampersaud, Arfaan, Ph.D.	Columbus NanoWorks, Inc.
Rangnekar, Vivek M., Ph.D.	University of Kentucky
Ransohoff, David F., M.D.	The University of North Carolina at Chapel Hill
Rao, Chinthalapally V., Ph.D.	University of Oklahoma Health Sciences Center
Rao, Dinesh S., M.D., Ph.D.	University of California, Los Angeles
Rapkin, Bruce D., Ph.D.	.Albert Einstein College of Medicine of Yeshiva University
• •	Albert Einstein College of Medicine of Yeshiva University
Ratajczak, Mariusz Z., M.D., Ph.D	•
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D	
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D	
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D	
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D Raubitschek, Andrew A., M.D	University of Louisville Purdue University Wayne State University Washington University in St. Louis
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D Raubitschek, Andrew A., M.D Rauscher, Frank J., Ph.D	
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D Raubitschek, Andrew A., M.D Rauscher, Frank J., Ph.D Ray, Krishanu, Ph.D	University of Louisville Purdue University Wayne State University Washington University in St. Louis City of Hope National Medical Center The Wistar Institute
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D Raubitschek, Andrew A., M.D Rauscher, Frank J., Ph.D Ray, Krishanu, Ph.D Ray, Ratna B., Ph.D Raychaudhuri, Pradip, Ph.D	University of Louisville Purdue University Wayne State University Washington University in St. Louis City of Hope National Medical Center The Wistar Institute University of Maryland, Baltimore Saint Louis University School of Medicine University of Illinois at Chicago
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D Raubitschek, Andrew A., M.D Rauscher, Frank J., Ph.D Ray, Krishanu, Ph.D Ray, Ratna B., Ph.D Raychaudhuri, Pradip, Ph.D	University of Louisville Purdue University Wayne State University Washington University in St. Louis City of Hope National Medical Center The Wistar Institute University of Maryland, Baltimore Saint Louis University School of Medicine
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D Raubitschek, Andrew A., M.D Rauscher, Frank J., Ph.D Ray, Krishanu, Ph.D Ray, Ratna B., Ph.D Raychaudhuri, Pradip, Ph.D Reader, Steven, Ph.D	University of Louisville Purdue University Wayne State University Washington University in St. Louis City of Hope National Medical Center The Wistar Institute University of Maryland, Baltimore Saint Louis University School of Medicine University of Illinois at Chicago
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D Raubitschek, Andrew A., M.D Rauscher, Frank J., Ph.D Ray, Krishanu, Ph.D Ray, Ratna B., Ph.D Raychaudhuri, Pradip, Ph.D Reddr, Steven, Ph.D Redd, William H., Ph.D Reddy, Kaladhar B., Ph.D	University of Louisville Purdue University Wayne State University Washington University in St. Louis City of Hope National Medical Center The Wistar Institute University of Maryland, Baltimore Saint Louis University School of Medicine University of Illinois at Chicago University of South Florida Icahn School of Medicine at Mount Sinai Wayne State University
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D Raubitschek, Andrew A., M.D Rauscher, Frank J., Ph.D Ray, Krishanu, Ph.D Ray, Ratna B., Ph.D Raychaudhuri, Pradip, Ph.D Redder, Steven, Ph.D Redd, William H., Ph.D Reddy, Kaladhar B., Ph.D Reddy, Sakamuri V., Ph.D	University of Louisville Purdue University Wayne State University Washington University in St. Louis City of Hope National Medical Center The Wistar Institute University of Maryland, Baltimore Saint Louis University School of Medicine University of Illinois at Chicago University of South Florida Icahn School of Medicine at Mount Sinai Medical University of South Carolina
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D Raubitschek, Andrew A., M.D Rauscher, Frank J., Ph.D Ray, Krishanu, Ph.D Ray, Ratna B., Ph.D Raychaudhuri, Pradip, Ph.D Redder, Steven, Ph.D Redd, William H., Ph.D Reddy, Kaladhar B., Ph.D Reddy, Sakamuri V., Ph.D	University of Louisville Purdue University Wayne State University Washington University in St. Louis City of Hope National Medical Center The Wistar Institute University of Maryland, Baltimore Saint Louis University School of Medicine University of Illinois at Chicago University of South Florida Icahn School of Medicine at Mount Sinai Wayne State University
Ratajczak, Mariusz Z., M.D., Ph.D Ratliff, Timothy L., Ph.D Ratnam, Manohar, Ph.D Ratner, Lee, M.D., Ph.D Raubitschek, Andrew A., M.D Rauscher, Frank J., Ph.D Ray, Krishanu, Ph.D Ray, Ratna B., Ph.D Raychaudhuri, Pradip, Ph.D Reddr, Steven, Ph.D Redd, William H., Ph.D Reddy, Kaladhar B., Ph.D Reddy, Sakamuri V., Ph.D Redmond, Carol K., Sc.D Reecy, James M., Ph.D	University of Louisville Purdue University Wayne State University Washington University in St. Louis City of Hope National Medical Center The Wistar Institute University of Maryland, Baltimore Saint Louis University School of Medicine University of Illinois at Chicago University of South Florida Icahn School of Medicine at Mount Sinai Wayne State University Medical University of South Carolina

Rejniak, Katarzyna A., Sc.D., Ph.I	D H. Lee Moffitt Cancer Center & Research Institute
Relling, Mary V., Pharm.D.	St. Jude Children's Research Hospital
Remick, Scot C., M.D.	West Virginia University
Renne, Rolf F., Ph.D.	University of Florida
Retterer, Scott T., Ph.D.	UT-Battelle, LLC
Revzin, Alexander, Ph.D.	University of California, Davis
Reynolds, Brady A., Ph.D.	University of Kentucky
	University of Florida
Rich, Jeremy N., M.D.	Cleveland Clinic Lerner College of Medicine
	of Case Western Reserve University
Richards, Nigel G., Ph.D.	Indiana University–Purdue University Indianapolis
Richardson, Adam D., Ph.D	Sanford Burnham Prebys Medical Discovery Institute
Richardson, Christine A., Ph.D	The University of North Carolina at Charlotte
Richmond, Ann, Ph.D.	
Ridner, Sheila H., Ph.D.	
Riethman, Harold, Ph.D.	
Riggins, Gregory J., M.D., Ph.D	Johns Hopkins University
Rigoutsos, Isidore, Ph.D.	
Riley, Barth B., Ph.D.	
Riley, James L., Ph.D.	University of Pennsylvania
Risch, Harvey A., M.D., Ph.D.	
· · ·	
Roberson, Noma L., Ph.D.	Roberson Consulting International
Roberson, Paula K., Ph.D.	University of Arkansas for Medical Sciences
Rocco, James W., M.D., Ph.D.	
	Johns Hopkins University
Rodland, Karin D., Ph.D.	Pacific Northwest National Laboratory
Roess, Amira A., Ph.D.	
	Cedars-Sinai Medical Center
- · · · ·	University of Kentucky
	The University of Texas Southwestern Medical Center at Dallas
.	Cleveland Clinic Lerner College of Medicine
····· , ····· , ····· , ····· , ····· , ····· , ····· , ····· , ····· , ······	of Case Western Reserve University
Rosenman, Julian G., M.D., Ph.D.	
	University of California, San Francisco
	City of Hope National Medical Center
, , , ,	
, ,	0

Rowan, Brian G., Ph.D	
Roy, Hemant K., M.D.	Boston Medical Center
Royston, Thomas J., Ph.D.	University of Illinois at Chicago
Rozek, Laura, Ph.D	University of Michigan
Rubnitz, Jeffrey E., M.D., Ph.D	St. Jude Children's Research Hospital
Rudd, Brian D., Ph.D., M.P.H.	Cornell University
Ruppert, John M., M.D., Ph.D.	West Virginia University
Rushton, Gerard, Ph.D	The University of Iowa
Russo, Jose, M.D.	Fox Chase Cancer Center
Rutter, Jared P., Ph.D	University of Utah

S

Sabbadini, Roger A., Ph.D	Lpath, Inc.
Safa, Ahmad R., Ph.D.	Indiana University–Purdue University, Indianapolis
Said, Jonathan W., M.D.	University of California, Los Angeles
Saigal, Christopher, M.D., M.P.H.	University of California, Los Angeles
Sakr, Wael A., M.D.	
Salgado, Roberto, M.D	GasthuisZusters Antwerpen Hospital
	Brown University
Saltz, Joel H., M.D., Ph.D.	The State University of New York at Stony Brook
Salvesen, Guy S., Ph.D.	Sanford Burnham Prebys Medical Discovery Institute
	Memorial Sloan Kettering Cancer Center
Sanderson, Maureen, Ph.D., M.P.H	Meharry Medical College
Sandison, George A., Ph.D.	University of Washington
Santangelo, Philip J., Ph.D.	Georgia Institute of Technology
Sargent, James D., M.D.	Dartmouth College
Sarkar, Fazlul H., Ph.D.	
Savage, Cary R., Ph.D.	University of Kansas Medical Center
Savaraj, Niramol, M.D	University of Miami Miller School of Medicine
	University of Florida
Scarpinato, Karin D., Ph.D.	University of Miami Miller School of Medicine
	Digital Infuzion, Inc.
Schechter, Clyde, M.D	Albert Einstein College of Medicine of Yeshiva University
Scheidt, Karl A., Ph.D.	Northwestern University
, , ,	Institute for Community Research
Scheurer, Michael E., Ph.D., M.P.H	Baylor College of Medicine
Schildkraut, Joellen M., Ph.D., M.P.H.	Duke University
, , ,	Case Western Reserve University
	The University of Texas MD Anderson Cancer Center
Schmidt, Edward E., Ph.D.	Montana State University, Bozeman
Schmidt, Jeanette P., Ph.D	Affymetrix, Inc.
Schmitz, Kathryn H., Ph.D., M.P.H	University of Pennsylvania
Schneider, Stefan, Ph.D.	University of Southern California
Schoen, Robert E., M.D., M.P.H.	University of Pittsburgh
Schootman, Mario, Ph.D	
Schultz, Kirk R., M.D.	University of British Columbia

Schwabe Robert F. M.D.	
, , , ,	
· · · ·	
	Albert Einstein College of Medicine of Yeshiva University
· · · · · ·	
	Oakland University
	Johns Hopkins University
8	
, ,	
1 / /	
	of Case Western Reserve University
Sharlow, Elizabeth R., Ph.D.	
	Johns Hopkins University
	University of Nebraska Medical Center
	University of Massachusetts Medical School, Worcester
	University of Texas Southwestern Medical Center at Dallas
	City College of New York
	ne State University of New York Upstate Medical University
	Rutgers Biomedical and Health Sciences
	Georgia Health Sciences University
,	University of Kentucky
	University of Southern California
	Johns Hopkins University
	1

Shih Wan V Ph D	Drexel University
	State University of New York Upstate Medical University
, , ,	University of Hawaii at Manoa
2 · · · · · ·	
, , ,	
· · · · · · · · · · · · · · · · · · ·	
•	
	The University of Texas MD Anderson Cancer Center
	Johns Hopkins University
8 , ,	
· · ·	
, , ,	
	· · ·
8	
	University of Pittsburgh
· ·	University Health Network
8, , , ,	Mayo Clinic
	Signature HealthCare
	Case Western Reserve University
, ,	University of California, San Francisco
5, ,	H. Lee Moffitt Cancer Center & Research Institute
	University of Maryland, College Park
	Louisiana State University
C ,	
	Rockefeller University
	University of Michigan
	University of California, Santa Barbara
	Wake Forest University Health Sciences Center
	University of Nebraska Medical Center
Sowers, Lawrence C., Ph.D.	The University of Texas Medical Branch at Galveston

Sparano Joseph A M D	Albert Einstein College of Medicine of Yeshiva University
1 / 1 /	
1 /	
i , 6 ,	Northwestern University at Chicago
1 0, ,	Sanford Burnham Prebys Medical Discovery Institute
- · · · · · · · · · · · · · · · · · · ·	
, , , ,	
· · · ·	.DPenn State Milton S. Hershey Medical Center
· · · · · · · · · · · · · · · · · · ·	. The University of Vermont and State Agricultural College
, , ,	
, , ,	St. Jude Children's Research Hospital
	Loyola University, Chicago
	University of California, Los Angeles
, , ,	
· ·	
, 5,	
, , ,	Oregon Health & Science University
	University of Pittsburgh
, , ,	University of Pennsylvania
, , ,	University of Maryland, Baltimore
	Portland State University
	Rutgers Biomedical and Health Sciences
	University of California, San Diego
e	University of Massachusetts, Amherst
	University of Michigan
	The University of North Carolina at Chapel Hill
	University of Texas Southwestern Medical Center at Dallas
	University of California, Davis
, , ,	Medical University of South Carolina
	Omneuron, Inc.
	University of Arkansas for Medical Sciences
	University of Utah
	Texas Tech University Health Sciences Center
	Los Alamos National Laboratory
	Northwestern University
Swartz, Harold M., M.D., Ph.D	Dartmouth College

Sweasy, Joann B., Ph.D.	University of Washington
Swinnen, Lode, M.D.	Johns Hopkins University
Syeda-Mahmood, Tanveer F., Ph.D.	IBM Research, Almaden
Synold, Timothy W., Pharm.D.	City of Hope National Medical Center

T

Tackett, Alan J., Ph.D	University of Arkansas for Medical Sciences
	University of Michigan
Taioli, Emanuela, M.D., Ph.D	Icahn School of Medicine at Mount Sinai
	Brigham and Women's Hospital
Tan, Ming, M.D., Ph.D.	University of South Alabama
Tan, Ming T., Ph.D.	Georgetown University
Tang, Keqi, Ph.D	Pacific Northwest National Laboratory
Tanjasiri, Sora P., M.P.H	California State University, Fullerton
Tannenbaum, Charles S., Ph.D	Cleveland Clinic Lerner College of Medicine
	of Case Western Reserve University
Tannous, Bakhos A., Ph.D	Massachusetts General Hospital
Tautz, Lutz, Ph.D	Sanford Burnham Prebys Medical Discovery Institute
Taxman, Faye S., Ph.D	George Mason University
Taylor, Jeremy M.G., Ph.D.	University of Michigan
Tearney, Guillermo J., M.D., Ph.D	Massachusetts General Hospital
Tekmal, Rajeshwar R., Ph.D Th	e University of Texas Health Science Center at San Antonio
Telleria, Carlos M., Ph.D	University of South Dakota
Tempst, Paul, Ph.D.	Memorial Sloan Kettering Cancer Center
Ten Haken, Randall K., Ph.D	University of Michigan
Terrazas, Alejandro, Ph.D	Nielsen Engineering and Research, Inc.
Terry, Mary B., Ph.D.	Columbia University Medical Center
Teter, Kenneth R., Ph.D	University of Colorado Denver
Tew, Kenneth D., D.Sc., Ph.D	Medical University of South Carolina
Tewari, Muneesh, M.D., Ph.D	University of Michigan
Thaler, Joshua P., M.D., Ph.D	University of Washington
Thangaraju, Muthusamy, Ph.D	Georgia Health Sciences University
Thiagalingam, Sam, Ph.D	Boston University Medical Campus
Thomas, David B., M.D	Fred Hutchinson Cancer Research Center
Thomas, Douglas D., Ph.D.	University of Illinois at Chicago
Thomas-Tikhonenko, Andrei, Ph.D	Children's Hospital of Philadelphia
	Case Western Reserve University
Thompson-Carino, Patricia A., Ph.D.	Stony Brook University School of Medicine
Thorburn, Andrew M., Ph.D	University of Colorado Denver
Thorne, Leigh B., M.D.	The University of North Carolina at Chapel Hill
Threadgill, David W., Ph.D	Texas A&M University Health Science Center
Tilley, Barbara C., Ph.D.	The University of Texas Health Science Center at Houston
	University of Michigan
Toker, Alex, Ph.D	Beth Israel Deaconess Medical Center
	South Texas Accelerated Research Therapeutics
	University of Florida
Tomlin, Claire J., Ph.D	Stanford University

Tomlinson, Gail E., M.D., Ph.D The U	Jniversity of Texas Health Science Center at Houston
	New York University School of Medicine
Towner, Rheal A., Ph.D	Oklahoma Medical Research Foundation
	Johns Hopkins University
	University of Rochester
	Children's Hospital of Los Angeles
	University of Massachusetts, Amherst
Trojanowska, Maria T., Ph.D	Boston University Medical Campus
	The University of North Carolina at Chapel Hill
Trudeau, Kimberlee J., Ph.D	Inflexxion, Inc.
True, Lawrence D., M.D	University of Washington
Tumiel-Berhalter, Laurene M., Ph.D	The State University of New York at Buffalo
Turchi, John J., Ph.D	Indiana University
Turker, Mitchell S., Ph.D	Oregon Health & Science University
Turner, Jessica, Ph.D	Georgia State University
	Pacific Biosciences of California, Inc.
	University of Michigan
	University of Illinois at Chicago
Tyner, Jeffrey W., Ph.D	Oregon Health & Science University
Tyson, John J., Ph.D	Virginia Polytechnic Institute and State University

V

Vadaparampil, Susan T., Ph.D., M.P.H	I H. Lee Moffitt Cancer Center & Research Institute
Vadlamudi, Ratna K., Ph.D	The University of Texas Health Science Center at Houston
Valenzuela, Manuel S., Ph.D	Meharry Medical College
Van Besien, Koen W., M.D., Ph.D	Weill Cornell Medical College of Cornell University
Van Breemen, Richard B., Ph.D	University of Illinois at Chicago
Vanderah, Todd W., Ph.D	
Vanderheyden, Jean-Luc E., Ph.D	JLVMI Consulting
Van Meir, Erwin G., Ph.D.	Emory University
Vannier, Michael W., M.D	The University of Chicago
Varghese, Sheelu, Ph.D	University of Maryland, Baltimore
Varki, Nissi M., M.D.	University of California, San Diego
Vaughan, Andrew T., Ph.D	University of California, Davis
Vaughan, Thomas L., M.D., M.P.H	Fred Hutchinson Cancer Research Center
	University of California, San Francisco
	University of California, San Diego
Verardi, Paulo H., Ph.D	University of Connecticut
Verbridge, Scott S., Ph.D	Virginia Polytechnic Institute and State University
Verma, Amit, M.D.	Albert Einstein College of Medicine of Yeshiva University
Vernon, Sally W., Ph.D.	The University of Texas Health Science Center at Houston
Verschraegen, Claire F., M.D	The University of Vermont and State Agricultural College
Vessella, Robert L., Ph.D	University of Washington
Viator, John A., Ph.D.	Duquesne University
Vile, Richard G., Ph.D.	Mayo Clinic
Villinger, Francois J., Ph.D	Emory University
Vogel, Carl-Wilhelm E., M.D., Ph.D.	University of Hawaii at Manoa

Volk, Robert J., Ph.D.	. The University of Texas MD Anderson Cancer Center
von Gunten, Charles F., M.D., Ph.D	OhioHealth Research Institute
Von Roenn, Jamie H., M.D.	American Society of Clinical Oncology

W

Wachsman, William, M.D., Ph.D.	University of California, San Diego
Wagner, David H., Ph.D	University of Colorado Denver
Wagner, Kay-Uwe, Ph.D	University of Nebraska Medical Center
	Johns Hopkins University
Walker, Joan L., M.D	University of Oklahoma Health Sciences Center
Waller, Edmund K., M.D., Ph.D	Emory University
Walton, S. Patrick., Sc.D.	
Wan, Yu-Jui Y., Ph.D	University of California, Davis
Wang, Chun, Ph.D.	University of Minnesota
	SRI International
Wang, Edwin, Ph.D	National Research Council Canada
Wang, Hong-Gang, Ph.D	Penn State Milton S. Hershey Medical Center
Wang, Judy H., Ph.D	Georgetown University
Wang, Kenneth K., M.D	
Wang, Liang, Ph.D	Medical College of Wisconsin
Wang, Lisa L., M.D	Baylor College of Medicine
Wang, Qiming J., Ph.D	University of Pittsburgh
Wang, Rong, Ph.D.	Illinois Institute of Technology
Wang, Shaopeng, Ph.D	Arizona State University, Tempe
Wang, Sophia S., Ph.D.	City of Hope National Medical Center
Wang, Tian-Li, Ph.D.	Johns Hopkins University
Wang, Tza-Huei, Ph.D	Johns Hopkins University
Wang, Xiao-Fan, Ph.D.	Duke University
Wang, Yingxiao, Ph.D	University of California, San Diego
	Case Western Reserve University
	The University of North Carolina at Chapel Hill
	University of Utah
	Sanford Burnham Prebys Medical Discovery Institute
Warren, Christopher L., Ph.D	Florida International University
Warren, Graham W., M.D., Ph.D	Medical University of South Carolina
Washington, Mary K., M.D., Ph.D	
, , ,	University of Pennsylvania
Watkins, Stephanie K., Ph.D	Loyola University, Chicago
Watson, Dennis K., Ph.D	Medical University of South Carolina
Wattenberg, Brian W., Ph.D	University of Louisville
Webb, Tonya J., Ph.D	University of Maryland, Baltimore
Weber, Michael J., Ph.D.	University of Virginia
	Imiplex, LLC
, , , ,	University of Colorado Denver
	Purdue University
Weidhaas, Joanne B., M.D., Ph.D	University of California, Los Angeles

Weier Heinz Ulrich C. Ph D	Lawrence Berkeley National Laboratory
	Life Beyond Cancer Foundation
	Georgetown University
· · · ·	
· · · · ·	University of Virginia
	University of California, Irvine
	University of Kentucky
	University of Miami Miller School of Medicine
	University of California, San Francisco
	University of Kansas Medical Center
, , ,	University of Pittsburgh
· · ·	University of Colorado Denver
, , ,	Public Health Institute
	Stanford University
	Roswell Park Cancer Institute
	The University of North Carolina at Chapel Hill
	Johns Hopkins University
Wheeler, Barbara L., Ph.D	Molloy College
, , ,	Massachusetts Institute of Technology
deVere White, Ralph W., M.D	University of California, Davis
White, Richard M., M.D., Ph.D	Memorial Sloan Kettering Cancer Center
	University of Pittsburgh
Whitley, Richard J., M.D.	The University of Alabama at Birmingham
Whitt, Michael A., Ph.D	The University of Tennessee Health Science Center
Whittemore, Alice, Ph.D	Stanford University
Wieder, Robert, M.D., Ph.D	Rutgers, The State University of New Jersey
Wigdahl, Brian, Ph.D.	Drexel University College of Medicine
	Duke University
Willett, Walter C., M.D., M.P.H	Harvard School of Public Health
	University of Toledo Medical Center
Williams, David A., M.D.	Children's Hospital Corporation
	isiana State University Health Sciences Center, New Orleans
	City of Hope National Medical Center
Williams, Scott M., Ph.D	Dartmouth College
	Virginia Commonwealth University
	University of Kansas Medical Center
· · ·	University of Toronto
Wilson, James N., Ph.D.	University of Miami Miller School of Medicine
	Virginia Commonwealth University
<u> </u>	······································

Winter, Stuart S., M.D.	The University of New Mexico
Wish, Eric D., Ph.D.	University of Maryland, College Park
Wisnivesky, Juan P., M.D., M.P.H	Icahn School of Medicine at Mount Sinai
Wolf, Wendy A., Ph.D.	Children's Hospital Corporation
Wollenweber, Scott D., Ph.D	Wake Forest University Health Sciences &
	Baptist Medical Center
Woloschak, Gayle E., Ph.D.	Northwestern University
Wondrak, Georg T., Ph.D.	The University of Arizona
Wong, David T., D.M.D., D.M.Sc	University of California, Los Angeles
Wong, Lee-Jun C., Ph.D.	Baylor College of Medicine
Wong, Lucas, M.D.	Scott and White Memorial Hospital
	Memorial Sloan Kettering Cancer Center
Wood, Marie E., M.D.	. The University of Vermont and State Agricultural College
Woods, Erik J., Ph.D.	General Biotechnology, LLC
	Children's Healthcare of Atlanta, Inc.
Woodward, Wendy A., M.D., Ph.D	The University of Texas MD Anderson Cancer Center
Worsham, Maria J., Ph.D.	Henry Ford Health System
Woster, Patrick M., Ph.D.	Medical University of South Carolina
Wright, Dennis L., Ph.D.	University of Connecticut, Storrs
Wu, Catherine J., M.D.	Dana-Farber Cancer Institute
Wu, Dianqing, Ph.D.	Yale University
Wu, Gen S., Ph.D.	Wayne State University
Wu, Guojun, Ph.D.	Wayne State University
Wu, Jennifer D., Ph.D.	Medical University of South Carolina
Wu, Mingming, Ph.D.	Cornell University
Wu, Thomas D., M.D., Ph.D.	Genentech, Inc.
	Johns Hopkins University
Wu, Xifeng, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Wyatt, Michael D., Ph.D.	University of South Carolina

X

Xi, Yaguang, M.D., Ph.D.	University of South Alabama
Xiao, Gutian, Ph.D.	University of Pittsburgh
Xiao, Hua, M.D., Ph.D	Michigan State University
Xie, Jingwu, Ph.D.	Indiana University–Purdue University, Indianapolis
Xie, Keping, M.D., Ph.D.	The University of Texas MD Anderson Cancer Center
Xu, Dong, Ph.D.	University of Missouri
Xu, Liang, M.D., Ph.D.	University of Kansas
Xu, Xiangxi M., Ph.D.	University of Miami Miller School of Medicine
Xu, Xiaowei, M.D., Ph.D	University of Pennsylvania
Xu, Yan, Ph.D	Indiana University–Purdue University, Indianapolis
Xuan, Jason J., Ph.D.	Virginia Polytechnic Institute and State University

Y

Yamamoto, Masato, M.D., Ph.D.	University of Minnesota
Yamashiro, Darrell J., M.D., Ph.D	Columbia University Health Sciences Campus

· · ·	University of Michigan
, , ,	
	Virginia Commonwealth University
	University of Illinois at Chicago
	Bayessoft, Inc.
, , ,	University of Kentucky
Ybarra, Michele, Ph.D., M.P.H.	Center for Innovative Public Health Research
, 0 ,	University of Minnesota
Yeh, Jen J., M.D.	
Yen, Yun, M.D., Ph.D	City of Hope National Medical Center
Yeo, Yoon, Ph.D.	Purdue University
Yeudall, William A., Ph.D	Virginia Commonwealth University
Yi, Qing, M.D., Ph.D	Cleveland Clinic Lerner College of Medicine
	of Case Western Reserve University
Yi, Richard, Ph.D	
	University of Southern California
Yothers, Greg, Ph.D.	
Young, Damian W., Ph.D.	
	Childhood Brain Tumor Foundation
0, ,	University of Maryland, Baltimore
	Icahn School of Medicine at Mount Sinai
	Auburn University at Auburn
, , ,	
,	The University of Texas Health Science Center at San Antonio
	Emory University
ran, changnyon c., r n.D	Linory Oniversity

Z

Zacharias, Wolfgang, Ph.D.	University of Louisville
Zahrbock, Cary A.C., M.S.W.	National Coalition for Cancer Survivorship
Zaia, John A., M.D.	City of Hope National Medical Center
Zaia, Joseph, Ph.D.	Boston University Medical Campus
Zarbl, Helmut, Ph.D	Rutgers Biomedical and Health Sciences
Zaren, Howard A., M.D.	St. Joseph's/Candler Health System, Inc.
Zarour, Hassane M., M.D.	University of Pittsburgh
Zehnder, James L., M.D.	Stanford University
Zeleniuch-Jacquotte, Anne, M.D	New York University School of Medicine
Zeleznik-Le, Nancy J., Ph.D.	Loyola University, Chicago
Zhang, David Y., M.D., Ph.D., M.P.H.	Icahn School of Medicine at Mount Sinai
Zhang, Donna D., Ph.D	The University of Arizona
Zhang, Huang-Ge, D.V.M., M.D., Ph.D	The University of Alabama at Birmingham
Zhang, Hui, Ph.D.	Johns Hopkins University
Zhang, Lin, M.D.	University of Pennsylvania

Zhang, Ming, Ph.D	Zhang, Lin, Ph.D	University of Pittsburgh
Zhang, Xiao-Kun, Ph.D. Krex Pharmaceuticals, Inc. Zhang, Xiaoliu, M.D., Ph.D. University of Houston Zhang, Zhiguo, Ph.D. Indiana University–Purdue University, Indianapolis Zhao, Dawen, M.D., Ph.D. The University of Texas Southwestern Medical Center at Dallas Zhao, Ming, Ph.D. The University of Texas Southwestern Medical Center at Dallas Zhao, Ming, Ph.D. The University of Texas Southwestern Medical Center at Dallas Zhao, Shaying, Ph.D. The University of Texas Southwestern University Zhao, Shaying, Ph.D. The University of Georgia Zheng, Bin, Ph.D. The University of Oklahoma Zheng, Gang, Ph.D. Valle University of Oklahoma Zheng, Gang, Ph.D. Yale University Zheng, Wei, M.D., Ph.D., M.P.H. Vanderbilt University Zheng, Xiaofeng S, Ph.D. Rutgers Biomedical and Health Sciences Zhou, Jin-Rong, Ph.D. Beth Israel Deaconess Medical Center Zhou, Pengbo, Ph.D. Weill Cornell Medical College of Cornell University Zhu, Shu-Hong, Ph.D. University of California, San Diego Zhu, Weimo, Ph.D. Case Western Reserve University Zhu, Shu-Hong, Ph.D. Case Western Reserve University Zhu, Xiaofeng, Ph.D. Indiana University of California, San Diego Zhu, Weing, Ph.D. Yale University Zhu, Xiaofeng, Ph.D. Valle University Zhu, Xiaofeng, Ph.D. Yale University Zhu, Yong, Ph.D. Yale University Zhu, Yong, Ph.D. Indiana University-Purdue University Zhu, Yong, Ph.D. University of California, Irvine Zong, Wei-Xing, Ph.D. The State University of New York at Stony Brook Zou, Weiping, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan		
Zhang, Xiao-Kun, Ph.D. Krex Pharmaceuticals, Inc. Zhang, Xiaoliu, M.D., Ph.D. University of Houston Zhang, Zhiguo, Ph.D. Indiana University–Purdue University, Indianapolis Zhao, Dawen, M.D., Ph.D. The University of Texas Southwestern Medical Center at Dallas Zhao, Ming, Ph.D. The University of Texas Southwestern Medical Center at Dallas Zhao, Ming, Ph.D. The University of Texas Southwestern Medical Center at Dallas Zhao, Shaying, Ph.D. The University of Texas Southwestern University Zhao, Shaying, Ph.D. The University of Georgia Zheng, Bin, Ph.D. The University of Oklahoma Zheng, Gang, Ph.D. Valle University of Oklahoma Zheng, Gang, Ph.D. Yale University Zheng, Wei, M.D., Ph.D., M.P.H. Vanderbilt University Zheng, Xiaofeng S, Ph.D. Rutgers Biomedical and Health Sciences Zhou, Jin-Rong, Ph.D. Beth Israel Deaconess Medical Center Zhou, Pengbo, Ph.D. Weill Cornell Medical College of Cornell University Zhu, Shu-Hong, Ph.D. University of California, San Diego Zhu, Weimo, Ph.D. Case Western Reserve University Zhu, Shu-Hong, Ph.D. Case Western Reserve University Zhu, Xiaofeng, Ph.D. Indiana University of California, San Diego Zhu, Weing, Ph.D. Yale University Zhu, Xiaofeng, Ph.D. Valle University Zhu, Xiaofeng, Ph.D. Yale University Zhu, Yong, Ph.D. Yale University Zhu, Yong, Ph.D. Indiana University-Purdue University Zhu, Yong, Ph.D. University of California, Irvine Zong, Wei-Xing, Ph.D. The State University of New York at Stony Brook Zou, Weiping, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The State University of Michigan	Zhang, Ruiwen, M.D., Ph.D.	Texas Tech University Health Sciences Center
Zhang, Xiaoliu, M.D., Ph.D. University of Houston Zhang, Zhiguo, Ph.D. Mayo Clinic Zhang, Zhong-Yin, Ph.D. Indiana University–Purdue University, Indianapolis Zhao, Dawen, M.D., Ph.D. The University of Texas Southwestern Medical Center at Dallas Zhao, Ming, Ph.D. Northwestern University Zhao, Shaying, Ph.D. Northwestern University Zhao, Shaying, Ph.D. The University of Georgia Zheng, Bin, Ph.D. The University of Georgia Zheng, Gang, Ph.D. The University Health Network Zheng, Tonzzhang, M.D. Yale University Zheng, Wei, M.D., Ph.D., M.P.H. Vanderbilt University Zheng, Xiaofeng S., Ph.D. Rutgers Biomedical and Health Sciences Zhou, Jin-Rong, Ph.D. Beth Israel Deaconess Medical Center Zhou, Pengbo, Ph.D. Weill Cornell Medical College of Cornell University Zhu, Liang, M.D., Ph.D. Albert Einstein College of Medicine of Yeshiva University Zhu, Shu-Hong, Ph.D. University of Illinois at Urbana-Champaign Zhu, Weino, Ph.D. Case Western Reserve University Zhu, Xiaofeng, Ph.D. Case Western Reserve University Zhu, Yong, Ph.D. Indiana University-Purdue University Zhu, Zongjian, M.D., Ph.D. Indiana University-Purdue University Zhu, Zongjian, M.D., Ph.D. The State University of California, Irvine Zondo, Neal J., Ph.D. The State University of New York at Stony Brook Zou, Weiping, M.D., Ph.D. The State University of New York at Stony Brook		
Zhang, Zhong-Yin, Ph.D. Indiana University-Purdue University, Indianapolis Zhao, Dawen, M.D., Ph.D. The University of Texas Southwestern Medical Center at Dallas Zhao, Ming, Ph.D. Northwestern University Zhao, Shaying, Ph.D. The University of Georgia Zheng, Bin, Ph.D. The University of Oklahoma Zheng, Gang, Ph.D. The University Health Network Zheng, Tongzhang, M.D. Yale University Health Network Zheng, N.D., Ph.D., M.P.H. Vanderbilt University Zhao, Siaofeng S., Ph.D. Beth Israel Deaconess Medical Center Zhou, Jin-Rong, Ph.D. Weill Cornell Medical College of Cornell University Zhu, Jin-Rong, Ph.D. Albert Einstein College of Medicine of Yeshiva University Zhu, Shu-Hong, Ph.D. University of Claifornia, San Diego Zhu, Weimo, Ph.D. Case Western Reserve University Zhu, Xiaofeng, Ph.D. Case Western Reserve University Zhu, Ziaofeng, Ph.D. Indiana University-Purdue University Zhu, Zongjian, M.D., Ph.D. Indiana University-Purdue University Iduiversity Zhu, Zongjian, M.D., Ph.D. Indiana University-Purdue University Idianapolis Zlotnik, Albert, Ph.D. University of California, Irvine Zondlo, Neal J., Ph.D. The State University of New York at Stony Brook Zou, Weiping, M.D., Ph.D. The State University of Meixing, Ph.D. University of Meixing, Ph.D. Indiana University of New York at Stony Brook Zou, Weiping, M.D., Ph.D. The State University of Michigan Zu, Youli, M.D., Ph.D. The Methodist Hospital Research Institute	Zhang, Xiaoliu, M.D., Ph.D.	
Zhao, Dawen, M.D., Ph.D The University of Texas Southwestern Medical Center at Dallas Zhao, Ming, Ph.D	Zhang, Zhiguo, Ph.D.	
Zhao, Ming, Ph.D	Zhang, Zhong-Yin, Ph.D.	Indiana University–Purdue University, Indianapolis
Zhao, Ming, Ph.D	Zhao, Dawen, M.D., Ph.D	The University of Texas Southwestern Medical Center at Dallas
Zheng, Bin, Ph.D		
Zheng, Gang, Ph.D.University Health NetworkZheng, Gang, Ph.D.Yale UniversityZheng, Wei, M.D., Ph.D., M.P.H.Naderbilt UniversityZheng, Xiaofeng S., Ph.D.Rutgers Biomedical and Health SciencesZhou, Jin-Rong, Ph.D.Beth Israel Deaconess Medical CenterZhou, Jin-Rong, Ph.D.Weill Cornell Medical College of Cornell UniversityZhu, Liang, M.D., Ph.D.Albert Einstein College of Medicine of Yeshiva UniversityZhu, Shu-Hong, Ph.D.University of California, San DiegoZhu, Weimo, Ph.D.University of Illinois at Urbana-ChampaignZhu, Wenge, Ph.D.Case Western Reserve UniversityZhu, Xiaofeng, Ph.D.Cale UniversityZhu, Yong, Ph.D.Indiana University-Purdue UniversityZhu, Zongjian, M.D., Ph.D.Indiana University-Purdue University, IndianapolisZlotnik, Albert, Ph.D.The State University of New York at Stony BrookZou, Weiping, M.D., Ph.D.The Methodist Hospital Research Institute	Zhao, Shaying, Ph.D.	
Zheng, Tongzhang, M.D.Yale UniversityZheng, Wei, M.D., Ph.D., M.P.H.Vanderbilt UniversityZheng, Xiaofeng S., Ph.D.Rutgers Biomedical and Health SciencesZhou, Jin-Rong, Ph.D.Beth Israel Deaconess Medical CenterZhou, Pengbo, Ph.D.Weill Cornell Medical College of Cornell UniversityZhu, Liang, M.D., Ph.D.Albert Einstein College of Medicine of Yeshiva UniversityZhu, Shu-Hong, Ph.D.University of California, San DiegoZhu, Weimo, Ph.D.University of Illinois at Urbana-ChampaignZhu, Weing, Ph.D.Case Western Reserve UniversityZhu, Xiaofeng, Ph.D.Cale UniversityZhu, Yong, Ph.D.Indiana University-Purdue UniversityZhu, Zongjian, M.D., Ph.D.Indiana University-Purdue University, IndianapolisZlotnik, Albert, Ph.D.Indiana University of New York at Stony BrookZou, Weiping, M.D., Ph.D.The State University of New York at Stony BrookZou, Weiping, M.D., Ph.D.The Methodist Hospital Research Institute	Zheng, Bin, Ph.D.	The University of Oklahoma
Zheng, Wei, M.D., Ph.D., M.P.H	Zheng, Gang, Ph.D.	University Health Network
Zheng, Xiaofeng S., Ph.D.Rutgers Biomedical and Health SciencesZhou, Jin-Rong, Ph.D.Beth Israel Deaconess Medical CenterZhou, Pengbo, Ph.D.Weill Cornell Medical College of Cornell UniversityZhu, Liang, M.D., Ph.D.Albert Einstein College of Medicine of Yeshiva UniversityZhu, Shu-Hong, Ph.D.University of California, San DiegoZhu, Weimo, Ph.D.University of Illinois at Urbana-ChampaignZhu, Weing, Ph.D.Case Western Reserve UniversityZhu, Yong, Ph.D.Case Western Reserve UniversityZhu, Yong, Ph.D.Yale UniversityZhu, Yong, Ph.D.Indiana University-Purdue University, IndianapolisZlotnik, Albert, Ph.D.University of California, IrvineZondlo, Neal J., Ph.D.The State University of New York at Stony BrookZou, Weiping, M.D., Ph.D.The Methodist Hospital Research Institute	Zheng, Tongzhang, M.D	
Zhou, Jin-Rong, Ph.D	Zheng, Wei, M.D., Ph.D., M.P.H.	
Zhou, Pengbo, Ph.D	Zheng, Xiaofeng S., Ph.D	Rutgers Biomedical and Health Sciences
Zhu, Liang, M.D., Ph.D.Albert Einstein College of Medicine of Yeshiva UniversityZhu, Shu-Hong, Ph.D.University of California, San DiegoZhu, Weimo, Ph.D.University of Illinois at Urbana-ChampaignZhu, Wenge, Ph.D.George Washington UniversityZhu, Xiaofeng, Ph.D.Case Western Reserve UniversityZhu, Yong, Ph.D.Case Western Reserve UniversityZhu, Zongjian, M.D., Ph.D.Indiana University-Purdue University, IndianapolisZlotnik, Albert, Ph.D.Indiana University of California, IrvineZondlo, Neal J., Ph.D.The State University of New York at Stony BrookZou, Weiping, M.D., Ph.D.The Methodist Hospital Research Institute		
Zhu, Shu-Hong, Ph.D	Zhou, Pengbo, Ph.D	Weill Cornell Medical College of Cornell University
Zhu, Weimo, Ph.D	Zhu, Liang, M.D., Ph.D	Albert Einstein College of Medicine of Yeshiva University
Zhu, Wenge, Ph.D	Zhu, Shu-Hong, Ph.D	University of California, San Diego
Zhu, Xiaofeng, Ph.D.Case Western Reserve UniversityZhu, Yong, Ph.D.Yale UniversityZhu, Zongjian, M.D., Ph.D.Colorado State UniversityZimmers, Teresa A., Ph.D.Indiana University–Purdue University, IndianapolisZlotnik, Albert, Ph.D.Indiana University of California, IrvineZondlo, Neal J., Ph.D.The State University of New York at Stony BrookZou, Weiping, M.D., Ph.D.The State University of MichiganZu, Youli, M.D., Ph.D.The Methodist Hospital Research Institute	Zhu, Weimo, Ph.D	University of Illinois at Urbana-Champaign
Zhu, Yong, Ph.D	Zhu, Wenge, Ph.D	George Washington University
Zhu, Zongjian, M.D., Ph.D	Zhu, Xiaofeng, Ph.D	Case Western Reserve University
Zimmers, Teresa A., Ph.D Indiana University–Purdue University, Indianapolis Zlotnik, Albert, Ph.D		
Zlotnik, Albert, Ph.DUniversity of California, Irvine Zondlo, Neal J., Ph.DUniversity of Delaware Zong, Wei-Xing, Ph.D		
Zondlo, Neal J., Ph.DUniversity of Delaware Zong, Wei-Xing, Ph.D	, , ,	5 5, 1
Zong, Wei-Xing, Ph.D The State University of New York at Stony Brook Zou, Weiping, M.D., Ph.D University of Michigan Zu, Youli, M.D., Ph.D The Methodist Hospital Research Institute	, , ,	5 ,
Zou, Weiping, M.D., Ph.DUniversity of Michigan Zu, Youli, M.D., Ph.D		
Zu, Youli, M.D., Ph.D The Methodist Hospital Research Institute	e, e,	
, , , , , 1	1 0	
Zuna, Rosemary E., M.D University of Oklahoma Health Sciences Center	, , , ,	1
	Zuna, Rosemary E., M.D	University of Oklahoma Health Sciences Center

Total Number of Reviewers: 2,098

Appendix E: NCI Grant Mechanisms and Descriptions

Below is a brief description of different NIH funding mechanisms. Additional information on grants, contracts, and extramural policy notices may be

found by viewing the NCI DEA Web page on Grants Guidelines and Descriptions at http:// deainfo.nci.nih.gov/flash/awards.htm.

C Ser	ies: Research Construction Programs
C06	Research Facilities Construction Grants To provide matching Federal funds, up to 75 percent, for construction or major remodeling to create new research facilities, which in addition to basic research laboratories may include, under certain circumstances, animal facilities and/or limited clinical facilities where they are an integral part of an overall research effort.
D Ser	ies: Institutional Training and Director Program Projects
D43	International Training Grants in Epidemiology To improve and expand epidemiologic research and the utilization of epidemiology in clinical trials and prevention research in foreign countries through support of training programs for foreign health professionals, technicians, and other health care workers.
DP1	NIH Director's Pioneer Award (NDPA) To support individuals who have the potential to make extraordinary contributions to medical research. The NIH Director's Pioneer Award is not renewable.
DP2	NIH Director's New Innovator Awards To support highly innovative research projects by new investigators in all areas of biomedical and behavioral research.
F Ser	ies: Fellowship Programs
F30	Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral M.D./ Ph.D. Degree Fellows To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward a research degree (e.g., Ph.D.).
F31	Ruth L. Kirschstein National Research Service Award for Predoctoral Individuals To provide predoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
F32	Ruth L. Kirschstein National Research Service Award for Individual Postdoctoral Fellows To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
F33	Ruth L. Kirschstein National Research Service Award for Senior Fellows To provide opportunities for experienced scientists to make major changes in the direction of research careers, broaden scientific backgrounds, acquire new research capabilities, enlarge command of an allied research field, or take time from regular professional responsibilities to increase capabilities to engage in health-related research.

K Seri	es: Career Development Programs
K01	The Howard Temin Award (no longer supported through use of the K01 by the NCI; see the K99/R00)
	A previously used NCI-specific variant of the NIH Mentored Research Scientist Development Award that was designed to provide research scientists with an additional period of sponsored research experience as a way to gain expertise in a research area new to the applicant or in an area that would demonstrably enhance the applicant's scientific career.
K01	Mentored Career Development Award for Underrepresented Minorities To support scientists committed to research who are in need of both advanced research train- ing and additional experience.
K05	Established Investigator Award in Cancer Prevention, Control, Behavioral, and Population
	Research To support scientists qualified to pursue independent research that would extend the research program of the sponsoring institution, or to direct an essential part of this program.
K07	Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award To support the postdoctoral career development of investigators who are committed to aca- demic research careers in cancer prevention, control, behavioral, epidemiological, and/or the population sciences. It supports up to 5 years of combined didactic and supervised (i.e., mentored) research experiences to acquire the methodological and theoretical research skills needed to become an independent scientist. The very broad nature of the prevention, con- trol, and population sciences makes it applicable to those individuals doctorally trained in the basic sciences, medicine, behavioral sciences, and/or public health. The K07 award has been expanded from a scope limited to "preventive oncology" to include the entire spectrum of fields that are of vital importance to cancer prevention and control such as nutrition, epide- miology, and behavioral sciences.
K08	Mentored Clinical Scientists Development Award To provide the opportunity for promising medical scientists with demonstrated aptitude to develop into independent investigators, or for faculty members to pursue research in categor- ical areas applicable to the awarding unit, and to aid in filling the academic faculty gap in specific shortage areas within U.S. health professions institutions.
K08	Mentored Clinical Scientists Development Award—Minorities in Clinical Oncology A specialized type of Mentored Clinical Scientist Developmental Award (K08) that supports the development of outstanding clinical research scientists, with this type being reserved for qualified individuals from underrepresented minority groups. Both types of K08 awards support periods of specialized study for clinically trained professionals who are committed to careers in research and who have the potential to develop into independent investigators. The K08 awards for Minorities in Clinical Oncology are distinct and important because they pro- vide opportunities for promising medical scientists with demonstrated aptitudes who belong to underrepresented minority groups to develop into independent investigators, or for faculty members who belong to underrepresented minority groups to pursue research aspects of cate- gorical areas applicable to the awarding unit(s), and aid in filling the academic faculty gaps in these shortage areas within U.S. health professions institutions.

K12	Institutional Clinical Oncology Research Career Development Award To support a newly trained clinician appointed by an institution for development of independent research skills and experience in a fundamental science within the framework of an interdisciplinary research and development program.
K18	The Career Enhancement Award Provides either full-time or part-time support for experienced scientists who would like to broaden their scientific capabilities or to make changes in their research careers by acquiring new research skills or knowledge. Career enhancement experiences supported by this award should usually last no more than 1 year.
K22	The NCI Transition Career Development Award for Underrepresented Minorities To provide support to outstanding newly trained basic or clinical investigators to develop their independent research skills through a two-phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. The award is intended to facilitate the establishment of a record of independent research by the investigator to sustain or promote a successful research career.
K22	The NCI Scholars Program To provide an opportunity for outstanding new investigators to begin their independent research careers, first within the special environment of the NCI and then at an institution of their choice. Specifically, this program provides necessary resources to initiate an independent research program of 3 to 4 years at the NCI, followed by an extramural funding mechanism (K22) to support their research program for 2 years at the extramural institution to which they are recruited.
K23	Mentored Patient-Oriented Research Career Development Award To provide support for the career development of investigators who have made a commit- ment to focus their research endeavors on patient-oriented research. This mechanism pro- vides support for a 3-year minimum up to a 5-year period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators.
K23	Mentored Patient-Oriented Research Career Development Award for Underrepresented Minorities To support the career development of investigators who have made a commitment to focus their research on patient-oriented research. This mechanism provides support for a period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators in patient-oriented research.
K24	Mid-Career Investigator Award in Patient-Oriented Research To provide support for clinicians to allow them protected time to devote to patient-oriented research and to act as mentors for beginning clinical investigators. The target candidates are outstanding clinical scientists engaged in patient-oriented research who are within 15 years of their specialty training, who can demonstrate the need for a period of intensive research focus as a means of enhancing their clinical research careers, and who are committed to mentoring the next generation of clinical investigators in patient-oriented research.

K25	Mentored Quantitative Research Career Development Award This award allows an independent scientist in a highly technical field of research to identify an appropriate mentor with extensive experience in cancer research and to receive the neces- sary training and career development required to become involved in multidisciplinary cancer
K99/ R00	research. NIH Pathway to Independence (PI) Award The Pathway to Independence Award, which is part of the NIH Roadmap Initiative but is known as the Howard Temin Award within the NCI, will provide up to 5 years of support consisting of two phases. The initial phase will provide 1 to 2 years of mentored support for highly promising postdoctoral research scientists. This phase will be followed by up to 3 years of independent support contingent on securing an independent research position. Award recipients will be expected to compete successfully for independent R01 support from the NIH during the career transition award period. The PI Award is limited to postdoctoral trainees within 5 years of completion of their training who propose research relevant to the mission of one or more of the participating NIH Institutes and Centers.
L Seri	ies: Loan Repayment Program
L30	Loan Repayment Program for Clinical Researchers To provide for the repayment of the educational loan debt of qualified health professionals involved in clinical research. Qualified health professionals who contractually agree to conduct qualified clinical research are eligible to apply for this program.
L32	Loan Repayment Program for Clinical Researchers From Disadvantaged Backgrounds To provide for the repayment of the educational loan debt of qualified health professionals from disadvantaged backgrounds involved in clinical research. Qualified health professionals from disadvantaged backgrounds who contractually agree to conduct qualified clinical research are eligible to apply for this program.
L40	Loan Repayment Program for Pediatric Research To provide for the repayment of the educational loan debt of qualified health professionals involved in research directly related to diseases, disorders, and other conditions in children. Qualified health professionals who contractually agree to conduct qualified pediatric research are eligible to apply for this program. (See the NIH Guidelines about Loan Repayment at http://www.lrp.nih.gov/index.aspx.)
L50	Loan Repayment Program for Contraception and Infertility Research To provide for the repayment of the educational loan debt of qualified health professionals (including graduate students) who contractually agree to commit to conduct qualified contra- ception and/or infertility research.
L60	Loan Repayment Program for Health Disparities Research To provide for the repayment of the educational loan debt of qualified health professionals involved in minority health and health disparities research, for the purposes of improving minority health and reducing health disparities. Qualified health professionals who contractually agree to conduct qualified minority health disparities research or other health disparities research are eligible to apply for this program.

P Ser	ies: Research Program Projects and Centers
P01	Research Program Projects To support multidisciplinary or multifaceted research programs that have a focused theme. Each component project should be directly related to and contribute to the common theme.
P20	Exploratory Grants To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.
P30	Center Core Grants To support shared use of resources and facilities for categorical research by investigators from different disciplines who provide a multidisciplinary approach to a joint research effort, or by investigators from the same discipline who focus on a common research problem. The core grant is integrated with the Center's component projects or Program Projects, though funded independently from them. By providing more accessible resources, this support is expected to ensure greater productivity than that provided through the separate projects and Program Projects.
P41	Biotechnology Resource Grants To support biotechnology resources available to all qualified investigators without regard to the scientific disciplines or disease orientations of their research activities or specifically directed to a categorical program area.
P50	Specialized Center Grants To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. This spectrum of activities comprises a multidisciplinary attack on a specific disease or biomedical problem area. These grants differ from Program Project grants in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division, and subsequently receive continuous attention from its staff. Centers also may serve as regional or national resources for special research purposes.

R Ser	R Series: Research Projects		
R01	Research Project Grants are awarded to institutions to allow a Principal Investigator to pursue a scientific focus or objective in his or her area of interest and competence. Institutional sponsorship assures the NIH that the institution will provide facilities necessary to conduct the research and will be accountable for the grant funds. Applications are accepted for health-related research and development in all areas within the scope of the NIH's mission.		
R03	Small Research Grants Small grants provide research support, specifically limited in time and amount, for activities such as pilot projects, testing of new techniques, or feasibility studies of innovative, high-risk research, which would provide a basis for more extended research.		
R13	Conferences The NIH provides funding for conferences to coordinate, exchange, and disseminate infor- mation related to its program interests. Generally, such awards are limited to participation with other organizations in supporting conferences rather than provision of sole support. Costs eligible for support include salaries, consultant services, equipment rental, travel, sup- plies, conference services, and publications. Prospective applicants are encouraged to inquire in advance concerning possible interest on the part of an awarding Institute/Center (IC), and to obtain more information on application procedures and costs.		
R15	The NIH Academic Research Enhancement Awards (AREA) To enhance the research environment of educational institutions that have not been traditional recipients of NIH research funds, this award provides limited funds to those institutions' fac-ulty members to develop new research projects or expand ongoing research activities in health sciences and to encourage students to participate in the research activity. As funds are anticipated to continue to be available each year, the NIH is now inviting applications for AREA grants through a standing, ongoing Program Announcement.		
R21	Exploratory/Developmental Grants To encourage the development of new research activities in categorical program areas. (Support generally is restricted in the level of support and duration.)		
R24	Resource-Related Research Projects To support research projects that will enhance the capability of resources to serve biomedical research.		

R25E Cancer Education Grant Program (CEGP)

A flexible, curriculum-driven program aimed at developing and sustaining innovative educational approaches that ultimately will have an impact on reducing cancer incidence, mortality, and morbidity, as well as on improving the quality of life of cancer patients. The CEGP accepts investigator-initiated grant applications that pursue a wide spectrum of objectives ranging from short courses; to the development of new curricula in academic institutions; to national forums and seminar series; to hands-on workshop experiences for the continuing education of health care professionals, biomedical researchers, and the lay community; to structured shortterm research experiences designed to motivate high school, college, medical, dental, and other health professional students to pursue careers in cancer research. Education grants can focus on education activities before, during, and after the completion of a doctoral-level degree, as long as they address a need that is not fulfilled adequately by any other grant mechanism available at the NIH and are dedicated to areas of particular concern to the National Cancer Program.

R25T Cancer Education and Career Development Program

To support the development and implementation of curriculum-dependent, team-oriented programs to train predoctoral and postdoctoral candidates in cancer research team settings that are highly interdisciplinary and collaborative. This specialized program is particularly applicable to the behavioral, prevention, control, nutrition, and population sciences but should also be considered by other areas of research (e.g., imaging, pathology) that will require sustained leadership, dedicated faculty time, specialized curriculum development and implementation, interdisciplinary research environments, and more than one mentor per program participant to achieve their education and research career development objectives.

R33 Exploratory/Developmental Grants, Phase II

To provide a second phase for support of innovative exploratory and developmental research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants who demonstrate program competency equivalent to that expected under R33

R35 Outstanding Investigator Award (OIA)

To provide long-term support to experienced investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit an application nominating an established Program Director/Principal Investigator (PD/PI) for a 7-year grant.

R37 Method to Extend Research in Time (MERIT) Award

To provide long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT Award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT Award during the course of reviewing competing research grant applications prepared and submitted in accordance with regular Public Health Service (PHS) requirements.

R55	James A. Shannon Director's Award To provide a limited award to investigators to further develop, test, and refine research tech- niques; perform secondary analysis of available data sets; test the feasibility of innovative and creative approaches; and conduct other discrete projects that can demonstrate their research capabilities and lend additional weight to their already meritorious applications. Essentially replaced in FY2005 by the R56 award.
R56	High-Priority, Short-Term Project Award Begun in FY2005, this grant provides funds for 1- or 2-year high-priority new or competing renewal R01 applications that fall just outside the limits of funding of the participating NIH Institutes and Centers (ICs); recipients of R56 awards will be selected by IC staff from R01 applications that fall at or near the payline margins.

Small Business Innovation Research (SBIR) (R43/44) and Small Business Technology Transfer (STTR) (R41/42) Programs

The NIH welcomes grant applications from small businesses in any biomedical or behavioral

research area as described in the solicitations below. Support under the SBIR program is normally provided for 6 months/\$100,000 for Phase I and 2 years/\$500,000 for Phase II. Applicants may propose longer periods of time and greater amounts of funds necessary for completion of the project.

R41	STTR Grants, Phase I To support cooperative research and development (R&D) projects between small business concerns and research institutions, limited in time and amount, to establish the technical merit and feasibility of ideas that have potential for commercialization.	
R42	STTR Grants, Phase II To support indepth development of cooperative R&D projects between small business con- cerns and research institutions, limited in time and amount, whose feasibility has been estab- lished in Phase I and that have potential for commercial products or services.	
R43	SBIR Grants, Phase I To support projects, limited in time and amount, to establish the technical merit and feasibil- ity of R&D ideas that may ultimately lead to commercial products or services.	
R44	SBIR Grants, Phase II To support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in commercial products or services.	
S Seri	S Series: Research-Related Programs	
SC1	Research Enhancement Award Individual investigator-initiated research projects aimed at developing researchers at minority- serving institutions (MSIs) to a stage where they can transition successfully to other extramural support (R01 or equivalent).	
SC2	Pilot Research Project Individual investigator-initiated pilot research projects for faculty at minority-serving institu- tions (MSIs) to generate preliminary data for a more ambitious research project.	
S06	Minority Biomedical Research Support (MBRS) To strengthen the biomedical research and research training capability of ethnic minority institutions and thus establish a more favorable milieu for increasing the involvement of minority faculty and students in biomedical research.	

S07	Biomedical Research Support Grants (NCRR BRSG) As an example of this funding mechanism, the NIH issued a Request for Applications (RFA) in FY2004 to provide short-term interim support for institutional activities that will strengthen oversight of human subjects research at institutions that receive significant NIH support for clinical research. Although there is considerable flexibility in the types of activities that could be supported under the BRSG program, that RFA emphasized the importance of efforts to enhance the protection of research subjects by means that would be sustained by the recipient institutions conducting human subjects research and are not currently funded under this program, and to share educational resources, computer technologies, best practices, etc. Although all NIH components supporting clinical research (including the NCI) are providing support for this program, it is administered by the National Center for Research Resources (NCRR).
S10	Biomedical Research Support Shared Instrumentation Grants (NCRR SIG) The National Center for Research Resources (NCRR) initiated its competitive Shared Instru- mentation Grant (SIG) Program in FY1982. Shared Instrumentation Grants provide support for expensive state-of-the-art instruments utilized in both basic and clinical research. This program is designed to meet the special problems of acquisition and updating of expensive shared-use instruments that are not generally available through other NIH funding mechanisms, such as the regular research project, program project, or center grant programs. Applications for funds to design or to advance the design of new instruments are not accepted. The objective of the program is to make available to institutions with a high concentration of NIH-supported biomedical investigators expensive research instruments that can only be justified on a shared- use basis and for which meritorious research projects are described.
S21	Research and Institutional Resources Health Disparities Endowment Grants—Capacity Building To strengthen the research and training infrastructure of the institution, while addressing current and emerging needs in minority health and other health disparities research.
T Serie	es: Training Programs
T15	Continuing Education Training Grants To assist professional schools and other public and nonprofit institutions in the establish- ment, expansion, or improvement of programs of continuing professional education, espe- cially for programs of extensive continuation, extension, or refresher education dealing with new developments in the science and technology of the profession.
T32	NIH National Research Service Award—Institutional Research Training Grants To enable institutions to make National Research Service Awards to individuals selected by them for predoctoral and postdoctoral research training in specified shortage areas.
T34	Undergraduate NRSA Institutional Research Training Grants To enhance the undergraduate research training of individuals from groups underrepresented in biomedical, behavioral, clinical, and social sciences through Institutional National Research Service Award Training Grants in preparation for research doctorate degree programs.

U Serie	U Series: Cooperative Agreements		
U01	Research Projects—Cooperative Agreements To support a discrete, specified, circumscribed project to be performed by the named inves- tigators in an area representing their specific interests and competencies.		
U10	Cooperative Clinical Research—Cooperative Agreements To support clinical evaluation of various methods of therapy and/or prevention in specific disease areas. These represent cooperative programs between participating institutions and Principal Investigators and are usually conducted under established protocols.		
U13	Conference—Cooperative Agreements To coordinate, exchange, and disseminate information related to its program interests, an NIH Institute or Center can use this type of award to provide funding and direction for appropriate scientific conferences. These cooperative agreements allow the NCI to partner with one or more outside organizations to support international, national, or regional meetings, conferences, and workshops that are of value in promoting the goals of the National Cancer Program.		
U19	Research Program—Cooperative Agreements To support a research program of multiple projects directed toward a specific major objec- tive, basic theme, or program goal, requiring a broadly based, multidisciplinary, and often long-term approach.		
U24	Resource-Related Research Projects—Cooperative Agreements To support research projects contributing to improvement of the capability of resources to serve biomedical research.		
U42	Animal (Mammalian and Nonmammalian) Model, and Animal and Biological Materials Resource Cooperative Agreements To develop and support animal (mammalian and nonmammalian) models or animal or bio- logical materials resources available to all qualified investigators without regard to the scien- tific disciplines or disease orientations of their research activities or specifically directed to a categorical program. Nonmammalian resources include nonmammalian vertebrates, inverte- brates, cell systems, and nonbiological systems.		
U43	Small Business Innovation Research (SBIR) Cooperative Agreements - Phase I To support projects, limited in time and amount, to establish the technical merit and feasibil- ity of R&D ideas that may ultimately lead to commercial products or services.		
U44	Small Business Innovation Research (SBIR) Cooperative Agreements - Phase II To support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in commercial products or services.		

U54	Specialized Center—Cooperative Agreements To support any part of the full range of research and development from very basic to clini- cal; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidiscipli- nary attack on a specific disease entity or biomedical problem area. These differ from pro- gram projects in that they are usually developed in response to an announcement of the pro- grammatic needs of an Institute or Division and subsequently receive continual attention from its staff. Centers also may serve as regional or national resources for special research purposes, with assistance from staff of the funding component in identifying appropriate priority needs.
U56	Exploratory Grants—Cooperative Agreements To support planning for new programs, expansion, or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers. Substantial Federal programmatic staff involvement is intended to assist investigators during performance of the research activities, as defined in the terms and conditions of award.
UH2	Exploratory/Developmental Cooperative Agreement Phase I To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.)
UM1	Research Project With Complex Structure Cooperative Agreement To support cooperative agreements involving large-scale research activities with complicated structures that cannot be appropriately categorized into an available single component activity code (e.g., clinical networks, research programs, or consortia). The components represent a variety of supporting functions and are not independent of each component. Substantial Federal programmatic staff involvement is intended to assist investigators during performance of the research activities, as defined in the terms and conditions of the award. The performance period may extend up to 7 years but only through the established deviation request process. ICs desiring to use this activity code for programs greater than 5 years must receive OPERA prior approval through the deviation request process.

Appendix F: Glossary of Acronyms

ABTC AHRQ	Adult Brain Tumor Consortium Agency for Healthcare Research and
AIDS	Quality Acquired Immune Deficiency
AISB AMC	Syndrome Applied Information Systems Branch AIDS Malignancy Clinial Trials Consortium
ARA AREA	Awaiting Receipt of Application Academic Research Enhancement Award
BRSG BSA BSC CAM	Biomedical Research Support Grant Board of Scientific Advisors Board of Scientific Counselors Complementary and Alternative Medicine
CATS CBIIT	Concept to Award Tracking System NCI Center for Biomedical Informatics and Information
CCCT CCR CCSG CCT CD CDC	Technology Coordinating Center for Clinical Trials Center for Cancer Research Cancer Center Support Grant Center for Cancer Training Career Development Centers for Disease Control and
CEGP CGCHR	Prevention Cancer Education Grant Program Center for Global Cancer Health
CHTN CISNET	Research Collaborative Human Tissue Network Cancer Intervention and Surveillance Modeling Network
CIT CMO COI CPACHE	Center for Information Technology Committee Management Office Conflict of Interest Comprehensive Partnerships to
CRCHD	Advance Cancer Health Equity Center to Reduce Cancer Health
CRP CSO CSPPC	Disparities Collaborative Research Partnership Common Scientific Outline Consortium of the Study of Chronic Pancreatitis, Diabetes, and Pancreatic
CSR CSSI	Cancer Center for Scientific Review Center for Strategic Scientific
CTAC	Initiatives Clinical Trials and Translational
DCB DCCPS	Research Advisory Committee Division of Cancer Biology Division of Cancer Control and
DCEG	Population Sciences Division of Cancer Epidemiology and

DCLG	Genetics Director's Consumer Liaison Group (now NCRA)
DCP DCTD	Division of Cancer Prevention Division of Cancer Treatment and
	Diagnosis
DEA DEAS	Division of Extramural Activities Division of Extramural Activities
DEAIS	Support DEA Information System
DFO	Designated Federal Officer
DHHS	U.S. Department of Health and
DPIC	Human Services (now HHS) Detection of Pathogen-Induced
Brio	Cancer
DRR	Division of Receipt and Referral
EDRN EEC	Early Detection Research Network
EPMC	Electronic Early Concurrence Extramural Program Management
LINO	Committee
eRA	Electronic Research Administration
ESA	Extramural Support Assistant
ESATTS	Extramural Officer Science
	Administrator Training – Tracking System
ETCTN	Experimental Therapeutics Clinical Trials Network
eTUG	NIH eRA Technical Users Group
FACA	Federal Advisory Committee Act
FDA	Food and Drug Administration
FFRDC	Federally Funded Research and
FIC	Development Center Fogarty International Center
FLARE	Fiscal Linked Analysis of Research
	Emphasis
FNLAC	Frederick National Laboratory
	Advisory Committee
FNLCR	Frederick National Laboratory for Cancer Research
FOA	
FOIA	Funding Opportunity Announcements Freedom of Information Act
FY	Fiscal Year
HHS	Department of Health and Human
IC	Services (replaces DHHS) Institute/Center
ICRP	International Cancer Research
	Partnership
IDeA	Institutional Development Award
IMAT	Innovative Molecular Analysis
IMPAC	Technologies Information for Management,
	Planning, Analysis, and Coordination
IRG	Initial Review Group
IRM	Information Resources Management

IT	Information Technology	PA
LOI	Letter of Intent	P
LRP	Loan Repayment Program	P
MBRS	Minority Biomedical Research Support	
		PI
MERIT	Method to Extend Research in Time	
MSI	Minority-Serving Institution	PI
NCAB	National Cancer Advisory Board	PI
NCCCP	NCI Community Cancer Centers	P
	Program	P
NCI	National Cancer Institute	P
NCORP	NCI Community Oncology Research	PI
	Program	
NCRA	NCI Council of Research Advocates	R
	(replaces DCLG)	
NCRR	National Center for Research	R
	Resources	R
NCTN	National Clinical Trials Network	R
NDPA	NIH Director Pioneer Award	R
NED	NIH Electronic Directory	R
NExT		R
	NCI Experimental Therapeutics	R
NFRP	NCI Funded Research Portfolio	
NGRAD	NCI Grant-Related Directory	R
NHLBI	National Heart, Lung, and Blood	R
	Institute	_
NIAAA	National Institute on Alcohol Abuse	R
	and Alcoholism	S
NIAID	National Institute of Allergy and	S
	Infectious Diseases	SI
NIEHS	National Institute of Environmental	SI
	Health Sciences	SI
NIH	National Institutes of Health	
NLM	National Library of Medicine	SI
NRSA	National Research Service Award	S
OBBR	Office of Biorepositories and	SI
• • • • • • • • • • • • • • • • • • • •	Biospecimen Research	SI
OBF	Office of Budget and Finance	SI
OCG	Office of Cancer Genomics	SI
OD	Office of the Director	SI
OEA		01
OER	Office of Extramural Applications	SI
	Office of Extramural Research	SI
OFACP	Office of Federal Advisory Committee	
0	Policy	SI
OHAM	Office of HIV and AIDS Malignancies	~
OIA	Outstanding Investigator Award	SI
OPERA	Office of Policy for Extramural	SI
	Research Administration	-
ORRPC	Office of Referral, Review, and	S
	Program Coordination	
OSP	Office of Scientific Programs	T
PA	Program Announcement	TI
	-	

BranchPDPharmacodynamicsPHSPublic Health Service (HHS)PIPrincipal InvestigatorPOProgram OfficialPOA&MPlan of Actions and MilestonesPQProvocative QuestionsPRESTOProgram Review and Extramural Staff Training OfficeRAEBResearch Analysis and Evaluation BranchR&DResearch and DevelopmentRFARequest for ApplicationsRFPRequest for ProposalsRIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResources and Training Review BranchRTCRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review and Logistics BranchSREAScientific Review and Logistics BranchSRESpecial Review Stennistrator)STTRSmall Business Technology Transfer ResearchT&ETraining and EducationTMENTumor Microenvironment Network	PAR PCP PCRB	Reviewed Program Announcement President's Cancer Panel Program Coordination and Referral
PHSPublic Health Service (HHS)PIPrincipal InvestigatorPOProgram OfficialPOA&MPlan of Actions and MilestonesPQProvocative QuestionsPRESTOProgram Review and Extramural Staff Training OfficeRAEBResearch Analysis and Evaluation BranchR&DResearch and DevelopmentRFARequest for ApplicationsRFPRequest for ProposalsRIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Technology and Contract Review BranchRTCRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAAASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Government EmployeeSIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review BranchSRESpecial Review BranchSRESpecial Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		Branch
PIPrincipal InvestigatorPOProgram OfficialPOA&MPlan of Actions and MilestonesPQProvocative QuestionsPRESTOProgram Review and Extramural Staff Training OfficeRAEBResearch Analysis and Evaluation BranchR&DResearch and DevelopmentRFARequest for ApplicationsRFPRequest for ProposalsRIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Technology and Contract Review BranchRTCRBResearch Technology and Contract Review BranchRTRBReseurch Training Review BranchSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSREAScientific Review and Logistics BranchSROScientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
POProgram OfficialPOA&MPlan of Actions and MilestonesPQProvocative QuestionsPRESTOProgram Review and Extramural Staff Training OfficeRAEBResearch Analysis and Evaluation BranchR&DResearch and DevelopmentRFARequest for ApplicationsRFPRequest for ProposalsRIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResources and Training Review BranchSTRBSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSRBSpecial Review and Logistics BranchSRBSpecial Review and Logistics BranchSRCScientific Review and Logistics BranchSRCScientific Review Administrator)STTRSmall Business Technology Transfer ResearchResearchT&E		
PQProvocative QuestionsPRESTOProgram Review and Extramural Staff Training OfficeRAEBResearch Analysis and Evaluation BranchR&DResearch and DevelopmentR&DResearch and DevelopmentRFARequest for ApplicationsRFPRequest for ProposalsRIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Interest CategorySIGShared Instrumentation GrantSMWScienctific Program LeaderSPORESpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		Program Official
PRESTOProgram Review and Extramural Staff Training OfficeRAEBResearch Analysis and Evaluation BranchR&DResearch and DevelopmentR&DResearch and DevelopmentRFARequest for ApplicationsRFPRequest for ProposalsRIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEEPSpecial Emphasis PanelSGESpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSRBSpecial Review and Evaluation ActivitiesSRBSpecial Review and Logistics BranchSROScientific Review and Logistics BranchSROScientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
Training OfficeRAEBResearch Analysis and Evaluation BranchR&DResearch And DevelopmentRFARequest for ApplicationsRFPRequest for ProposalsRIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSRBSpecial Review and Evaluation ActivitiesSRBSpecial Review and Logistics BranchSROScientific Review and Logistics BranchSROScientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
 RAEB Research Analysis and Evaluation Branch R&D Research and Development RFA Request for Applications RFP Request for Proposals RIO Research Integrity Officer RM Road Map RO Referral Officer RPG Research Project Grant RPRB Research Programs Review Branch RTCRB Research Technology and Contract Review Branch RTRB Resources and Training Review Branch SA& Staff Assistant SA&A Security Assessment and Authorization SBIR Small Business Innovation Research SBIRDC SBIR Development Center SEER Surveillance, Epidemiology, and End Results SEP Special Emphasis Panel SGE Special Interest Category SIG Shared Instrumentation Grant SMW Science Management Workspace SPL Scientific Program Leader SPORE Special Review Branch SRB Special Review and Evaluation Activities SRB Special Review Branch SREA Scientific Review and Evaluation Activities SREA Scientific Review Administrator) STTR Small Business Technology Transfer Research T&E Training and Education 	THEOTO	
R&DResearch and DevelopmentRFARequest for ApplicationsRFPRequest for ProposalsRIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResearch Technology and Contract Review BranchRTRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSRBSpecial Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education	RAEB	Research Analysis and Evaluation
RFARequest for ApplicationsRFPRequest for ProposalsRIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program JeaderSPORESpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education	חפס	
RFPRequest for ProposalsRIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResearch Technology and ContractReview BranchRTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review Gficer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
RIOResearch Integrity OfficerRMRoad MapROReferral OfficerRPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecialized Program of Research ExcellenceSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
RPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSRBSpecial Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		Research Integrity Officer
RPGResearch Project GrantRPRBResearch Programs Review BranchRTCRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSRBSpecial Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		Road Map
RPRBResearch Programs Review BranchRTCRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecialized Program of Research ExcellenceSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
RTCRBResearch Technology and Contract Review BranchRTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSRBSpecial Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
RTRBResources and Training Review BranchSAStaff AssistantSA&ASecurity Assessment and AuthorizationSBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecial Review BranchSRBSpecial Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		Research Technology and Contract
 SA Staff Assistant SA& Security Assessment and Authorization SBIR Small Business Innovation Research SBIRDC SBIR Development Center SEER Surveillance, Epidemiology, and End Results SEP Special Emphasis Panel SGE Special Government Employee SIC Special Interest Category SIG Shared Instrumentation Grant SMW Science Management Workspace SPL Scientific Program Leader SPORE Special Review Branch SREA Scientific Review and Evaluation Activities SRLB Special Review and Logistics Branch SRO Scientific Review Administrator) STTR Small Business Technology Transfer Research T&E Training and Education 	DTDD	
 SA&A Security Assessment and Authorization SBIR Small Business Innovation Research SBIRDC SBIR Development Center SEER Surveillance, Epidemiology, and End Results SEP Special Emphasis Panel SGE Special Government Employee SIC Special Interest Category SIG Shared Instrumentation Grant SMW Science Management Workspace SPL Scientific Program Leader SPORE Special Review Branch SREA Scientific Review and Evaluation Activities SRLB Special Review and Logistics Branch SRO Scientific Review Administrator) STTR Small Business Technology Transfer Research T&E Training and Education 		
SBIRSmall Business Innovation ResearchSBIRDCSBIR Development CenterSEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecialized Program of Research ExcellenceSPRSSecure Payee Reimbursement SystemSRBSpecial Review and Evaluation ActivitiesSRLBSpecial Review and Logistics Branch SROSCientific Review Administrator)STTRSTTRSmall Business Technology Transfer ResearchT&ETraining and Education		
SEERSurveillance, Epidemiology, and End ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecialized Program of Research ExcellenceSPRSSecure Payee Reimbursement SystemSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics Branch 	SBIR	
ResultsSEPSpecial Emphasis PanelSGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecialized Program of Research ExcellenceSPRSSecure Payee Reimbursement SystemSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
SEPSpecial Emphasis PanelSGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecialized Program of Research ExcellenceSPRSSecure Payee Reimbursement SystemSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education	SEER	
SGESpecial Government EmployeeSICSpecial Interest CategorySIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecialized Program of Research ExcellenceSPRSSecure Payee Reimbursement SystemSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education	SEP	
SIGShared Instrumentation GrantSMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecialized Program of Research ExcellenceSPRSSecure Payee Reimbursement SystemSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education	SGE	Special Government Employee
SMWScience Management WorkspaceSPLScientific Program LeaderSPORESpecialized Program of Research ExcellenceSPRSSecure Payee Reimbursement SystemSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		Special Interest Category
SPLScientific Program LeaderSPORESpecialized Program of Research ExcellenceSPRSSecure Payee Reimbursement SystemSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
SPORESpecialized Program of Research ExcellenceSPRSSecure Payee Reimbursement SystemSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
SPRSSecure Payee Reimbursement SystemSRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
SRBSpecial Review BranchSREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education	0000	
SREAScientific Review and Evaluation ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		Secure Payee Reimbursement System
ActivitiesSRLBSpecial Review and Logistics BranchSROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		Scientific Review and Evaluation
SROScientific Review Officer (formerly Scientific Review Administrator)STTRSmall Business Technology Transfer ResearchT&ETraining and Education		
Scientific Review Administrator) STTR Small Business Technology Transfer Research T&E Training and Education		Special Review and Logistics Branch
STTRSmall Business Technology Transfer ResearchT&ETraining and Education	SRO	Scientific Review Officer (formerly
Research T&E Training and Education	STTR	Small Business Technology Transfer
IMEN Tumor Microenvironment Network		
	IMEN	Tumor Microenvironment Network

Appendix G: Cancer Information Sources on the Internet

NCI Website

The National Cancer Institute maintains a number of websites containing information about the Institute and its programs. All NCI websites, including those designed to provide cancer-related information to the general public and physicians, can be reached from the NCI home page at http://www. cancer.gov/.

DEA Websites

The following websites are maintained by the DEA to provide detailed information to researchers and the public about NCI funding opportunities and the Advisory Boards and groups supported by the DEA.

Links to the individual DEA Web pages via the DEA home page are listed below.

Advisory Boards and Groups

http://deainfo.nci.nih.gov/advisory/boards.htm Links to the home page of each NCI Advisory Board, Committee, Group, etc.

http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm President's Cancer Panel Charter; meeting agendas, meeting minutes, annual reports.

http://deainfo.nci.nih.gov/advisory/ncab/ncab.htm National Cancer Advisory Board Charter; members of subcommittees, meeting agendas.

http://deainfo.nci.nih.gov/advisory/ncab/ncab meetings.htm

NCAB meeting information (agenda, minutes, and presentations).

http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm Board of Scientific Advisors Charter; members of subcommittees, meeting agendas.

http://deainfo.nci.nih.gov/advisory/bsa/bsa meetings.htm

BSA meeting information (agenda, minutes, and presentations).

http://deainfo.nci.nih.gov/advisory/fac/fac.htm NCI Frederick National Laboratory Advisory Committee Charter, functional statement, members, meeting information and subcommittees.

http://deainfo.nci.nih.gov/advisory/bsc/bs/bs.htm Board of Scientific Counselors (Basic Sciences) Charter; functional statement, and members.

http://deainfo.nci.nih.gov/advisory/bsc/cse/cse.htm Board of Scientific Counselors (Clinical Sciences and Epidemiology) Charter; functional statement, and members.

http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm Clinical Trials and Translational Research Advisory Committee Charter; members, minutes, and agendas.

http://deainfo.nci.nih.gov/advisory/ncra/ncra.htm NCI Council of Research Advocates (NCRA) Charter, functional statement, members, and meeting information

http://deainfo.nci.nih.gov/advisory/irg/irg.htm NCI Initial Review Group (IRG) Charter; functional statement, and members.

http://deainfo.nci.nih.gov/advisory/sep/sep.htm Special Emphasis Panel Charter; functional statement, rosters of most recent review meetings.

Funding Opportunities/Policies

http://deainfo.nci.nih.gov/funding.htm

Comprehensive information about external funding opportunities for cancer research; lists of active PAs and RFAs; recently cleared concepts; grant policies and guidelines; downloadable application forms.

http://deais.nci.nih.gov/foastatus/RFA-PA.jsp?nt=P Active PAs, with links to detailed descriptions.

http://deais.nci.nih.gov/foastatus/RFA-PA.jsp Active RFAs, with links to detailed descriptions.

http://deainfo.nci.nih.gov/grantspolicies/index.htm Links to full-text NCI and NIH policies related to grants and grant review (e.g., *Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research and Instructions to Reviewers for Evaluating Research Involving Human Subjects in Grant and Cooperative Agreement Applications*).

http://grants.nih.gov/grants/new_investigators/ index.htm New and Early Stage Investigator Policies.

http://www.cancer.gov/researchandfunding/ training The Center for Cancer Training (CCT).

http://report.nih.gov/index.aspx

Research Portfolio Online Reporting Tools (RePORT): Reports, Data, and Analyses of NIH Research Activities.

Other NIH Websites

http://www.nih.gov NIH Homepage

http://grants.nih.gov/grants/ElectronicReceipt/ Grants & Funding – Applying electronically

http://grants.nih.gov/grants/policy/policy.htm Grants & Funding – Grants policies and guidance

http://grants.nih.gov/grants/guide/index.html Grants & Funding – Funding opportunities and notices

http://grants.nih.gov/training/extramural.htm Extramural training mechanisms

An electronic version of this document can be viewed and downloaded from the Internet at http://deainfo.nci.nih.gov/



December 2015